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Pre-eclampsia, a pregnancy specific condition associated with significant morbidity 
and mortality, is characterised by high blood pressure accompanied by and/or 
proteinuria, acute kidney injury (AKI), liver dysfunction fetal growth restriction 
(FGR) after 20 weeks’ gestation in the second half of pregnancy. It affects 2-5% of 
pregnancies worldwide. There is overwhelming evidence showing oxidative stress 
plays a significant role in the aetiology of this disorder. The mitochondria are known 
to be a dominant cellular producer of reactive oxygen species. Mitochondrial 
dysfunction acts as a pathogenic mediator of oxidative stress in pre-eclampsia and 
modulates the clinical characteristics of this syndrome. There is evidence that 
mitochondrial dysfunction and the innate immune system both play roles in the 
pathophysiology of this disease. Mitochondrial damage-associated molecular 
patterns (DAMPs) such as mtDNA bind specific pattern recognition receptors such 
as Toll-like receptor 9 (TLR9) on the surface of immune cells, particularly 
neutrophils, subsequently activating them and triggering an innate immune response.  
Currently there is no treatment for pre-eclampsia except delivery of the placenta and 
the baby, with the resultant risk of iatrogenic prematurity and significant neonatal 
morbidity and mortality. As a result, intensive research endeavours have focused on 
defining the molecular mechanisms of pre-eclampsia and thereby expediting 
identification of new therapeutic targets for this condition. In pregnancies affected by 
pre-eclampsia there is an exaggerated oxidative stress phenotype with a 
correspondent deficient antioxidant response. The therapeutic potential of vitamin 
antioxidants in the prevention of pre-eclampsia was supported by extensive research, 
however, ultimately, they were unsuccessful in clinical trials. The ongoing 
hypothesis is that these vitamin antioxidants were sequestered in the cytosol and 
22 
 
didn’t reach the mitochondria to alleviate the excess oxidative stress. Therefore, 
there is a need for the development of a specific mitochondrial-targeted antioxidant 
as a potential therapy for pre-eclampsia.  
This body of research provided evidence of mitochondrial dysfunction and a 
deficient antioxidant response in women who developed pre-eclampsia as early as 15 
weeks’ gestation. However, there was no association found between lifestyle factors 
on mitochondrial dysfunction in the study cohort. Furthermore, there was increased 
activation of TLR9, a mediator of mtDNA induced innate inflammation in the same 
cohort, albeit at a later point in gestation. Additionally, there was a significant 
increase in the production of a number of neutrophil activation markers; calprotectin, 
myeloperoxidase and Interleukin-8 in women who developed pre-eclampsia. In the 
next study, I examined if L-ergothioneine, a water-soluble amino acid, and potential 
mitochondrial targeted antioxidant could mediate oxidative stress in an in vitro Jeg-3 
placental cell line. In this novel study, L-ergothioneine exhibited cytoprotective 
effects against H2O2-induce cell death and significantly reduced exaggerated 
mitochondrial-specific ROS production in part by altering mild uncoupling. The 
protective effects of pre-treatment with L-ergothioneine were more pronounced 
when compared with another mitochondrial targeted antioxidant, MitoTempo and the 
non-mitochondrial targeted antioxidant N-acetylcysteine. 
The final study examined the potential therapeutic effects of L-ergothioneine in vivo 
using the reduced uterine perfusion pressure (RUPP) rat model of pre-eclampsia. In 
this study, treatment with L-ergothioneine significantly reduced blood pressure and 
rescued fetal growth restriction in RUPP rats. Furthermore, sFlt-1, an anti-
angiogenic factor evident in pre-eclampsia, was significantly decreased in rats 
treated with L-ergothioneine. Additionally, using a novel ratiometric mass 
23 
 
spectrometry probe, I showed that mitochondrial H2O2 production in vivo was 
significantly increased in the kidney from the RUPP rats and that pre-treatment with 
L-ergothioneine significantly reduced mitochondrial H2O2 production in vivo.  
In summary, this thesis has provided evidence of mitochondrial dysfunction in 
women who develop pre-eclampsia. Additionally, this work has shown that 
mitochondrial dysfunction activates a neutrophil-driven innate immune response in 
women with pre-eclampsia which is mediated in part by activation of the TLR9 
receptor. Furthermore, this novel work established that L-ergothioneine, a unique 
antioxidant directly targets the mitochondria and reduces exaggerated mitochondrial 
specific ROS production in both in vitro and in vivo models of pre-eclampsia. 
Additionally, in the in vivo model of pre-eclampsia, treatment with L-ergothioneine 
positively modulates some of the detrimental clinical characteristics evident in 
women with pre-eclampsia, highlighting the therapeutic potential of this 
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1.0 Chapter 1: Introduction 
 
1.1.1 Definition and epidemiology of pre-eclampsia 
 
Pre-eclampsia is defined by the International Society for the Study of Hypertension 
in Pregnancy (ISSHP) as gestational maternal hypertension of at least 140/90mmHg 
after 20 weeks’ gestation and accompanied by proteinuria and/or evidence of 
maternal acute kidney injury (AKI), neurological features, haemolysis, liver 
dysfunction, or fetal growth restriction (1). Pre-eclampsia is a major cause of 
maternal and perinatal mortality and morbidity worldwide, accounting for nearly 
18% of all maternal deaths worldwide; an estimated 77,000 maternal deaths per year 
and affects 10 million women globally (2). This hypertensive pregnancy 
complication occurs during the second half of pregnancy and complicates around 2-
8% of pregnancies (3). Whilst low to middle income countries bear the burden of 
maternal and perinatal mortality, worryingly, maternal mortality is increasing in 
some high resource settings due to global epidemics of obesity and diabetes mellitus. 
When women present with early-onset pre-eclampsia prior to 33 weeks’ gestation, 
the risk of serious maternal and perinatal morbidity and mortality is significantly 
increased. Maternal and perinatal outcomes are less severe when late-onset pre-
eclampsia develops after 36 weeks’ gestation. Suspected pre-eclampsia is the most 
frequent clinical presentation to obstetric day-care units in Ireland and those with 
early-onset are at greater risk. Preterm delivery is a serious complication of early-
onset pre-eclampsia with fetal morbidity and mortality being directly correlated with 
gestational age at delivery. Furthermore, according to the Perinatal mortality in 
Ireland report, pregnancies affected by pre-eclampsia had an increased risk of 




1.1.2 Risk factors and long-term prognosis 
 
The risk of pre-eclampsia is increased in women with a previous history of pre-
eclampsia with a relative risk (RR) of 7.19 (95% confidence interval 5.85-8.83). 
Further risk factors for pre-eclampsia include maternal age, greater than 40 years of 
age (RR 1.96, 1.34-2.87), pre-existing diabetes (RR 3.56, 2.54-4.99), family history 
of pre-eclampsia (RR 2.90, 1.70-4.93), raised blood pressure, ≥80 mmHg, at booking 
(RR 1.38, 1.01-1.87), multiple (twin) pregnancy (RR 2.93, 2.04-4.21) and pre-
pregnancy obesity (RR 2.47, 1.66-3.67) (4). Furthermore, pre-eclampsia risk is 
higher among African American women (5.2%; odds ratio [OR] 1.41, 95% 
confidence interval [CI] 1.25–1.62) while lower among Latina (4.0%; OR 0.90, 95% 
CI 0.84–0.97) and Asian women (3.5%; OR 0.79, 95% CI 0.72–0.88), compared 
with Caucasian women (5). 
Short term maternal and fetal complications associated with pre-eclampsia include 
an increased risk of eclampsia (seizures in the mother). Furthermore, fetal 
complications include small for gestational age (SGA) and intrauterine growth 
restriction (IUGR) and in some cases, fetal death (6, 7). Women who develop pre-
eclampsia have a further increased risk of developing HELLP (Hemolysis, Elevated 
Liver enzymes and Low Platelets) syndrome. HELLP syndrome is a complication of 
severe pre-eclampsia, which can cause liver failure and maternal death, occurs in 
about 12% of pregnancies complicated by pre-eclampsia or eclampsia (8). Pre-
eclampsia has been shown to carry long-term health implications later in adult life 
for both mother and baby, with offspring of affected pregnancies demonstrating an 
increased risk of hypertension (9), stroke (10) and diabetes (11).  Following a pre-
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eclamptic pregnancy, a woman is at an increased risk of developing cardiovascular 
complications (4-10 fold) (12), with 20% of women developing cardiovascular 
disease within 7 years (13).  
1.1.3 The Screening for Pregnancy Endpoints (SCOPE) International Cohort 
Study. 
 
More than half of all cases of pre-eclampsia occur in healthy first-time pregnant 
women. The primary objective of the SCOPE study was to develop a multivariable 
predictive model for the prediction of preeclampsia by combining measurements of 
the best performing biomarkers (selected from >100 previously associated with pre-
eclampsia) measured at 14 to 16 weeks’ gestation, clinical risk factors and 
ultrasound estimates of uteroplacental perfusion and fetal measurements at 19 to 21 
weeks’ gestation. This study was carried out across 4 countries including New 
Zealand, Australia, United Kingdom; and Ireland where 5690 women were recruited.  
Pregnancy outcome data were available for 5623 (99%). Pre-eclampsia developed in 
278 (4.9%), of which 209 had term pre-eclampsia (3.7%), 69 (1.2%) had preterm 
pre-eclampsia, and 28 (0.5%) had early-onset pre-eclampsia. The diagnosis of pre-
eclampsia was based on hypertension with proteinuria in 90% and on hypertension 
in combination with multisystem complications in 10% (n=29) (14). A total of 1,774 
participants were involved in the Cork cohort, of which 68 (3.8%) women were 
diagnosed with pre-eclampsia. This multicentre cohort has created a vast amount of 
publications across all areas of research in regards to maternal and fetal health (14-
18) 
1.2 Aetiology of pre-eclampsia 
 




The placenta is a specialised organ of pregnancy along with the fetal membranes and 
amniotic fluid, which supports the normal growth and development of the fetus. 
During pregnancy, the placenta plays a number of key roles and functions 
predominantly at the site of maternal-fetal exchange.  These include; 1) exchange of 
oxygen and CO2; 2) as a digestive system which supplies nutrients for fetal growth 
and development; 3) removes waste products; 4) as an immune barrier that prevents 
any antigenic attacks from the mother; 5) as a key mediator of endocrine function 
during pregnancy. From the earliest days of pregnancy, trophoblasts generate a 
variety of hormones including gonadotropin and progesterone. The primary source 
of these placental hormones is the syncytiotrophoblast layer. The two most important 
protein hormones produced by the placenta are human chorionic gonadotropin (hCG) 
and human placental lactogen (hPL) (19, 20).  
hCG is involved in pleotropic roles throughout pregnancy owing to its autocrine and 
paracrine actions, in turn linking with many processes that are crucial for the 
pregnancy outcome. In pregnancy this glycoprotein is critical since it rescues the 
corpus luteum from involution, which subsequently maintains progesterone secretion 
by the ovarian granulosa cells. Similarly, progesterone is crucial for gestational 
maintenance. After 6-8 weeks of gestation, hCG peaks and tends to plateau to a 
lower level for the remainder of pregnancy. Therefore, the production of 
progesterone declines due to diminished placenta production of hCG and the 
placental trophoblasts take over as the main source of progesterone production (21). 
Human placental lactogen (hPL), is produced and secreted by the 
syncytiotrophoblast layer of the placenta and is first detected in the maternal 
circulation at 6 weeks of gestation (22). This hormone modifies the metabolic state 
of the mother during pregnancy to facilitate the energy supply of the fetus. 
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Placental development involves the coordination and function of many cell types 
including cytotrophoblasts and syncytiotrophoblasts (23). During the second week of 
development, implantation of the blastocyst in the endometrium of the uterus is 
complete. The amniotic cavity, yolk sac, connecting stalk and chorion equally 
develop during the second week. Villi are first recognisable around the 12th day of 
development. During normal implantation, the uterine spiral arterioles undergo 
extensive remodelling as they are invaded by endovascular trophoblasts. 
Endovascular trophoblasts invade and replace the vascular endothelial and muscular 
linings to enlarge the vessel diameter (24, 25). Maternal spiral arterioles are eroded 
on the 14th or 15th day, and maternal arterial blood enters the developing intervillous 
space. Both fetal and maternal blood vessels are active and the placental circulation 
is established around the 17th day after conception (19). At the time of implantation, 
the actively erosive trophoblasts continue to invade the endometrium containing 
connective tissues, capillaries and glands in a process called placentation. As 
trophoblasts invade the endometrium, they differentiate into two distinct layers; 
cytotrophoblast and syncytiotrophoblast. 
The cytotrophoblast is composed of mononuclear cells whereas the 
syncytiotrophoblast consists of a thick multinucleated protoplasmic mass. There are 
spaces left between syncytial cells which are known as the lacunae and they appear 
in the syncytiotrophoblast and soon become filled with blood from ruptured maternal 
capillaries. The successful development of a normal placenta is dependent on the 
orchestrated balance of cytotrophoblast cell proliferation and differentiation into 
either one of the differentiated cell types, invasive cytotrophoblasts or 
syncytiotrophoblast (26). After implantation, the invasive trophoblasts proliferate 
and differentiate along two pathways defined as villous and extravillous. Villous 
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cytotrophoblast cells fuse to form the multinucleated syncytiotrophoblast, whereas 
the extravillous trophoblasts form the outer epithelial later of the chorionic villi. 
Differentiating and invading cytotrophoblasts undergo a process known as pseudo-
vasculogenesis, where these cells acquire an adhesion receptor repertoire resembling 
that of endothelial cells (27). There are a variety of molecular families including 
vascular endothelial growth factor (VEGF) and placental growth factor (PLGF) that 
play important roles in vasculogenesis and/or angiogenesis (28). Both maternal and 
fetal macrophages in addition to cytotrophoblasts produce these angiogenic 












Figure 1.1: Placental structure: The placenta has two surfaces, maternal and fetal. The chorion, amnion, yolk sac and allantois constitute 
the fetal membranes. The appearance of the maternal surface of a placenta is a “cobblestone–like” structure consisting of 10-38 
cotyledons. A cotyledon is made up of approximately 10 and 20 lobules which then correspond with the opening of a maternal 




1.2.2 Placental development in pre-eclampsia 
 
In pre-eclamptic pregnancies placentation is compromised and incomplete, where 
remodelling of spiral arterioles and the uterine decidua and myometrium is 
inadequate which in turn leads to shallow extravillous trophoblast (EVT) invasion 
and migration (Figure 1.2). In pre-eclampsia, there is histopathological evidence of 
incomplete trophoblastic invasion. Pathological changes are the most common with 
severe pre-eclampsia (32). In a large study cohort (n = 6410) a series of placental 
measurements were performed in Finland between 1934 and 1944 (33). They found 
that rather than the circular shape usually present in pregnancy, there was a greater 
discrepancy between the shortest and longest diameter in placentas from pre-
eclampsia pregnancies. The hypothesis is that such an abnormal placental shape is 
associated with reduced endovascular invasion (34). As a result only the decidual 
vessels become lined with endovascular trophoblasts while the myometrial vessels 
remain uninvaded and narrow (25). Histologically, normal third-trimester decidual 
vessels are characterized by flat endothelium and a loss of medial smooth muscle, 
while pre-eclamptic decidua show signs of loose, oedematous endothelium, 
hypertrophy of the vessel media, and loss of smooth muscle modifications (35). In 
more recent years, atherosclerotic changes in maternal radial arteries that supply the 
decidua are examined as opposed to the spiral arteries and have been observed in 
pre-eclampsia. Therefore, due to deficient trophoblast invasion and narrow vessel 
structure there is an intermittency of arterial O2 blood flow delivered to the 











Figure 1.2: Remodelling of the spiral arteries by the trophoblast. 
 (a) During implantation, trophoblastic cells (shown in blue) migrate from the anchoring villi and invade the vascular endothelium and 
muscular layers of the uterine spiral arterioles (shown in yellow), where they enlarge the vessel diameter and create a high capacitance, 
low resistance circulation, a process known as “remodelling”. (b)  However, in pre-eclampsia, this trophoblastic invasion is incomplete. 
This has been proposed to be due to increased oxidative stress and cytokine production which impairs migration and invasion of the 
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extravillous trophoblast. (c) List of major placental structures and the various trophoblast cell types associated with them. This figure 
was created by Williamson et al (37). 
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Several years ago a concept originally introduced by Professor Chris Redman and 
colleagues described how pre-eclampsia can considered as a two stage disorder (38). 
This two-stage model suggests that a poorly perfused placenta (stage 1) in turn 
produces circulating factors leading to the clinical manifestations of the disease 
(stage 2). In more recent years, further knowledge has been obtained in relation to 
the pathophysiology of pre-eclampsia and the consensus is that pre-eclampsia is 
more complex than the two-stage model previously described (39). This led to the 
idea that maternal constitutional factors (obesity, diet and diabetes), behavioural, 
environmental and genetic factors, modified by the physiological changes in 
pregnancy were essential to interact, leading to maternal abnormalities in pre-



















Figure 1.3: Pathogenic mediators that affect placental dysfunction in pre-eclampsia. 
This figure was generated from Karumanchi et al (41). 
 
1.2.3 Endothelial dysfunction and pre-eclampsia 
 
The key physiologic function of endothelial cells are to control vascular function by 
detecting circulating blood composition and furthermore providing a physical barrier 
to the inadequate movement of proteins, ions, water and cells from the blood into the 
vascular wall (42). Endothelial dysfunction in pregnancy is defined as a lack of 
enhanced vasodilation of the uterine arteries in early pregnancy. Endothelial 
dysfunction contributes to all major symptoms of pre-eclampsia. Impairment in 
remodelling of spiral arteries and poor placentation due to shallow trophoblastic 
invasion results in deficient placental perfusion (43). The reduced placental 
perfusion mediated changes release circulating pathogenic mediators such as sFlt-1, 
sEng, VEGF and ROS, which challenge endothelial cells through different 
mechanisms, resulting in endothelial dysfunction. 
Both vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) 
and their receptors are important mediators of angiogenesis and placental 
maintenance. VEGF is widely expressed at the feto-maternal interface and has been 
established as a major angiogenic factor that mediates endothelial proliferation and 
vascular permeability by inducing the expression of integrins on endothelial cell 
(29). Likewise, PIGF mediates pro-angiogenic effects on the feto-placental 
circulation and supports trophoblast growth. Low levels of circulating PlGF leads the 
manifestation of clinical disease in pre-eclamptic pregnancies (44). Soluble fms-like 
tyrosine kinase 1 (sFlt-1) is a splice variant of the VEGF receptor, Flt-1, that lacks 
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both the transmembrane and cytoplasmic domains of the cell membrane bound 
receptor. sFlt-1 acts as a soluble receptor that binds PlGF and also binds and 
deactivates circulating VEGF. The primary receptor for VEGF is VEGF receptor-2 
(VEGFR-2) which is essential for normal endothelial proliferation and vascular 
formation. VEGFR-2 is expressed in endothelial cells, megakaryocytes and 
haematopoietic stem cells and also in the trophoblast layer in human placenta (41). 
Research has shown that sFlt-1 directly interacts with VEGFR-2 in-vivo, and is 
significantly more evident in placental tissue from pre-eclamptic patients (45).  
Increase in circulating sFlt-1 results in a decrease in the plasma levels of free VEGF 
and PlGF and these changes are linked with both the occurrence and severity of pre-
eclampsia (46-48). Endoglin (Eng) is a type I membrane glycoprotein located on cell 
surfaces and is part of the transforming growth factor beta (TGF-β) receptor complex 
and plays a vital role in angiogenesis. Eng is expressed by trophoblast and 
endothelial cells (49), soluble endoglin (sEng) is a condensed form of Eng. Similar 
to sFlt-1, sEng is also detected at increased concentrations in placental tissue from 
pre-eclamptic pregnancies (50). sEng cause endothelial dysfunction by antagonizing 
TGF-β1 signalling in pre-eclampsia.  Proteinuria is one of the primary clinical 
manifestations of pre-eclampsia. Podocytes are a major source of VEGF production 
in the glomerulus. To date, there is evidence that VEGF is important in maintaining 
glomerular endothelial cell health (51), however, with its absence, proteinuria is 
induced (52, 53). Renal pathologic abnormalities in the form of endotheliosis have 
been recognised and proteinuria has been commonly viewed as a consequence of 
endothelial cell swelling. However, renal involvement has been often understood to 
be in the context of endothelial dysfunction (54). 
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1.3 Oxidative stress and pre-eclampsia 
 
There is overwhelming evidence that oxidative stress plays a role in the 
pathophysiology of pre-eclampsia (55-58). Oxidative stress is an imbalance between 
the production of reactive oxygen species (ROS) and antioxidant defences (59), 
resulting in increased levels of ROS with resultant damage of cellular components 
including DNA, proteins and lipids. Uncomplicated healthy pregnancy is 
characterised by a low grade oxidative stress; there are increased circulating levels of 
oxidised low-density lipoproteins and a reduction in total antioxidant capacity in 
pregnant women when compared with non-pregnant women (60). Excessive oxidative 
stress is generally thought to be involved in the pathology of many pregnancy-related 
disorders such as fetal growth restriction (FGR), pre-eclampsia and miscarriage (61). 
Dysfunctional placentation is proposed to provoke an ischaemic environment due to 
fluctuations in the delivery of oxygen to the fetus, resulting in elevated oxidative stress 
seen in pre-eclampsia.  
By 10–12 weeks’ gestation in normal pregnancy maternal blood flow in the placenta 
causes a local increase in oxygen and elevation in the activity of the antioxidant 
enzymes (62). However, in pregnancies complicated by pre-eclampsia there is a 
decrease in antioxidant enzyme activity at the same time in gestation (63).  Increased 
lipid peroxidation as a result of exaggerated oxidative stress plays a vital role in the 
pathology of pre-eclampsia by provoking endothelial dysfunction. Plasma 
malondialdehyde (MDA) levels have been found to be significantly higher in pre-
eclampsia in comparison with uncomplicated pregnancy (60). Additionally, 
superoxide dismutase (SOD) antioxidant levels were significantly lower in pre-
eclampsia in this study (60).  
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In recent years, increased levels of cell-free fetal haemoglobin (HbF) has been 
implicated as a new pathological factor of pre-eclampsia (64). Haemoglobin reacts 
spontaneously with oxygen generating free oxygen radicals. Haemoglobin and its 
degradation products are toxic and can lead to oxidative stress in the maternal 
circulation (65). Recent work has demonstrated elevated levels of several 
haemoglobin related metabolites including heme, bilirubin and biliverdin in pre-
eclampsia patients (66).  
1.3.1 Reactive Oxygen species 
 
Reactive oxygen species (ROS) are produced as a by-product of the electron 
transport chain. ROS are typically recognised as two groups; free radicals and non-
radical products. Free radicals include superoxide (O2-), the hydroxyl radical (HO), 
lipid peroxy-radicals (LOO) and alkoxy-radicals (LO). These are unstable and have a 
short half-life. Non-radical derivatives are more stable with a longer half-life, 
however, they can have strong oxidant properties. Non-radicals include hydrogen 
peroxide (H2O2), peroxynitrite (ONOO
-) and hypochlorous acid (HOCl-) (59). 
Superoxide acts as an oxidant as well as a reductant in many biological systems (67) 
and-serves as an origin for many other biologically relevant ROS including H2O2, 
HO radical and ONOO- (59). H2O2 is created by dis-mutation of O
2-, this molecule 
can occur spontaneously, or it can be promoted by superoxide dismutase (SOD).  
Hydroxyl radical (HO) is created when O2 donates one electron to H2O2 in a reaction 
known as the Haber Weiss Reaction. The HO molecule is a highly reactive oxidant 
that attacks a variety of biomolecules such as lipids, proteins and DNA. Peroxynitrite 
(OONO-) results from the spontaneous reaction between O2 and nitric oxide (NO) 
and is a very strong oxidant and reacts with lipids, DNA and proteins (59). This 
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molecule reacts and modifies proteins and other cellular structures inflicting 
oxidative damage on these molecules. OONO- can oxidize lipids, oxidize methionine 
and tyrosine residues in proteins and oxidizes DNA to form nitroguanine (68). 
Furthermore, nitroguanine residues are considered as a marker of peroxynitrite 
induced cellular damage (69).  
Redox signalling occurs when a biological system alters in response to a change in 
the level of ROS or due to the shift in redox state of a responsive group such as 
dithiol-disulphide (70). The mitochondria are deemed to play a role in redox 
signalling due to the flux in O2˙
- generated by the electron transport chain and other 
metabolic processes in the mitochondria (70). The main ROS involved in redox 
signalling both to and from the mitochondria is H2O2. 
1.3.2 Producers of Reactive oxygen species 
 
There are several different sources of ROS including Nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase, xanthine oxidase and mitochondria. 
NADPH oxidases are activated by a variety of physiological and pathophysiological 
stimuli including inflammatory cytokines, mechanical forces and growth factors. 
Xanthine oxidoreductase exists in two forms; xanthine oxidase and xanthine 
dehydrogenase. Xanthine dehydrogenase transfers electrons from hypoxanthine and 
xanthine to NAD+ generating NADH and uric acid (59). When a critical cysteine 
residue is oxidised by peroxynitrite, xanthine dehydrogenase (XDH) is converted to 
xanthine oxidase. Xanthine oxidase then transfers electrons to oxygen from NADH 
and uric acid generating O2
- and H2O2. Xanthine oxidase has been shown to 
contribute to experimental hypertension in animal models, however currently there is 
limited evidence supporting the role of xanthine oxidase in human hypertension (71).   
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The natural defence against ROS comprises both enzymatic and non-enzymatic 
systems. Superoxide dismutase (SOD) is a well-known antioxidant enzyme that 
prevents free radical mediated injury by metabolising superoxide anions that are 
known to damage human tissues (72). SOD is categorised into three isoforms, 
cytosolic Cu, Zn-SOD, and mitochondrial Mn-SOD, which catalyse the dismutation 
of O2- into H2O2 and O2. In addition to requirements for metal ion cofactors, SOD 
enzymes also have distinct subcellular localizations. Eukaryotes only express Cu/Zn 
SODs (in the cytoplasm and extracellularly) and Mn SODs (in the mitochondria). 
A decrease in the endogenous SOD antioxidant defence systems weakens the normal 
metabolic removal of O2. Additionally, endogenous protein alpha-1-microglobulin 
acts as a radical scavenger and an antioxidant. It provides protection to tissue and 
protects the mitochondria from oxidative damage.  
Non-enzymatic antioxidants also act as ROS scavengers and include vitamins A, C 
and E; glutathione, bilirubin and uric acid. Vitamin E is a fat-soluble vitamin and its 
main role is to protect against lipid peroxidation. Vitamin A (retinol) is crucial for a 
diversity of physiological processes, including embryonic development and immune 
system function. Vitamin C scavenges free radicals in aqueous solution. Glutathione 
is largely known to reduce the lipid peroxidation of cellular membranes (73). Bilirubin 
has both antioxidant and anti-inflammatory activities, and is inversely correlated with 
disease risk of the cardiovascular system, such as hypertension (74).  Uric acid is a 
plasma antioxidant capable of scavenging superoxide, hydroxyl radical and singlet 
oxygen (75) as well as decreasing nitrosylation of tyrosine residues on proteins and is 






Mitochondria are rod-shaped organelles that are considered to be the power house of 
the cell due to their central role in Adenosine triphosphate (ATP) production. The 
location of the mitochondria in the cell and their size vary significantly depending on 
the cell type. Mitochondria are actively involved in a number of cellular activities such 
as proliferation, redox signalling oxidative stress and inflammation. The 
mitochondrion consists of two phospholipid bilayers which further segregate into four 
sectors; outer membrane, the inter-membrane space, inner membrane and the matrix 
(Figure 1.4) (77). The outer membrane contains porins that allow molecules that are 
less than 5KDa to diffuse freely. The outer membrane acts as a permeability barrier to 
the cytosolic components. The inner membrane of the mitochondria is the most 
extensively studied part of the organelle due to its importance in oxidative 
phosphorylation. The inner membrane is also different from other membranes due to 
the presence of cristae which allows the surface area to increase and allows for 
compartmentalisation.  
Mitochondria also contain their own genetic material known as mtDNA. Each mtDNA 
molecule consists of approximately 15000-17000 bp. The mtDNA strands differ in the 
nucleotide content with the heavy strand being rich in guanine and the light strand 
being rich in cytosine. mtDNA encodes for a total of 37 genes programmed by the 
mitochondrial genome (78). The mitochondrial matrix of the cell contains both 
mitochondrial DNA (mtDNA) and the majority of the enzymes that are required for 














Figure 1.4: Mitochondrial structure and components. This figure was generated 




1.3.4 Oxidative Phosphorylation 
 
The main function of mitochondria is the synthesis of ATP by oxidative 
phosphorylation through the transfer of electrons through multi-subunit complexes 
(79). Four complex units configure the electron transport chain (ETC) on the inner 
mitochondrial membrane; complex I, II, III and IV (Figure 1.5). Oxidative 
phosphorylation starts with the arrival of nicotinamide adenine dinucleotide (NADH) 
and Flavin adenine dinucleotide (FADH2) from the citric acid cycle. NADH transfers 
high energy molecules to complex I, while FADH2 transfers high energy molecules 
to complex II. This transfer of high energy molecules results in loss of electrons 
from both NADH and FADH2 known as oxidation. The free electrons are transferred 
to protein complex III and are picked up by cytochrome C which carries the 











In complex IV, there is a high concentration of protons outside of the inner 
mitochondrial membrane, resulting in protons being pushed through ATP synthase. 
This movement of protons causes ATP synthase to spin to produce ATP (79, 80). 
The ETC generates a proton motive force (pmf) by pumping protons from the 
mitochondrial matrix to the intermembrane space. When the pmf is high, the ETC 
slows due to the pump of protons against a stronger electrochemical force, therefore 
the energy of the substrate oxidation is insufficient to move protons up the gradient. 
Higher pmf is linked with greater ROS formation, whereas a decrease in pmf can 
reduce ROS production (81-83).   
1.3.5 Mediators of mitochondrial function  
 
Mitochondria are constantly undergoing fission and fusion events, which control 
their morphology, function and integrity (77, 84). Mitochondrial fission and fusion 
processes are both mediated by large guanosine triphosphatases (GTPases) (85). 
Their combined actions divide and fuse the two lipid bilayers that enclose the 
mitochondria. Fusion is the mixing of the mitochondrial genomes, diluting and in 
turn protecting against damaged DNA (86). Fission is required for normal 
mitochondrial function and is essential for growing and dividing cells to provide 
them with adequate numbers of mitochondria. Furthermore damaged mitochondria 
are segregated by the fission process to preserve the function of the mitochondrial 
network (87). Changes in metabolism are linked to the rates of mitochondrial fission 
and fusion (88). Distorted mitochondrial dynamics have been investigated as 
potential instigators of mitochondrial dysfunction. Mitochondrial homoeostasis is 
crucial to maintain efficiency of the mitochondria, therefore exaggerated 
dysregulation of either the fission or fusion mechanisms could lead to mitochondrial 
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dysfunction with subsequent elevation in mitochondrial ROS (mROS) generation 
(77).  
The health of mitochondria is regulated by their biogenesis and its orchestrator 
peroxisome proliferator-activated receptor gamma coactivator alpha (PGC-1α). 
Disrupted PGC1-α signalling can lead to altered mitochondrial biogenesis and 
further influence dysregulated metabolic outcomes (89). Mitophagy is the selective 
degradation of mitochondria by autophagy. This process occurs in defective 
mitochondria following damage by oxidative stress. Ca2+ ions are involved in a 
number of signalling pathways that regulate mitochondrial function (90).  
Mitochondria accumulate calcium via membrane-potential driven uniporters and 
release calcium by electroneutral exchange for sodium or protons (91). Excessive 
mitochondrial Ca2+ uptake establishes the fundamental steps in mROS generation in 
excitotoxicity (92) and calcium induced toxicity (93), mitochondrial Ca2+ overload 
also plays a role in the mechanisms of oxidative stress in ischemic-reperfusion injury 
and oxidation injury (94, 95). Many studies have documented that pre-eclampsia is 
linked with changes in intracellular Ca2+ homeostasis (96-98). Further research is 
needed to examine whether alterations in Ca2+ regulation is a consequence in pre-
eclampsia due to alterations ion-channel activity because of an imbalance between 
prooxidants and antioxidants.  
Cellular events such as decreased ATP production, calcium dysregulation, increased 
generation of ROS and mtDNA damage are intrinsically linked to mitochondrial 
dysfunction (99). Mitochondrial dysfunction has a critical role in the 
pathophysiology of many human pathologies such as atherosclerosis and diabetes, 
mainly due to the function of dynamic mitochondria in cellular metabolism. 
Mitochondrial ROS (mROS) are biologically important mediators in numerous 
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physiological systems including adaptation to hypoxia and regulation of 
differentiation (100). Mitochondria have significant DNA repair capacity, however 
mtDNA are vulnerable to oxidative damage due to its proximity to the electron 
transport chain (ETC) as well as the lack of protection by histones and chromatin 
(99). Mitochondrial dysfunction and mtDNA damage are often linked to diseases 
associated with exaggerated oxidative stress including hypertension and 
atherosclerosis (101). mtDNA is therefore often used as a biomarker of 
mitochondrial dysfunction. Furthermore, mtDNA lesions have been found in the 
circulating cells and hearts of patients that had coronary heart disease (102). 
1.3.6 Evidence of mitochondrial dysfunction in pre-eclampsia 
 
Mitochondrial activity is fundamental in pregnancy as it maintains the metabolic 
activity of the placenta (103). Research has shown elevated mitochondrial lipid 
peroxidation and increased evidence of susceptibility to oxidation in mitochondria of 
pre-eclamptic placentas (104). Furthermore, increased activity of the placental 
mitochondrial electron transport chain in preterm pre-eclamptic patients compared to 
normotensive controls has been reported (105). Changes in the pre-eclamptic 
placental proteomes may explain the significance of mitochondria in the 
development of pre-eclampsia. Shi et al carried out a comparative proteomic analysis 
of mitochondrial proteins in normal placentas compared to severe pre-eclampsia 
placentas. Here they found 26 differentially expressed mitochondrial proteins 
between the two groups. Furthermore, they illustrated the majority of these proteins 
were found to be involved in many biological processes including oxidative stress, 
ROS generation and mitochondrial damage (106). As well as this, they also observed 
degenerative changes and swollen mitochondria in the placentas from pre-eclamptic 
women. Research has shown disruption in oxygen consumption rate in trophoblast 
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cells isolated from pre-eclamptic placentas compared to normotensive placental 
trophoblasts (107).  
Hypertension is a central clinical characteristic of pre-eclampsia and elegant work by 
Dikalova et al, showed that mitochondrial dysregulation and resultant elevation in 
mROS resulted in elevation in hypertension in vivo (108).  Research carried out by 
McCarthy et al, showed that mROS is elevated in HUVEC cells treated with plasma 
from pregnancies complicated with pre-eclampsia. Similarly, they showed that 
plasma from pre-eclamptic women significantly reduced mitochondrial respiration in 
treated HUVEC. These results highlight that mROS plays a role in mediating 




1.4 Role of Inflammation in pre-eclampsia 
 
During normal pregnancy, three different immunological phases can be characterised. 
These include; a pro-inflammatory environment during embryo implantation, 
placentation and early stage of pregnancy, an anti-inflammatory milieu during mid 
trimester and a pro-inflammatory environment in third trimester and end of pregnancy 
(110). The innate immune system acts as both a protector and effector during 
pregnancy. As a protector, the innate system releases cells such as macrophages, 
dendritic cells, natural killer cells and neutrophils which protect the mother from 
invading pathogens. Furthermore, gamma delta (γδ) T cells are upregulated during 
pregnancy in order to protect the mother against pathogens while the adaptive immune 
system is dampened so as not to prompt a specific immune response toward the fetus. 
T cells have been examined extensively in healthy and complicated pregnancies. T-
helper cells mediate their effects by the secretion of cytokines. Th1 cells produce pro-
inflammatory cytokines including interferon IFN-γ and tumour necrosis factor (TNF)-
α, which are involved in cell-mediated responses, whereas Th2 cells produce 
predominantly anti-inflammatory cytokines such as IL-4, IL-5, IL-10 (111).  
Cytokines are proposed to control trophoblast behaviour by either modulating 
proliferation and migration or by inducing trophoblasts to differentiate into a non-
invasive phenotype (112).  The exact role of cytokines in the development of pre-
eclampsia is yet to be fully elucidated but they may be involved in either the initial 
placental insult or the maternal response to initial placental insult. For example, TNF-
α has a role in the maternal vascular dysfunction by decreasing the availability of the 
vasodilator nitric oxide (NO) by reducing eNOS expression in the endothelial cells 
thereby reducing NO formation (113).  
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Cytokine levels in pre-eclampsia have been a constant source of conflict in many 
publications in regard to its association with the disease. Several studies have shown 
an increase in pro-inflammatory cytokines in serum and plasma of women with pre-
eclampsia such as TNF-α, IL-6, IFN-ƴ  and IL-1β and anti-inflammatory cytokines, 
IL-10 (114-125) (Table 1.1).  
TNF-α promotes apoptosis and leakage of the endothelial vessels, leading to systemic 
endothelial activation and thereby signs associated with pre-eclampsia. There was 
elevation in pro-inflammatory cytokine TNF-α seen in the majority of cases with the 
exception of one study carried out by Kumar et al, where they saw a decrease in TNF-
α expression in pre-eclampsia (111). In this study they examined TNF-α levels in the 
second trimester of women who went on to develop pre-eclampsia (n=14) compared 
with normotensive pregnancies (n=162) as well as examining TNF-α levels 24 hours 
after delivery. These lower levels of TNF-α seen in pre-eclampsia compared with 
controls may be due to measuring in the second trimester and before the manifestation 
of the disease (111). Furthermore in this study, IL-10 showed lower levels in pre-
eclampsia compared to normal pregnancy (111), however, IL-10 was increased in two 
further studies (120, 126). 
IL-10 affects the interaction between trophoblasts and endothelial cells during 
placentation of the placenta and undesirably regulates the levels of TNF-α and IL-6. 
Szarka et al, examined IL-10 levels in the third trimester in 60 women who developed 
pre-eclampsia and found a significant increase in levels compared to controls (126). 
Similarly, Silvia et al, found a significant increase in IL-10 levels in women in the 
third trimester who had pre-eclampsia (n= 40) compared with controls (n=36) (120).   
IL-6 is a multi-functional pro-inflammatory cytokine that is produced by the activated 
vascular endothelial cell and placenta (127) and it functions to control the immune 
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response and inflammation. IL-6 was seen to be increased in all studies examining 
levels in the third trimester of women with pre-eclampsia compared to healthy controls 
(118, 120, 121). 
 
Table 1.1: Inflammatory cytokines in pre-eclampsia 
 
Study Serum TNF-α IL-6 IL-1β IL-10 INF-ƴ 
Kumar et al. 
2013 x ↓   ↓ ↓ 
Roudsari et al. 
2009 x ─      
Founds et al. 
2008 x ↑      
Szarka et al. 
2010 x ↑ ↑  ↑   
Koçyıgıt et a. 
2004 x ↑ ↑ ↑    
Silva et al. 2013  ↑ ↑  ↑   
Xiao et al. 2012 x  ↑     
Hamai et al. 
1997  ↑      
Williams et al. 
1999  ↑      
Sibai et al. 2009 x ↑         
 
1.4.1 Neutrophils and pre-eclampsia 
 
Neutrophils have been viewed as short-lived effector cells of the innate immune 
system, where their primary role is in the clearance of extracellular pathogens. 
Neutrophils spontaneously or following appropriate stimulation, have been shown to 
produce many cytokines, chemokines and angiogenic factors. Neutrophils are also 
known mediators of the T helper 17 pathway of resistance to pathogens. 
Uncomplicated healthy pregnancy is characterised by the presence of neutrophils at 
the feto-maternal interface from the first trimester (124). 
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In pre-eclampsia, neutrophilia is further increased compared to uncomplicated 
pregnancy (128), and there is extensive evidence that neutrophils are activated in 
both the peripheral blood and decidua of pre-eclamptic patients (129, 130). 
Neutrophils have been strongly linked with vascular dysfunction in women with pre-
eclampsia, due to their ability to form neutrophil extracellular traps (NETs) and 
adhere to the endothelium in high concentrations (131). Neutrophil extracellular trap 
formation is triggered when mtDNA binds to receptors, including Toll-like receptor 
9 (TLR9) on the surface of the neutrophils. Increased NETs formation is seen in pre-
eclampsia and is proposed to significantly contribute to the underlying pathology of 
pre-eclampsia (132).   
1.4.2 TLR9 activation of the neutrophil mediated innate immune response 
 
Toll-like receptors (TLRs) are fundamental components of the innate immune 
system that recognise both microbial ligands and host products circulating during 
tissue damage. TLRs specifically bind to highly conserved protein sequences, also 
known as pathogen associated molecular patterns (PAMPs) (133). However, some 
TLRs bind to endogenous non-pathogen associated ligands, also known as damage-
associated molecular patterns (DAMPs). The activation of TLRs via PAMPs and/or 
DAMPs results in a pro-inflammatory innate immune response.  
Endogenous DAMPs are derived from many sources such as the endoplasmic 
reticulum, nucleus, plasma membrane, cytosol and mitochondria (134). 
Mitochondrial DAMPs (mtDAMPs) express two unique molecular signatures that 
are evolutionarily conserved from their bacterial origin, N-formyl peptides and 
mitochondrial DNA (mtDNA). Mitochondria evolved from saprophytic bacteria to 
become intracellular organelles, hence mtDNA is structurally similar to bacterial 
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DNA and share unmethylated CpG DNA repeats (135). Bacterial DNA is a known 
ligand of TLR9. Subsequently, the molecular motifs expressed by mtDNA also 
activate the TLR9 signalling pathway and induce an innate immune response (136). 
In normal pregnancy and pre-eclampsia, TLR9 is expressed in the vascular 
endothelium and trophoblasts. There is evidence of increased TLR9 expression in 
both placental tissue (137-140), and vascular endothelial cells in pre-eclampsia 
(141), implying that TLR9 signalling may be implicated in the development of 
placental dysfunction and the pathogenesis of pre-eclampsia.  
 




Calprotectin is a calcium and zinc-binding protein found in cells of myeloid origin, 
such as neutrophils and monocytes and plays a role in many physiologic functions 
including the neutrophil defence against bacterial infections. Calprotectin is also 
known as S100A8/S100A9 (142). This protein has been shown to be increased in 
patient plasma during bacterial infections (143). Calprotectin production is increased 
in cytotrophoblasts, placental-tissue macrophages, endothelial cells during the first 
and second trimester of pregnancy (144). Furthermore, there is a decrease in 
calprotectin expression in the placenta at the end of pregnancy. In pre-eclampsia, 
calprotectin concentrations are found to be 2-fold higher in maternal plasma when 






 Myeloperoxidase (MPO) is a lysosomal enzyme which is produced and released by 
activated neutrophils. MPO catalyses the formation of reactive oxygen intermediates 
such as hypochlorous, hypobromous and hypothioxyanous acids (145, 146). MPO 
has been found to be implicated in the pathogenesis of numerous inflammatory 
diseases such as kidney disease, rheumatoid arthritis and metabolic syndromes. 
Furthermore, this enzyme has been linked to vascular injury and is associated with 
the pathogenesis of cardiovascular disease, largely due to its oxidative and pro-
inflammatory properties (147, 148). MPO is associated with nitric oxide and its 
impairment of bioavailability (148, 149) causing nitration of protein tyrosines (150, 
151). Nitric oxide is known to be reduced in pre-eclampsia, this in turn gives rise to 
elevated blood pressure due to the imbalance between vasodilators and 
vasoconstrictor influences on the smooth muscle suggesting that MPO contributes to 
vascular dysfunction during acute inflammation by modulating endothelial NO 
bioavailability (152).   
MPO has been shown to accumulate on the surface of neutrophils in pregnant 
women, therefore enhancing the metabolic activity and oxidant production of 
neutrophils throughout pregnancy (153). Furthermore, MPO levels have been found 
to be increased in maternal circulation and placental tissue of women with pre-
eclampsia (154-156). However, other studies have failed to show this increased 
MPO levels in women with pre-eclampsia (157, 158). This may be due to sampling 
period during pregnancy, those with no evidence of increased MPO were sampled at 
20 weeks before the manifestation of pre-eclampsia, while those reporting increased 
MPO were taken in the third trimester.  
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1.4.3.3 Matrix Metalloproteinase-8 
 
Matrix Metalloproteinase (MMPs) consist of 23 zinc and calcium dependent 
proteases that cause degradation of different components of the extracellular matrix. 
The levels of MMPs are generally very low in normal adult tissues, however, their 
expression is increased in tissues with inflammation or undergoing active 
remodelling (159, 160). Increased expression and activity of MMPs are linked to 
pathological conditions such as chronic inflammation and cancer (161-163). MMPs 
participate in tissue turnover at the beginning of the pregnancy and are important for 
the cytotrophoblast invasion of uterine spiral arteries. MMPs also play a crucial role 
in the activation of labour at term (164, 165).  In recent years, MMPs have been an 
emerging area of interest in relation to the role they play in pre-eclampsia. MMP-8 is 
known as neutrophil collagenase or collagesase-2. Neutrophil collagenase was 
initially described in the 1990s when it was cloned from neutrophils taken from a 
patient with granulocytic leukaemia (166).  MMP-8 expression is inducible and 
upregulated by many inflammatory cytokines including TNF-α and IL-1β (167). 
Recent research shows strong evidence that MMP-8 plays an important role in 
mediating endothelial cell angiogenesis (168). Furthermore, endothelial dysfunction 
is a pathogenic characteristic of pre-eclampsia, dysregulated MMP8 expression may 
play a crucial role in the disruption of angiogenesis in pre-eclampsia leading to 






 Chemokines, a subset of cytokines, specific in their ability to attract and activate 
immune cells, may be particularly important mediators of pregnancy. IL-8 is a known 
pro-inflammatory chemokine and increased levels have been associated with 
pregnancy complications including  IUGR (169) and preterm delivery (170).  IL-8 is 
also a neutrophil chemoattractant and activator, is produced by many tissues such as 
the placenta (171, 172). The role of IL-8 is to promote movement of neutrophils across 
endothelial monolayers and towards the site of inflammation. Furthermore, IL-8 
regulates endothelial cell proliferation, angiogenesis, and tumour growth as well as 
participating in placental infection (173-175). In neutrophils, IL-8 triggers the 
secretion of superoxide anions and lysosomal enzymes which indirectly expand the 
permeability of blood vessels (176).  
Similarly, when compared with healthy uncomplicated pregnancies, the majority of 
studies report increased maternal serum and plasma levels of IL-8 in pregnancies 
complicated by pre-eclampsia (177, 178). A recent study reported a significant 
increase in IL-8 in early gestation (5-15 weeks’) in women who subsequently went on 
to develop pre-eclampsia. However, a limitation of their study was the small sample 
size (n=9) (179). Other studies investigating IL-8 throughout pregnancy reported no 
significant increase evident in the second trimester (180, 181) but a significant increase 
in IL-8 was evident in the third trimester in women with pre-eclampsia compared to 
healthy controls (182, 183) therefore supporting the role of IL-8 in mediating an 








Vitamin C and Vitamin E are exogenous antioxidants that down-regulate NADPH 
oxidase, a major source of ROS in the vasculature, while upregulating eNOS, leading 
to vasorelaxation and a reduction in blood pressure (56). The therapeutic potential of 
these particular antioxidants in the prevention of conditions associated with oxidative 
stress is supported by an extensive evidence base comprising of experimental studies 
(184), observational studies (185) and small clinical studies (186). However, in stark 
contrast, large scale appropriately powered randomised clinical trials (RCTs) of 
antioxidants as a treatment for pre-eclampsia have been disappointing. The VIP trial 
(Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia) was a RCT of 
vitamin C and vitamin E in 2410 women identified as being at an increased risk of 
pre-eclampsia (187). This study assigned women with 1000mg vitamin C and 400 IU 
vitamin E or matched placebo daily from the period of the second trimester of 
pregnancy until delivery. This trial concluded that supplementation with vitamin C 
and vitamin E did not prevent pre-eclampsia. However, a secondary outcome from 
this clinical trial showed that vitamin supplementation increased the rate of babies 
born with low birthweight (187).  
Another multicentre, randomised, double-blinded trial was carried out on 10,154 
nulliparous women looking at daily supplementation of 1000 mg of vitamin C and 400 
IU of vitamin E to prevent complications in pregnancy (188). The primary outcome 
for this clinical trial was to reduce severe pregnancy-associated hypertension or severe 
or mild hypertension with many clinical outcomes such as eclamptic seizures. 
Supplementation with vitamin C and E did not reduce the incidence of gestational 
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hypertension or pre-eclampsia in low risk nulliparous women (188). In comparison 
with the VIP trial, this study did not find significant differences between groups in the 
rates of low birth rate and stillbirth.  
The administration of Vitamins C and E for prevention of pre-eclampsia in women 
with type 1 diabetes (DAPIT) was a randomised placebo-controlled clinical trial in the 
UK and Northern Ireland running from 2003-2008 assessing vitamin  supplementation 
for the prevention of pre-eclampsia in women with type 1 diabetes (189). Women in 
this study were randomly allocated to receive 1000 mg of vitamin C and 400 IU 
vitamin E or matched placebo every-day from between 8 weeks’ gestation and 22 
weeks’ gestation until delivery. This study showed no significant differences between 
vitamin and the placebo groups for any of the maternal outcomes. However, plasma 
ascorbate concentrations for both vitamin-treated groups were significantly higher in 
comparison to the placebo group at 26 weeks’ gestation and 34 weeks’ gestation with 
a low antioxidant status at baseline (189). In summary, in contrast to a significant 
supportive pre-clinical research base, these large clinical trials suggest that vitamin 
antioxidant therapy is ineffective in the treatment of disorders such as pre-eclampsia. 
An explanation into why these antioxidants have been unsuccessful may be due to 
them being sequestered in the cytosol and not specifically reaching the mitochondria, 




1.5.1.2 Mitochondrial-Targeted antioxidants 
 
Currently, mitochondria are being recognised as key mediators in many unexpected 
areas of biomedical science. Mitochondria are the primary source of ROS, therefore, 
by directly targeting the mitochondria, it provides an opportunity to treat conditions 
precipitated by exaggerated oxidative stress. To date, two pharmacological strategies 
have been proven to be useful in targeting small molecule antioxidants to 
mitochondria; firstly, conjugation to lipophilic cations (190) or secondly 
incorporation into mitochondrial-targeted peptides (191). Lipophilic cations such as 
triphenylphosphonium (TPP) derivatives are rapidly and extensively taken up by  
mitochondria (192). This is due to the mitochondria being negatively charged, 
therefore using a positively charged lipophilic cations permits direct targeting of the 
mitochondrial.  To date, mitochondrial targeted antioxidants have been examined for 
the use of many mitochondrial diseases. In particular, research carried out by Stealth 
Therapeutics using elamipretide, a peptide compound that readily penetrates cell 
membranes, and targets the inner mitochondrial membrane where it binds reversibly 
to cardiolipin (193). This peptide increases mitochondrial respiration, improves 
electron transport chain function, ATP production and reduces formation of 
pathogenic ROS levels (193-195).   
The most studied mitochondrial-targeted antioxidant has been the TTP-modified 
ubiquinone MitoQ, which has shown efficacy in a number of animal models and also 
in human studies (196). This compound is largely absorbed by the mitochondrial 
matrix facing surface of the inner membrane, therefore protecting the components 
involved in oxidative phosphorylation (197). The first study to look at the protective 
effects of MitoQ in a rat model of cardiac ischemia/reperfusion (I/R) injury (198). In 
this study MitoQ was protective against heart dysfunction, tissue damage as well as 
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mitochondrial function. Another study examined the effects of MitoQ on blood 
pressure in spontaneously hypertensive rats and showed a reduction in blood 
pressure (199). The research carried out in animal studied highlighted MitoQ as an 
attractive therapeutic intervention in human diseases. Phase 1 trials of MitoQ showed 
good pharmacokinetic behaviour with oral dosing at 80mg (1mg/Kg) (196). MitoQ 
was administered to patients with Parkinson’s disease in the PROTECT study, a 
double blinded placebo-controlled study ran over 12 months. 128 newly diagnosed 
untreated patients with Parkinson’s disease were enrolled into the study. This study 
showed that treatment with MitoQ did not slow down the progress of Parkinson’s 
disease (200).  
Similarly, MitoQ was used for the treatment of chronic Hepatitis C in the CLEAR 
study (201). This study was a phase II study carried out due to evidence of the 
pathological role of increasing oxidative stress and subsequent mitochondrial 
damage in liver damage. The participants received either 40 mg or 80 mg or placebo 
for 28 days. This study reported that MitoQ significantly decreased plasma alanine 
transaminase and aspartate aminotransferase in patients with chronic HCV infection 
suggesting that MitoQ can reduce liver damage in hepatitis C viral infection. 
Therefore, mitochondrial targeted antioxidants have shown to have the potential to 
decrease mitochondrial oxidative damage in a range of diseases as well as being safe 




MitoTempo is a mitochondrial targeted superoxide dismutase antioxidant mimetic. 
MitoTempo has the ability to pass through lipid bilayers easily and accumulate 
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selectively in mitochondria (202). MitoTempo combines the antioxidant piperidine 
nitroxide (Tempo) with the lipophilic cation triphenylphosphonium (TPP) for 
mitochondria targeting (203).  Recent work has established that MitoTempo 
accumulates in the mitochondria by increasing superoxide dismutation and without 
affecting cytoplasmic dismutation in endothelial cells (108). This study provided 
evidence that scavenging of mitochondrial O2
- improves endothelial function and 
reduces hypertension. They showed that treatment with MitoTempo in two murine 
models of hypertension reduced blood pressure and substantially improved 
endothelium-dependent vasodilation. In comparison, MitoTempo had no effect on 
blood pressure in normotensive animals.  
In recent years, research using the SCOPE (Screening for Pregnancy Endpoints) 
study, showed that deleterious plasma mediators present in pre-eclampsia, generate 
increased mitochondrial-specific superoxide production in HUVEC cells (109). 
Additionally, this increase in mROS production was shown to provoke vascular 
dysfunction and inflammation. The authors expanded this study and reported that 
pre-treatment with MitoTempo prevented the observed increase in mROS production 
following plasma incubation.   
Recently a study by Vaka et al examined MitoTempo as a treatment for pre-
eclampsia using the RUPP model (204). This study established that treatment with 
MitoTempo attenuated elevated blood pressure in the RUPP rats, in addition to 
improving fetal outcomes. Furthermore, placental complex activities, expressions 
and respiration rates were significantly reduced and mROS was increased in RUPP 






Ergothioneine (ERG) is a dietary water-soluble amino acid which is derived from 
histidine and was discovered in 1909 by Charles Tanret (Figure 1.6). In humans, 
ERG has been shown accumulate in many cells and tissues in high concentrations, 
such as erythrocytes, liver, kidney, bone marrow and seminal fluid (205-207). There 
have been many physiological roles of ERG proposed such as a direct antioxidant 







Figure 1.6: Chemical structure of Ergothioneine. It exists predominately in the 
thione (left hand side) form as opposed to the thiol (right hand side) form, ensuring 
its resistance to autoxidation.  
ERG crosses the intestinal epithelium through the organic cation transporter novel 
type 1 (OCTN1), which is currently known as solute carrier family 22, number 4 
(SLC22A4) (214). Organic cation transporters function primarily in the elimination 
of drugs in tissues such as kidney, intestine, liver and placenta by mechanisms 
dependent on or independent of sodium-gradient, pH or membrane potential (215).  
Previously, SLC22A4 had been considered to be a carnitine transporter, however 




(216). Using untargeted metabolomics, this group found when comparing HEK 293 
cells with or without extra clones SLC224A, ERG was transported 100 times quicker 
than carnitine. The localisation of ERG is somewhat less clear, however, many 
papers have focused on its mitochondrial accumulation and localisation (217, 218).  
There is strong evidence to support an antioxidant role for ERG, with numerous in 
vitro studies highlighting its ROS scavenging capacity (210, 211, 219-222). To date, 
research has shown that a reduction in ERG concentration in HeLa cells’ resulted in 
a significant increase in the oxidative burden on mitochondrial mechanism's (223). 
However, even though the antioxidant role of ERG has been well established in 
vitro, this is a paucity of in vivo studies. There is some evidence in vivo to suggest 
that ERG acts as an antioxidant in animal models of lung injury (224) and 
ischaemia/reperfusion injury (225). To date, the role of ERG has been examined in 
chronic inflammatory diseases (226, 227) highlighting the association between 
SLC22A4 and Crohn’s disease, neurodegeneration (228) where ERG has been 
shown to be decreased in patients with Parkinson disease  and cardiovascular disease 
(229, 230) by protecting against endothelial dysfunction in human brain 
microvascular endothelial cells (HBMEC’s). To date, studies have investigated the 
reproductive safety in Sprague Dawley rats, and have found no adverse effects (231). 
Similarly, supplementation of ERG to diabetic pregnant rats for the first 11.5 days of 
gestation, decreased the embryo malformations in comparison to non-diabetic 
controls (229).  
Currently, only one study has investigated the pharmacokinetics of ERG 
administration in humans (232). This study administered 5mg or 25mg dose of ERG 
to healthy human subjects every morning for one week. Plasma ERG was ardently 
absorbed and retained by the body with significant elevations in plasma and whole 
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blood concentrations, and relatively low urinary excretion.  There were no reported 
adverse effects from the administration of ERG in humans. Following ERG 
administration, decreasing trends in biomarkers of oxidative damage and 
inflammation were evident. In addition, no changes were observed in liver and 
kidney function tests and lipid profiles from administration of ERG demonstrating its 
safety (232).  ERG has received GRAS (generally regarded as safe) status, received 
EC authorisation and was launched to market as a dietary supplement in 2016.  
There are a number of studies which administered high-doses of ERG and have  
indicated that ERG is safe for mammalian consumption at levels far in excess of 
those likely to be encountered in foodstuffs (232-235). It also lacks any detectable 
mutagenicity or genotoxicity in such assays, even at very high doses. ERG has been 
declared safe by relevant Committees such as the European Food Standards Agency 
(236, 237).  
The evidence from current studies investigating the uptake and retention of ERG 
imply that this amino acid has an important physiological role but potentially only 
under the conditions of oxidative stress. The potential of ERG to accumulate in high 
oxidative stress organs makes this a promising target for a viable therapy for pre-
eclampsia (211). In pre-eclampsia, data suggests that erythrocyte ERG levels are 
increased (238). This could be due to increased SLC224A expression in response to 
inflammatory cytokines seen in pre-eclampsia (209). Despite the rarity of a defined 
role for ERG in mediation of mitochondrial metabolism, the strong antioxidant 
effects and its localisation to mitochondria suggest that ERG should have a 




1.6 Animal models of pre-eclampsia 
 
Our understanding of the pathophysiology of pre-eclampsia has greatly improved in 
the last two decades. Despite this, development of interventions to prevent pre-
eclampsia are severely lacking. Therefore, to improve both our understanding of the 
disorder and the development of new therapeutic strategies, well-validated animal 
models of pre-eclampsia are required. The benefit of performing these in vivo studies 
is that they allow an insight into complex interactions that underlie pre-eclampsia 
that in vitro experimentation, while valuable, are limited due to the heterogeneous 
nature of the condition. Currently, there are no in vitro systems available, which 
mimic human pre-eclampsia. Indeed even isolation of cells involved in pre-
eclampsia doesn’t reflect the pathogenesis of the disease, as central to the 
progression of the disease is cell-cell interactions and cell signalling (239). Animal 
models of pre-eclampsia have facilitated the examination of many of the 
pathophysiological mechanisms that underlie the development of pre-eclampsia.  
Pre-eclampsia is thought to originate spontaneously in women, subsequently animal 
models of pre-eclampsia have obvious limitations. Many animal models have been 
recommended based on the apparent causes and mediators of pre-eclampsia. These 
models include the placental ischaemia model (reduced uterine perfusion pressure 
model) (240, 241), nitric oxide abnormalities (Nitric oxide synthase knockout mice) 
(242), impaired angiogenesis (sFlt-1 infusion models) (243) and renin angiotensin 
abnormalities (transgenic models) (244). An ideal model of pre-eclampsia would 
display all the phenotypic characterisations seen in women such as hypertension, 
proteinuria, endothelial dysfunction, and an imbalance of angiogenic factors, 
therefore this makes in vivo models very hard to replicate. The most closely related 
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phenotype to that of human pre-eclampsia that can be replicated, is the reduced 






1.6.1 Reduced uterine perfusion pressure (RUPP) model 
 
The Reduce Uterine Perfusion Pressure (RUPP) model is one of the most published 
models for studying pre-eclampsia. This model has been examined in many animals 
including dogs (245, 246), sheep (247, 248), rabbits (241), primates (249, 250) and 
rats (251-253). The most well recognised and characterised RUPP model is in the 
rat. The RUPP model of pre-eclampsia was adapted by Crews and colleagues (254), 
in relation to the gestation time and the clips size and position. On gestational day 
14, pregnant rats undergo surgery, which entails the clipping of aorta above the iliac 
bifurcation (Figure 1.7) One surgical clip is placed on both the left and right ovarian 






















Figure 1.7: Induction of reduced uterine perfusion pressure (RUPP) model in 
pregnant rats. In the rat RUPP model, on day 14 of gestation, a silver clip with a 
0.203-mm internal diameter is placed around the aorta right above the iliac 
bifurcation, and silver clips with 0.1 mm internal diameter were placed around the 
left and right uterine arcade at the ovarian artery. 
The RUPP rat model has the closest phenotype to that evident in women with pre-
eclampsia as it possesses a number of physiological features of pre-eclampsia 
including hypertension (20-30 mmHg increase in mean arterial blood pressure) and 
proteinuria (255). Furthermore, IUGR also occurs in the pups in this model 
illustrating a decrease in litter size and pup weight (253, 256). Inflammatory 
cytokines TNF-α and IL-6 are increased in the RUPP model, similar to women who 
develop pre-eclampsia (257). Anti-angiogenic factors including sFlt and sEng are 
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important in the development of pre-eclampsia in women. Similarly, the RUPP 
model also displays an increase in plasma and placental sFlt and a decrease in PlGF 
and VEGF (258). The RUPP model also mimics endothelial dysfunction as evident 
in pre-eclampsia (254). Evidence has shown impaired vasorelaxation in resistance 
vessels from RUPP compared with control rats (259). Similarly, plasma from RUPP 
rats reduced the vasorelaxant response in normal pregnant rats. Therefore, the 
RUPP-rat model has numerous features of pre-eclampsia evident in women and 
provides a distinguished model for the investigation of novel therapeutic targets for 
the treatment of pre-eclampsia. 
1.6.2 Challenges of Clinical Trials in pregnancy  
 
The uniquely vulnerable nature of the pregnant and new-born population poses 
significant logistical, ethical, and regulatory challenges, which have limited the 
discovery of biomarkers and other predictors for adverse outcomes and the 
development of diagnostics and therapeutics in general. To date, there are limited 
number of clinical trials and human studies carried out in regard to pregnancy. 
Thalidomide was used to treat morning sickness and could be bought over the 
counter. Pregnant woman who took thalidomide as a treatment for morning sickness 
had a detrimental effect on the unborn fetus, which resulted in malformation of the 
limbs. Other defects included malformed eyes and hearts, deformed gastrointestinal 
and urinary tracts, blindness and deafness.  
In more recent years, there was a multisite clinical trial using sildenafil as a potential 
treatment for IUGR (261). In this instance, extensive research was carried out in 
many in vivo models which  had shown promising data for the potential of this drug 
to treat IUGR (262-265). Sildenafil, a phosphodiesterase type 5 inhibitor, potentiates 
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the actions of nitric oxide, which leads to vasodilatation of the uterine vessels and 
might improve fetal growth in utero. However, in this clinical trial, the Dutch site 
reported the Sildenafil intervention resulted in 11 infant deaths due to lung related 
problems. Therefore, this study was terminated.  
Another clinical trial was carried out recently in regards to the use of statins for the 
treatment of pre-eclampsia, the StAMP trial. This clinical trial was carried out in 
women diagnosed with pre-eclampsia according to the ISSHP guidelines with a 
singleton pregnancy. Women were given 40mg pravastatin or an identical placebo, 
once per day until their baby was born. (ref)  
While pre-clinical data from both animal models and in vitro experimentation were 
deemed successful to proceed humans, unfortunately there were still adverse effects 
seen in both StAMP or Sildenafil trial. Nonetheless, currently there is no treatment 
for pre-eclampsia and this thesis work will aim to address the indisputable need for 





1.7 Summary  
 
Pre-eclampsia is a complex multisystem vascular syndrome characterised by the 
onset of hypertension on or after 20 weeks’ gestation. It affects 5% of first-time 
mothers and globally this disorder causes around 70,000 maternal deaths annually. 
As described throughout this introduction, pre-eclampsia is thought to result from 
inadequate invasion of the spiral arteries, resulting in deterioration of the 
uteroplacental perfusion. This therefore leads to intermittent fluctuations in oxygen 
delivery and exposes the placenta to oxidative stress (266). In pre-eclampsia, the 
properties regulating the placental oxidative state are aggravated, causing an increase 
in production of deleterious inflammatory factors and in turn, vascular dysfunction. 
The mitochondria are regulators of cell death and are the main cellular source of 
ROS. As previously described, excessive mROS is liked to mitochondrial 
dysfunction (136, 267). Research has described a positive association of mtDNA in 
maternal circulation with the risk of pre-eclampsia (268). Further to this, research 
has shown that the mitochondria may provide a possible trigger to activating the 
innate immune system (269). Previous work from our lab has hypothesised that 
mtDNA may act as DAMP’s and instigate an innate immune response by binding to 
TLR9 (109, 270). As previously mentioned, there is substantial evidence indicating a 
potential role for dysregulation of mitochondrial function in mediating the clinical 
characteristics of pre-eclampsia (268, 271, 272). Currently there is no treatment for 
pre-eclampsia except delivery of the placenta and the baby, with the resultant risk of 
iatrogenic prematurity and significant neonatal morbidity and mortality. As a result, 
intensive research endeavours have focused on defining the molecular mechanisms 
of pre-eclampsia and thereby expediting identification of new therapeutic targets for 
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this condition. In pregnancies affected by pre-eclampsia there is an exaggerated 
oxidative stress phenotype with a correspondent deficient antioxidant response. The 
therapeutic potential of vitamin antioxidants in the prevention of pre-eclampsia was 
supported by extensive research, however, ultimately, they were unsuccessful in 
clinical trials. In more recent years, mROS has been identified as playing a 
prominent role in modulating hypertension (108). This highlights the need for a 
specific targeted approach to oxidative stress in pre-eclampsia. L-Ergothioneine as 
previously described, is a water-soluble amino acid is currently FDA approved, 




1.8 Hypothesis  
 
Targeting mROS and oxidative stress seen in pre-eclampsia with a specific 
mitochondrial targeted antioxidant will alleviate pre-eclampsia phenotype. 
 
1.9 Objectives  
 
1. To characterise the role of mitochondrial dysfunction in women with pre-
eclampsia compared to uncomplicated pregnancies.  
 
2. To delineate the role of mitochondrial dysfunction in provoking a neutrophil-
mediated immune response in pre-eclampsia. 
 
3. To examine the mechanistic role of mitochondrial targeted antioxidant L-
ergothioneine in modulating mitochondrial function in an in vitro model of 
placental oxidative stress and its role as a therapeutic target of pre-eclampsia. 
 
4. To analyse the therapeutic potential of mitochondrial targeted antioxidant L-
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2.0 Chapter 2: Exploring the role of mitochondrial 
dysfunction in the pathophysiology of pre-eclampsia. 
 
2.1 Abstract  
 
Background: Uncomplicated pregnancy is associated with an increase in oxidative 
stress; however, in pregnancies affected by pre-eclampsia there is an exaggerated 
oxidative stress phenotype with a correspondent deficient antioxidant response. 
There is circumstantial evidence linking mitochondrial dysfunction as a source of 
oxidative stress in pre-eclampsia.  
Objectives: This study aimed to investigate if mitochondrial dysfunction was 
evident in pre-eclampsia by measuring superoxide dismutase activity and 
mitochondrial DNA in maternal blood. This study also investigated if lifestyle and 
dietary factors impact mitochondrial function and alter the risk of pre-eclampsia. 
Study Design: A nested case-control study was performed within the SCOPE 
Ireland study. Plasma samples were taken at 15 and 20 weeks’ gestation from 
women who subsequently developed pre-eclampsia (n=60) and matched with 
controls (n=120). SOD activity was determined using a superoxide dismutase assay 
kit. mtDNA was measured by absolute quantification using real-time PCR. 
Statistical analysis was performed using GraphPad Prism and SPSS version 22. 
Results: There was significant reduction in antioxidant SOD activity at 15 weeks’ 
gestation 1.69 ng/ml ± 0.06 vs 1.94 ng/ml ± 0.06; p< 0.01) and an increase in the 
mean difference in mtDNA [2236 ± 796.0 copies/ml vs -555.3 ± 599.3 copies/ml; 
p<0.0065] (between 15 and 20 weeks’ gestation) in cases compared to controls. 
Lifestyle or dietary factors had no effect on mitochondrial function.  
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Conclusion: This study confirms a pathogenic role for mitochondrial dysfunction in 
the pathophysiology of pre-eclampsia. Further research is required in larger diverse 
populations to explore targeting mitochondrial dysfunction as a potential therapeutic 




2.2 Introduction  
 
Pre-eclampsia is a pregnancy disease that complicates 2-5% of pregnancies 
worldwide (273). It is characterised by the development of hypertension and 
proteinuria after 20 weeks’ gestation (273). Pre-eclampsia is thought to occur 
secondary to abnormal placentation in early pregnancy (274) resulting from impaired 
placental trophoblast invasion and subsequent generation of an ischemic 
environment (266). Placental ischemia is proposed to increase placental oxidative 
stress leading to the shedding of syncytiotrophoblast debris into the maternal 
circulation where it initiates a systemic maternal inflammatory response and 
subsequent endothelial dysfunction (275).  
Oxidative stress is a physiological condition of elevated levels of reactive oxygen 
species (ROS) which damage cell structure and function. Antioxidant enzymes 
including superoxide dismutase (SOD) and glutathione peroxidase are components 
of the body’s mechanism for combating oxidative stress. SOD is a powerful 
antioxidant that catalyses the reaction between two identical molecules of superoxide 
radical into oxygen or hydrogen peroxide. There is significant evidence that 
oxidative stress plays a role in the pathophysiology of pre-eclampsia (276, 277). 
Normal pregnancy is associated with an increase in oxidative stress due to a rise in 
maternal metabolism and maternal blood flow in the placenta by 10–12 weeks’ 
gestation (57). However, in pregnancies complicated by pre-eclampsia there is an 
exaggerated oxidative stress phenotype with a correspondent deficient antioxidant 
response.  
Mitochondria are the dominant cellular source of ROS and there is strong evidence 
that mitochondrial ROS (mROS) play an important role in a variety of physiological 
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processes including the regulation of cell differentiation, apoptosis, redox cell 
signalling and inflammation (270, 278, 279). Furthermore, our research has 
implicated mitochondrial dysfunction as a potential mediator of oxidative stress in 
pre-eclampsia (279). Cell-free DNA (cf-DNA) has been investigated as a universal 
diagnostic biomarker for a number of clinical applications, such as prenatal diagnosis 
and cancer monitoring (280, 281). Circulating cell free DNA is composed of both 
nuclear and mitochondrial DNA.  
 
Mitochondrial DNA (mtDNA) encodes for 37 genes programmed by the 
mitochondrial genome (78) and is often used as a biomarker of mitochondrial 
dysfunction. mtDNA are particularly vulnerable to oxidative damage due to its 
intimate location in  the electron transport chain (ETC) in the mitochondrial matrix 
and its lack of protective histones (282). More recently, there is emerging evidence 
suggesting that cell-free mtDNA (cf-mtDNA) is linked to disease progression such 
as cardiovascular disease (283). Circulating DNA in maternal plasma is mostly of 
maternal origin (hematopoietic and stromal derived) depending on gestational week 
and maternal bodyweight. Approximately 5-20% of the circulating DNA is derived 
from fetal/placental cells (284).  
 
Our research has previously shown an increase in mtDNA in plasma samples at time 
of disease (TOD) in women with pre-eclampsia (109). Hence the aim of this study 
was to characterise the role of mitochondrial dysfunction in women with pre-
eclampsia compared to uncomplicated pregnancies by assessing levels of antioxidant 
enzyme superoxide dismutase and mtDNA at earlier time-points in pregnancy. We 
also examined if lifestyle and dietary factors affected mtDNA levels in pregnancy. 
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2.3.1 Study subjects 
 
Subjects were recruited from the SCOPE study Ireland which is an international 
multicentre prospective cohort study of nulliparous singleton pregnancies aimed to 
develop a screening test to predict adverse pregnancy outcomes including pre-
eclampsia, SGA infants and spontaneous pre-term birth (285, 286). The Clinical 
Research Ethics Committee, University College Cork, approved the collection and 
use of samples for research purposes. A nested case-control study within SCOPE 
Ireland was conducted which included all pre-eclampsia cases in SCOPE Ireland and 
matched controls with a case-to-control ratio of 1:2.  
Pre-eclampsia cases were defined as women with systolic blood pressure ≥ 140mm 
Hg and/or diastolic blood pressure ≥ 90 mm Hg on at least two occasions 4 hrs apart 
after 20 weeks’ gestation and with proteinuria (24 hour urinary protein ≥ 300mg or 
urine dipstick protein ≥ +2). Randomly selected controls were taken from healthy 
pregnant women who had uncomplicated pregnancies which were defined as 
pregnancies not affected by pre-eclampsia, preterm birth or growth restriction and 
delivered at >37 weeks. All blood pressure readings were <140 and/or <90 mmHg 
prior to the onset of labour. These were matched with the cases for maternal age, 
body mass index (BMI) and gestational age.  Both 15 and 20 week samples were 
taken from the SCOPE study from women who subsequently went onto develop pre-
eclampsia (n=60) and controls (n=120). Samples were also taken from a subset of 





2.3.2 Superoxide Dismutase enzyme activity  
 
Superoxide dismutase activity was quantified in citrate plasma samples using a 
superoxide dismutase assay kit (Cayman Chemical) which was used as per 
manufacturer’s instructions. This assay utilizes tetrazolium salt for detection of 
superoxide radicals generated by xanthine oxidase and hypoxanthine. This assay 
measures a combination of activity from all three isoforms. 
2.3.3 Sample collection and DNA extractions 
 
Plasma samples were collected in BD Heparin Vacutainer tubes, placed on ice, and 
centrifuged at 2,400g for 10 minutes at 4˚C according to the standardised protocol. 
Plasma samples were stored at -80˚C until analysis. Samples were analysed in a 
blinded manner. Total DNA was extracted from 200µl of plasma from both controls 
and cases respectively with a QIAamp DNA mini kit (Qiagen). DNA was sonicated 
at 38 kHz ± 10% for 10 minutes to optimise DNA yield. 
2.3.4 mtDNA quantification 
 
Mitochondrial DNA was measured by real-time PCR using StepOne Plus Detection 
system using Taqman assays for mitochondrial DNA (hMitoF5, hMitoR5) (287). 
Absolute quantification of the concentration of mitochondrial DNA (mtDNA) was 
determined by standard curve analysis and presented as copies/ml (287, 288). 
2.3.5 Maternal lifestyle factors 
 
Women were asked at recruitment (15 ± 1 weeks of gestation) and at their second 
visit (20 ± 1 weeks of gestation) how many times each week did they carry out 
exercise that did not result in heavy breathing, which was the SCOPE definition of 
moderate-intensity exercise. The response was categorised as never, 1-3 times a 
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week and daily. Similarly, the questionnaire which was completes at both time 
points asked women to report the frequency in which the consumed fruit and leafy 
vegetables. Scoring was similar to exercise, where the response was categorised as 
never, less than five pieces a week, and daily. Multivitamins intake were categorised 
into never, less than daily and daily.  
2.3.6 Statistical analysis  
 
Analysis was performed using GraphPad Prism and SPSS version 22 (SPSS Inc. 
Chicago, Illinois). Data were presented using median (±Interquartile range [IQR]) 
and comparisons of data between cases and controls were performed using a non-
parametric Mann Whitney U test or Wilcoxon signed rank test as appropriate when 
data was not normally distributed. Data that was normally distributed were 
represented as mean (±SEM) and comparisons of data between cases and controls 
were performed using an unpaired t-test. P values <0.05 were considered as 
statistically significant. Chi-squared test and the odds ratio (OR) was used to 






2.4.1 Patient Characteristics 
 
There were 1,774 participants in the SCOPE Ireland study. 68 (3.8%) women were 
diagnosed with pre-eclampsia and 60 were included in the nested case-control study 
with 120 participants selected as controls. The 60 women with pre-eclampsia were 
composed of 39 women who developed term pre-eclampsia and 21 preterm pre-
eclampsia cases. As all cases and controls were matched nulliparous women, there 
was no significant differences observed between case-controls studies for maternal 
age, BMI, and gestational age at delivery. There was a significant difference in mean 
arterial blood pressure (MAP) in controls versus cases at both 15 and 20 weeks’ 
gestation respectively (median [IQR]; 78.0 mmHg [73.33-83.33], n=120, vs median 
[IQR]; 82.0 mmHg [75.0- 87.66], n=60, p= 0.0015 and media [IQR] 80.41 mmHg 
[75.3333- 85.0], n=120, vs median [IQR]; 83.5 mmHg [77.5- 89.83] n=60, p= 0.02). 
There was a significant difference in birthweight in controls compared to cases 














Mean Maternal age, 
years 31 29 29 
Mean BMI 25 26 25 
    
Maternal    
Mean Arterial Blood 







    
Mean Arterial Blood 







    
Fetal     
Mean Birth weight, g 2104 3300 3608 
Mean gestational age at 
delivery (weeks) 34 38 40 
Perinatal death 1 1 0 
 
Data are presented as mean or Median [IQR]. Mean Arterial blood pressure was calculated 
as MAP = (2 x diastolic) + systolic/3 and 
 
2.4.2 Evidence of altered plasma SOD activity before pre-eclampsia 
 
There was a statistically significant reduction in antioxidant SOD activity at 15 
weeks’ gestation between controls and cases (1.94 ng/ml ± 0.06 vs 1.69 ng/ml ± 
0.06; n=60, n=119; p< 0.01; 95% CI; 0.04 to 0.45; Figure 2.1A). There was no 
significant difference in SOD activity at 20 weeks’ gestation between controls and 
cases, (0.82 ng/ml ± 0.02 vs 0.77 ng/ml ± 0.03; n=119 p=0.21; 95% CI; -0.02 to 











Figure 2.1: A) SOD activity (U/ml) was significantly reduced at 15 weeks in cases compared to healthy controls (P<0.01). B) SOD 
activity (U/ml) at 20 weeks was reduced in cases compared to healthy controls. Data are expressed as mean ± SEM. 
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2.4.3 Increased ΔmtDNA levels was evident between 15 and 20 weeks’ gestation 
before the onset of clinical symptoms of pre-eclampsia 
 
There was no significant difference in the amount of total DNA between controls 
and cases at both 15 and 20 weeks’ gestation (15 weeks: 7.06 ng/ml ± 4.08 vs 7.70 
ng/ml ± 5.43, n =60 n=120, p=0.38; 20 weeks 6.71 ± 3.26 vs 7.15 ± 3.44, n= 60 
n=120, p=0.40; Figure 2.2A). There was no significant difference in mtDNA at 15 
weeks’ gestation between controls and cases (median [IQR]: 2832.96 copies/ml 
[1711.17-5002.82] vs 2337.32 copies/ml [1357.11-5328.35], n=58-117; p< 0.3381, 
Figure 2.2B). Similarly, there was no significant difference in mtDNA at 20 weeks’ 
gestation between controls and cases and (median [IQR]:  2885.57 copies/ml 
[1914.54-4834.12] vs 3307.7 copies/ml [1544.49-7396.92], n=58-117; p<0.7873, 
Figure 2.2C). As pregnancy progressed the amount of mtDNA significantly 
increased in cases and controls (median [IQR]: 2337.32 copies/ml [1357.11-
5328.35], 3307.7 copies/ml [1544.49-7396.92] and 6449.8 copies/ml [477.54-
11145.9] n=58 and n=22.p< 0.0001, and median [IQR]: 2855.41 copies/ml [1740.19-
5322.08], 2900.95 copies/ml [1958.36-5055.16], 5983.88 copies/ml [3209.67-
16901.5] n-117 and n=23. P=0.009, Figure 2.2D) at 15 weeks’, 20 weeks’ and TOD 
respectively. 
However, the mean difference in mtDNA (ΔmtDNA, difference in mtDNA copy 
number between 20 weeks and 15 weeks) was calculated for each individual patient 
in both cases and controls. The mean difference in mtDNA between 20 weeks and 15 
weeks gestation was then calculated for control group and case group. These values 
were then compared between cases and controls and found that there was 
significantly higher ΔmtDNA in cases compared with controls between 15 weeks’ 
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and 20 weeks’ gestation (2236 ± 796.0 copies/ml vs -555.3 ± 599.3 copies/ml 





































































































































Figure 2.2: A) Total DNA in maternal plasma in controls and cases showed no significant difference. B) mtDNA at 15 weeks showed 
no significant difference in controls when compared to cases C) mtDNA at 20 weeks was higher in controls compared to cases but not 
statistically significant D) Mitochondrial dysfunction is significantly increased as gestation progresses in pre-eclampsia and 
uncomplicated pregnancies (p<0.001 and p=0.0009) respectively ●=cases, ■=control. Data represented as the median; [IQR]. E) 
Significant increase in the mean difference in mtDNA concentration between 15 and 20 weeks’ gestation in cases compared to controls 




2.4.4 Lifestyle and nutritional factors; effect of these factors on mtDNA  
 
Moderate exercise had no significant impact on the amount of mtDNA in controls 
compared with cases at 15 or 20 weeks’ gestation OR 1.00; [CI 1.00-1.00 vs 1.00 CI 
[1.00-1.00] respectively (Table 2.2A). Similarly, when assessing dietary factors such 
as leafy vegetable intake, fruit intake and multivitamin consumption, there was no 
effect on the amount of mtDNA at 15 or 20 weeks’ gestation in controls compared 
with cases (Table 2.3A, 3B, 3C).  
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Table 2.2: The effect of lifestyle factors (Exercise) on mtDNA in cases compared to controls at 15 and 20 weeks’ gestation  
Moderate exercise activity  N=58 Case (mtDNA copy 
number/ml) 
N=117 Control (mtDNA (copy 
number/ml 
OR  (95% 
CI) 
Never exercised (15 weeks’ gestation) 19 1631.02 (815.92-3445.15) 23 2817.51 (1856.43-5602.91) 1.00 1.00-
1.00 
More than Once a week (15 weeks’ 
gestation) 
31 2742.43 (1510.48-5328.35) 60 2676.89 (1669.87-3734.28)   
Daily (15 weeks’ gestation) 8 3928.08 (934.06-11509.39) 34 3070.21 (1912.75-5322.08)   
Never exercised (20 weeks’ gestation) 12 3242 (1367.75-9276.86) 20 2649.15 (1849.56-4454.55) 1.00 1.00-
1.00 
More than once a week (20 weeks’ 
gestation) 
37 3249.79 (1493.10-7562.22) 67 2847.66 (1758.46-4248.59)   
Daily (20 weeks’ gestation) 9 4198.29 (1632.68-5398.94) 30 2790.07 (1998.00-5385.22)   
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Table 2.3 (A): The effect of dietary factors (Fruit intake) on mtDNA in cases compared to controls at 15 and 20 weeks’ gestation 
High fruit intake   N=58 Case (mtDNA copy 
number/ml) 
N=117 Control (mtDNA copy 
number/ml) 
OR  (95% 
CI) 
Never (15 weeks’ gestation) 7 2158.15 (1357.11-3119.63) 9 1856.43 (617.47-9759.18) 1.00 1.00-
1.00 
<6 times a week (15 weeks’ 
gestation) 
11 3445.15 (1140.94-6661.19) 25 2617.49 (1683.27-4005.63)   
>5 a day (15 weeks’ gestation) 40 2466.71 (1339.17-4526.35) 83 2829.32 (1868.68-4786.10)   
Never (20 weeks’ gestation) 0  1 6802.61 1.00 1.00-
1.00 
<6 times a week (20 weeks’ 
gestation) 
6 2650.57 (1063.15-6136.60) 16 2384.71 (1471.25-5954.11)   
>5 a day (20 weeks’ gestation) 52 3344.25 (1548.32-7395.89) 108 2856.83 (1980.26-4711.28)   
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Table 2.3 (B): The effect of dietary factors (leafy vegetable intake) on mtDNA in cases compared to controls at 15 and 20 weeks’ 
gestation 
Leafy vegetable intake  N=58 Case (mtDNA copy 
number/ml) 
N=117 Control (mtDNA (copy 
number/ml 
OR  (95% 
CI) 
Never (15 weeks’ gestation) 22 2064.62 (1443.17-5873.68) 49 2862.43 (1964.75-5110.42) 1.00 1.00-
1.00 
<6 times a week (15 weeks’ 
gestation) 
27 2133.39 (1140.94-4068.91) 42 2547.10 (1644.76-4838.29)   
>5 a day (15 weeks’ gestation) 9 3119.63 (1677.58-5812.97) 26 2676.89 (1184.76-3950.15)   
Never (20 weeks’ gestation) 1 4198.29 (4198.29-4198.29) 3 1846.20 (1108.22-) 1.00 1.00-
1.00 
<6 times a week (20 weeks’ 
gestation) 
23 3104.99 (1366.01-7396.91) 46 2596.07 (1636.75-4126.70)   
>5 a day (20 weeks’ gestation) 34 3315.32 (1518.79-6499.72) 68 3067.12 (2151.85-5347.62)   
94 
 
Table 2.3 (C): The effect of dietary factors (Multivitamin intake) on mtDNA in cases compared to controls at 15 and 20 weeks’ 
gestation 
 
Multivitamin intake N=58 Case (mtDNA copy 
number/ml) 





No (15 weeks’ gestation) 44 2206.55 (1186.20-4709.44) 71 2617.49 (1856.43-4778.04) 1.00 1-1.00 
Daily (15 weeks’ gestation) 14 2745.61 (1504.21-6598.51) 39 2850.34 (1626.85-5111.71)   
Less than daily (15 weeks’ 
gestation) 
0  7 3518.35 (1856.43-4315.26)   
No (20 weeks’ gestation) 38 4032.60 (1744.82-7789.96) 57 2777.50 (1769.47-5184.31) 1.00 1-1.00 
Less than daily (20 weeks’ 
gestation) 
4 1374.57 (332.18-5948.15) 15 3647.68 (2278.63-4711.28)   
Daily (20 weeks’ gestation) 16 2384.71 (1471.25-5954.11) 45 2754.95 (1822.09-4421.01)   
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2.5 Discussion  
 
Mitochondrial dysfunction is a pathogenic mediator of oxidative stress in pre-
eclampsia with elevated mitochondrial lipid peroxidation and increased vulnerability 
to oxidation evident in placental mitochondria in pregnancies complicated by pre-
eclampsia (104). In this study we showed a significant reduction in antioxidant SOD 
activity at 15 weeks’ gestation and a corresponding increase in ΔmtDNA (between 
15 and 20 weeks’ gestation) in cases compared to controls.  
Oxidative stress results from an imbalance in the production of ROS and the 
responsive antioxidant levels. There is a vast amount of evidence for antioxidant 
decline and elevation of ROS in pre-eclampsia (277, 289). SOD is the first barrier 
and antioxidant defence against ROS and its activity is increased in the placenta of a 
normal pregnancy (62), while SOD activity in placental tissue from women with pre-
eclampsia is decreased (290). In our study, we showed lower levels of SOD activity 
at 15 weeks’ gestation in cases compared to controls. This correlates with previous 
work which showed lower levels of SOD at both 10-14 and 20-24 weeks’ gestation 
respectively in pre-eclampsia (291). Similarly, the levels of maternal erythrocyte 
SOD were also lower in the second half of pregnancy in pre-eclampsia when 
compared with normotensive pregnancies (277).  
Mitochondrial DNA is correlated with the number and size of the mitochondria 
(292), furthermore mtDNA are particularly susceptible to oxidative damage. While 
the origin of cf-mtDNA is difficult to phenotype, the quantitative assessment of cf-
mtDNA may permit the evaluation of mitochondrial dysfunction in pre-eclampsia. 
There have been a number of studies that suggest mitochondrial abundance may be 
associated with placental insufficiency and pre-eclampsia (268, 272, 293, 294). Our 
96 
 
research previously showed evidence of increased mtDNA at time of disease in 
women with pre-eclampsia, furthermore, we expanded this work and provided 
additional evidence of mitochondrial dysfunction by demonstrating increased 
mitochondrial-specific ROS and  reduced oxygen consumption (109). In this current 
study, while there was no significant difference in mtDNA copy number at both 15 
and 20 weeks’ gestation respectively in cases compared with controls, we reported a 
significant increase in ΔmtDNA copy number between 15 and 20 weeks’ gestation in 
cases compared with controls.  
Given the critical role of SOD antioxidants in mediating oxidative damage provoked 
by exaggerated superoxide generation, the compromised antioxidant defence evident 
at 15 weeks’ gestation in cases in our study group may be partly responsible for 
increased vulnerability of mtDNA to damage as evident by the increase in ΔmtDNA 
between 15-20 weeks’ gestation. Previous work in retinal endothelial cells 
overexpressing SOD2 (295) and in SOD2-depleted chrondrocytes (296) established 
an essential protective role for this enzyme in preventing mtDNA damage. 
Furthermore, we showed that mtDNA copy number increases as pregnancy 
progresses in women with pre-eclampsia and we hypothesise that the initial insult to 
mitochondrial antioxidant function seen early in pregnancy (15 weeks) could be 
exacerbated later in pregnancy resulting in a more significant increase in mtDNA 
copy number in pre-eclampsia as we previously described.  
The strength of our data compared to previous work in this area is attributable to the 
longitudinal examination of mtDNA through gestation, whereas previous studies 
have focused on mtDNA quantitation in the third trimester of pregnancy. This work 
correlates with previous studies, where mtDNA copy number was assessed in a case-
control study and reported that the odds of pre-eclampsia were positively associated 
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with increased maternal blood mtDNA copy number (268). These findings strongly 
suggest that altered mitochondrial function is evident very early in the development 
of pre-eclampsia. This study was performed in the Irish SCOPE cohort and while we 
provide evidence of mitochondrial dysfunction in pre-eclampsia, further larger 
studies in different populations are warranted.  
Lifestyle interventions such as healthy diet (fruit and vegetable consumption) and 
exercise have been examined in mitochondrial diseases (297, 298) given their 
physiological effect on mitochondrial function.  In recent years, exercise has been 
intensively examined in relation to reducing risk of pre-eclampsia (299, 300). The 
next step in this study was to assess whether lifestyle and nutritional factors had an 
effect on the amount of mtDNA in controls and cases.  However, we showed that 
exercise had no significant difference on mtDNA copy number during pregnancy in 
controls or cases. Similarly, a previous study assessed exercise and mtDNA copy 
number in controls and pre-eclampsia cases and showed no association between 
exercise and mtDNA copy number (268).  
Diet has been suggested to play a potential role in the management of pre-eclampsia 
(301). In our study we found no association between fruit and vegetable intake on 
mtDNA copy number in control and cases. Similarly, Clausen et al, showed no 
association between pregnancies affected by pre-eclampsia and healthy pregnancies 
when investigating meat, fish, vegetables and fruit intake (302). Finally, we 
investigated multivitamin intake and its association with mtDNA copy number in 
control and cases and found no association. Both Vitamin C and E have been 
extensively studied as antioxidant therapeutic options in pre-eclampsia (187, 303), 
however the results were largely disappointing. This may have occurred as these 
exogenous antioxidant vitamins do not penetrate the intracellular source of ROS, the 
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mitochondria, and are sequestered in the cytosol. Therefore, we propose a 
mitochondrial-targeted antioxidant may represent a more promising clinically 
effective treatment strategy for pre-eclampsia.  
2.6 Conclusion 
 
In this study, we provide evidence that in early gestation there is a significant 
reduction in mitochondrial antioxidant SOD activity in women who developed pre-
eclampsia. Furthermore, there is a significant increase in ΔmtDNA levels between 
15 and 20 weeks’ in women who subsequently went on to develop pre-eclampsia. 
Our findings support a pathogenic role for mitochondrial dysfunction in the 
pathophysiology of pre-eclampsia. Finally, we found no effect of either lifestyle or 
dietary factors in mediating mitochondrial dysfunction in this study cohort, 
highlighting the potential need for the development for mitochondrial targeted 
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3.0 Chapter 3: Activation of a TLR9 mediated innate 




Introduction: Pre-eclampsia is a multisystemic disorder leading to the development 
of a placental ischemic microenvironment with a resultant increase in oxidative 
stress. There is evidence that mitochondrial dysfunction and the innate immune 
system both play a role in the pathophysiology of this disease. Mitochondrial 
DAMPs such as mtDNA bind specific pattern recognition receptors such as Toll-like 
receptor 9 (TLR9) on the endosomal surface of immune cells, in particular 
neutrophils, subsequently activating them and triggering an innate response.  
Objective: We hypothesised that the exaggerated innate immune response seen in 
preeclampsia is provoked by dysfunctional mitochondria.  
Results: Here we provide evidence that TLR9 activity is significantly increased at 
time of disease in women with pre-eclampsia. Furthermore, we show activation of 
neutrophil markers, calprotectin, myeloperoxidase (MPO), and IL-8 are significantly 
increased at time of disease compared to uncomplicated pregnancies.  
Conclusion: This research supports a potential role of TLR9 activation of an innate 
immune response evident in pre-eclampsia which may possibly be initially triggered 




3.2 Introduction  
 
Pre-eclampsia is multifactorial disorder of pregnancy that is defined by the onset of 
hypertension and proteinuria after 20 weeks’ gestation. One of the most established 
characteristics of this disorder is the inability of the trophoblasts to invade the 
maternal uterine decidual arteries, resulting in poor placentation. Production of 
placental anti-angiogenic factors such as soluble fms-related tyrosine kinase 1 (sFlt-
1) and soluble endoglin (sEng) have been extensively researched in pre-eclampsia 
(304, 305). More recently, the cardiovascular system and its role in the development 
of pre-eclampsia is being explored (306). Other pathological characteristics of pre-
eclampsia include placental and systemic oxidative stress and dysfunction of the 
maternal vasculature (259, 307). In normal pregnancies there is evidence of a 
controlled systemic inflammatory response where cytokines promote the infiltration 
of the spiral arteries by invading trophoblast cells (308). This controlled 
inflammatory response becomes dysregulated in pre-eclampsia resulting in abnormal 
activation of monocytes, neutrophils and the endothelium causing maternal 
inflammation (309).  
There is overwhelming evidence that oxidative stress plays a key role in the 
pathophysiology of pre-eclampsia (55, 276). In turn oxidative stress, as a result of a 
placental ischemic microenvironment, releases reactive oxygen species into the 
maternal circulation, which can provoke a systemic inflammatory response (275). 
The innate immune system acts as both a protector and effector during pregnancy. 
The innate system encompasses neutrophils, dendritic cells, natural killer cells and 
macrophages and these immune responders are activated to protect the mother from 
pathogens. Toll-like receptors (TLRs) are a family of type I transmembrane pattern 
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recognition receptors (PRRs) that identify invading pathogens or endogenous 
damage signals and instigate an innate immune response.  
TLR9 can detect conserved sequences known as pathogen-associated molecular 
patterns (PAMPs) and also specifically respond to endogenous molecular structures 
known as damage-associated molecular patterns (DAMPs) via unmethylated CpG 
dinucleotide motifs as evident on mitochondrial DNA (270). Activation of 
endosomal TLR9 involves an intracytoplasmic signalling cascade that leads to the 
up-regulation of pro-inflammatory transcription factors and subsequent liberation of 
pro-inflammatory cytokines (134). There is evidence of increased TLR9 expression 
in both placental tissue and peripheral blood mononuclear cells (PBMC) from 
patients with pre-eclampsia compared with controls (140, 310). 
Neutrophils are short-lived effector cells of the innate immune system. These 
immune cells are activated in women during pregnancy and are further stimulated in 
pre-eclampsia (311). Histopathological evidence has shown extensive infiltration of 
neutrophils in the systemic vasculature of women with pre-eclampsia compared to 
controls (312, 313). Neutrophils express a number of TLRs on their surface 
including TLR9 (314). Mitochondrial DNA (mtDNA) has been shown to activate 
neutrophils via a TLR9 signalling cascade, which elicits a neutrophil pro-
inflammatory phenotype (136, 141, 315). Neutrophil activation results in the 
secretion of a number of markers including reactive oxygen species (ROS), matrix 
metalloproteinase-8 (MMP-8), calprotectin, myeloperoxidase (MPO) and the pro-
inflammatory cytokine IL-8 (316). 
Our research has previously provided evidence of a role for mitochondrial 
dysfunction in the pathophysiology of pre-eclampsia with an increase in ΔmtDNA 
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evident between 15 and 20 weeks in women with pre-eclampsia (317). Interestingly 
we also showed a significant increase in mtDNA at time of disease (TOD) in women 
with pre-eclampsia compared to controls (109). The aim of this study was to 
investigate if the increase in mtDNA we previously reported in pre-eclampsia 
triggers activation of TLR9 signalling cascade. We also wanted to determine if a 
subsequent neutrophil pro-inflammatory phenotype was elicited in pre-eclampsia 
compared to controls by measuring a number of neutrophil activation markers 
longitudinally in pregnancy. We hypothesised that dysfunctional mitochondria 




3.3 Materials and Methods  
 
3.3.1 Study subjects 
 
Subjects were recruited from the SCOPE study Ireland which is an international 
multicentre prospective cohort study of nulliparous singleton pregnancies aimed to 
develop a screening test to predict adverse pregnancy outcomes including pre-
eclampsia, SGA infants and spontaneous pre-term birth (285, 286). A nested case-
control study within SCOPE Ireland was conducted which included all pre-eclampsia 
cases in SCOPE Ireland and matched controls with a case-to-control ratio of 1:2. 
Pre-eclampsia cases was defined as a systolic blood pressure ≥ 140mm Hg and/or 
diastolic blood pressure ≥ 90 mm Hg on at least two occasions 4 hrs apart after 20 
weeks’ gestation and with proteinuria (24 hour urinary protein ≥ 300mg or urine 
dipstick protein ≥ +2). Randomly selected controls were taken from healthy pregnant 
women who had uncomplicated pregnancies which were defined as pregnancies not 
affected by pre-eclampsia, preterm birth or growth restriction and delivered at >37 
weeks. All blood pressure readings were <140 and/or <90 mmHg prior to the onset 
of labour. These were matched with the cases for maternal age, body mass index 
(BMI) and gestational age.  
Both 15 and 20 week samples were taken from the SCOPE study from women who 
subsequently went onto develop pre-eclampsia (n=60) and controls (n=120). 
Samples were also taken from a subset of women (n=25) at the time of disease 
(TOD) with pre-eclampsia and matched controls. The 60 women with pre-eclampsia 
were composed of 39 women who developed term pre-eclampsia and 21 preterm 
pre-eclampsia cases. The SCOPE study was conducted according to the guidelines 
laid down in the Declaration of Helsinki, and all the procedures were approved by 
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the Clinical Research Ethics Committee of the Cork Teaching (EMC5(10)05/02/08), 
and all women provided written informed consent.   
 
3.3.2 Sample collection  
 
Plasma samples were collected in BD Heparin Vacutainer tubes, placed on ice, and 
centrifuged at 2,400g for 10 minutes at 4˚C according to a standardised protocol. 
Plasma samples were stored at -80˚C until analysis.  
 
3.3.3 TLR-9 Activity  
 
TLR9 ligand activity was monitored with HEK-blue TLR9 Reporter Cell assay 
(InvivoGen). All experiments were performed using a cell density of 50,000 cells in 
a 96 well plate. Cells were initially seeded and left overnight prior to treatment for 
24 hrs with 3% plasma taken at 15 and 20 weeks’ gestation (cases, n=60, controls, 
n=120) and TOD (cases, n=25, controls, n=25). The supernatant was incubated with 
Quanti-Blue detection medium (InvivoGen) and the activity was read on a Varioskan 
Flash plate reader (Thermo Scientific) at a wavelength of 630 nm. 
 
3.3.4 Calprotectin analysis 
 
Plasma calprotectin (S100A8/S100A9) concentrations were measured by enzyme-
linked immunosorbent assay (ELISA) using human S100A8/S100A9 Quantikine kit. 
Heparin plasma samples from all time-points were initially diluted a 100-fold in 
assay buffer and then directly added to a pre-coated plate. The ELISA was 
performed as per manufacturers’ instructions.  
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3.3.5 Myeloperoxidase, MMP8, IL-8 analysis 
 
Myeloperoxidase (MPO), Matrix metalloproteinases-8 (MMP8) and interleukin-8 
(IL-8) concentrations were measured respectively at all time-points by individual 
ELISA DuoSet kits (R&D SYSTEMS. USA & Canada). ELISA was carried out as 
per manufacturer’s instructions.  
3.3.6 Statistical analysis 
 
Analysis was performed using GraphPad Prism. Data were presented using median 
(±Interquartile range [IQR]) and comparisons of data between cases and controls 
were performed using a non-parametric Mann Whitney U test or Wilcoxon signed 
rank test as appropriate when data was not normally distributed. Data that was 
normally distributed were represented as mean (±SEM) and comparisons of data 
between cases and controls were performed using an unpaired t-test. P values <0.05 




3.4 Results  
 
3.4.1 Determination of TLR9 activity and downstream markers of neutrophil 
activation at 15 weeks’ gestation 
 
To determine if TLR9 was activated by circulating mediators present in pre-
eclampsia, HEK-TLR9 cells were treated with 3% plasma. The level of neutrophil 
activation markers, calprotectin, MPO, MMP8 and IL-8 were also examined. Firstly, 
there was no significant increase in TLR9 activity at 15 weeks’ gestation in cases 
compared to controls (0.28 ± 0.02 v 0.2 ± 0.02; P=0.99) (Figure 3.1a). We 
subsequently measured a number of well described markers of neutrophil activation 
in both study groups at 15 weeks’ gestation. There was no significant increase in 
calprotectin (1319 ng/ml ± 87.96, v 1198 ng/ml ± 56.76; P= 0.23) (Figure 3.1b) or 
myeloperoxidase (Median [IQR]: 6.72 ng/ml [2.20 - 13.13] v 4.83 ng/ml [2.11 - 
8.41]; P= 0.14) between cases and controls (Figure 3.1c). There was also no 
significant difference in MMP8 (1041.27 pg/ml ± 42.96 v 1075.62 pg/ml ± 88.24; P= 
0.69) (Figure 3.1d) or the pro-inflammatory cytokine IL-8 (median [IQR]: 8.99 
[3.32-30.70] v 9.32 [2.18-29.85]; P=0.95) between cases and controls at 15 weeks’ 





















Figure 3.1: TLR9 activity and downstream markers of neutrophil activation did not alter at 15 weeks’ gestation. There was no 
significant increase in TLR9 activity (a) or neutrophil activation markers Calprotectin (b), MPO, (c) MMP-8 (d) and IL-8 (e) at 15 
weeks’ gestation between cases and controls. 











































































3.4.2 Determination of TLR9 activity and downstream markers of neutrophil 
activation at 20 weeks’ gestation 
 
There was no significant increase in TLR9 activity at 20 weeks’ gestation in cases 
compared to controls (0.29 ± 0.01, v 0.30 ± 0.02; P=0.88) (Figure 3.2a). While there 
was no change in the levels of calprotectin between cases and controls at 20 weeks’ 
gestation (1155 ng/ml ± 68.45 v 1234 ng/ml ± 61.10; P=0.42) (Figure 3.2b), there 
was a significant increase in myeloperoxidase in cases compared to controls (Median 
[IQR]: 5.02 ng/ml [2.36-9.08] v 7.07 ng/ml [2.74-17.24]; P= 0.02) (Figure 3.2c). 
There was no significant change in the levels of MMP8 between cases and controls 
(1116.73 pg/ml ± 48.24 v 1053.74 pg/ml ± 54.05; P= 0.41) (Figure 3.2d). There was 
no significant increase in IL-8 in cases compared to controls at 20 weeks’ gestation 













Figure 3.2: TLR9 activity and downstream markers of neutrophil activation did not alter at 20 weeks’ gestation. There was no 
significant increase in TLR9 activity (a) or neutrophil activation markers Calprotectin (b), MMP-8 (d) and IL-8 (e) at 20 weeks’ 
gestation between cases and controls. MPO expression (c) was significantly increased in cases compared with controls (P= 0.02). 













































































3.4.3 Activation of TLR9 activity provokes a neutrophil-derived pro-
inflammatory phenotype at time of disease in pre-eclampsia 
 
There was a significant increase in TLR9 activity at TOD in pre-eclampsia cases 
compared to controls (0.29 ± 0.01 v 0.35 ± 0.01; P=0.01) (Figure 3.3a). 
Subsequently, there was also a significant increase in both calprotectin (1946.55 
ng/ml ± 155.08 v 1516.45 ng/ml ± 145.84; P= 0.04) (Figure 3.3b) and 
myeloperoxidase (Median [IQR]: 8.33 ng/ml [5.70 - 14.20] v 4.52 ng/ml [3.53 - 
8.73]; P= 0.01) (Figure 3.3c) respectively at TOD in cases compared to controls. 
There was no significant increase in MMP-8 in cases when compared with controls 
at time of TOD, (842.92 pg/ml ± 87.07 v 1140.64 pg/ml ± 144.77; P= 0.08) (Figure 
3.3d). Finally, there was a significant increase in the pro-inflammatory cytokine IL-8 
(Median [IQR]: 6.13pg/ml [1.18 - 28.68] v 24.63 pg/ml [5.37 -71.20]; P=0.01) at 













Figure 3.3: Circulating plasma mediators activate a TRL9-mediated innate immune response in pre-eclampsia at TOD. TLR-9 
activity (a), Calprotectin (b), MPO (c), and IL-8 (e) were significantly increased at time of disease in cases compared to controls 
(P=0.01). There was no significant increase in MMP-8 (d) at TOD in cases in comparison to controls.














































































3.4.4 Evidence of elevated innate immune response across gestation in pre-
eclampsia 
 
We investigated if the neutrophil-mediated innate immune response were altered 
longitudinally in pregnancy. Initially, there was no difference in TLR9 activity 
across gestation in controls. (Figure 3.4a). Similarly, there was no significant change 
in calprotectin, MPO and IL-8 expression in controls (Figure 3.4b, c and e). MMP-8 
was significantly decreased in uncomplicated pregnancies (Figure 3.4d). 
In cases complicated with pre-eclampsia, both TLR9 and calprotectin were 
significantly increased across gestation (0.28 ± 0.02, 0.30 ±0.02, 0.37 ±0.02; P=0.01) 
and (1318.69 ng/ml ± 87.95, 1233.77 ng/ml ± 68.45, 1946.55 ng/ml ± 145.84; P = 
0.0001) respectively. (Figure 3.5a and b). There was no significant increase in MPO, 
(6.72 ng/ml [2.20-13.13], 7.09 ng/ml [2.74-17.24], 8.33 ng/ml [5.70-14.20]; P= 
0.14), MMP-8 (1075.62 pg/ml ± 88.24, 1053.74 pg/ml ± 54.05, 1140.64 pg/ml ± 
87.08; P= 0.82) or IL-8 (9.32 pg/ml [2.18-29.85], 13.49 pg/ml [3.66-46.66], and 
24.63 pg/ml [5.37-71.20]; P= 0.13) across gestation in pre-eclampsia cases (Figure 












Figure 3.4: Normal pregnancy did not activate a TLR9 mediated innate immune response. There was no significant increase in 
TLR9 activity (a), Calprotectin (b), MPO (c) in healthy control pregnancies across gestation. MMP8 (d) was significantly reduced at 
term pregnancies (P= 0.01), while IL-8 (e) showed no significant difference across gestation in healthy control pregnancies





















































































Figure 3.5: Neutrophil activation markers are increased across pregnancy in pre-eclampsia. TLR9 activity (a), Calprotectin (b), 
were both significantly increased across gestation in cases with pre-eclampsia (P=0.01). There was no significant increase in neutrophil 
activation markers MPO (c), MMP8 (d) and IL-8 (e) across gestation in cases with pre-eclampsia.
















































































3.4.5 Determination of TLR9 activity and downstream markers of neutrophil 
activation in preterm cases versus term cases  
 
We next explored if there was a difference in the neutrophil pro-inflammatory 
phenotype across all time-points in women who developed pre-eclampsia and 
delivered either before 37 weeks or after 37 weeks’ gestation (Table 3.1). There was 
no significant difference in TLR9 activity in preterm pre-eclampsia compared to 
term pre-eclampsia across gestation. Similarly, there was no significance difference 
at each time-point when comparing expression of calprotectin, MPO and MMP8 in 
preterm pre-eclampsia versus term pre-eclampsia. Interestingly IL-8 expression is 
initially increased at 15 weeks’ gestation in women who developed preterm pre-




Table 3.1: Plasma levels of TLR9 activity, neutrophil activation markers and pro-inflammatory cytokine IL-8 in patients with preterm 
and term pre-eclampsia. 
































0.16 886.99 ± ng/ml 
245.48 1167.96 ng/ml ± 
77.80 

























































Pregnancy is associated with a maternal systemic inflammatory response; however, 
this response is exaggerated in pre-eclampsia. There has been a number of studies 
which have provided evidence of increased neutrophil activation in women with pre-
eclampsia (312, 318, 319). In this present study, we investigated if circulating 
mediators (including mtDNA) (317), trigger TLR9 activity with the subsequent 
downstream activation of a neutrophil-mediated innate immune response in women 
with pre-eclampsia and healthy controls. We showed TLR9 activity is significantly 
increased in women with pre-eclampsia compared to healthy controls at time of 
disease. There was a corresponding increase in production of downstream neutrophil 
activation markers, calprotectin, myeloperoxidase, MMP8 and the pro-inflammatory 
cytokine IL-8 in women with pre-eclampsia compared to healthy controls at time of 
disease, indicating that complete activation of neutrophil pro-inflammatory 
phenotype only became evident late in pregnancy in pre-eclampsia.   
The innate immune response plays a well described role in the pathophysiology of 
pre-eclampsia. Mitochondrial DAMPs such as mtDNA bind specific pattern 
recognition receptors such as TLR9 on the endosomal surface of the immune cells, in 
particular, neutrophils and activate an innate response. TLR9 receptors are also 
localised to trophoblasts and the villous stromal vascular endothelium and their 
expression is increased in pre-eclampsia (140). We have shown a significant increase 
in TLR9 activity using a reporter cell assay incubated with plasma taken at time of 
disease in pre-eclampsia cases compared to healthy controls. Furthermore, previous 
work in our lab examined mtDNA (as a marker of mitochondrial dysfunction) and 
reported that mtDNA was also significantly increased at time of disease in pre-
eclampsia cases in the same study cohort (317). This indicates that the increase in 
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mitochondrial DAMP (mtDNA) at time of disease may activate a TLR9 mediated 
innate immune response in pre-eclampsia cases only. Exciting new work by He et al. 
has identified an additional role for TLR9 in pre-eclampsia where they established 
that TLR9 supressed angiogenesis in part by increasing sFlt-1 expression in a murine 
model of pre-eclampsia (320). Furthermore, research carried out in spontaneous 
hypertensive rats, established that circulating mtDNA may lead to the activation of 
the innate immune system through TLR9 (315). Research by Goulopoulou et al., has 
also shown preliminary data indicating that TLR9 activation provokes pre-
eclampsia–like symptoms in pregnant rats (141) emphasising the pathogenic role of 
TLR9 in pre-eclampsia.  
Calprotectin is a calcium binding protein that is located in the cytosol of neutrophils 
and is released upon neutrophil activation. In our study, calprotectin was 
significantly increased at time of disease compared to controls. This is in agreement 
with recent work by Akçum et al, who reported increased circulating calprotectin 
levels at term in women with pre-eclampsia, and interestingly found an additional 
increase in women with severe pre-eclampsia (319). 
MPO is a lysosomal enzyme mainly produced and released by activated neutrophils. 
In this study, we showed a significant increase in MPO in cases as early as 20 
weeks’ gestation when compared with controls and this significant increase was 
equally evident at time of disease in pre-eclampsia. Previous studies measuring MPO 
in pre-eclampsia have reported conflicting results; some studies have reported no 
difference in MPO in pre-eclampsia in samples taken at 24 weeks or later in the third 
trimester (158, 321), whereas Gandley et al, reported a 3-fold increase in circulating 
MPO levels in women with pre-eclampsia compared to matched healthy controls at 
32- 38 weeks’ gestation (154). The variation in MPO levels in previous pre-
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eclampsia studies may be due to small sample size. In our study we compared 60 
cases and 120 matched controls, which to our knowledge is one of the largest studies 
measuring MPO in pre-eclampsia.  
MMP8 is part of the MMP family which consists of 23 zinc and calcium dependent 
proteases that effect different mechanisms of the extracellular matrix. In recent 
years, MMPs have become a target of interest in pre-eclampsia due to their role in 
vascular function and remodelling (168, 322). Recent research shows strong 
evidence that MMP8 plays an important role in mediating endothelial cell 
angiogenesis (168). Furthermore, as endothelial dysfunction is a pathogenic 
characteristic of pre-eclampsia, dysregulated MMP8 production may play a crucial 
role in the disruption of angiogenesis in pre-eclampsia leading to endothelial 
dysfunction. In our study, there was an increase in circulating levels of MMP8 at 
TOD in women with pre-eclampsia cases compared to healthy controls. 
Cytokines and chemokines have been extensively studied as markers of 
inflammation involved in the pathophysiology of pre-eclampsia. In this study, we 
showed a significant increase in circulating IL-8 levels at time of disease in cases 
compared to controls. IL-8 has previously shown to be increased in women with pre-
eclampsia in the third trimester (323). Additionally, a recent study reported a 
significant increase in IL-8 in early gestation (5-15 weeks’) in women who 
subsequently went on to develop pre-eclampsia. However, a limitation of their study 
was the small sample size (n=9) (179). Other studies investigating IL-8 throughout 
pregnancy reported similar results to ours with no significant increase evident in the 
second trimester (180, 181) but a significant increase in IL-8 is evident in the third 
trimester in women with pre-eclampsia compared to healthy controls.(182).  
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Preterm pre-eclampsia occurs before 37 weeks’ gestation and is frequently regarded 
as a slightly different phenotype to pre-eclampsia occurring at term. Therefore, we 
investigated whether neutrophil activation triggers an altered innate immune 
response in preterm pre-eclampsia compared to term pre-eclampsia. In this study, 
there was no statistically significant difference in the concentration of neutrophil 
activation makers in preterm versus term pre-eclampsia respectively in our cohort. 
When investigating the activation of a TLR9 mediated innate immune response 
across pregnancy, there was no significant difference in expression of any of the 
neutrophil markers measured in healthy controls. However, in pre-eclampsia, 
significant increases were seen in neutrophil activation markers, TLR9 and 
calprotectin, illustrating that the innate immune response may be initially triggered 
earlier in pre-eclampsia, but complete activation is not significantly evident until 
later in pregnancy. This is in agreement with recent studies of maternal inflammation 
(cytokines such as IL-6, TNF-α) in pre-eclampsia, whereby low level inflammation 
is evident early in pregnancies but is amplified in the third trimester of pregnancy 
(324-326). This current study shows that the TLR9 activation of the innate immune 




3.6 Conclusion  
 
Here we provide evidence that circulating plasma mediators may activate a TRL9-
mediated innate immune response in pre-eclampsia. We show that the activity of 
TLR9, a receptor for mtDNA, is significantly increased at time of disease in pre-
eclampsia. Subsequently we have shown increased production of neutrophil 
activation markers particularly late in pregnancy in pre-eclampsia. Finally, we have 
shown that possible activation of TLR9 by dysfunctional mitochondria may provoke 
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4.0 Chapter 4: Investigating the molecular mechanisms of 
the antioxidant L-ergothioneine in regulating mitochondrial 




Introduction: Placental oxidative stress due to abnormal placentation is proposed to 
play a vital role in the pathophysiology of pre-eclampsia. To date, however, the 
results of testing antioxidant interventions in therapeutic trials have been 
overwhelmingly disappointing. There is preliminary evidence linking mitochondrial 
dysfunction as a potential mediator of exaggerated oxidative stress, evident in pre-
eclampsia. The aim of this study was to investigate the potential therapeutic 
properties of L-ergothioneine, a promising and unusual antioxidant, in an in vitro 
model of oxidative stress. 
Methods: Jeg-3 placental choriocarcinoma cells were pre-treated with 1mM L-
ergothioneine, 20µM Mito-Tempo and 1mM N-acetylcysteine for 2 hrs and 
subsequently treated with 200µM H2O2 for 4 hrs. Cell viability, mitochondrial-
specific superoxide production, mitochondrial mass and mitochondrial superoxide 
detoxifying enzymes were measured. 
Results:  Pre-treatment with L-ergothioneine significantly increased cytoprotection 
in Jeg-3 cells (91% ± 4.95% v 46.73 % ± 10.0%, n=3, P<0.01). L-ergothioneine 
significantly reduced mitochondrial-specific superoxide (100% v 48.36% ± 13.78 
n=3; P≤0.01). Compared with MitoTempo and N-acetylcysteine, L-ergothioneine 
had a more pronounced effect across all measured parameters. PGC-1α (1.8-fold ± 
0.3, n=3, P= 0.03) and UCP-1 (1.6 fold ± 0.3, n=3, P=0.03) were significantly 
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altered in cells pre-treated with L-ergothioneine and subsequently exposed to 
oxidative stress.  
Discussion: Here we provide evidence of ERG’s potential protective mechanisms in 
an in vitro model of oxidative stress. L-ergothioneine had more pronounced 
cytoprotective properties compared with either the mitochondrial-targeted 
antioxidant MitoTempo or N-acetylcysteine. L-ergothioneine alleviated the effects of 
the H2O2 oxidative insult on mitochondrial reactive oxygen species generation. 
Finally, we provide evidence that ERG may mediate its cytoprotective effects, at 
least in part, by regulating markers involved in mild mitochondrial uncoupling which 




4.2 Introduction  
 
Pre-eclampsia is characterised as de-novo hypertension in pregnancy (BP ≥140 
mm Hg systolic or ≥90 mm Hg diastolic) at or after 20 weeks’ gestation 
accompanied by proteinuria and/or evidence of maternal acute kidney injury (AKI), 
neurological features, haemolysis, liver dysfunction, or fetal growth restriction. It 
results in over 500,000 fetal and neonatal deaths and more than 70,000 maternal 
deaths globally (327). There is substantial evidence that defective placentation in 
early pregnancy is a vital event in the development of this condition (274). 
Furthermore, the ischemic placental microenvironment evident in pre-eclampsia is 
initially triggered by a reduction in placental perfusion due to oscillations in oxygen 
delivery to the placenta and fetus, which in turn results in exaggerated oxidative 
stress (266). Inflammation is also a significant factor (328). To date, research has 
shown that abnormally elevated oxidative stress is present in pre-eclampsia as early 
as 8-10 weeks’ gestation (329). 
There are many sources of reactive oxygen species (ROS) within the cell; however, 
mitochondria are the dominant cellular producer of ROS (330). There is growing 
evidence that mitochondrial dysfunction may play a role in the pathophysiology of 
pre-eclampsia (279, 317), where research has shown elevated levels of mtDNA in 
plasma from women with pre-eclampsia when compared with matched healthy 
controls (6).  Mitochondrial DNA is generally sequestered inside mitochondria, 
however after physiological stressors such as trauma, infection, oxidative stress, 
mtDNA molecules are evident in circulation (136). Furthermore, there is evidence of 
diminished mitochondrial antioxidant defence in pre-eclampsia as early as 15 weeks’ 
gestation (317, 331).  
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The placenta requires an extensive number of functional mitochondria to meet the 
elevated metabolic demands of pregnancy. To maintain the appropriate number, 
function and morphology, there needs to be a balance between fusion and fission 
(332, 333). Peroxisome proliferation-activated receptor ƴ co-activator 1α (PGC-1α) 
is a transcriptional coactivator that regulates numerous auxiliary biological functions 
associated with mitochondria, including antioxidant defence system, angiogenesis, 
cellular respiration and oxidative metabolism (334, 335) . Furthermore, PGC-1α 
directs a wide programme of mitochondrial gene expression of mitochondrial-ROS 
detoxifying enzymes including superoxide dismutase (SOD1, SOD2) and uncoupling 
protein-1 (UCP-1), which are directly induced by this transcriptional orchestrator 
(336). UCP-1 is a mitochondrial transporter present in the inner mitochondrial 
membrane of mitochondria with a well-known role in mediating adaptive 
thermogenesis (335) but more recently has been shown to regulate exaggerated 
mROS production in part by altering the proton gradient via mild uncoupling (337). 
L-ergothioneine (ERG) is a dietary, water-soluble amino acid derived from histidine, 
cysteine and methionine. It is synthesised by various bacteria and fungi and taken up 
by higher organisms. Many physiological roles have been proposed for ERG 
including immune regulation, scavenging of free radicals and cation chelation (210). 
Furthermore, ERG has been shown to possess cytoprotective and antioxidant 
properties in both in vitro and in vivo models (208, 210, 211, 219, 221, 338-341), in 
addition to being involved in  anti-inflammatory responses (342). ERG crosses the 
intestinal epithelium using the type 1 organic cation transporter SLC22A4 
(previously known as OCTN1). This cation transporter’s primarily role had been 
considered to be in the elimination of drugs from tissues such as the kidneys (215). 
SLC22A4 was initially considered to be a carnitine transporter, however it transports 
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ERG at a rate almost two orders of magnitude greater (216, 343), indicating that the 
ability to accumulate ERG was selected by evolution. ERG accumulates in 
conditions of high oxidative stress, indicating it may be an encouraging target for a 
therapeutic agent for diseases involving oxidative stress, such as pre-eclampsia (213, 
344). Furthermore, no adverse effects were seen in pregnant Sprague Dawley rats 
administered ERG in their drinking water (231). ERG is a commercially available 
amino acid, with proven pharmacovigilance for consumption in humans (232) 
indicating its potential as a safe treatment for humans, as confirmed by the European 
Food Standards (237, 345) Agency.  
The aim of this study is to investigate the mechanistic role of ERG in modulating 
mitochondrial function in an in vitro model of placental oxidative stress and assess 




4.3 Materials and Methods  
 
4.3.1 Cell culture and treatments. 
 
The human JEG-3 choriocarcinoma placental cell line (ATTC), was grown in Ham’s 
F-12 (Invitrogen) media supplemented with 10% Fetal bovine serum (FBS), 1% L-
glutamine and 1% Penicillin Streptomycin (Biosciences). Cells were maintained at 
37 ͦC and 5% CO2 and were routinely passaged at 80% confluency. All experiments 
were performed on cells seeded 24-48 h in advance and serum starved for 1 hour prior 
to treatments. Cells were pre-treated initially with increasing concentrations of L-
ergothioneine (1µM–1mM) and Mito-Tempo (1µM-100µM), and N-acetylcysteine 
(NAC) (1µM-1mM) 24hr. For co-treatments, cells were pre-treated with optimal 
concentrations of 1mM L-ergothioneine, 20 µM Mito-Tempo and 1µM N-
acetylcysteine (NAC) for 2 hrs and 200µM H2O2 was then added for 4 hrs. The 
oxidative stressor insult (200µM H2O2) was chosen based on our previous in vitro 
investigations (109). 
 
4.3.2 Assessment of Cell Viability using MTT assay 
 
The thiazolyl blue tetrazolium bromide MTT assay assesses cell viability as it 
requires the metabolic conversion of MTT to an insoluble derivative formazan, 
thereby reflecting the number of viable cells present.  Cells were treated as described 
in section 4.3.1 and were incubated at 37 ͦC with MTT solution for 4 hrs. Following 
treatment, 10 ul of MTT (final concentration 5 mg/ml) was added to each well and 
absorbance read at 570 nm, with 630 nm as a reference. Cell viability % = 




4.3.3 Isolation of RNA and Real-time PCR analysis 
 
RNA was extracted using the RNeasy mini-kit (Qiagen). Transcripts encoding 
Peroxisome proliferator-activated receptor-gamma coactivator (PGC-1α), superoxide 
dismutase (SOD1), SOD2, uncoupling protein-1 (UCP-1) and SLC22A4 were 
quantified by real-time PCR using StepONE Plus Detection system. Taqman assay 
(Applied Biosciences) and Sybr Green primers were used for quantification. The 
amounts of the target gene was normalised to the geometric mean of internal control 
gene 18S, and were determined using the comparative 2-ΔΔCT method (346).    
 
4.3.4 Detection of mitochondrial superoxide by fluorescence microscopy 
 
MitoSOX Red fluorescence reagent (Invitrogen) was used to measure 
intramitochondrial superoxide. This fluorogenic dye is specifically oxidised by 
superoxide anions in the mitochondria. This oxidation reaction produces a red 
fluorescent dye once bound to the mitochondrial DNA. Cells were treated as 
described in section 4.3.1. Media were then removed and 0.5µM MitoSOX red was 
added to the cells for 30 mins at 37˚C. Cells were then fixed and permeabilized prior 
to nuclear staining with DAPI. Mean fluorescence intensity was analysed using 
Image J software in at least 10 random fields of view and compared to DMSO 
controls.  
 
4.3.5 Determination of mitochondrial mass 
 
Mitochondrial mass was measured using MitoID green fluorescent marker (Enzo Life 
Sciences) according to the manufacturer’s instructions. MitoID is a cell permeable 
small organic probe that is considered to localise to the mitochondria irrespective of 
any membrane potential they might possess. All experiments were performed at a cell 
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density of 50,000 cells per well in a 12 well plate. Cells were serum starved for 1 hour 
and subsequently pre-treated with either 1mM L-ergothioneine, 1mM NAC or 20 µM 
Mito-Tempo for 2 hrs. Thereafter, cells were treated with 200 µM H2O2 for 4 hrs.  
 
4.3.6 Statistical analysis 
 
Analyses were performed using GraphPad Prism. Data were presented as mean 
(±SEM), or fold change relative to control. Comparisons of data between in vitro 
groups were performed using t-test or analyses of variance (ANOVA) where 
appropriate to determine statistical significance between groups in in vitro studies 






4.4.1 Determine the preferred concentration of antioxidants on cell viability 
 
To examine the preferred concentration of ERG, Jeg-3 cells were treated with a 
range of increasing concentrations (1μM to 1mM) for 24 hrs. In summary, 1mM was 
used for subsequent experiments (Figure 4.1A). Similar cell viability assays were 
performed with a mitochondrial-targeted antioxidant Mito-Tempo (1μM- 100μM) 
(Figure 4.1B) and NAC a non-mitochondrial antioxidant (1μM-1mM) (Figure 4.1C).  
In summary, 20μM Mito-Tempo and 1mM NAC were used in subsequent 
experiments. 
 
4.4.2 Cytoprotective effects of ERG on H2O2 -induced cell death 
 
The next set of experiments were designed to determine whether ERG had 
cytoprotective properties on H2O2-treated cells. H2O2 is commonly used as a cellular 
stressor representative of oxidative stress in in vitro models. 200 µM H2O2 was used 
for subsequent experiments (Figure 4.1D). Pre-treatment with 1mM ERG 
significantly rescued H2O2 –induced cell death (91% ± 4.95% v 46.73 % ± 10.0%, 
n=3, P= 0.01), when compared with the mitochondrial-targeted antioxidant Mito-
Tempo (72% ± 8.1% v 46.73% ± 10%, n=3, P=0.11). Furthermore, ERG-mediated 
protective effect was similar to that of non-mitochondrial antioxidant NAC (96% ± 


















































































































Figure 4.1: Cytoprotective effects of ERG, MitoTempo and NAC on H2O2 –induced-cell death. A-C) Dose dependent effect of ERG, 
MitoTempo and NAC on Jeg-3 cell viability was assessed using a MTT assay. Jeg-3 cells were treated with varying concentrations of ERG, 
MitoTempo and NAC for 24 hrs. Data are expressed as mean ± SEM. D) Dose dependent effect of H2O2 on Jeg-3 cell viability was assessed 
using a MTT assay. Jeg-3 cells were treated with varying concentrations of H2O2 for 24 hrs. Data are expressed as mean ± SEM. E) ERG is 
protective of H2O2-induced cell death in Jeg-3 cells. Cells were pre-treated with ERG, MitoTempo or NAC for 2 hrs and subsequently exposed 
to 200µM H2O2 for 4 hrs, cell viability was assessed by MTT assay. Data are expressed as mean ±SEM. (*P<0.05, **P<0.01; v Control). Data 




4.4.3 ERG reduces mitochondrial specific ROS in H2O2 treated cells  
 
Increased production of mitochondrial-specific ROS (mROS) is inherently linked to 
mitochondrial dysfunction. To examine mitochondrial-specific superoxide 
production, cells were labelled with MitoSOX Red fluorescent dye and quantified by 
fluorescent microscopy. Mitochondrial-specific superoxide was significantly reduced 
in cells pre-treated with ERG (100% v 48% ± 14%, n=3; P<0.01) compared with 
control cells (Figure 4.2). Similarly, MitoTempo significantly reduced 
mitochondrial-specific superoxide production, (100% v 51% ± 12%, n=3; P= 0.01), 
while NAC didn’t significantly reduce mROS production respectively (100% v 68% 































































Figure 4.2: ERG reduced mitochondrial superoxide production in Jeg-3 cells. 
Jeg-3 cells were pre-treated with ERG, MitoTempo or NAC for 2 hrs and 
subsequently treated with H2O2 for 4hrs and mitochondrial-specific superoxide was 
detected using fluorogenic MitoSox Red dye. MitoSox Red generation was 
quantified using Image J software. Data are the mean of 10 independent experiments 
and are expressed as difference in percentage pixel intensity between study groups ± 




4.4.4 Effect of ERG on mitochondrial mass in Jeg-3 treated cells 
 
The effect of ERG on mitochondrial mass in JEG-3 cells was measured using 
fluorescent MitoID Green. MitoID Green accumulates in the mitochondria and 
becomes fluorescent in a lipid environment, fluorescence was quantified by 
microscopy. There was no significant change in mitochondrial mass in cells pre-
treated with ERG compared to control cells (85% ± 7% v 100%, n=3, P=0.06). 
Equally, MitoTempo (84% ± 27% v 100%, n=3, P= 0.35) or NAC treated cells 
didn’t significantly alter mitochondrial mass when compared to control cells (81% ± 
7% v 100%, n=3; P=0.09). (Figure 4.3).  
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Figure 4.3: Effect of antioxidants on mitochondrial mass in H2O2 treated cells.  
Jeg-3 cells were pre-treated with ERG, MitoTempo or NAC for 2 hrs and 
subsequently treated with H2O2 for 4hrs. Mitochondrial mass was determined using 
fluorogenic MitoID green dye. Mitochondrial mass was quantified using Image J 
software. Data are the mean of 3 independent experiments and are expressed as 


























4.4.5 ERG regulates endogenous UCP-1 expression in placental cells 
 
We assessed the effect of ERG treatment on expression of PGC-1α and its directly 
regulated mitochondrial detoxifying enzymes SOD1, SOD2 and UCP-1.  We also 
measured SLC22A4 expression in ERG-treated cells. This study showed that ERG 
treatment did not have a significant effect on the expression of PGC-1α, SOD1, 
SOD2, SLC22A4 in Jeg-3 cells compared with untreated cells. (Figure 4.4). 
However, UCP-1 expression was increased in cells treated with ERG (2 fold ± 0.5, 









Figure 4.4: Effects of antioxidants on endogenous expression of mitochondrial-
detoxifying enzymes in untreated Jeg-3 cells. Jeg-3 cells were treated with 
antioxidants as described for 24hrs and placental expression of markers of 
mitochondrial-detoxifying enzymes were quantified by real-time PCR. Gene 
expression of PGC-1α, UCP-1 SOD1, SOD2, and SLC22A4 were determined in Jeg-
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3 cells. Data are representative of 3 independent experiments. Data are mean fold 
change compared to untreated Jeg-3 cells ± SEM. *P<0.01.  
 
4.4.6 ERG alters the profile of mitochondrial superoxide detoxifying enzymes in 
response to oxidative stress   
 
ERG significantly increased the expression of PGC-1α (1.8-fold ± 0.3, n=3, P= 0.03) 
compared to control cells. (Figure 4.5). Additionally, Mito-Tempo (1.5 fold ± 0.2, 
n=3, P=0.04) and NAC (1.4 fold ± 0.1, n=3, P=0.002) significantly increased PCG-
1α expression, albeit with a reduced effect. UCP-1 is known to mediate mROS 
production in part by mild uncoupling therefore, we wanted to investigate the effect 
of ERG treatment on UCP-1 expression. ERG significantly increased the expression 
of UCP-1 (1.6 fold ± 0.3, n=3, P=0.03) compared with controls (Figure 4.5). Mito-
Tempo (0.7 fold ± 0.33, n=3, P= 0.66) and NAC (0.76 fold ± 0.38, n=3, P= 0.61) did 
not alter UCP-1 expression. The expression of SOD1, SOD2 or SLC22A4 did not 












Figure 4.5: Effects of ERG, MitoTempo and NAC on placental expression of mitochondrial-detoxifying enzymes in H2O2 treated cells: 
Jeg-3 cells were pre-treated with ERG, MitoTempo and NAC for 2 hrs prior to exposure to H2O2 for 4 hrs and gene expression of markers of 
mitochondrial-detoxifying enzymes were quantified by real-time PCR. The amounts of amplified products were expressed relative to geometric 






4.5 Discussion  
 
To date, research has demonstrated that oxidative stress is a prime mediator in the 
pathophysiology of pre-eclampsia, and more recently there has been a specific focus 
on the role of mitochondrial dysfunction in regulating oxidative stress in pre-
eclampsia (109, 204). However, a number of vitamin antioxidants have been 
overwhelmingly unsuccessful as treatment strategies for pre-eclampsia (187, 347). 
This may be due to the fact that they remain sequestered in the cytoplasm and fail to 
reach the mitochondria, therefore restricting their capacity to alter the oxidative 
damage seen in pre-eclampsia, or because in the presence of free iron they are 
actually pro-oxidant (330). The overall aim of this study was to explore the 
mechanism of action of a novel, potential mitochondrial antioxidant, L-ergothioneine 
in regulating mitochondrial function in an in vitro model of placental oxidative stress 
and subsequently elucidate its role as a potential therapeutic target for pre-eclampsia.   
Initially, we wanted to investigate the cytoprotective effects of ERG on H2O2-
induced oxidative damage in Jeg-3 cells. We observed that 1mM ERG significantly 
preserved cell viability in response to the oxidative stress. Similarly, Paul et al, 
showed ERG exerted cytoprotective effects on HeLa cells following H2O2 treatment. 
Furthermore, these authors indicated that depletion of SLC22A4 markedly 
augmented sensitivity to pyrogallol-induced cell damage and death, reinforcing the 
physiologic antioxidant role of ERG (209). ERG has previously been used for the 
treatment of oxidative stress in human brain microvascular endothelial cells 
(HBMECs) where Li et al, showed ERG reduced cell death as well as oxidative 
stress (229). MitoTempo is an extensively studied mitochondrial-targeted antioxidant 
(109); therefore, we wanted to compare the efficacy of ERG in protecting cell 
143 
 
viability in comparison to the established MitoTempo. We demonstrated that ERG 
had increased cytoprotective properties when compared with MitoTempo. 
In the present study, we showed that ERG significantly reduced mitochondrial-
specific ROS production in Jeg-3 cells. Similarly, MitoTempo significantly reduced 
mROS production but with less potency than ERG. We have previously shown that 
MitoTempo also reduced mROS production in HUVEC cells incubated with plasma 
from women with pre-eclampsia (109). In comparison, in this in vitro model, ERG 
appeared to be more effective than was the non-mitochondrial antioxidant NAC, in 
reducing mROS generation, highlighting that ERG may combat placental oxidative 
stress evident in pre-eclampsia, by regulating mitochondrial reactive oxygen species 
production.  
Mitochondrial biogenesis is involved in the control of cell metabolism, signal 
transduction and regulation of mROS production. Mitochondrial mass describes the 
equilibrium between rates of biogenesis and degradation (348). We measured 
mitochondrial mass and found no significant difference in Jeg-3 cells pre-treated 
with ERG which would suggest that the dampening of mROS upon ERG treatment is 
not directly related to a disruption in mitochondrial dynamics. We previously 
reported that mitochondrial-targeted antioxidant MitoTempo reduced mROS 
generation without altering mitochondrial mass in pre-eclampsia plasma treated 
(109), a similar effect was also evident in placental cells upon MitoTempo treatment.  
PGC-1α is co-induced with numerous ROS-detoxifying enzymes upon exposure of 
cells to an oxidative insult and is often required for the activation of many these 
ROS-detoxifying enzymes, including SOD1, SOD2 and UCP-1 (336). We 
subsequently investigated if ERG altered the expression profile of mitochondrial-
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ROS detoxifying enzymes in response to H2O2-induced oxidative stress. We 
identified a significant increase in expression of both PGC-1α and its downstream 
target UCP-1, in cells pre-treated with ERG. PGC-1α has previously been shown to 
be significantly reduced in placental tissue in women with pre-eclampsia (349), 
additionally, there was significant evidence of dysregulation of mitochondrial 
biogenesis in these placental tissues. UCP-1 is directly regulated by PGC-1α (336) 
and has recently been shown to regulate mROS production, in addition to its 
recognised role in adaptive thermogenesis (350, 351). Mild uncoupling due to 
increased UCP-1 expression may participate in an antioxidant defence mechanism to 
dampen exaggerated mROS production. Proton leakage back to the mitochondrial 
matrix from the intermembrane space induced by UCP-1, alters membrane potential 
and decreases mROS production (Figure 4.6). (351).  
UCP-1 expression was also significantly increased by ERG treatment without 
exposure to H2O2-induced oxidative stress, suggesting that ERG treatment may 
prime trophoblast cells to respond more effectively to oxidative insult. While both 
MitoTempo and NAC had a marginal effect on PGC-1α expression, there was no 
additional effect on UCP-1 expression suggesting that ERG treatment may recruit 




Under non-pathological circumstances, the production of mROS is strictly regulated 
by many antioxidant systems in order to sustain redox-signaling homeostasis. We 
subsequently investigated the effect of ERG on both endogenous and H2O2 - induced 
expression of SOD1 and SOD2 antioxidants in JEG-3 cells and found no significant 
effect of ERG in either physiological state. Similarly, MitoTempo or NAC had no 
significant effect on the expression of either antioxidant. We have previously shown 
that MitoTempo-mediated reduction of mROS in HUVEC cells also didn’t directly 
alter the expression of SOD antioxidants.  
Here we provide evidence that the antioxidant ERG has significant cytoprotective 
properties in response to oxidative stress. ERG significantly reduced the generation 
of mROS without altering mitochondrial mass or antioxidant expression. This study 
presents novel data that ERG may be mediating its effects via increasing UCP-1 
expression which induces mild coupling and subsequent dampening of inflated 
mROS production. Finally, our study provides evidence that directly targeting 
mitochondrial superoxide scavenging with ERG could be a therapeutic candidate for 













Figure 4.6: Proposed mechanism of action of ERG in the placenta. There is 
evidence that links the potential role of ERG as: 1. A cytoprotective compound 
against H2O2 induced cell death. ERG works through SLC22A4 transporter. 2.  ERG 
directly scavenges mitochondrial-specific reactive oxygen species. 3. ERG modules 
mild uncoupling via alteration in expression of mitochondrial markers PGC-1α and 
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5.0 Chapter 5: L-ergothioneine as a potential therapeutic 
intervention in the treatment of Pre-eclampsia.  
 
5.1 Abstract  
 
Introduction: Pre-eclampsia is a multifactorial disorder of pregnancy and abnormal 
placentation and the resultant placental ischemia microenvironment is thought to 
play a crucial role in its pathophysiology. Placental ischemia due to fluctuations in 
the delivery of oxygen results in oxidative stress, and recent evidence suggests that 
mitochondrial dysfunction may be a prime mediator of oxidative stress in response 
to placental ischaemia. However, large clinical trials of therapeutic antioxidants for 
the treatment of pre-eclampsia have been disappointing. L-ergothioneine, an unusual 
amino acid derived from histidine, has important cytoprotective and antioxidant 
properties under conditions of high oxidative stress. 
Objective: In this study, we investigated the potential therapeutic effects of 
administration of L-ergothioneine in the reduced uterine perfusion pressure RUPP rat 
model of pre-eclampsia.  
Method: L-ergothioneine (25mg/kg/day) was administered to rats on gestational day 
11. On gestational day 14 RUPP surgery was performed and on gestational day 19, 
blood pressure (mean arterial pressure), fetal growth were measured. Kidney tissue 
samples were analysed for production mitochondrial-specific H2O2 in vivo. 
Results: L-ergothioneine ameliorated hypertension and significantly increased pup 
weight in RUPP rats. Mitochondrial-specific H2O2 was significantly increased in 
kidney tissue in RUPP rats compared with sham group. L-ergothioneine treatment 
significantly reduced mitochondrial-specific H2O2 generation in kidney tissue from 
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RUPP rats. L-ergothioneine significantly decreased circulating levels of anti-
angiogenic sFlt-1 in RUPP rats.  
Conclusion: This novel data supports the potential for a mitochondrial targeted 




5.2 Introduction  
 
Pre-eclampsia is a multisystemic disorder of pregnancy which results in high blood 
pressure accompanied by and/or proteinuria, acute kidney injury (AKI), liver 
dysfunction fetal growth restriction (FGR) after 20 weeks’ gestation (327), which 
affects more than eight million pregnancies worldwide annually and is the leading 
cause of maternal death (273). Despite extensive research, the exact 
pathophysiological mechanisms underlying this syndrome remain poorly elucidated.  
Nonetheless, defective placentation is strongly considered to be a critical event in the 
pathology of the disorder. Failure to remodel spiral arteries results in high-pressure 
blood-flow mediated placental damage and intermittent fluctuations in oxygen 
delivery, which expose the placenta to oxidative stress (266). The resultant placental 
ischaemic microenvironment is inherently linked to increased production and 
secretion of deleterious soluble mediators that provoke extensive maternal 
inflammation and endothelial dysfunction (352).  Several reports have observed 
higher levels of markers of oxidative stress (F2-isoprostanes, nitrotyrosine and 4-
hydroxynonenal staining) in placental tissue from pre-eclamptic pregnancies 
compared with uncomplicated pregnancies (353-356).  
While there are a number of different cellular sources of reactive oxygen species 
(ROS), mitochondria are the major cellular producers of ROS.  Furthermore, in 
terms of pre- eclampsia, there is growing evidence incriminating mitochondrial 
dysfunction in its underlying pathophysiology (279). Initial studies showed increased 
mitochondrial lipid peroxidation and enhanced susceptibility to oxidative damage in 
placental tissue of pregnancies complicated by pre- eclampsia (104).  More recently,  
work has confirmed this association with strong evidence of perturbation of 
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mitochondrial function in the metabolite profile of plasma samples taken at 15 
week’s gestation from patients who subsequently developed pre-eclampsia (66). 
There is significant evidence for the pathogenic role of oxidative stress in the 
development of pre-eclampsia, yet clinical trials of antioxidant interventions were 
disappointing and not clinically effective in treating the disorder. One very plausible 
explanation is that these antioxidants missed the intracellular location of ROS 
production, namely the mitochondria; hence they have failed to alleviate the 
pathological oxidative damage. L-ergothioneine (ERG) is an unusual thio-histidine 
betaine amino acid and is a naturally occurring anti-oxidant discovered over a 
century ago in the rye ergot (208-210, 357).  The predominant role of ERG, via a 
variety of mechanisms is to serve as an antioxidant and cellular protectant against 
various kinds of reactive oxygen species (358). Additionally, there has been some 
circumstantial evidence that ERG localises to mitochondria (216) and may dampen 
exaggerated mitochondrial-specific ROS in response to oxidative stress.  
 
Therefore, we aimed to investigate the role of ERG as a potential therapeutic target 
for pre-eclampsia using the reduced uterine perfusion pressure (RUPP) model in 
pregnant rats. The placental ischaemic RUPP model has numerous features of pre-
eclampsia that are evident in women and has been used as a preclinical model for the 
investigation of novel therapeutic targets for the treatment of pre-eclampsia (240, 
359). Moreover, we additionally wanted to examine if ERG ameliorated the clinical 
characteristics of pre-eclampsia in part via regulation of mitochondrial-specific ROS 
production. Therefore, using a novel ratiometric mass spectrometry probe MitoB that 
specifically accumulates in mitochondria and generates a MitoP phenol product upon 
reaction with H2O2 which can be subsequently be analysed ex vivo by mass 
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5.3 Materials and Methods  
 
5.3.1 Animals  
 
Sprague Dawley-timed pregnant rats were supplied and maintained by the University 
College Cork Biological Services Unit. Animals were maintained at a temperature of 
21˚C, with a 12-hour light/dark cycle and free access to food and tap water. All the 
procedures were performed in accordance with National Guidelines and the 
European Directive 2010/63/EU, under an authorization issued by the Health 
Products Regulatory Authority Ireland and approved by the Animal Ethics 
Committee of University College Cork (AE19130/P037).  
5.3.2 RUPP procedure  
 
The RUPP procedure is a well-established surgical model for studying the link 
between placental ischemia and hypertension in the pregnant rat and has been 
previously described in detail (240, 253). In brief, on gestational day (GD) 14, RUPP 
reduction in blood flow to the uteroplacental unit was achieved by placing silver clip 
(0.2 mm ID) on the abdominal aorta (1 clip) above the iliac bifurcation and 
furthermore, 2 clips (0.1 mm ID) were carefully placed around the left and right 
ovarian arteries. Sham surgery was performed as controls, which involved abdominal 
incision but didn’t involve insertion of any clips on either abdominal aorta or ovarian 
arteries. On GD18, a chronic indwelling catheter was inserted into the carotid artery 






5.3.3 L-ergothioneine In vivo experimental protocol  
 
Four experimental groups were used to investigate the effect of administration of 
ERG in the RUPP rat model of pre-eclampisa. Pregnant rats were divided into Sham 
(n=8), Sham+ERG (n=8) or RUPP (n=8), and RUPP+ERG (n=8). ERG was 
administered at (25mg/kg/day) in their drinking water on GD11 until the end of the 
experiment on GD19. The dose for ERG (25mg/kg/day) were selected based on 
previously published rodent studies using this antioxidant (360, 361).  L-
ergothioneine were provided by Tetrahedron (Paris, France; www.tetrahedron.fr).  
 
5.3.4 Plasma Collection  
 
Blood collected from EDTA vacutainers were centrifuged at 2000g and 2400g for 10 
minutes respectively at 4˚C, plasma was removed and stored at -80˚C for further 
analysis.  
5.3.5 Urine analysis  
 
On GD18, each rat was singularly housed in a metabolic cage and urine collected 
overnight. All samples were stored immediately following collection at -80oC. 
Microalbumin creatinine ratios were calculated following measurement of albumin 
using an immuno-turbidimetric test for the quantitative determination of albumin in 
an OLYMPUS AU5832 analyser® and creatinine using a kinetic colour test (Jaffé 
method) (362) for the quantitative determination of creatinine in urine. Similarly, 
protein creatinine ratios were calculated following measurement of protein by adding 
benzethonium chloride which resulted in the formation of a fine suspension, which 




5.3.6 Measurement of anti-angiogenic protein sFlt-1 by ELISA 
 
Circulating sFlt-1 concentration in plasma samples from all experimental groups 
were quantified by enzyme-linked immunosorbent assay (ELISA) using a 
Quantikine sFlt-1 immunoassay (R&D Systems) as per manufacturers’ instructions.  
5.3.7 Isolation of RNA and Real-time PCR analysis 
 
RNA was extracted from placental tissue using the Trizol method. SLC22A4 (ERG 
transporter), superoxide dismutase 1 (SOD1), SOD2, and uncoupling protein-1 
(UCP-1), PCG-1α and Nrf2 gene expression was quantified by Real-time PCR using 
StepONE Plus Detection system. Taqman assays (Applied Biosciences) and Sybr 
Green primers were used for quantification. The amounts of target gene normalised 
to geometric mean control of 18S were determined using 2-ΔΔCT.  
5.3.8 Isometic Myography 
 
In all groups, third order mesenteric arteries were dissected and mounted on a 4-
channel wire myograph (Model 610 mol/L Danish Myo Technology) containing 
oxygenated (95% O2 and 5% CO2) physiological salt solution (PSS) at 37˚C. Vessels 
were normalized to achieve a transmural pressure of 100mmHg using the DMT 
Normalization software. Isometric tension was recorded and displayed using 
Powerlab Chart Software (AD Instruments). The viability of the smooth muscle was 
examined by the addition of a 123 mmol/L KCl solution. After PSS washes, 
concentration responses were carried out with thromboxane mimetic U46619 (9,11-
Dideoxy-11α,9α-epoxymethanoprostaglandin F2α; 10
-9 to 10-5 mol/L) ,and either 
Bradykinin (BK; 10-8 to 10-5 mol/L), Acetylcholine (ACh; 10-8 to 10-5 mol/L), or 
Sodium Nitroprusside (SNP; 10-8 to 10-5 mol/L) respectively (259, 363). 
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5.3.9 Measurement of mitochondrial H2O2 in the RUPP model In vivo  
 
Mitochondrial hydrogen peroxide was measured in vivo by Cayman Chemical using 
Cayman’s Hydrogen Peroxide Ratiometric MaxSpec kit based on the MitoB mass 
spectrometric probe as described previously (364). Briefly, 75 nmol MitoB in 50μl 
saline was administered by tail-vein injection to rats in the 4 experimental groups on 
GD19, 4 hours prior to end of the experiment. At the end of the procedure, kidney 
tissues were dissected out, snap frozen and stored at −80 °C. For mitochondrial H2O2 
analysis, kidney tissues were homogenised, spiked with deuterated internal standards 
and MitoB and its product MitoP were extracted using acetonitrile/formic acid. 
MitoB and MitoP present in kidney tissue were measured using UPLC Xevo TQD 
mass spectrometer (Waters) and the amounts of MitoP and MitoB in each sample 
was determined relative to a standard curve. The MitoP/MitoB ratios for each sample 
were then calculated. 
5.3.10 Statistical analysis  
 
All data are expressed as mean ± SEM, or fold change relative to control. Analysis 
was performed using GraphPad Prism. Data was represented as mean (±SEM) and 
comparisons of data between cases and controls were performed using an unpaired t-




5.4 Results  
 
5.4.1 L-ergothioneine ameliorated RUPP induced hypertension  
 
MABP was significantly increased in the RUPP group compared with sham group 
(130.87 ± 3.54 mmHg vs 119.99 ± 6.27 mmHg, P = 0.02; Figure 5.1). Furthermore, 
administration of ERG significantly reduced MABP in the RUPP rats (130.87 ± 3.54 
mmHg v 118.38 ± 4.86 mmHg) (P= 0.05; Figure 5.1). MABP in sham rats treated 
with ERG was not different from RUPPs treated with ERG, indicating the beneficial 
effect of ERG antioxidant in reducing blood pressure in response to placental 
ischemia. There was no significant difference in microalbumin:creatinine (MCR) 
ratio in the RUPP group compared to Sham group, equally, there was no significant 
difference in the MCR ratio in the RUPPs treated with ERG (Figure 5.2).  
 


















Figure 5.1: L-ergothioneine attenuates blood pressure in reduced uterine 
perfusion pressure (RUPP) rats: a) RUPP rats (n=8) showed significantly elevated 
mean arterial blood pressure (MABP) compared with sham group (n=8). L-
ergothioneine (25mg/kg/day) reduced MABP in RUPP rats (n=8). Data is presented 
as mean ± SEM, P<0.05 
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Figure 5.2: L-ergothioneine did not alter microalbumin:creatinine ratio in 
RUPP rats: Administration of L-ergothioneine (25mg/kg/day) did not significantly 




5.4.2 Effect of L-ergothioneine of fetal weight 
 
Fetal weight was significantly decreased in the RUPP group compared to the Sham 
group (1.80 ± 0.04 g v 1.99 ± 0.03 g; P= 0.0004; Figure 5.3A). Administration of 
ERG significantly rescued fetal growth restriction in the RUPP rats (1.98 ± 0.03 g v 
1.80 ± 0.04g, P= 0.0006; Figure 5.3A). Placental weights were significantly reduced 
in RUPP group compared to Sham group (0.43 ± 0.01 g v 0.50 ± 0.01 g; P= 0.002, 
Figure 3B). The administration of ERG had no effect on placental weight in the 
RUPP rats (0.42 ± 0.007 g v 0.43 ± 0.01 g) (Figure 5.3B). A significant decrease in 
pup number was observed in the RUPP group compared to Sham group (10.5 ± 1.40 
v 13.5 ± 1.08; P= 0.02, Figure 5.3C). There was no significant difference in pup 
number in RUPPs treated with ERG (12.87 ± 1.60 v 10.5 ± 1.40). Pup weight was 
not significantly different between Sham or RUPPs treated with ERG, indicating the 
beneficial effect of mitochondrial antioxidants in rescuing fetal weight during 
placental ischemia. There was no significant difference in the crown to rump length 
(CRL) of pups in any of the studied groups (Figure 7.S1. Supplementary). Finally, 










































































Figure 5.3: L-ergothioneine, improves fetal outcomes in RUPP rats: RUPP rats (n=8) show reduced a) pup weight and b) placental weight 
and c) litter size compared with sham group (n=8).  Administration of L-ergothioneine (25mg/kg/day) improved fetal outcome in RUPP rats. 
Data is presented as mean ± SEM, P<0.05. 
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5.4.3 Effect of L-ergothioneine on circulating sFlt-1 
 
There was no significant increase in the circulating soluble anti-angiogenic mediator 
sFlt-1 in the RUPP group compared to the sham group (2245.18 ± 263.18 pg/ml v 
1365.99 ± 345.73 pg/ml, P= 0.27) (Figure 5.4). Administration of ERG significantly 
decreased circulating sFlt-1levels in RUPP rats (1444.04 ± 220.61 pg/ml, P= 0.03; 
Figure 4).  
 


















Figure 5.4: L-ergothioneine reduces circulating anti-angiogenic factor sFlt-1 in 
RUPP rats: Circulating levels of sFlt-1 were higher in RUPP rats (n=8) compared 
with sham controls (n=8). L-ergothioneine significantly reduced circulating sFlt-1 





5.4.4 Effect of L-ergothioneine on vasorelaxation in the RUPP model  
 
Mesenteric arteries from the RUPP group displayed impaired vasorelaxation in 
response to bradykinin (BK) when compared to the sham group (Rmax: 28 ± 7% 
versus 52 ± 9%; P= 0.01, log EC50: -6.62 ± 0.18 versus -6.77 ± 0.32 mol/L; P=0.67, 
Figure 5.5). However, no significant differences were seen in the vascular response 
to the endothelial independent vasodilator sodium nitroprusside (SNP) (Rmax: 78 ± 
5% versus 80 ± 4.5%; P= 0.36, log EC50: -7.09 ± 0.17 versus -7.17 ± 0.35 mol/L, 
P=0.85, Figure S3.A) or Acetycholine (ACh) (Rmax: 83 ± 8% versus 81 ± 6%; P= 
0.14, log EC50: -7.097 ± 0.15 versus -7.006 ± 0.10 mol/L, P= 0.62 Figure S.3B). 
Treatment with ERG had a significant effect on Ach (Rmax: 83 ± 8% versus 71 ± 4%; 
P= 0.66, logEC50: -7.127 ±0.17 versus -6.809 ± 0.11, P= 0.04, Figure 5.10.SA) in 
RUPP rats. Treatment with ERG had no significant effect on the vasorelaxant 
responses of mesenteric vessels in response to BK (Rmax: 23 ± 5% versus 28 ± 7%; 
P= 0.87, log EC50:-6.627 ± 0.18 versus -6.755 ± 0.21 mol/L, P=0.67, Figure 5.5), or 
SNP (Rmax: 78 ± 5.7% versus 74 ± 4%; P= 0.76, log EC50: -7.079 ± 0.17 versus -
7.145 ± 0.24, P=0.87, Figure 5.10.SB) in RUPP rats. 

























Figure 5.5: Impaired vasorelaxtion in mesenteric arteries in the RUPP model 
RUPP rats: RUPP rats (n=8) showed significant impaired vasorelaxation to 
bradykinin compared to sham group. L-ergothioneine did not attenuate the impaired 
vasorelaxation to bradykinin compared to the RUPP group. Relaxation is calculated 
as a percentage of the maximum contraction and expressed as mean ± SEM. P<0.05.   
5.4.5 L-ergothioneine alters placental expression of markers of mitochondrial-
ROS detoxifying enzymes 
 
Placental expression of mitochondrial orchestrator proliferator activated receptor ƴ 
co-activator 1-α (PGC-1α) (0.4 fold ± 0.2, P= 0.008, Figure 5.6A) and 
mitochondrial-ROS detoxifying enzymes including uncoupling protein 1 (UCP-1) 
(0.2 fold ± 0.5, P= 0.04) were significantly decreased in the RUPP group compared 
to sham group. Nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a transcriptional 
regulator of the mitochondrial antioxidant defence system and coactivated by PGC-
1α was also significantly reduced in the RUPP group when compared with the sham 
group (0.4 fold ± 0.3, P= 0.001, Figure 5.6). Placental expression of SOD1 
antioxidant was significantly increased (1.4 fold ± 0.4, P= 0.02; Figure 5.6B), while 
mitochondrial SOD2 antioxidant was significantly reduced (0.6 fold ± 0.3, P= 0.01, 
Figure 5.6B) in RUPP group compared with sham group. 
ERG treatment significantly increased placental expression of PGC-1α (1.7 fold ± 
0.2, P= 0.02), UCP-1 (4.9 fold ± 0.5, P= 0.001) and Nrf2 (1.58 fold ± 0.3, P= 0.02, 
Figure 5.6A) in RUPP rats. ERG treatment significantly increased placental 
expression of SOD2 in RUPP rats (1.5 fold ± 0.3, P= 0.01, Figure 5.6B). There was 
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no significant difference in placental expression of the ERG transporter SLC22A4 in 


































































Figure 5.6: L-ergothioneine regulates placental expression of both markers of mitochondrial-ROS detoxifying enzymes in RUPP rats: a) 
Placental expression of PGC-1α, UCP-1 and Nrf2 expression were significantly reduced in RUPP rats (n=8) compared with sham group (n=8). 
L-ergothioneine significantly increased placental expression of all these mitochondrial markers in RUPP rats. b) Placental expression of 
antioxidant SOD1 was significantly increases while mitochondrial SOD2 expression was significantly decreased in the RUPP group compared to 
sham group. L-ergothioneine significantly increased mitochondrial antioxidant SOD2 expression in RUPP rats.  SLC22A4 expression was not 




5.4.6 L-ergothioneine reduces mitochondrial-specific H2O2 in kidney tissue  
 
MitoP/MitoB ratio showed an increasing trend in kidney tissue of the RUPP group 
compared with the Sham group (0.028 ± 0.001 v 0.024 ± 0.006; n=3, P=0.01, Figure 
5.7), indicating for the first time that mitochondrial-specific H2O2 is increased in vivo 
as a result of placental ischaemia. Furthermore, pre-treatment with ERG significantly 
reduced the MitoP/MitoB ratio in kidney tissue in RUPP rats (0.024 ± 0.003 v 0.022 
± 0.001; n=3, P=0.05, Figure 5.7), establishing that L-ergothioneine reduces 
mitochondrial-specific H2O2 production in vivo. 
 



























Figure 5.7:  L-ergothioneine reduces mitochondrial-specific H2O2 levels 
Rats were injected with MitoB for 4 hrs and the ratios of MitoP/MitoB were 
determined by LC/MS/MS. Data is represented as Mean ± SEM of 3 samples per 
group and corrected for ratio. Statistical analysis was determined by a two-tailed 
student t-test: * P < 0.05.  
 




Despite a significant amount of publications providing evidence for the pathological 
role of oxidative stress in the development of pre-eclampsia, clinical data from 
antioxidant vitamin trials have been negative (187, 365). One probable reason for 
these negative findings  may be due to the fact these interventions missed the 
primary intracellular producer of ROS, namely the mitochondria; or because in the 
presence of free iron they are actually pro-oxidant (330).  In the present study, L-
ergothioneine, an amino acid with potent antioxidant properties, attenuated 
hypertension and rescued fetal growth restriction in the preclinical RUPP rat model 
of pre-eclampsia, which closely mimics many aspects of pre-eclampsia during 
pregnancy. Additionally, this study also reported the novel finding of reduced 
mitochondrial H2O2 levels in vivo following L-ergothioneine administration. This 
work has established L-ergothioneine as a mitochondrial-targeted antioxidant, which 
ameliorated a number of phenotypic features of pre-eclampsia in a preclinical model 
of disease, mediated in part by the reduction of mitochondrial-ROS, and 
subsequently highlighted its potential as a viable therapeutic for the treatment of pre-
eclampsia. 
 
L-ergothioneine is a water-soluble amino acid that is derived entirely from dietary 
sources. It has garnered much attention recently, as a potential therapeutic 
intervention due to its influential antioxidant resources, in addition to its preferential 
accumulation within tissues undergoing significant oxidative stress. A recent study 
investigating the reproductive safety profile of ERG in pregnant Sprague Dawley 
rats, established that ERG was well tolerated and with no adverse effects on a 
number of parameters (number of mating days, gestation length, pup viability index 
or litter parameters) (231). Furthermore, ERG treatment of diabetic rats significantly 
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improved embryo formation and quality (366).  Collectively these data suggest ERG 
treatment may be safe to use in pregnancy and may prevent embryo malformations 
mediated by oxidative stress early in pregnancy, hence we decided to administer 
ERG at an early point in pregnancy (GD11) in the preclinical RUPP model of pre-
eclampsia. 
 
The therapeutic effects of ERG in response to induced tissue damage in models of 
ischemic-reperfusion injury in the liver (225) and intestine (360)  have previously 
been reported by the dampening of markers of oxidative stress and inflammation. 
Our novel data using ERG reported a reduction in hypertension and an improvement 
in fetal weight in response to placental ischemia in the preclinical RUPP model of 
pre-eclampsia, in part due to regulation of mitochondrial-specific ROS.  Recent 
evidence identified a prominent role for mitochondrial-specific ROS (mROS) in 
modulating hypertension (108). Using two in vivo murine models of hypertension 
(Ang II-induced and DOCA salt), this group established that using a mitochondria-
targeted antioxidant (Mito-Tempo) alleviated endothelial dysfunction, reduced 
vascular mitochondrial superoxide and subsequent hypertension (108).  Furthermore, 
similar to our work, Vaka et al showed in the preclinical RUPP model that placental 
ischemia dysregulated mitochondrial function with elevated mROS and identified 
that treatment with mitochondrial targeted antioxidants attenuated hypertension with 
improvement in fetal outcomes in treated RUPP rats (204). 
Deleterious circulating mediators including sFlt-1 are secreted in response to 
placental ischemia and have devastating consequences on the maternal vasculature. 
Furthermore, we previously detected increased levels of mitochondrial-specific 
superoxide production in HUVEC’s incubated with plasma from women with pre-
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eclampsia compared with matched controls and non-pregnant controls (109). 
Additionally, Zsengeller et al. established an inverse correlation between placental 
sFlt-1 and mitochondrial complex IV, suggesting that sFlt-1 may be harmful to 
mitochondria in pre-eclampsia (30).  In our study, ERG treatment reduced the 
circulating levels of sFlt-1 in RUPP rats, indicating that ERG may preserve 
mitochondrial function in part by reducing the availability of sFlt-1 to induce 
mitochondrial damage. The reduction in sFlt-1 as a result of ERG treatment didn’t 
result in a subsequent reduction in maternal vascular dysfunction in the RUPP rats.  
The capacity to accurately measure the concentration of reactive oxygen species, in 
particular mitochondrial-specific ROS in vivo has proved to be extremely 
challenging yet is essential in understanding their physiological roles in certain 
disease entities. The detection of mitochondrial-specific ROS such as superoxide 
using fluorescent probes can be inferred, with certain caveats, specifically in regards 
to the difficulty of accurately quantifying fluorescence changes , or ex-vivo tissue 
measurements of ETC complexs, these methods can be less selective and sensitive 
due to excess processes and equally not physiologically relevant. One potential 
alternative is to use exogenous ratiometric probes (MitoB) injected into the animal 
models, that readily accumulate in mitochondria of tissues due to its 
triphenylphosphonium cation composition and which reacts with H2O2  in vivo to 
produce a diagnostic exomarker (MitoP) that can be accurately quantified by mass 
spectrometry (367).  
In this study, we have shown for the first time that this method of measuring 
mitochondrial H2O2 production in vivo is applicable in a rat model, without any 
adverse effects on reproductive safety. Furthermore, we reported that mitochondrial 
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H2O2 was significantly increased in kidney tissue in the RUPP group compared with 
the Sham group. This is in agreement with recent work by Vaka et al, have shown an 
increase in mROS in kidney tissue in the RUPP group by examining ETC activity 
and cellular respiration ex-vivo using isolated mitochondria from kidney tissues 
(204). More importantly, treatment with ERG resulted in a significant reduction in 
mitochondrial-specific H2O2 production in kidney tissue in RUPP rats, indicating 
that ERG may be mediating its therapeutic effects in part by directly reducing mROS 
production in the preclinical model of pre-eclampsia. Further evidence to support our 
theory is provided by the fact that placental expression of markers of mitochondrial-
ROS detoxifying enzymes and their transcriptional regulators were significantly 
improved in ERG treated RUPP rats in contrast to their reduced expression in RUPP 
rats.  
At present, only one study has investigated the pharmacokinetics of ERG 
administration in human subjects (232).  ERG was rapidly absorbed and retained 
within the tissue/plasma with relatively low urinary excretion (<4% of administered 
dose). This work was further extended by YiTang et al. who established that ERG 
and its metabolites are widely distributed in various tissues in male mice 
administered ERG over a range of days, this group also established that ERG was 
highly retained in the body and suggested this could be as a result of possible 
reabsorption by the kidneys (234). 
This study provides evidence of the therapeutic potential of ERG in in a preclinical 
model of pre-eclampsia.  ERG improved high blood pressure and fetal weight in the 
RUPP rat model of pre-eclampsia. Furthermore, ERG treatment significantly altered 
mitochondrial function in both the kidney and placental tissue which may in part be 
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responsible for the beneficial effects on phenotypic features of pre-eclampsia in the 
RUPP model. Given its favourable safety profile, it’s long half-life and resistance to 
auto-oxidation and multiple mechanisms of action, not least its ability to regulate 
mitochondrial function, further studies are needed to explicitly define the protective 




The cause of pre-eclampsia has remained an enigma despite intense research efforts 
in recent decades. Consequently, effective interventions and treatments remain 
elusive and currently there is no effective treatment for pre-eclampsia. Overall, this 
thesis provides evidence that exaggerated mitochondrial-specific ROS plays a 
pathological role in the development of hypertension in response to placental 
ischemia in a preclinical rat model of pre-eclampsia. Additionally, this thesis 
demonstrates that ERG, a nutraceutical antioxidant that targets mitochondria and 
reduces mitochondrial-specific ROS opens a new avenue of investigations for new 




































Figure 5.7 S.1: L-ergothioneine did not affect maternal weight in RUPP rats: 








Figure 5.8 S.1: L-ergothioneine did not alter fetal crown to rump measurements 













Figure 5.9.S: Vasorelaxtion in mesenteric arteries: RUPP rats (n=8) showed no vasorelaxation impairment to a) Sodium nitroprusside and b) 
Acetylcholine compared to sham group. Relaxation is calculated as a percentage of the maximum contraction and expressed as mean ± SEM. 
P<0.05 


















































Figure 5.10.S: L-ergothioenine had no significant effect on endothelial dysfunction RUPP rats: L-ergothioneine treatment of RUPP rats 
(n=8) significantly decreased the impaired vasorelaxation to a) Acetylcholine and did not attenuate the impaired vasorelaxation to b) Sodium 























































Chapter 6: Final Discussion   
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6.0 Chapter 6: Final Discussion  
 
6.1 Summary of Results  
 
This thesis focused on the pathophysiological role of mitochondrial dysfunction in 
pre-eclampsia and investigated the potential therapeutic potential of mitochondrial- 
targeted antioxidants, specifically L-ergothioneine for the treatment of this disorder. 
Pre-eclampsia is proposed to result from placental disease and progresses in two 
stages; abnormal placentation early in the first trimester subsequently followed by a 
maternal syndrome in the late second and third trimesters (38, 368), which 
consequently exposes the placenta to elevated levels of oxidative stress due to 
fluctuations in oxygen delivery. There is a growing body of evidence indicating that 
mitochondrial dysfunction acts as a pathogenic mediator of oxidative stress in pre-
eclampsia and modulates the clinical characteristics of this syndrome (268, 271, 272). 
Mitochondria are the central cellular source of reactive oxygen species (ROS) and 
excessive production of mitochondrial-specific ROS is intrinsically linked to 
mitochondrial dysfunction (136, 267). During pre-eclampsia the compensatory 
properties regulating placental oxidative state are exhausted, leading to increased 
production of deleterious inflammatory factors and subsequent vascular dysfunction.  
Mitochondrial DNA (mtDNA) are extremely vulnerable to damage due to their 
proximity to the region of ROS production and their deficiency of histone protection, 
and are often expelled into circulation as an indicator of mitochondrial dysfunction 
(89). There is genetic evidence which supports the involvement of mitochondrial 
dysfunction in mediating pre-eclampsia, as there was a high incidence of pre-
eclampsia in families with pre-diagnosed mitochondrial dysfunction (271). Similarly, 
research has shown a positive association of mtDNA in maternal circulation with 
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increased risk of pre-eclampsia (268). Therefore, firstly I wanted to determine if 
mitochondrial dysfunction was evident in our cohort of 60 pre-eclampsia cases 
compared to 120 matched healthy controls from the SCOPE Cork cohort (Chapter 2). 
I showed that SOD antioxidant activity was significantly decreased at 15 weeks’ 
gestation with a corresponding increase in ΔmtDNA copy number at 15 and 20 weeks’ 
gestation in the pre-eclampsia cases compared to healthy matched controls. These 
findings highlighted that mitochondrial dysfunction has a role in the pathophysiology 
of pre-eclampsia.  
The next step of this thesis was to determine if mitochondrial dysfunction evident in 
the pre-eclampsia cases of our study cohort provoked an innate inflammatory response 
(Chapter 3). In this chapter, I showed that TLR9 activity, a receptor for mtDNA, was 
significantly increased at time of disease in pre-eclampsia. Furthermore, I have shown 
a corresponding increase in production of neutrophil activation markers of innate 
inflammation particularly at the time of disease in pre-eclampsia. This provides 
evidence that circulating plasma mediators (including dysfunctional mitochondria) 
activate a TLR9-mediated innate immune response in pre-eclampsia.  
Given that I have provided preliminary evidence that mitochondrial dysfunction has a 
potential pathophysiological role in pre-eclampsia, I wanted to test the hypothesis, that 
using a specific mitochondrial-targeted antioxidant, ERG, would alleviate 
mitochondrial-specific ROS generation evident in pre-eclampsia. To support this 
hypothesis, I initially performed in vitro experiments with a Jeg-3 trophoblast cell line 
pre-treated with ERG and subsequently exposed to an oxidative insult H2O2 and a 
number of mitochondrial parameters were measured (Chapter 4). In this chapter, I 
determined that pre-treatment with ERG had cytoprotective effects following 
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exposure to H2O2 insult. I showed ERG significantly reduced mitochondrial specific 
superoxide production, without altering mitochondrial mass. Furthermore, I described 
that ERG potentially mediated its protective effects via a PGC1-α regulated response 
involving increased expression of UCP-1 which may provide an alternative route to 
reducing exaggerated mROS generation and allied deleterious properties.    
To further support the potential therapeutic role of ERG in dampening exaggerated 
oxidative stress and possibly mediating some of the clinical characteristics of pre-
eclampsia, I wanted to examine its therapeutic effects in the Reduced Uterine 
Perfusion Pressure (RUPP) rat model, a preclinical in vivo model of pre-eclampsia 
(Chapter 5). Rats were administered ERG on GD 11 prior to RUPP surgery. In this 
study, I showed that ERG significantly reduced blood pressure in the ERG treated 
RUPP rats. Furthermore, I saw a significant increase in pup weight in the ERG treated 
RUPP rats. Interestingly, I provided novel evidence that ERG significantly dampened 
mitochondrial H2O2 production in vivo in kidney tissue using unique ratiometric 
exomarker probes. Additionally, I also provided evidence that ERG positively altered 
the placental expression profile of mitochondrial-ROS detoxifying enzymes and their 
mitochondrial transcriptional regulators in RUPP rats, similar to the changes I had 
seen in my in vitro placental model (Chapter 4). 
This current thesis highlights that mitochondrial dysfunction has a role in the aetiology 
of pre-eclampsia by potentially provoking a neutrophil-driven innate immune 
response via TLR9 activation. Furthermore, I have shown that mitochondrial-targeted 
antioxidant ERG mediates its protective properties in in vitro and in vivo models of 
pre-eclampsia in part by directly educing mROS production with consequent 
amelioration of clinical characteristics of pre-eclampsia. 
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 6.2 Implications of this work  
 
This thesis has shown that mitochondrial dysfunction plays a pathophysiological role 
in pre-eclampsia by potentially activating a neutrophil-mediated innate immune 
response and that treatment of this disorder with specific mitochondrial-targeted 
antioxidants warrants future investigations. Pre-eclampsia was first considered to be a 
mitochondrial disorder in the 1980s (271). It was shown later that mitochondrial 
dysfunction in pre-eclampsia placentas induces oxidative stress (104). To date, there 
is evidence of disruptive homeostasis in factors regulating oxidative stress, with a 
decline in the antioxidant system and an increase in prooxidative ROS in women with 
pre-eclampsia (277, 289, 369). I provide evidence in this thesis that mitochondrial 
dysfunction is a significant contributor to this disruption. Mitochondrial DNA 
(mtDNA) encodes for 37 genes programmed by the mitochondrial genome (78) and is 
frequently used as a biomarker of mitochondrial dysfunction. mtDNA is particularly 
vulnerable to oxidative damage due to their intimate location in  the electron transport 
chain (ETC) in the mitochondrial matrix and their lack of protective histones (282). 
In the first study (Chapter 2), my results are in agreement with previous research 
investigating the role of mitochondrial dysfunction in pre-eclampsia (109, 268, 272, 
294, 370). In Chapter 2, I investigated for evidence of mitochondrial dysfunction 
longitudinally in the SCOPE Cork cohort. In early gestation, mtDNA was not 
significantly different between cases and controls at 15 and 20 weeks’ gestation. 
However, a significant increase in ΔmtDNA (15 and 20 week cases v 15 and 20 week 
controls) was evident. This increase in mtDNA early in gestation in women with pre-
eclampsia correlated with the increased in mtDNA at time of disease in pre-eclampsia 
previously described by our research team (109). Upon longitudinal investigation, I 
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showed that mtDNA increased in cases as gestation progressed. The limitations to this 
study was the sample size for time of disease (n=25), even though there was a 
significant difference seen between cases and controls, the TOD cohort was smaller 
than 15 and 20 weeks (n=60) cohorts used in my investigations. Equally, in this thesis 
I used samples from the SCOPE Cork cohort, therefore it would be interesting for 
future studies to examine mtDNA in a larger multinational cohort to examine 
additional determinants of mtDNA levels such as ethnicity.  
Oxidative stress results from an imbalance in production of ROS and antioxidant 
levels. SOD antioxidants play a critical role in mediating oxidative damage instigated 
by exaggerated superoxide generation in pre-eclampsia. In this thesis, I showed that 
there was a significant reduction in SOD activity at 15 weeks’ gestation in pre-
eclampsia. This result correlates with previous research where SOD levels at 10-14 
weeks’ and 20-24 weeks gestation were significantly lower in pre-eclampsia (291). 
When examining the point in gestation where the decrease in SOD activity was most 
evident in my cohort, my results propose that the increase in ΔmtDNA seen between 
15-20 weeks in pre-eclampsia may be a consequence of reduced SOD antioxidant 
activity at 15 weeks which consequently increased vulnerability of mtDNA to 
oxidative damage.  
There is circumstantial evidence that both exercise and healthy eating protect against 
mitochondrial diseases by maintaining mitochondrial function (297, 298), therefore, 
in this thesis, I wanted to examine if lifestyle and nutritional factors had an effect on 
the amount of mtDNA (mitochondrial dysfunction) in cases and controls throughout 
pregnancy. In this study, I showed that there both exercise and nutritional intake had 
no significant effect on mtDNA. This was in agreement with previous studies (268, 
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302), where no association between lifestyle and nutritional factors and pregnancy 
outcome, despite diet being suggested to play a possible role in the management of 
pre-eclampsia (301). Future research specifically focused on the role of lifestyle and 
nutritional factors in mediating mitochondrial function using additional biochemical 
markers would be of interest. In this current study I used retrospective data from the 
SCOPE cohort from women who self-reported on their exercise levels. One potential 
improvement to generate more quantitative correlations in future research could 
involve monitoring exercise in study participants using mobile monitoring devices 
such as the FitBit.  
While highlighting that mitochondrial dysfunction plays a pathophysiological role in 
pre-eclampsia in Chapter 2 in my thesis, the next part of my thesis was to examine if 
mtDNA provokes an innate immune response in pre-eclampsia (Chapter 3). The innate 
immune system and its mediators particularly neutrophils, play a role in the aetiology 
of pre-eclampsia (129, 130, 371, 372). In healthy uncomplicated pregnancy, there is 
evidence of a control systemic inflammatory response (373). Neutrophils are activated 
during pregnancy, however they are further stimulated in pre-eclampsia (374). There 
is exciting evidence that dysfunctional mitochondria may provide a possible trigger in 
activating the innate immune system (136). It is thought that mtDNA may act as 
DAMPs and provoke an innate immune response by binding to TLR9 on the surface 
of immune cells particularly circulating neutrophils. In this thesis, I showed that there 
was a significant increase in TLR9 activity at time of disease in women with pre-
eclampsia compared to matched controls. In agreement with my results, previous 
studies have shown an increase in TLR9 expression in both placental and PMBC from 
women with pre-eclampsia (140, 310).  
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I also showed there was a corresponding increase in the production of neutrophil 
activation markers, calprotectin, myeloperoxidase, MMP8 and pro-inflammatory 
cytokine IL-8 in pre-eclampsia compared with matched controls. In this thesis, I 
wanted to measure TLR9 activation throughout gestation in both cases and controls. 
Interestingly, TLR9 was only significantly activated at time of disease (late in 
gestation) which correlates with the significant increase in mtDNA at this point also 
in gestation. When examining markers of neutrophil activation and innate 
inflammation, it became evident that while the inflammatory system may be initially 
activated early in pregnancy, the systemic response is significantly heightened in the 
third trimester of pregnancy which is further supported by a number of recent studies 
investigating inflammatory cytokine profiles in women with pre-eclampsia (325, 326, 
375). Access to neutrophil counts would have allowed me to directly correlate the 
results from neutrophil activation markers from both study cohorts, however, this was 
not possible in SCOPE study. 
Having determined that mitochondrial dysfunction plays a pathogenic role in pre-
eclampsia, I next sought to examine the possibility of directly targeting mitochondria 
by using specific antioxidants to see if they could ameliorate some of the deleterious 
effects of mitochondrial dysfunction and exaggerated oxidative stress. The antioxidant 
I used in my thesis was the mitochondrial-targeted antioxidant L-ergothioneine, in part 
due to its safety profile in humans and subsequent potential to rapidly translate to a 
clinical setting. To date, there has been extensive research showing that oxidative 
stress is a prime mediator in the pathophysiology of pre-eclampsia yet antioxidants 
have been overwhelmingly unsuccessful in the treatment of pre-eclampsia as evident 
from numerous large clinical trials (187, 347). This may be due to the fact that these 
vitamin antioxidants remain sequestered in the cytosol and fail to reach the 
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mitochondria, therefore restricting the capacity to alter the oxidative damage seen in 
pre-eclampsia. In Chapter 4, for the first time I showed ERG’s potential mechanism 
in a model of oxidant stress in placental cells. In this chapter I presented novel data 
that ERG may be mediating its effects via increasing UCP-1 expression which induces 
mild coupling and subsequent dampening of inflated mROS production while 
highlighting its potential as a therapeutic intervention in pre-eclampsia. 
In my final chapter (Chapter 5), I examined ERG’s therapeutic potential in an in vivo 
preclinical model of pre-eclampsia. The RUPP model is most widely used model for 
the study of pre-eclampsia (240, 253, 376, 377). In this chapter, I showed that ERG 
ameliorated some of the clinical characteristics of pre-eclampsia, namely reduction 
in mean arterial blood pressure, while rescuing fetal growth restriction, in the RUPP 
model of pre-eclampsia. Interestingly, I also provided evidence that these therapeutic 
effects are mediated in part by directly dampening mitochondrial-ROS production. 
In terms of clinical relevance, ERG is an amino acid that is currently FDA approved 
and is available as a supplement. While ERG has been extensively examined in vitro 
and to a lesser extent in in vivo models, to date, only one study has investigated the 
pharmacokinetics of ERG administration in humans (232). Healthy human subjects 
were administered either a 5mg or 25mg dose every morning for one week with 
follow up of a further 28 days with no adverse effects observed. From this study, 
ERG was rapidly retained and absorbed within tissue and plasma as well as low 
urinary excretion. Furthermore, there was evidence of a reduction in markers of 
oxidative stress in the study groups. The wider implication of my research 
demonstrates that ERG, a nutraceutical antioxidant that directly targets mitochondria 
and reduces mitochondrial-specific ROS could be a new therapeutic avenue of 
investigation for the treatment of pre-eclampsia.  
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6.3 Strength and Limitations  
 
There are many strengths to this thesis. Firstly, in Chapter 2 and Chapter 3, the 
primary strength of my thesis was the use of a well-defined pregnancy cohort of 
first-time mothers, which enabled a thorough investigation of the role of 
mitochondrial dysfunction in pre-eclampsia. Many aspects of this cohort have 
strengthened the work in chapter 2 and 3 of this thesis namely: Using a well 
characterised cohort allowed me to gain information on Demographic, biochemical, 
physiological and clinical data collected from each mother enrolled in the SCOPE 
study. Furthermore, a total population of 1774 women were recruited to SCOPE 
Ireland Study, therefore providing matched controls to the 60 women with pre-
eclampsia. This is a significant strength to this thesis as I could examine mtDNA and 
inflammation is the same cohort of women longitudinally across 3 gestational time 
points.  Upon examining the literature, previous studies examining mitochondrial 
dysfunction in pre-eclampsia, the cohort sizes were very limited. In my thesis, I 
examine mitochondrial dysfunction longitudinally throughout pregnancy, whereas, 
the vast majority of the literature focuses on the third trimester when investigating 
mtDNA and the innate immune system in pre-eclampsia. Throughout my thesis, I 
have provided strong evidence for the role of mitochondrial dysfunction in a human 
cohort of pre-eclampsia and that directly targeting mitochondria with ERG using 
both in vitro and an in vivo model, I showed alleviation of oxidative stress and 
phenotypic features of pre-eclampsia. Finally, using the RUPP rat model of pre-
eclampsia equally strengthened my thesis due to the number of phenotypic features 
of human pre-eclampsia that are evident in this preclinical model of disease. This 
thesis is the first time mROS was examined in vivo in the rat model. This is a novel 
technique to examine real time mROS is a massive strength to this area. Previous 
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research measuring mROS is done outside of the animal which alters and 
manipulates the tissue and therefore is not a true representation of mitochondrial 
stress. Here I showed for the first time, there is an increase in specific mROS in the 
kidney of the RUPP model and furthermore, treating this with Ergothioneine 
significantly reduced the mROS production. This also highlights that Ergothioneine 
is specifically acting on mitochondrial dysfunction strengthening my hypothesis.  
Certain limitations are recognised. The study cohort in Chapter 2 and 3, while being 
a strength of my thesis, the use of samples from the SCOPE cohort collected outside 
of Cork, including UK, New Zealand, and Australia to generate a larger study cohort 
would be of benefit to validate my research outcomes. As well as this, in chapter 2 
and chapter 3, more details could have been obtained from my patient cohort, 
specifically, how severe the pre-eclampsia outcome was for each of my women 
(such as the severity of the preterm pre-eclampsia cases). This could of gave an 
insight into whether there was a difference in the amount of mtDNA and 
inflammatory makers in the women who had an outcome of severe pre-term pre-
eclampsia complications. Additionally, blood pressure measurements from the 
women at time of disease in my cohort, would have been a valuable addition in 
Chapter 2, table 2.1.  When examining modifiable factors, in particular exercise, 
there is a clear limitation to this data and a definitive conclusion is hard to quantify. 
The data collected regarding exercise and diet was self-reported, therefore not a true 
representation of the data. To overcome this obstacle, this is further discussed in 
future work section 6.4.  Furthermore, in Chapter 3, the initial experimental plan was 
to examine the inflammatory pathway early in pregnancy, however, on carrying out 
this experimental research, I showed that the inflammatory makers I was measuring 
were not activated early in pregnancy, therefore, the idea of looking at the 
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inflammatory response late in pregnancy was subsequently undertaken.  
Furthermore, it would have been beneficial to have the neutrophil count for the 
women who subsequently went on to develop pre-eclampsia to correlate with the 
results of the neutrophil activation markers. Additionally, having access to clinical 
data regarding the severity of cases within my case cohort, it would have been 
interesting to examine and correlate the increases seen within individual cases and 
the severity of the pregnancy outcome.    
This PhD specifically looked at mitochondrial ROS and has illustrated the potential 
role of mROS plays in pre-eclampsia. However, there are other sources of ROS such 
as NADPH oxidase which plays a significant role in mediating oxidative stress. 
NADPH oxidases are activated by a variety of physiological and pathophysiological 
stimuli including inflammatory cytokines, mechanical forces and growth factors. 
While the mitochondria were the main focus as a source of ROS for this body of 
work, I acknowledge that there are many pathways involved in the role of oxidative 
stress, that may be worth examining in future work.  
In this thesis, I have shown that Ergothioneine plays a role in potentially regulating 
mitochondrial function. However, I acknowledge that there is more research to be 
done regards to investigating mitochondrial dynamics as well as examining 
mitochondrial respiration as discussed in future work.   
Finally, in Chapter 5, while animal models are excellent to examine the aetiology of 





6.4 Future work  
 
It would be exciting to examine the role of mitochondrial dysfunction in the aetiology 
of pre-eclampsia in a larger study cohort. A recent phase II clinical trial, IMPROvED 
(IMproved Pregnancy Outcomes by Early Detection) was carried out in 7 European 
Centres as a validation study for biomarkers initially identified in the SCOPE study. 
The IMPROvED cohort could further validate my study findings investigating the role 
of mitochondrial dysfunction in pre-eclampsia using larger sample numbers.  
It would be interesting to examine the effect of ERG on additional mitochondrial 
parameters including cellular respiration and oxygen consumption in the Jeg-3 
placental cell line. This could be achieved using the Agilent Seahorse technology 
and would strengthen my existing body of work. Though the focus of ERG is as a 
potential mitochondrial antioxidant in this body of work, the many sources of ROS 
are interlinked in some shape or form therefore, future research could potentially 
examine the effects of ERG on different sources of ROS and different pathways. 
Throughout this body of work, I have highlighted that ERG is a mitochondrial 
specific targeted antioxidant. I have provided evidence of this in Chapter 4 by 
highlighting its role in regulating mitochondrial function and furthermore in Chapter 
5, by showing ERG reduces specific mROS in the kidneys in an in vivo model. 
However, future work is warrened to further elucidate its specific role in mROS. To 
further prove ERG is a mitochondrial specific antioxidant, carrying out an 
experiment to extract the mitochondria from treated cells would add to this body of 




In this thesis, I have shown that TLR9 activation of the innate immune system may 
play a role in the pathophysiology of pre-eclampsia in late gestation. However, it 
would be exciting to examine the potential signalling pathways involved in mtDNA 
and TLR9 activation. Mitogen-activated protein kinase (MAPK) pathway is involved 
in oxidative stress, and DNA damage, therefore would be a potential pathway to 
further elucidate our hypothesis that mitochondrial dysfunction activates TLR9 
signal and effects neutrophil downstream markers instigating an inflammatory 
response seen in late pre-eclampsia. Furthermore, an exciting avenue of investigation 
would be to elucidate how mtDNA triggers TLR9 activation.  This would involve 
isolating placental mitochondria and extracting DNA from these mitochondria. DNA 
could be extracted from patients with pre-eclampsia and uncomplicated pregnancies 
and then used to treat TLR specific reporter cells to show that mtDNA contained 
within maternal plasma is the primary mediator of TLR9 activation.   
To date, clinical trials in pregnancy have been very limited. This is due to the 
unknown effect a drug would have on the unborn foetus. Furthermore, the VIP trial, 
examining the role of antioxidants in pregnancy, highlighted a secondary outcome of 
reduced fetal weight in mothers that received Vitamin C. This trial highlights the 
challenges of treating pregnant women. Even though the in vitro data supporting the 
use of vitamin C as a potential therapeutic for pre-eclampsia to date it has proven to 
be very challenging to determine the optimal equilibrium between reducing oxidative 
stress while maintaining physiologically important redox signalling when 
administering antioxidant treatment in vivo.  There has been no clinical trial 
investigating the use of ERG in pregnancy , however, there was one study examining 
ERG in pregnant rats and reported no adverse effects (231). To further add to the 
intergenerational effect of antioxidant treatment it would be interesting to examine 
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the offspring from a pre-eclampsia induced rat with and without ERG treatment to 
see if there was any adverse effect in pup outcome throughout life. In Chapter 5 I 
have shown that pup weight was increased in the ERG treated group, which is 
already an exciting start.  
Finally, the RUPP model is a very good preclinical model for examining the 
maternal phenotype of pre-eclampsia and for the development of future novel 
therapeutics to treat this obstetric complication. In Chapter 5, ERG was administered 
on GD11, 3 days prior to RUPP surgery which induces the pre-eclampsia phenotype. 
However, most women who attend antenatal clinics present with some symptoms of 
pre-eclampsia. Hence future investigation of the translational impact of this novel 
antioxidant should involve beginning treatment with ERG on GD14, immediately 
after RUPP surgery.  Given the fact that ERG has received FDA approval and is safe 
for human consumption, it makes the transition to future human clinical studies a 
very achievable target, however further pre-clinical investigations are warranted 





7.0 Conclusion  
 
This thesis has provided evidence of mitochondrial dysfunction in women who 
develop pre-eclampsia. Additionally, this work has shown that mitochondrial 
dysfunction activates a neutrophil-driven innate immune response in women with 
pre-eclampsia which is mediated in part by activation of the TLR9 receptor. 
Furthermore, this novel work established that L-ergothioneine, a unique antioxidant 
directly targets the mitochondria and reduces exaggerated mitochondrial specific 
ROS production in both in vitro and in vivo models of pre-eclampsia. Additionally, 
in the in vivo model of pre-eclampsia, treatment with L-ergothioneine positively 
modulates some of the detrimental clinical characteristics evident in women with 
pre-eclampsia, highlighting the therapeutic potential of this mitochondrial-targeted 





8.0 Bibliography  
 
1. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. 
Hypertensive Disorders of Pregnancy: ISSHP Classification, Diagnosis, and Management 
Recommendations for International Practice. Hypertension. 2018;72(1):24-43. 
2. Khan KS, Wojdyla D, Say L, Gulmezoglu AM, Van Look PF. WHO analysis of causes of 
maternal death: a systematic review. Lancet. 2006;367(9516):1066-74. 
3. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 
2009;33(3):130-7. 
4. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: 
systematic review of controlled studies. BMJ : British Medical Journal. 2005;330(7491):565-
. 
5. Caughey AB, Stotland NE, Washington AE, Escobar GJ. Maternal Ethnicity, Paternal 
Ethnicity, and Parental Ethnic Discordance: Predictors of Preeclampsia. Obstetrics & 
Gynecology. 2005;106(1):156-61. 
6. Hutcheon JA, Lisonkova S, Joseph KS. Epidemiology of pre-eclampsia and the other 
hypertensive disorders of pregnancy. Best practice & research Clinical obstetrics & 
gynaecology. 2011;25(4):391-403. 
7. Chaiworapongsa T, Chaemsaithong P, Yeo L, Romero R. Pre-eclampsia part 1: 
current understanding of its pathophysiology. Nature reviews Nephrology. 2014;10(8):466-
80. 
8. Weinstein L. It has been a great ride: The history of HELLP syndrome. Am J Obstet 
Gynecol. 2005;193(3 Pt 1):860-3. 
9. Palmsten K, Buka SL, Michels KB. Maternal pregnancy-related hypertension and risk 
for hypertension in offspring later in life. Obstetrics and gynecology. 2010;116(4):858-64. 
10. Kajantie E, Eriksson JG, Osmond C, Thornburg K, Barker DJ. Pre-eclampsia is 
associated with increased risk of stroke in the adult offspring: the Helsinki birth cohort 
study. Stroke; a journal of cerebral circulation. 2009;40(4):1176-80. 
11. Weissgerber TL, Mudd LM. Preeclampsia and diabetes. Current diabetes reports. 
2015;15(3):9-. 
12. Behrens I, Basit S, Melbye M, Lykke JA, Wohlfahrt J, Bundgaard H, et al. Risk of 
post-pregnancy hypertension in women with a history of hypertensive disorders of 
pregnancy: nationwide cohort study. Bmj. 2017;358. 
13. Nisell H, Lintu H, Lunell NO, Mollerstrom G, Pettersson E. Blood pressure and renal 
function seven years after pregnancy complicated by hypertension. Br J Obstet Gynaecol. 
1995;102(11):876-81. 
14. Kenny LC, Black MA, Poston L, Taylor R, Myers JE, Baker PN, et al. Early pregnancy 
prediction of preeclampsia in nulliparous women, combining clinical risk and biomarkers: 
the Screening for Pregnancy Endpoints (SCOPE) international cohort study. Hypertension. 
2014;64(3):644-52. 
15. Myers Jenny E, Tuytten R, Thomas G, Laroy W, Kas K, Vanpoucke G, et al. 
Integrated Proteomics Pipeline Yields Novel Biomarkers for Predicting Preeclampsia. 
Hypertension. 2013;61(6):1281-8. 
16. Vieira MC, McCowan LME, North RA, Myers JE, Walker JJ, Baker PN, et al. Antenatal 
risk factors associated with neonatal morbidity in large-for-gestational-age infants: an 




17. Dalrymple KV, Thompson JMD, Begum S, Godfrey KM, Poston L, Seed PT, et al. 
Relationships of maternal body mass index and plasma biomarkers with childhood body 
mass index and adiposity at 6 years: The Children of SCOPE study. Pediatric Obesity. 
2019;14(10):e12537. 
18. Townsend R, Duffy JMN, Sileo F, Perry H, Ganzevoort W, Reed K, et al. A core 
outcome set for studies investigating the management of selective fetal growth restriction 
in twins. Ultrasound in Obstetrics & Gynecology. 2019;0(ja). 
19. Ahokas. R ME. Development and physiology of the placenta and membranes. Glob 
libr women's med,2008. 
20. Costa MA. The endocrine function of human placenta: an overview. Reproductive 
BioMedicine Online. 2016;32(1):14-43. 
21. Tuckey RC. Progesterone synthesis by the human placenta. Placenta. 
2005;26(4):273-81. 
22. Gurtunca N, Sperling MA. 144 - Growth Hormone, Prolactin, and Placental Lactogen 
in the Fetus and Newborn. In: Polin RA, Abman SH, Rowitch DH, Benitz WE, Fox WW, 
editors. Fetal and Neonatal Physiology (Fifth Edition): Elsevier; 2017. p. 1470-6.e1. 
23. Gude NM, Roberts CT, Kalionis B, King RG. Growth and function of the normal 
human placenta. Thrombosis Research. 2004;114(5–6):397-407. 
24. Pijnenborg R, Vercruysse L, Hanssens M. The uterine spiral arteries in human 
pregnancy: facts and controversies. Placenta. 2006;27(9-10):939-58. 
25. Zhou Y. Preeclampsia is associated with failure of human cytotrophoblasts to mimic 
a vascular adhesion phenotype: One cause of defective endovascular invasion in this 
syndrome? J Clin Invest. 1997;99:2152-64. 
26. Cross JC, Werb Z, Fisher SJ. Implantation and the Placenta - Key Pieces of the 
Development Puzzle. Science. 1994;266(5190):1508-18. 
27. Damsky CH, Fisher SJ. Trophoblast pseudo-vasculogenesis: faking it with 
endothelial adhesion receptors. Current Opinion in Cell Biology. 1998;10(5):660-6. 
28. Yancopoulos GD, Klagsbrun M, Folkman J. Vasculogenesis, angiogenesis, and 
growth factors: ephrins enter the fray at the border. Cell. 1998;93(5):661-4. 
29. Charnock-Jones DS, Sharkey AM, Boocock CA, Ahmed A, Plevin R, Ferrara N, et al. 
Vascular endothelial growth factor receptor localization and activation in human 
trophoblast and choriocarcinoma cells. Biology of reproduction. 1994;51(3):524-30. 
30. Vuorela P, Hatva E, Lymboussaki A, Kaipainen A, Joukov V, Persico MG, et al. 
Expression of vascular endothelial growth factor and placenta growth factor in human 
placenta. Biology of reproduction. 1997;56(2):489-94. 
31. Lofthouse E. The accumulation of glutamate in the placental syncytiotrophoblast as 
a driver of membrane transport 2014. 
32. Roberts DJ, Post MD. The placenta in pre-eclampsia and intrauterine growth 
restriction. Journal of clinical pathology. 2008;61(12):1254-60. 
33. Kajantie E, Thornburg KL, Eriksson JG, Osmond C, Barker DJ. In preeclampsia, the 
placenta grows slowly along its minor axis. The International journal of developmental 
biology. 2010;54(2-3):469-73. 
34. Burton GJ, Jauniaux E, Charnock-Jones DS. The influence of the intrauterine 
environment on human placental development. The International journal of developmental 
biology. 2010;54(2-3):303-12. 
35. Rana S, Lemoine E, Granger J, Karumanchi SA. Preeclampsia. Circulation research. 
2019;124(7):1094-112. 
36. Myatt L, Webster RP. Vascular biology of preeclampsia. Journal of thrombosis and 
haemostasis : JTH. 2009;7(3):375-84. 
37. Williamson RD, O'Keeffe GW, Kenny LC. Activin signalling and pre-eclampsia: From 
genetic risk to pre-symptomatic biomarker. Cytokine. 2014. 
196 
 
38. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 
2005;308(5728):1592-4. 
39. Redman CWG. The six stages of pre-eclampsia. Pregnancy Hypertension: An 
International Journal of Women's Cardiovascular Health. 2014;4(3):246. 
40. Roberts JM, Bell, Mandy J. If we know so much about preeclampsia, why haven't 
we cured the disease? Journal of reproductive immunology. 2013;99(0):1-9. 
41. Do women with pre-eclampsia, and their babies, benefit from magnesium 
sulphate? The Magpie Trial: a randomised placebo-controlled trial. The 
Lancet.359(9321):1877-90. 
42. Boeldt DS, Bird IM. Vascular adaptation in pregnancy and endothelial dysfunction 
in preeclampsia. The Journal of endocrinology. 2017;232(1):R27-r44. 
43. Redman CW, Sargent IL. Pre-eclampsia, the placenta and the maternal systemic 
inflammatory response--a review. Placenta. 2003;24 Suppl A:S21-7. 
44. Chau K, Hennessy A, Makris A. Placental growth factor and pre-eclampsia. Journal 
of human hypertension. 2017;31:782. 
45. Nevo O, Lee DK, Caniggia I. Attenuation of VEGFR-2 Expression by sFlt-1 and Low 
Oxygen in Human Placenta. PloS one. 2013;8(11):e81176. 
46. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating 
angiogenic factors and the risk of preeclampsia. The New England journal of medicine. 
2004;350(7):672-83. 
47. Chaiworapongsa T, Romero R, Espinoza J, Bujold E, Mee Kim Y, Goncalves LF, et al. 
Evidence supporting a role for blockade of the vascular endothelial growth factor system in 
the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol. 
2004;190(6):1541-7; discussion 7-50. 
48. Nikuei P, Malekzadeh K, Rajaei M, Nejatizadeh A, Ghasemi N. The imbalance in 
expression of angiogenic and anti-angiogenic factors as candidate predictive biomarker in 
preeclampsia. Iran J Reprod Med. 2015;13(5):251-62. 
49. St-Jacques S, Forte M, Lye SJ, Letarte M. Localization of endoglin, a transforming 
growth factor-beta binding protein, and of CD44 and integrins in placenta during the first 
trimester of pregnancy. Biology of reproduction. 1994;51(3):405-13. 
50. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. Soluble endoglin and 
other circulating antiangiogenic factors in preeclampsia. The New England journal of 
medicine. 2006;355(10):992-1005. 
51. Ostendorf T, Kunter U, Eitner F, Loos A, Regele H, Kerjaschki D, et al. VEGF(165) 
mediates glomerular endothelial repair. J Clin Invest. 1999;104(7):913-23. 
52. Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A, et al. 
Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF 
antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem. 
2003;278(15):12605-8. 
53. Karumanchi SA, Maynard SE, Stillman IE, Epstein FH, Sukhatme VP. Preeclampsia: a 
renal perspective. Kidney international. 2005;67(6):2101-13. 
54. Roberts JM. Endothelial dysfunction in preeclampsia. Seminars in reproductive 
endocrinology. 1998;16(1):5-15. 
55. Aouache R, Biquard L, Vaiman D. Oxidative Stress in Preeclampsia and Placental 
Diseases. 2018;19(5). 
56. Briones AM, Touyz RM. Oxidative stress and hypertension: current concepts. Curr 
Hypertens Rep. 2010;12(2):135-42. 
57. Myatt L, Cui X. Oxidative stress in the placenta. Histochemistry and cell biology. 
2004;122(4):369-82. 
58. Wu F, Tian F-J, Lin Y. Oxidative Stress in Placenta: Health and Diseases. BioMed 
Research International. 2015;2015:293271. 
197 
 
59. Wu J, Harrison DG. Oxidative Stress and Hypertension. In: Safar EM, O'Rourke FM, 
Frohlich DE, editors. Blood Pressure and Arterial Wall Mechanics in Cardiovascular 
Diseases. London: Springer London; 2014. p. 175-91. 
60. Belo L, Caslake M, Santos-Silva A, Castro EM, Pereira-Leite L, Quintanilha A, et al. 
LDL size, total antioxidant status and oxidised LDL in normal human pregnancy: a 
longitudinal study. Atherosclerosis. 2004;177(2):391-9. 
61. Jauniaux E, Poston L, Burton GJ. Placental-related diseases of pregnancy: 
involvement of oxidative stress and implications in human evolution. Hum Reprod Update. 
2006;12(6):747-55. 
62. Jauniaux E, Watson AL, Hempstock J, Bao YP, Skepper JN, Burton GJ. Onset of 
maternal arterial blood flow and placental oxidative stress. A possible factor in human early 
pregnancy failure. Am J Pathol. 2000;157(6):2111-22. 
63. Raijmakers MT, Dechend R, Poston L. Oxidative stress and preeclampsia: rationale 
for antioxidant clinical trials. Hypertension. 2004;44(4):374-80. 
64. Centlow M, Carninci P, Nemeth K, Mezey E, Brownstein M, Hansson SR. Placental 
expression profiling in preeclampsia: local overproduction of hemoglobin may drive 
pathological changes. Fertil Steril. 2008;90(5):1834-43. 
65. Buehler PW, D'Agnillo F. Toxicological consequences of extracellular hemoglobin: 
biochemical and physiological perspectives. Antioxidants & redox signaling. 
2010;12(2):275-91. 
66. Kenny LC, Broadhurst DI, Dunn W, Brown M, North RA, McCowan L, et al. Robust 
early pregnancy prediction of later preeclampsia using metabolomic biomarkers. 
Hypertension. 2010;56(4):741-9. 
67. Afanas' ev IB. Superoxide ion: chemistry and biological implications: CRC Press; 
1991. 
68. Douki T, Cadet J. Peroxynitrite mediated oxidation of purine bases of nucleosides 
and isolated DNA. Free radical research. 1996;24(5):369-80. 
69. Ischiropoulos H, al-Mehdi AB. Peroxynitrite-mediated oxidative protein 
modifications. FEBS Lett. 1995;364(3):279-82. 
70. Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress. Curr 
Biol. 2014;24(10):R453-R62. 
71. Centlow M, Junus K, Nystrom H, May K, Larsson I, Olsson MG, et al. Perfusion of the 
human placenta with red blood cells and xanthine oxidase mimics preeclampsia in-vitro. 
Zeitschrift fur Geburtshilfe und Neonatologie. 2009;213(3):89-95. 
72. Ilhan N, Ilhan N, Simsek M. The changes of trace elements, malondialdehyde levels 
and superoxide dismutase activities in pregnancy with or without preeclampsia. Clinical 
biochemistry. 2002;35(5):393-7. 
73. Kerksick C, Willoughby D. The Antioxidant Role of Glutathione and N-Acetyl-
Cysteine Supplements and Exercise-Induced Oxidative Stress. Journal of the International 
Society of Sports Nutrition. 2005;2(2):38-44. 
74. Boon AC, Lam AK, Gopalan V, Benzie IF, Briskey D, Coombes JS, et al. Endogenously 
elevated bilirubin modulates kidney function and protects from circulating oxidative stress 
in a rat model of adenine-induced kidney failure. Scientific reports. 2015;5:15482. 
75. Simic MG, Jovanovic SV. Antioxidation mechanisms of uric acid. Journal of the 
American Chemical Society. 1989;111(15):5778-82. 
76. Hink HU, Santanam N, Dikalov S, McCann L, Nguyen AD, Parthasarathy S, et al. 
Peroxidase properties of extracellular superoxide dismutase: role of uric acid in modulating 
in vivo activity. Arteriosclerosis, thrombosis, and vascular biology. 2002;22(9):1402-8. 
77. Bolisetty S, Jaimes EA. Mitochondria and reactive oxygen species: physiology and 
pathophysiology. International journal of molecular sciences. 2013;14(3):6306-44. 
198 
 
78. Iacobazzi V, Castegna A, Infantino V, Andria G. Mitochondrial DNA methylation as a 
next-generation biomarker and diagnostic tool. Molecular genetics and metabolism. 
2013;110(1-2):25-34. 
79. Murphy MP. How mitochondria produce reactive oxygen species. The Biochemical 
journal. 2009;417(1):1-13. 
80. Korshunov SS, Korkina OV, Ruuge EK, Skulachev VP, Starkov AA. Fatty acids as 
natural uncouplers preventing generation of O(·-)2 and H2O2 by mitochondria in the 
resting state. FEBS Letters. 1998;435(2-3):215-8. 
81. Korshunov SS, Skulachev VP, Starkov AA. High protonic potential actuates a 
mechanism of production of reactive oxygen species in mitochondria. FEBS Letters. 
1997;416(1):15-8. 
82. Rottenberg H, Covian R, Trumpower BL. Membrane potential greatly enhances 
superoxide generation by the cytochrome bc1 complex reconstituted into phospholipid 
vesicles. Journal of Biological Chemistry. 2009;284(29):19203-10. 
83. Lambert AJ, Brand MD. Superoxide production by NADH:ubiquinone 
oxidoreductase (complex I) depends on the pH gradient across the mitochondrial inner 
membrane. Biochemical Journal. 2004;382(2):511-7. 
84. Chen H, Detmer SA, Ewald AJ, Griffin EE, Fraser SE, Chan DC. Mitofusins Mfn1 and 
Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic 
development. The Journal of cell biology. 2003;160(2):189-200. 
85. Hoppins S, Lackner L, Nunnari J. The machines that divide and fuse mitochondria. 
Annual review of biochemistry. 2007;76:751-80. 
86. Ono T, Isobe K, Nakada K, Hayashi JI. Human cells are protected from mitochondrial 
dysfunction by complementation of DNA products in fused mitochondria. Nature genetics. 
2001;28(3):272-5. 
87. Youle RJ, van der Bliek AM. Mitochondrial fission, fusion, and stress. Science. 
2012;337(6098):1062-5. 
88. Rossignol R, Gilkerson R, Aggeler R, Yamagata K, Remington SJ, Capaldi RA. Energy 
substrate modulates mitochondrial structure and oxidative capacity in cancer cells. Cancer 
research. 2004;64(3):985-93. 
89. Yu EP, Bennett MR. Mitochondrial DNA damage and atherosclerosis. Trends in 
endocrinology and metabolism: TEM. 2014;25(9):481-7. 
90. Berridge MJ. Calcium signalling remodelling and disease. Biochemical Society 
transactions. 2012;40(2):297-309. 
91. Babcock DF, Hille B. Mitochondrial oversight of cellular Ca2+ signaling. Current 
opinion in neurobiology. 1998;8(3):398-404. 
92. Nicholls DG. Mitochondrial dysfunction and glutamate excitotoxicity studied in 
primary neuronal cultures. Current molecular medicine. 2004;4(2):149-77. 
93. Jou MJ, Peng TI, Hsu LF, Jou SB, Reiter RJ, Yang CM, et al. Visualization of 
melatonin's multiple mitochondrial levels of protection against mitochondrial Ca(2+)-
mediated permeability transition and beyond in rat brain astrocytes. Journal of pineal 
research. 2010;48(1):20-38. 
94. Jou MJ, Peng TI, Reiter RJ, Jou SB, Wu HY, Wen ST. Visualization of the antioxidative 
effects of melatonin at the mitochondrial level during oxidative stress-induced apoptosis of 
rat brain astrocytes. Journal of pineal research. 2004;37(1):55-70. 
95. Peng TI, Yu PR, Chen JY, Wang HL, Wu HY, Wei YH, et al. Visualizing common 
deletion of mitochondrial DNA-augmented mitochondrial reactive oxygen species 
generation and apoptosis upon oxidative stress. Biochimica et biophysica acta. 
2006;1762(2):241-55. 
96. Carrera F, Casart YC, Proverbio T, Proverbio F, Marin R. Preeclampsia and calcium-
ATPase activity of plasma membranes from human myometrium and placental trophoblast. 
199 
 
Hypertension in pregnancy : official journal of the International Society for the Study of 
Hypertension in Pregnancy. 2003;22(3):295-304. 
97. Mahdy Z, Otun HA, Dunlop W, Gillespie JI. The responsiveness of isolated human 
hand vein endothelial cells in normal pregnancy and in pre-eclampsia. The Journal of 
physiology. 1998;508 ( Pt 2):609-17. 
98. Steinert JR, Wyatt AW, Poston L, Jacob R, Mann GE. Preeclampsia is associated with 
altered Ca2+ regulation and NO production in human fetal venous endothelial cells. FASEB 
journal : official publication of the Federation of American Societies for Experimental 
Biology. 2002;16(7):721-3. 
99. Yu E, Mercer J, Bennett M. Mitochondria in vascular disease. Cardiovascular 
research. 2012;95(2):173-82. 
100. Sena LA, Chandel NS. Physiological roles of mitochondrial reactive oxygen species. 
Molecular cell. 2012;48(2):158-67. 
101. Yu E, Calvert PA, Mercer JR, Harrison J, Baker L, Figg NL, et al. Mitochondrial DNA 
damage can promote atherosclerosis independently of reactive oxygen species through 
effects on smooth muscle cells and monocytes and correlates with higher-risk plaques in 
humans. Circulation. 2013;128(7):702-12. 
102. Botto N, Berti S, Manfredi S, Al-Jabri A, Federici C, Clerico A, et al. Detection of 
mtDNA with 4977 bp deletion in blood cells and atherosclerotic lesions of patients with 
coronary artery disease. Mutation research. 2005;570(1):81-8. 
103. Mandò C, De Palma C, Stampalija T, Anelli GM, Figus M, Novielli C, et al. Placental 
mitochondrial content and function in intrauterine growth restriction and preeclampsia. 
American Journal of Physiology - Endocrinology and Metabolism. 2014;306(4):E404-E13. 
104. Wang Y, Walsh SW. Placental mitochondria as a source of oxidative stress in pre-
eclampsia. Placenta. 1998;19(8):581-6. 
105. Brownfoot FC, Hastie R, Hannan NJ, Cannon P, Tuohey L, Parry LJ, et al. Metformin 
as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 
1 and soluble endoglin secretion and endothelial dysfunction. Am J Obstet Gynecol. 
2016;214(3):356 e1- e15. 
106. Shi Z, Long W, Zhao C, Guo X, Shen R, Ding H. Comparative proteomics analysis 
suggests that placental mitochondria are involved in the development of pre-eclampsia. 
PloS one. 2013;8(5):e64351-e. 
107. Maloyan A, Mele J, Muralimanohara B, Myatt L. Measurement of mitochondrial 
respiration in trophoblast culture. Placenta. 2012;33(5):456-8. 
108. Dikalova AE, Bikineyeva AT, Budzyn K, Nazarewicz RR, McCann L, Lewis W, et al. 
Therapeutic targeting of mitochondrial superoxide in hypertension. Circulation research. 
2010;107(1):106-16. 
109. McCarthy C, Kenny LC. Therapeutically targeting mitochondrial redox signalling 
alleviates endothelial dysfunction in preeclampsia. Scientific reports. 2016;6:32683. 
110. Mor G, Cardenas I, Abrahams V, Guller S. Inflammation and pregnancy: the role of 
the immune system at the implantation site. Annals of the New York Academy of Sciences. 
2011;1221:80-7. 
111. Kumar A, Begum N, Prasad S, Agarwal S, Sharma S. IL-10, TNF-α &amp; IFN-γ: 
Potential early biomarkers for preeclampsia. Cellular Immunology. 2013;283(1–2):70-4. 
112. Fitzgerald JS, Busch S, Wengenmayer T, Foerster K, de la Motte T, Poehlmann TG, 
et al. Signal transduction in trophoblast invasion. Chemical immunology and allergy. 
2005;88:181-99. 
113. Yoshizumi M, Perrella MA, Burnett JC, Jr., Lee ME. Tumor necrosis factor 
downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. 
Circulation research. 1993;73(1):205-9. 
200 
 
114. Greer IA, Lyall F, Perera T, Boswell F, Macara LM. Increased concentrations of 
cytokines interleukin-6 and interleukin-1 receptor antagonist in plasma of women with 
preeclampsia: a mechanism for endothelial dysfunction? Obstetrics and gynecology. 
1994;84(6):937-40. 
115. Conrad KP, Miles TM, Benyo DF. Circulating levels of immunoreactive cytokines in 
women with preeclampsia. Am J Reprod Immunol. 1998;40(2):102-11. 
116. Founds SA, Powers RW, Patrick TE, Ren D, Harger GF, Markovic N, et al. A 
comparison of circulating TNF-alpha in obese and lean women with and without 
preeclampsia. Hypertension in pregnancy : official journal of the International Society for 
the Study of Hypertension in Pregnancy. 2008;27(1):39-48. 
117. Roudsari FV, Ayati S, Ayatollahi H, Esmaeily H, Hasanzadeh M, Shahabian M, et al. 
Comparison of maternal serum Tumor Necrosis Factor-alpha (TNF-alpha) in severe and mild 
preeclampsia versus normal pregnancy. Iran J Reprod Med. 2009;7(4):153-6. 
118. Szarka A, Rigo J, Lazar L, Beko G, Molvarec A. Circulating cytokines, chemokines and 
adhesion molecules in normal pregnancy and preeclampsia determined by multiplex 
suspension array. BMC immunology. 2010;11(1):59. 
119. Koçyıgıt Y, Atamer Y, Atamer A, Tuzcu A, Akkus Z. Changes in serum levels of leptin, 
cytokines and lipoprotein in pre-eclamptic and normotensive pregnant women. 
Gynecological Endocrinology. 2004;19(5):267-73. 
120. Silva DMCe, Marreiro DdN, Moita Neto JM, Brito JA, Neta EAdS, Matias JP, et al. 
Oxidative stress and immunological alteration in women with preeclampsia. Hypertension 
in Pregnancy. 2013;32(3):304-11. 
121. Xiao JP, Yin YX, Gao YF, Lau S, Shen F, Zhao M, et al. The increased maternal serum 
levels of IL-6 are associated with the severity and onset of preeclampsia. Cytokine. 
2012;60(3):856-60. 
122. Williams MA, Farrand A, Mittendorf R, Sorensen TK, Zingheim RW, O'Reilly GC, et 
al. Maternal second trimester serum tumor necrosis factor-alpha-soluble receptor p55 
(sTNFp55) and subsequent risk of preeclampsia. American journal of epidemiology. 
1999;149(4):323-9. 
123. Hamai Y, Fujii T, Yamashita T, Nishina H, Kozuma S, Mikami Y, et al. Evidence for an 
elevation in serum interleukin-2 and tumor necrosis factor-alpha levels before the clinical 
manifestations of preeclampsia. Am J Reprod Immunol. 1997;38(2):89-93. 
124. Sibai B, Romero R, Klebanoff MA, Rice MM, Caritis S, Lindheimer MD, et al. 
Maternal plasma concentrations of the soluble tumor necrosis factor receptor 2 are 
increased prior to the diagnosis of preeclampsia. Am J Obstet Gynecol. 2009;200(6):630 e1-
8. 
125. Rein DT, Breidenbach M, Hönscheid B, Friebe-Hoffmann U, Engel H, Göhring UJ, et 
al. Preeclamptic women are deficient of interleukin-10 as assessed by cytokine release of 
trophoblast cells in vitro. Cytokine.23(4–5):119-25. 
126. Szarka A, Rigo J, Jr., Lazar L, Beko G, Molvarec A. Circulating cytokines, chemokines 
and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex 
suspension array. BMC immunology. 2010;11:59. 
127. Lotz M. Interleukin-6: A comprehensive review. In: Kurzrock R, Talpaz M, editors. 
Cytokines: Interleukins and Their Receptors. Boston, MA: Springer US; 1995. p. 209-33. 
128. Barden A, Graham D, Beilin LJ, Ritchie J, Baker R, Walters BN, et al. Neutrophil 
CD11B expression and neutrophil activation in pre-eclampsia. Clinical Science. 
1997;92(1):37-44. 
129. Greer IA, Haddad NG, Dawes J, Johnstone FD, Calder AA. Neutrophil activation in 
pregnancy-induced hypertension. Br J Obstet Gynaecol. 1989;96(8):978-82. 
201 
 
130. Greer IA, Dawes J, Johnston TA, Calder AA. Neutrophil activation is confined to the 
maternal circulation in pregnancy-induced hypertension. Obstetrics and gynecology. 
1991;78(1):28-32. 
131. Cadden KA, Walsh SW. Neutrophils, but not lymphocytes or monocytes, infiltrate 
maternal systemic vasculature in women with preeclampsia. Hypertension in pregnancy : 
official journal of the International Society for the Study of Hypertension in Pregnancy. 
2008;27(4):396-405. 
132. Gupta AK, Hasler P, Holzgreve W, Gebhardt S, Hahn S. Induction of neutrophil 
extracellular DNA lattices by placental microparticles and IL-8 and their presence in 
preeclampsia. Human immunology. 2005;66(11):1146-54. 
133. Janeway CA, Jr., Medzhitov R. Innate immune recognition. Annu Rev Immunol. 
2002;20:197-216. 
134. Krysko DV, Agostinis P, Krysko O, Garg AD, Bachert C, Lambrecht BN, et al. 
Emerging role of damage-associated molecular patterns derived from mitochondria in 
inflammation. Trends in immunology. 2011;32(4):157-64. 
135. Gray MW, Burger G, Lang BF. The origin and early evolution of mitochondria. 
Genome Biol. 2001;2(6):REVIEWS1018. 
136. Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, et al. Circulating 
mitochondrial DAMPs cause inflammatory responses to injury. Nature. 
2010;464(7285):104-7. 
137. Holmlund U, Cebers G, Dahlfors AR, Sandstedt B, Bremme K, Ekstrom ES, et al. 
Expression and regulation of the pattern recognition receptors Toll-like receptor-2 and Toll-
like receptor-4 in the human placenta. Immunology. 2002;107(1):145-51. 
138. Hsu CD, Witter FR. Urogenital infection in preeclampsia. International journal of 
gynaecology and obstetrics: the official organ of the International Federation of 
Gynaecology and Obstetrics. 1995;49(3):271-5. 
139. Medzhitov R, Janeway C, Jr. The Toll receptor family and microbial recognition. 
Trends in microbiology. 2000;8(10):452-6. 
140. Pineda A, Verdin-Teran SL, Camacho A, Moreno-Fierros L. Expression of toll-like 
receptor TLR-2, TLR-3, TLR-4 and TLR-9 is increased in placentas from patients with 
preeclampsia. Archives of medical research. 2011;42(5):382-91. 
141. Goulopoulou S, Matsumoto T, Bomfim GF, Webb RC. Toll-like receptor 9 activation: 
a novel mechanism linking placenta-derived mitochondrial DNA and vascular dysfunction in 
pre-eclampsia. Clinical science (London, England : 1979). 2012;123(7):429-35. 
142. Yui S, Nakatani Y, Mikami M. Calprotectin (S100A8/S100A9), an inflammatory 
protein complex from neutrophils with a broad apoptosis-inducing activity. Biological and 
Pharmaceutical Bulletin. 2003;26(6):753-60. 
143. Johne B, Fagerhol MK, Lyberg T, Prydz H, Brandtzaeg P, Naess-Andresen CF, et al. 
Functional and clinical aspects of the myelomonocyte protein calprotectin. Molecular 
pathology : MP. 1997;50(3):113-23. 
144. Kostakis ID, Cholidou KG, Kallianidis K, Perrea D, Antsaklis A. The role of 
calprotectin in obstetrics and gynecology. European journal of obstetrics, gynecology, and 
reproductive biology. 2010;151(1):3-9. 
145. Pattison DI, Davies MJ, Hawkins CL. Reactions and reactivity of myeloperoxidase-
derived oxidants: differential biological effects of hypochlorous and hypothiocyanous acids. 
Free radical research. 2012;46(8):975-95. 
146. Rayner BS, Love DT, Hawkins CL. Comparative reactivity of myeloperoxidase-
derived oxidants with mammalian cells. Free radical biology & medicine. 2014;71:240-55. 
147. van der Veen BS, de Winther MP, Heeringa P. Myeloperoxidase: molecular 
mechanisms of action and their relevance to human health and disease. Antioxidants & 
redox signaling. 2009;11(11):2899-937. 
202 
 
148. Nussbaum C, Klinke A, Adam M, Baldus S, Sperandio M. Myeloperoxidase: a 
leukocyte-derived protagonist of inflammation and cardiovascular disease. Antioxidants & 
redox signaling. 2013;18(6):692-713. 
149. Anatoliotakis N, Deftereos S, Bouras G, Giannopoulos G, Tsounis D, Angelidis C, et 
al. Myeloperoxidase: expressing inflammation and oxidative stress in cardiovascular 
disease. Current topics in medicinal chemistry. 2013;13(2):115-38. 
150. Baldus S, Eiserich JP, Mani A, Castro L, Figueroa M, Chumley P, et al. Endothelial 
transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets of 
tyrosine nitration. J Clin Invest. 2001;108(12):1759-70. 
151. Hazen SL, Zhang R, Shen Z, Wu W, Podrez EA, MacPherson JC, et al. Formation of 
nitric oxide-derived oxidants by myeloperoxidase in monocytes: pathways for monocyte-
mediated protein nitration and lipid peroxidation In vivo. Circulation research. 
1999;85(10):950-8. 
152. Eiserich JP, Baldus S, Brennan ML, Ma W, Zhang C, Tousson A, et al. 
Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science. 2002;296(5577):2391-
4. 
153. Kindzelskii AL, Clark AJ, Espinoza J, Maeda N, Aratani Y, Romero R, et al. 
Myeloperoxidase accumulates at the neutrophil surface and enhances cell metabolism and 
oxidant release during pregnancy. European journal of immunology. 2006;36(6):1619-28. 
154. Gandley RE, Rohland J, Zhou Y, Shibata E, Harger GF, Rajakumar A, et al. Increased 
myeloperoxidase in the placenta and circulation of women with preeclampsia. 
Hypertension. 2008;52(2):387-93. 
155. Mellembakken JR, Hogasen K, Mollnes TE, Hack CE, Abyholm T, Videm V. Increased 
systemic activation of neutrophils but not complement in preeclampsia. Obstetrics and 
gynecology. 2001;97(3):371-4. 
156. Noyan T, Güler A, Şekeroǧlu MR, Kamaci M. Serum advanced oxidation protein 
products, myeloperoxidase and ascorbic acid in pre-eclampsia and eclampsia. Australian 
and New Zealand Journal of Obstetrics and Gynaecology. 2006;46(6):486-91. 
157. Bowen RS, Moodley J, Dutton MF, Fickl H. Systemic inflammatory indices in pre-
eclampsia and eclampsia. Journal of Obstetrics and Gynaecology. 2001;21(6):563-9. 
158. Stepan H, Heihoff-Klose A, Faber R. Pathological uterine perfusion in the second 
trimester is not associated with neutrophil activation. Hypertension in pregnancy : official 
journal of the International Society for the Study of Hypertension in Pregnancy. 
2003;22(3):239-45. 
159. Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal-Hansen B, 
DeCarlo A, et al. Matrix metalloproteinases: a review. Critical reviews in oral biology and 
medicine : an official publication of the American Association of Oral Biologists. 
1993;4(2):197-250. 
160. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. 
Annual review of cell and developmental biology. 2001;17:463-516. 
161. Lopez-Avila V, Spencer JV. Methods for Detection of Matrix Metalloproteinases as 
Biomarkers in Cardiovascular Disease. Clinical medicine Cardiology. 2008;2:CMC.S484. 
162. Klein T, Bischoff R. Physiology and pathophysiology of matrix metalloproteases. 
Amino acids. 2011;41(2):271-90. 
163. Strauss JF, 3rd. Extracellular matrix dynamics and fetal membrane rupture. 
Reproductive sciences. 2013;20(2):140-53. 
164. Huppertz B, Kertschanska S, Demir AY, Frank HG, Kaufmann P. 
Immunohistochemistry of matrix metalloproteinases (MMP), their substrates, and their 




165. Weiss A, Goldman S, Shalev E. The matrix metalloproteinases (MMPS) in the 
decidua and fetal membranes. Frontiers in bioscience : a journal and virtual library. 
2007;12:649-59. 
166. Hasty KA, Pourmotabbed TF, Goldberg GI, Thompson JP, Spinella DG, Stevens RM, 
et al. Human neutrophil collagenase. A distinct gene product with homology to other 
matrix metalloproteinases. J Biol Chem. 1990;265(20):11421-4. 
167. Herman MP, Sukhova GK, Libby P, Gerdes N, Tang N, Horton DB, et al. Expression of 
neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel 
collagenolytic pathway suggested by transcriptional profiling. Circulation. 
2001;104(16):1899-904. 
168. Fang C, Wen G, Zhang L, Lin L, Moore A, Wu S, et al. An important role of matrix 
metalloproteinase-8 in angiogenesis in vitro and in vivo. Cardiovascular research. 
2013;99(1):146-55. 
169. Raghupathy R, Al-Azemi M, Azizieh F. Intrauterine growth restriction: cytokine 
profiles of trophoblast antigen-stimulated maternal lymphocytes. Clinical & developmental 
immunology. 2012;2012:734865. 
170. Arababadi MK, Aminzadeh F, Hassanshahi G, Khorramdelazad H, Norouzi M, 
Zarandi ER, et al. Cytokines in Preterm Delivery. Laboratory Medicine. 2012;43(4):27-30. 
171. Shimoya K, Matsuzaki N, Taniguchi T, Kameda T, Koyama M, Neki R, et al. Human 
placenta constitutively produces interleukin-8 during pregnancy and enhances its 
production in intrauterine infection. Biology of reproduction. 1992;47(2):220-6. 
172. Borish LC, Steinke JW. 2. Cytokines and chemokines. Journal of Allergy and Clinical 
Immunology. 2003;111(2, Supplement 2):S460-S75. 
173. Bruijnzeel PL, Uddin M, Koenderman L. Targeting neutrophilic inflammation in 
severe neutrophilic asthma: can we target the disease-relevant neutrophil phenotype? J 
Leukoc Biol. 2015;98(4):549-56. 
174. Salcedo R, Ponce ML, Young HA, Wasserman K, Ward JM, Kleinman HK, et al. 
Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in 
angiogenesis and tumor progression. Blood. 2000;96(1):34-40. 
175. Li A, Dubey S, Varney ML, Dave BJ, Singh RK. IL-8 directly enhanced endothelial cell 
survival, proliferation, and matrix metalloproteinases production and regulated 
angiogenesis. J Immunol. 2003;170(6):3369-76. 
176. Sticherling M, Bornscheuer E, Schroder JM, Christophers E. Localization of 
neutrophil-activating peptide-1/interleukin-8-immunoreactivity in normal and psoriatic 
skin. The Journal of investigative dermatology. 1991;96(1):26-30. 
177. Tosun M, Celik H, Avci B, Yavuz E, Alper T, Malatyalioglu E. Maternal and umbilical 
serum levels of interleukin-6, interleukin-8, and tumor necrosis factor-alpha in normal 
pregnancies and in pregnancies complicated by preeclampsia. J Matern Fetal Neonatal 
Med. 2010;23(8):880-6. 
178. Freeman DJ, McManus F, Brown EA, Cherry L, Norrie J, Ramsay JE, et al. Short- and 
long-term changes in plasma inflammatory markers associated with preeclampsia. 
Hypertension. 2004;44(5):708-14. 
179. Salazar Garcia MD, Mobley Y, Henson J, Davies M, Skariah A, Dambaeva S, et al. 
Early pregnancy immune biomarkers in peripheral blood may predict preeclampsia. Journal 
of Reproductive Immunology. 2018;125:25-31. 
180. Taylor BD, Tang G, Ness RB, Olsen J, Hougaard DM, Skogstrand K, et al. Mid-
pregnancy circulating immune biomarkers in women with preeclampsia and normotensive 
controls. Pregnancy Hypertens. 2016;6(1):72-8. 
181. Carty DM, Anderson LA, Freeman DJ, Welsh PI, Brennand JE, Dominiczak AF, et al. 




182. Sun L, Mao D, Cai Y, Tan W, Hao Y, Li L, et al. Association between higher 
expression of interleukin-8 (IL-8) and haplotype −353A/−251A/+678T of IL-8 gene with 
preeclampsia: A case–control study. Medicine. 2016;95(52):e5537. 
183. Velzing-Aarts FV, Muskiet FA, van der Dijs FP, Duits AJ. High serum interleukin-8 
levels in afro-caribbean women with pre-eclampsia. Relations with tumor necrosis factor-
alpha, duffy negative phenotype and von Willebrand factor. Am J Reprod Immunol. 
2002;48(5):319-22. 
184. Guan Z, Li HF, Guo LL, Yang X. Effects of vitamin C, vitamin E, and molecular 
hydrogen on the placental function in trophoblast cells. Arch Gynecol Obstet. 
2015;292(2):337-42. 
185. Mercer BM, Abdelrahim A, Moore RM, Novak J, Kumar D, Mansour JM, et al. The 
impact of Vitamin C supplementation in pregnancy and in-vitro upon fetal membrane 
strength and remodeling. Reproductive sciences (Thousand Oaks, Calif). 2010;17(7):685-95. 
186. Chappell LC, Seed PT, Briley AL, Kelly FJ, Lee R, Hunt BJ, et al. Effect of antioxidants 
on the occurrence of pre-eclampsia in women at increased risk: a randomised trial. The 
Lancet. 1999;354(9181):810-6. 
187. Poston L, Briley AL, Seed PT, Kelly FJ, Shennan AH. Vitamin C and vitamin E in 
pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. 
Lancet. 2006;367(9517):1145-54. 
188. Roberts JM, Myatt L, Spong CY, Thom EA, Hauth JC, Leveno KJ, et al. Vitamins C and 
E to prevent complications of pregnancy-associated hypertension. The New England journal 
of medicine. 2010;362(14):1282-91. 
189. McCance DR, Holmes VA, Maresh MJ, Patterson CC, Walker JD, Pearson DW, et al. 
Vitamins C and E for prevention of pre-eclampsia in women with type 1 diabetes (DAPIT): a 
randomised placebo-controlled trial. Lancet. 2010;376(9737):259-66. 
190. Murphy MP, Smith RA. Targeting antioxidants to mitochondria by conjugation to 
lipophilic cations. Annual review of pharmacology and toxicology. 2007;47:629-56. 
191. Horton KL, Stewart KM, Fonseca SB, Guo Q, Kelley SO. Mitochondria-penetrating 
peptides. Chemistry & biology. 2008;15(4):375-82. 
192. Smith RA, Hartley RC, Murphy MP. Mitochondria-targeted small molecule 
therapeutics and probes. Antioxidants & redox signaling. 2011;15(12):3021-38. 
193. Karaa A, Haas R, Goldstein A, Vockley J, Weaver WD, Cohen BH. Randomized dose-
escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. 
2018;90(14):e1212-e21. 
194. Szeto HH, Liu S, Soong Y, Wu D, Darrah SF, Cheng FY, et al. Mitochondria-targeted 
peptide accelerates ATP recovery and reduces ischemic kidney injury. Journal of the 
American Society of Nephrology : JASN. 2011;22(6):1041-52. 
195. Eirin A, Ebrahimi B, Zhang X, Zhu XY, Woollard JR, He Q, et al. Mitochondrial 
protection restores renal function in swine atherosclerotic renovascular disease. 
Cardiovascular research. 2014;103(4):461-72. 
196. Smith RA, Murphy MP. Animal and human studies with the mitochondria-targeted 
antioxidant MitoQ. Annals of the New York Academy of Sciences. 2010;1201:96-103. 
197. Smith RAJ, Hartley RC, Cochemé HM, Murphy MP. Mitochondrial pharmacology. 
Trends in Pharmacological Sciences. 2012;33(6):341-52. 
198. Adlam VJ, Harrison JC, Porteous CM, James AM, Smith RA, Murphy MP, et al. 
Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury. 
FASEB journal : official publication of the Federation of American Societies for Experimental 
Biology. 2005;19(9):1088-95. 
199. Graham D, Huynh NN, Hamilton CA, Beattie E, Smith RA, Cocheme HM, et al. 
Mitochondria-targeted antioxidant MitoQ10 improves endothelial function and attenuates 
cardiac hypertrophy. Hypertension. 2009;54(2):322-8. 
205 
 
200. Snow BJ, Rolfe FL, Lockhart MM, Frampton CM, O'Sullivan JD, Fung V, et al. A 
double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant 
MitoQ as a disease-modifying therapy in Parkinson's disease. Movement disorders : official 
journal of the Movement Disorder Society. 2010;25(11):1670-4. 
201. Gane EJ, Weilert F, Orr DW, Keogh GF, Gibson M, Lockhart MM, et al. The 
mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study 
of hepatitis C patients. Liver international : official journal of the International Association 
for the Study of the Liver. 2010;30(7):1019-26. 
202. Dikalova AE, Bikineyeva AT, Budzyn K, Nazarewicz RR, McCann L, Lewis W, et al. 
Therapeutic targeting of mitochondrial superoxide in hypertension. Circulation research. 
2010;107(1):106-16. 
203. Trnka J, Blaikie FH, Smith RA, Murphy MP. A mitochondria-targeted nitroxide is 
reduced to its hydroxylamine by ubiquinol in mitochondria. Free radical biology & 
medicine. 2008;44(7):1406-19. 
204. Vaka VR, McMaster KM, Cunningham MW, Jr., Ibrahim T, Hazlewood R, Usry N, et 
al. Role of Mitochondrial Dysfunction and Reactive Oxygen Species in Mediating 
Hypertension in the Reduced Uterine Perfusion Pressure Rat Model of Preeclampsia. 
Hypertension. 2018. 
205. Melville DB, Horner WH, Lubschez R. Tissue ergothioneine. J Biol Chem. 
1954;206(1):221-8. 
206. Shires TK, Brummel MC, Pulido JS, Stegink LD. Ergothioneine distribution in bovine 
and porcine ocular tissues. Comparative biochemistry and physiology Part C, Pharmacology, 
toxicology & endocrinology. 1997;117(1):117-20. 
207. Salt HB. The ergothioneine content of the blood in health and disease. The 
Biochemical journal. 1931;25(5):1712-9. 
208. Halliwell B, Cheah IK, Drum CL. Ergothioneine, an adaptive antioxidant for the 
protection of injured tissues? A hypothesis. Biochemical and biophysical research 
communications. 2016;470(2):245-50. 
209. Paul BD, Snyder SH. The unusual amino acid L-ergothioneine is a physiologic 
cytoprotectant. Cell Death Differ. 2010;17(7):1134-40. 
210. Zhu BZ, Mao L, Fan RM, Zhu JG, Zhang YN, Wang J, et al. Ergothioneine prevents 
copper-induced oxidative damage to DNA and protein by forming a redox-inactive 
ergothioneine-copper complex. Chemical research in toxicology. 2011;24(1):30-4. 
211. Cheah IK, Halliwell B. Ergothioneine; antioxidant potential, physiological function 
and role in disease. Biochimica et biophysica acta. 2012;1822(5):784-93. 
212. Cheah IK, Tang R, Ye P, Yew TS, Lim KH, Halliwell B. Liver ergothioneine 
accumulation in a guinea pig model of non-alcoholic fatty liver disease. A possible 
mechanism of defence? Free radical research. 2016;50(1):14-25. 
213. Motohashi N, Mori I, Sugiura Y. Complexing of copper ion by ergothioneine. 
Chemical & pharmaceutical bulletin. 1976;24(10):2364-8. 
214. Koepsell H. The SLC22 family with transporters of organic cations, anions and 
zwitterions. Mol Aspects Med. 2013;34(2-3):413-35. 
215. Wagner DJ, Hu T, Wang J. Polyspecific organic cation transporters and their impact 
on drug intracellular levels and pharmacodynamics. Pharmacological research. 
2016;111:237-46. 
216. Grundemann D, Harlfinger S, Golz S, Geerts A, Lazar A, Berkels R, et al. Discovery of 
the ergothioneine transporter. Proc Natl Acad Sci U S A. 2005;102(14):5256-61. 
217. Lamhonwah AM, Tein I. Novel localization of OCTN1, an organic cation/carnitine 




218. Lamhonwah AM, Hawkins CE, Tam C, Wong J, Mai L, Tein I. Expression patterns of 
the organic cation/carnitine transporter family in adult murine brain. Brain & development. 
2008;30(1):31-42. 
219. Franzoni F, Colognato R, Galetta F, Laurenza I, Barsotti M, Di Stefano R, et al. An in 
vitro study on the free radical scavenging capacity of ergothioneine: comparison with 
reduced glutathione, uric acid and trolox. Biomedicine & pharmacotherapy = Biomedecine 
& pharmacotherapie. 2006;60(8):453-7. 
220. Hseu YC, Lo HW, Korivi M, Tsai YC, Tang MJ, Yang HL. Dermato-protective 
properties of ergothioneine through induction of Nrf2/ARE-mediated antioxidant genes in 
UVA-irradiated Human keratinocytes. Free radical biology & medicine. 2015;86:102-17. 
221. Martin KR. The bioactive agent ergothioneine, a key component of dietary 
mushrooms, inhibits monocyte binding to endothelial cells characteristic of early 
cardiovascular disease. Journal of medicinal food. 2010;13(6):1340-6. 
222. Zullo G, Albero G, Neglia G, De Canditiis C, Bifulco G, Campanile G, et al. L-
ergothioneine supplementation during culture improves quality of bovine in vitro-produced 
embryos. Theriogenology. 2016;85(4):688-97. 
223. Chevion M, Berenshtein E, Stadtman ER. Human studies related to protein 
oxidation: protein carbonyl content as a marker of damage. Free radical research. 2000;33 
Suppl:S99-108. 
224. Kawano H, Cho K, Haruna Y, Kawai Y, Mayumi T, Hama T. Studies on ergothioneine. 
X. Effects of ergothioneine on the hepatic drug metabolizing enzyme system and on 
experimental hepatic injury in rats. Chemical & pharmaceutical bulletin. 1983;31(5):1676-
81. 
225. Bedirli A, Sakrak O, Muhtaroglu S, Soyuer I, Guler I, Riza Erdogan A, et al. 
Ergothioneine pretreatment protects the liver from ischemia-reperfusion injury caused by 
increasing hepatic heat shock protein 70. The Journal of surgical research. 2004;122(1):96-
102. 
226. Taubert D, Lazar A, Grimberg G, Jung N, Rubbert A, Delank KS, et al. Association of 
rheumatoid arthritis with ergothioneine levels in red blood cells: a case control study. The 
Journal of rheumatology. 2006;33(11):2139-45. 
227. Peltekova VD, Wintle RF, Rubin LA, Amos CI, Huang Q, Gu X, et al. Functional 
variants of OCTN cation transporter genes are associated with Crohn disease. Nature 
genetics. 2004;36(5):471-5. 
228. Hatano T, Saiki S, Okuzumi A, Mohney RP, Hattori N. Identification of novel 
biomarkers for Parkinson's disease by metabolomic technologies. Journal of neurology, 
neurosurgery, and psychiatry. 2016;87(3):295-301. 
229. Li RW, Yang C, Sit AS, Kwan YW, Lee SM, Hoi MP, et al. Uptake and protective 
effects of ergothioneine in human endothelial cells. The Journal of pharmacology and 
experimental therapeutics. 2014;350(3):691-700. 
230. Servillo L, D'Onofrio N, Balestrieri ML. Ergothioneine Antioxidant Function: From 
Chemistry to Cardiovascular Therapeutic Potential. Journal of cardiovascular pharmacology. 
2017;69(4):183-91. 
231. Forster R, Spezia F, Papineau D, Sabadie C, Erdelmeier I, Moutet M, et al. 
Reproductive safety evaluation of L-Ergothioneine. Food and chemical toxicology : an 
international journal published for the British Industrial Biological Research Association. 
2015;80:85-91. 
232. Cheah IK, Tang RM, Yew TS, Lim KH, Halliwell B. Administration of Pure 
Ergothioneine to Healthy Human Subjects: Uptake, Metabolism, and Effects on Biomarkers 




233. Weigand-Heller AJ, Kris-Etherton PM, Beelman RB. The bioavailability of 
ergothioneine from mushrooms (Agaricus bisporus) and the acute effects on antioxidant 
capacity and biomarkers of inflammation. Preventive medicine. 2012;54 Suppl:S75-8. 
234. Tang RMY, Cheah IK, Yew TSK, Halliwell B. Distribution and accumulation of dietary 
ergothioneine and its metabolites in mouse tissues. Scientific reports. 2018;8(1):1601. 
235. Marone PA, Trampota J, Weisman S. A Safety Evaluation of a Nature-Identical l-
Ergothioneine in Sprague Dawley Rats. International journal of toxicology. 2016;35(5):568-
83. 
236. Turck D, Bresson JL, Burlingame B, Dean T, Fairweather-Tait S, Heinonen M, et al. 
Safety of synthetic l‐ergothioneine (Ergoneine®) as a novel food pursuant to Regulation (EC) 
No 258/972016. 
237. Efsa Panel on Dietetic Products N, Allergies, Turck D, Bresson J-L, Burlingame B, 
Dean T, et al. Statement on the safety of synthetic l-ergothioneine as a novel food – 
supplementary dietary exposure and safety assessment for infants and young children, 
pregnant and breastfeeding women. EFSA Journal. 2017;15(11):e05060. 
238. Turner E, Brewster JA, Simpson NA, Walker JJ, Fisher J. Imidazole-based erythrocyte 
markers of oxidative stress in preeclampsia--an NMR investigation. Reproductive sciences. 
2009;16(11):1040-51. 
239. McNally R, Alqudah A, Obradovic D, McClements L. Elucidating the Pathogenesis of 
Pre-eclampsia Using In Vitro Models of Spiral Uterine Artery Remodelling. Current 
Hypertension Reports. 2017;19(11):93. 
240. Granger JP, LaMarca BB, Cockrell K, Sedeek M, Balzi C, Chandler D, et al. Reduced 
uterine perfusion pressure (RUPP) model for studying cardiovascular-renal dysfunction in 
response to placental ischemia. Methods in molecular medicine. 2006;122:383-92. 
241. Losonczy G, Brown G, Venuto RC. Increased peripheral resistance during reduced 
uterine perfusion pressure hypertension in pregnant rabbits. The American journal of the 
medical sciences. 1992;303(4):233-40. 
242. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, et al. 
Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature. 
1995;377(6546):239-42. 
243. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental 
soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, 
hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111(5):649-58. 
244. Ianosi-Irimie M, Vu HV, Whitbred JM, Pridjian CA, Nadig JD, Williams MY, et al. A rat 
model of preeclampsia. Clinical and experimental hypertension. 2005;27(8):605-17. 
245. Woods LL. Importance of prostaglandins in hypertension during reduced 
uteroplacental perfusion pressure. Am J Physiol. 1989;257(6 Pt 2):R1558-61. 
246. Woods LL, Brooks VL. Role of the renin-angiotensin system in hypertension during 
reduced uteroplacental perfusion pressure. Am J Physiol. 1989;257(1 Pt 2):R204-9. 
247. Clark KE, Durnwald M, Austin JE. A model for studying chronic reduction in uterine 
blood flow in pregnant sheep. Am J Physiol. 1982;242(2):H297-301. 
248. Leffler CW, Hessler JR, Green RS, Fletcher AM. Effects of sodium chloride on 
pregnant sheep with reduced uteroplacental perfusion pressure. Hypertension. 
1986;8(1):62-5. 
249. Abitbol MM, Ober MB, Gallo GR, Driscoll SG, Pirani CL. Experimental toxemia of 
pregnancy in the monkey, with a preliminary report on renin and aldosterone. Am J Pathol. 
1977;86(3):573-90. 
250. Cavanagh D, Rao PS, Knuppel RA, Desai U, Balis JU. Pregnancy-induced 




251. Abitbol MM. Simplified technique to produce toxemia in the rat: considerations on 
cause of toxemia. Clinical and experimental hypertension Part B, Hypertension in 
pregnancy. 1982;1(1):93-103. 
252. Alexander BT, Kassab SE, Miller MT, Abram SR, Reckelhoff JF, Bennett WA, et al. 
Reduced uterine perfusion pressure during pregnancy in the rat is associated with increases 
in arterial pressure and changes in renal nitric oxide. Hypertension. 2001;37(4):1191-5. 
253. McCarthy FP, Drewlo S, Kingdom J, Johns EJ, Walsh SK, Kenny LC. Peroxisome 
proliferator-activated receptor-gamma as a potential therapeutic target in the treatment of 
preeclampsia. Hypertension. 2011;58(2):280-6. 
254. Crews JK, Herrington JN, Granger JP, Khalil RA. Decreased endothelium-dependent 
vascular relaxation during reduction of uterine perfusion pressure in pregnant rat. 
Hypertension. 2000;35(1 Pt 2):367-72. 
255. Sholook MM, Gilbert JS, Sedeek MH, Huang M, Hester RL, Granger JP. Systemic 
hemodynamic and regional blood flow changes in response to chronic reductions in uterine 
perfusion pressure in pregnant rats. American journal of physiology Heart and circulatory 
physiology. 2007;293(4):H2080-4. 
256. Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA. Pathophysiology of 
preeclampsia: linking placental ischemia/hypoxia with microvascular dysfunction. 
Microcirculation. 2002;9(3):147-60. 
257. Joyner J, Neves LA, Granger JP, Alexander BT, Merrill DC, Chappell MC, et al. 
Temporal-spatial expression of ANG-(1-7) and angiotensin-converting enzyme 2 in the 
kidney of normal and hypertensive pregnant rats. American journal of physiology 
Regulatory, integrative and comparative physiology. 2007;293(1):R169-77. 
258. Gilbert JS, Babcock SA, Granger JP. Hypertension produced by reduced uterine 
perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 
expression. Hypertension. 2007;50(6):1142-7. 
259. Walsh SK, English FA, Johns EJ, Kenny LC. Plasma-mediated vascular dysfunction in 
the reduced uterine perfusion pressure model of preeclampsia: a microvascular 
characterization. Hypertension. 2009;54(2):345-51. 
260. Miller MT. Thalidomide embryopathy: a model for the study of congenital 
incomitant horizontal strabismus. Trans Am Ophthalmol Soc. 1991;89:623-74. 
261. Sharp A, Cornforth C, Jackson R, Harrold J, Turner MA, Kenny LC, et al. Maternal 
sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-
controlled, double-blind trial. The Lancet Child & adolescent health. 2018;2(2):93-102. 
262. Refuerzo JS, Sokol RJ, Aranda JV, Hallak M, Hotra JW, Kruger M, et al. Sildenafil 
Citrate and Fetal Outcome in Pregnant Rats. Fetal diagnosis and therapy. 2006;21(3):259-
63. 
263. Sánchez-Aparicio P, Mota-Rojas D, Nava-Ocampo AA, Trujillo-Ortega ME, Alfaro-
Rodríguez A, Arch E, et al. Effects of sildenafil on the fetal growth of guinea pigs and their 
ability to survive induced intrapartum asphyxia. American Journal of Obstetrics and 
Gynecology. 2008;198(1):127.e1-.e6. 
264. Wareing M, Myers JE, O’Hara M, Baker PN. Sildenafil Citrate (Viagra) Enhances 
Vasodilatation in Fetal Growth Restriction. The Journal of Clinical Endocrinology & 
Metabolism. 2005;90(5):2550-5. 
265. Stanley Joanna L, Andersson Irene J, Poudel R, Rueda-Clausen Christian F, Sibley 
Colin P, Davidge Sandra T, et al. Sildenafil Citrate Rescues Fetal Growth in the Catechol-O-
Methyl Transferase Knockout Mouse Model. Hypertension. 2012;59(5):1021-8. 
266. Redman CW. Preeclampsia: a multi-stress disorder. La Revue de medecine interne. 
2011;32 Suppl 1:S41-4. 
267. Swerdlow RH. Treating neurodegeneration by modifying mitochondria: potential 
solutions to a "complex" problem. Antioxidants & redox signaling. 2007;9(10):1591-603. 
209 
 
268. Qiu C, Hevner K, Enquobahrie DA, Williams MA. A case-control study of maternal 
blood mitochondrial DNA copy number and preeclampsia risk. International Journal of 
Molecular Epidemiology and Genetics. 2012;3(3):237-44. 
269. Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, et al. Circulating 
mitochondrial DAMPs cause inflammatory responses to injury. Nature. 
2010;464(7285):104-7. 
270. McCarthy CM, Kenny LC. Immunostimulatory role of mitochondrial DAMPs: 
alarming for pre-eclampsia? Am J Reprod Immunol. 2016;76(5):341-7. 
271. Torbergsen T, Oian P, Mathiesen E, Borud O. Pre-eclampsia--a mitochondrial 
disease? Acta Obstet Gynecol Scand. 1989;68(2):145-8. 
272. Lattuada D, Colleoni F, Martinelli A, Garretto A, Magni R, Radaelli T, et al. Higher 
mitochondrial DNA content in human IUGR placenta. Placenta. 2008;29(12):1029-33. 
273. Tranquilli AL, Dekker G, Magee L, Roberts J, Sibai BM, Steyn W, et al. The 
classification, diagnosis and management of the hypertensive disorders of pregnancy: A 
revised statement from the ISSHP. Pregnancy Hypertension: An International Journal of 
Women's Cardiovascular Health. 2014;4(2):97-104. 
274. Young BC, Levine RJ, Karumanchi SA. Pathogenesis of preeclampsia. Annual review 
of pathology. 2010;5:173-92. 
275. Redman CWG. Pre-eclampsia and the placenta. Placenta. 1991;12(4):301-8. 
276. Sánchez-Aranguren LC, Prada CE, Riaño-Medina CE, Lopez M. Endothelial 
dysfunction and preeclampsia: role of oxidative stress. Frontiers in Physiology. 2014;5:372. 
277. D'Souza V, Rani A, Patil V, Pisal H, Randhir K, Mehendale S, et al. Increased 
oxidative stress from early pregnancy in women who develop preeclampsia. Clinical and 
experimental hypertension. 2016;38(2):225-32. 
278. Sena LA, Chandel NS. Physiological roles of mitochondrial reactive oxygen species. 
Molecular cell. 2012;48(2):158-67. 
279. McCarthy CM, Kenny LC. Mitochondrial [dys]function; culprit in pre-eclampsia? 
Clinical science (London, England : 1979). 2016;130(14):1179-84. 
280. Chiu RW, Chan KC, Gao Y, Lau VY, Zheng W, Leung TY, et al. Noninvasive prenatal 
diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of 
DNA in maternal plasma. Proc Natl Acad Sci U S A. 2008;105(51):20458-63. 
281. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, et al. Analysis of 
circulating tumor DNA to monitor metastatic breast cancer. The New England journal of 
medicine. 2013;368(13):1199-209. 
282. Wenceslau CF, McCarthy CG, Szasz T, Spitler K, Goulopoulou S, Webb RC, et al. 
Mitochondrial damage-associated molecular patterns and vascular function. European 
heart journal. 2014;35(18):1172-7. 
283. Wang L, Xie L, Zhang Q, Cai X, Tang Y, Wang L, et al. Plasma nuclear and 
mitochondrial DNA levels in acute myocardial infarction patients. Coronary artery disease. 
2015;26(4):296-300. 
284. Suzumori N, Ebara T, Yamada T, Samura O, Yotsumoto J, Nishiyama M, et al. Fetal 
cell-free DNA fraction in maternal plasma is affected by fetal trisomy. Journal of human 
genetics. 2016;61(7):647-52. 
285. McCarthy FP, Khashan AS, North RA, Moss-Morris R, Baker PN, Dekker G, et al. A 
prospective cohort study investigating associations between hyperemesis gravidarum and 
cognitive, behavioural and emotional well-being in pregnancy. PloS one. 
2011;6(11):e27678. 
286. McCarthy FP, O'Keeffe LM, Khashan AS, North RA, Poston L, McCowan LM, et al. 
Association between maternal alcohol consumption in early pregnancy and pregnancy 
outcomes. Obstetrics and gynecology. 2013;122(4):830-7. 
210 
 
287. Ajaz S, Czajka A, Malik A. Accurate measurement of circulating mitochondrial DNA 
content from human blood samples using real-time quantitative PCR. Methods in molecular 
biology (Clifton, NJ). 2015;1264:117-31. 
288. Chiu RW, Chan LY, Lam NY, Tsui NB, Ng EK, Rainer TH, et al. Quantitative analysis of 
circulating mitochondrial DNA in plasma. Clin Chem. 2003;49(5):719-26. 
289. Padmini E, Lavanya S, Uthra V. Preeclamptic placental stress and over expression of 
mitochondrial HSP70. Clinical chemistry and laboratory medicine : CCLM / FESCC. 
2009;47(9):1073-80. 
290. Wang Y, Walsh SW. Increased superoxide generation is associated with decreased 
superoxide dismutase activity and mRNA expression in placental trophoblast cells in pre-
eclampsia. Placenta. 2001;22(2-3):206-12. 
291. Genc H, Uzun H, Benian A, Simsek G, Gelisgen R, Madazli R, et al. Evaluation of 
oxidative stress markers in first trimester for assessment of preeclampsia risk. Arch Gynecol 
Obstet. 2011;284(6):1367-73. 
292. Lee HC, Wei YH. Mitochondrial role in life and death of the cell. Journal of 
biomedical science. 2000;7(1):2-15. 
293. Widschwendter M, Schrocksnadel H, Mortl MG. Pre-eclampsia: a disorder of 
placental mitochondria? Molecular medicine today. 1998;4(7):286-91. 
294. Mando C, De Palma C, Stampalija T, Anelli GM, Figus M, Novielli C, et al. Placental 
mitochondrial content and function in intrauterine growth restriction and preeclampsia. 
American journal of physiology Endocrinology and metabolism. 2014;306(4):E404-13. 
295. Madsen-Bouterse SA, Zhong Q, Mohammad G, Ho YS, Kowluru RA. Oxidative 
damage of mitochondrial DNA in diabetes and its protection by manganese superoxide 
dismutase. Free radical research. 2010;44(3):313-21. 
296. Gavriilidis C, Miwa S, von Zglinicki T, Taylor RW, Young DA. Mitochondrial 
dysfunction in osteoarthritis is associated with down-regulation of superoxide dismutase 2. 
Arthritis and rheumatism. 2013;65(2):378-87. 
297. Wilkins HM, Morris JK. New Therapeutics to Modulate Mitochondrial Function in 
Neurodegenerative Disorders. Current pharmaceutical design. 2017;23(5):731-52. 
298. Buttar HS, Li T, Ravi N. Prevention of cardiovascular diseases: Role of exercise, 
dietary interventions, obesity and smoking cessation. Experimental & Clinical Cardiology. 
2005;10(4):229-49. 
299. Aune D, Saugstad OD, Henriksen T, Tonstad S. Physical activity and the risk of 
preeclampsia: a systematic review and meta-analysis. Epidemiology. 2014;25(3):331-43. 
300. Fiuza-Luces C, Garatachea N, Berger NA, Lucia A. Exercise is the real polypill. 
Physiology (Bethesda, Md). 2013;28(5):330-58. 
301. Brantsæter AL, Haugen M, Samuelsen SO, Torjusen H, Trogstad L, Alexander J, et al. 
A Dietary Pattern Characterized by High Intake of Vegetables, Fruits, and Vegetable Oils Is 
Associated with Reduced Risk of Preeclampsia in Nulliparous Pregnant Norwegian Women. 
The Journal of nutrition. 2009;139(6):1162-8. 
302. Clausen T, Slott M, Solvoll K, Drevon CA, Vollset SE, Henriksen T. High intake of 
energy, sucrose, and polyunsaturated fatty acids is associated with increased risk of 
preeclampsia. Am J Obstet Gynecol. 2001;185(2):451-8. 
303. Rumbold A, Ota E, Nagata C, Shahrook S, Crowther CA. Vitamin C supplementation 
in pregnancy. Cochrane Database Syst Rev. 2015;9:Cd004072. 
304. Maynard S. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may 
contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin 
Invest. 2003;111:649-58. 
305. Wang A, Rana S, Karumanchi SA. Preeclampsia: the role of angiogenic factors in its 
pathogenesis. Physiology (Bethesda, Md). 2009;24:147-58. 
211 
 
306. Thilaganathan B. Cardiovascular origins of Preeclampsia. Pregnancy Hypertension: 
An International Journal of Women's Cardiovascular Health. 2017;7:62-3. 
307. Sedeek M, Gilbert JS, LaMarca BB, Sholook M, Chandler DL, Wang Y, et al. Role of 
reactive oxygen species in hypertension produced by reduced uterine perfusion in pregnant 
rats. Am J Hypertens. 2008;21(10):1152-6. 
308. Redman C, Sacks G, Sargent I. Preeclampsia: an excessive maternal inflammatory 
response to pregnancy. Am J Obstet Gynecol. 1999;180:499 - 506. 
309. Redman C, Sargent I. Preeclampsia and the systemic inflammatory response. Semin 
Nephrol. 2004;24:565 - 70. 
310. Panda B, Panda A, Ueda I, Abrahams VM, Norwitz ER, Stanic AK, et al. Dendritic 
cells in the circulation of women with preeclampsia demonstrate a pro-inflammatory bias 
secondary to dysregulation of TLR receptors. J Reprod Immunol. 2012;94(2):210-5. 
311. Sacks GP, Studena K, Sargent K, Redman CW. Normal pregnancy and preeclampsia 
both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. 
Am J Obstet Gynecol. 1998;179(1):80-6. 
312. Leik CE, Walsh SW. Neutrophils infiltrate resistance-sized vessels of subcutaneous 
fat in women with preeclampsia. Hypertension. 2004;44(1):72-7. 
313. Shah TJ, Walsh SW. Activation of NF-kappaB and expression of COX-2 in association 
with neutrophil infiltration in systemic vascular tissue of women with preeclampsia. Am J 
Obstet Gynecol. 2007;196(1):48 e1-8. 
314. Hayashi F, Means TK, Luster AD. Toll-like receptors stimulate human neutrophil 
function. Blood. 2003;102(7):2660-9. 
315. McCarthy CG, Wenceslau CF, Goulopoulou S, Ogbi S, Baban B, Sullivan JC, et al. 
Circulating mitochondrial DNA and Toll-like receptor 9 are associated with vascular 
dysfunction in spontaneously hypertensive rats. Cardiovascular research. 2015;107(1):119-
30. 
316. Walsh SW. Plasma from preeclamptic women stimulates transendothelial 
migration of neutrophils. Reproductive sciences. 2009;16(3):320-5. 
317. Williamson RD, McCarthy FP, Khashan AS, Totorika A, Kenny LC, McCarthy C. 
Exploring the role of mitochondrial dysfunction in the pathophysiology of pre-eclampsia. 
Pregnancy Hypertension. 2018;13:248-53. 
318. Jaremo P, Lindahl TL, Lennmarken C, Forsgren H. The use of platelet density and 
volume measurements to estimate the severity of pre-eclampsia. Eur J Clin Invest. 
2000;30(12):1113-8. 
319. Braekke K, Holthe MR, Harsem NK, Fagerhol MK, Staff AC. Calprotectin, a marker of 
inflammation, is elevated in the maternal but not in the fetal circulation in preeclampsia. 
Am J Obstet Gynecol. 2005;193(1):227-33. 
320. He B, Yang X, Li Y, Huang D, Xu X, Yang W, et al. TLR9 (Toll-Like Receptor 9) Agonist 
Suppresses Angiogenesis by Differentially Regulating VEGFA (Vascular Endothelial Growth 
Factor A) and sFLT1 (Soluble Vascular Endothelial Growth Factor Receptor 1) in 
Preeclampsia. Hypertension. 2018;71(4):671-80. 
321. Rocha-Penha L, Bettiol H, Barbieri MA, Cardoso VC, Cavalli RC, Sandrim VC. 
Myeloperoxidase is not a good biomarker for preeclampsia prediction. Scientific reports. 
2017;7(1):10257. 
322. Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular 
remodeling and vascular disease. Biochemical pharmacology. 2008;75(2):346-59. 
323. Jonsson Y, Ruber M, Matthiesen L, Berg G, Nieminen K, Sharma S, et al. Cytokine 
mapping of sera from women with preeclampsia and normal pregnancies. J Reprod 
Immunol. 2006;70(1-2):83-91. 
324. Lau SY, Guild SJ, Barrett CJ, Chen Q, McCowan L, Jordan V, et al. Tumor necrosis 
factor-alpha, interleukin-6, and interleukin-10 levels are altered in preeclampsia: a 
212 
 
systematic review and meta-analysis. American journal of reproductive immunology. 
2013;70(5):412-27. 
325. Mihu D, Razvan C, Malutan A, Mihaela C. Evaluation of maternal systemic 
inflammatory response in preeclampsia. Taiwanese journal of obstetrics & gynecology. 
2015;54(2):160-6. 
326. Valencia-Ortega J, Zarate A, Saucedo R, Hernandez-Valencia M, Cruz JG, Puello E. 
Placental Proinflammatory State and Maternal Endothelial Dysfunction in Preeclampsia. 
Gynecologic and obstetric investigation. 2018:1-8. 
327. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. The 
hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management 
recommendations for international practice. Pregnancy Hypertension. 2018;13:291-310. 
328. Kell DB, Kenny LC. A Dormant Microbial Component in the Development of 
Preeclampsia. Frontiers in medicine. 2016;3:60-. 
329. Burton GJ, Jauniaux E. Placental oxidative stress: from miscarriage to preeclampsia. 
J Soc Gynecol Investig. 2004;11(6):342-52. 
330. Kell DB. Iron behaving badly: inappropriate iron chelation as a major contributor to 
the aetiology of vascular and other progressive inflammatory and degenerative diseases. 
BMC medical genomics. 2009;2:2. 
331. Wang Y, Walsh SW. Antioxidant activities and mRNA expression of superoxide 
dismutase, catalase, and glutathione peroxidase in normal and preeclamptic placentas. 
Journal of the Society for Gynecologic Investigation. 1996;3(4):179-84. 
332. Caja S, Enriquez JA. Mitochondria in endothelial cells: Sensors and integrators of 
environmental cues. Redox Biol. 2017;12:821-7. 
333. Puigserver P. Tissue-specific regulation of metabolic pathways through the 
transcriptional coactivator PGC1-alpha. Int J Obes (Lond). 2005;29 Suppl 1:S5-9. 
334. Kelly DP, Scarpulla RC. Transcriptional regulatory circuits controlling mitochondrial 
biogenesis and function. Genes Dev. 2004;18(4):357-68. 
335. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM. A cold-inducible 
coactivator of nuclear receptors linked to adaptive thermogenesis. Cell. 1998;92(6):829-39. 
336. St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jager S, et al. Suppression of 
reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. 
Cell. 2006;127(2):397-408. 
337. Oelkrug R, Kutschke M, Meyer CW, Heldmaier G, Jastroch M. Uncoupling protein 1 
decreases superoxide production in brown adipose tissue mitochondria. J Biol Chem. 
2010;285(29):21961-8. 
338. Hartman PE. [32] Ergothioneine as antioxidant.  Methods in Enzymology. 186: 
Academic Press; 1990. p. 310-8. 
339. Asmus K-D, Bensasson RV, Bernier J-L, Houssin R, Land EJ. One-electron oxidation 
of ergothioneine and analogues investigated by pulse radiolysis: redox reaction involving 
ergothioneine and vitamin C. Biochemical Journal. 1996;315(2):625. 
340. Akanmu D, Cecchini R, Aruoma OI, Halliwell B. The antioxidant action of 
ergothioneine. Archives of Biochemistry and Biophysics. 1991;288(1):10-6. 
341. Song TY, Chen CL, Liao JW, Ou HC, Tsai MS. Ergothioneine protects against neuronal 
injury induced by cisplatin both in vitro and in vivo. Food and chemical toxicology : an 
international journal published for the British Industrial Biological Research Association. 
2010;48(12):3492-9. 
342. Laurenza I, Colognato R, Migliore L, Del Prato S, Benzi L. Modulation of palmitic 
acid-induced cell death by ergothioneine: evidence of an anti-inflammatory action. 
BioFactors (Oxford, England). 2008;33(4):237-47. 
213 
 
343. Tschirka J, Kreisor M, Betz J, Grundemann D. Substrate Selectivity Check of the 
Ergothioneine Transporter. Drug metabolism and disposition: the biological fate of 
chemicals. 2018;46(6):779-85. 
344. Taubert D, Jung N, Goeser T, Schomig E. Increased ergothioneine tissue 
concentrations in carriers of the Crohn's disease risk-associated 503F variant of the organic 
cation transporter OCTN1. Gut. 2009;58(2):312-4. 
345. urck DB, Jean‐Louis ; Burlingame, Barbara ; Dean, Tara ; Fairweather‐Tait, Susan ; 
Heinonen, Marina ; Hirsch‐Ernst, Karen Ildico ; Mangelsdorf, Inge ; McArdle, Harry J ; Naska, 
Androniki ; Neuhäuser‐Berthold, Monika ; Nowicka, Grażyna ; Pentieva, Kristina ; Sanz, 
Yolanda ; Siani, Alfonso ; Sjödin, Anders ; Stern, Martin ; Tomé, Daniel ; Vinceti, Marco ; 
Willatts, Peter ; Engel, Karl–Heinz ; Marchelli, Rosangela ; Pöting, Annette ; Poulsen, 
Morten ; Schlatter, Josef ; Ackerl, Reinhard ; van Loveren, Henk. Safety of synthetic l‐
ergothioneine (Ergoneine®) as a novel food pursuant to Regulation (EC) No 258/97. EFSA 
Journal. 2016;Vol. 14,No. 11. 
346. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT 
method. Nature protocols. 2008;3:1101. 
347. Chappell L. Effect of antioxidants on the occurrence of pre-eclampsia in women at 
increased risk: a randomized trial. Lancet. 1999;354:810-6. 
348. Dominy JE, Puigserver P. Mitochondrial biogenesis through activation of nuclear 
signaling proteins. Cold Spring Harb Perspect Biol. 2013;5(7). 
349. Zhou X, Han T-L, Chen H, Baker PN, Qi H, Zhang H. Impaired mitochondrial fusion, 
autophagy, biogenesis and dysregulated lipid metabolism is associated with preeclampsia. 
Experimental Cell Research. 2017;359(1):195-204. 
350. Dlasková A, Clarke KJ, Porter RK. The role of UCP 1 in production of reactive oxygen 
species by mitochondria isolated from brown adipose tissue. Biochimica et Biophysica Acta 
(BBA) - Bioenergetics. 2010;1797(8):1470-6. 
351. Kazak L, Chouchani ET, Stavrovskaya IG, Lu GZ, Jedrychowski MP, Egan DF, et al. 
UCP1 deficiency causes brown fat respiratory chain depletion and sensitizes mitochondria 
to calcium overload-induced dysfunction. Proc Natl Acad Sci U S A. 2017;114(30):7981-6. 
352. Hubel CA. Oxidative stress in the pathogenesis of preeclampsia. Proc Soc Exp Biol 
Med. 1999;222(3):222-35. 
353. Giilmezoglu AM, Oosthuizen MMJ, Hofmeyr GJ. Placental Malondialdehyde and 
Glutathione Levels in a Controlled Trial of Antioxidant Treatment in Severe Preeclampsia. 
Hypertension in Pregnancy. 1996;15(3):287-95. 
354. Gratacos E, Casals E, Deulofeu R, Cararach V, Alonso PL, Fortuny A. Lipid peroxide 
and vitamin E patterns in pregnant women with different types of hypertension in 
pregnancy. Am J Obstet Gynecol. 1998;178(5):1072-6. 
355. Walsh SW, Vaughan JE, Wang Y, Roberts LJ, 2nd. Placental isoprostane is 
significantly increased in preeclampsia. FASEB journal : official publication of the Federation 
of American Societies for Experimental Biology. 2000;14(10):1289-96. 
356. Noris M, Todeschini M, Cassis P, Pasta F, Cappellini A, Bonazzola S, et al. L-arginine 
depletion in preeclampsia orients nitric oxide synthase toward oxidant species. 
Hypertension. 2004;43(3):614-22. 
357. Tanret C. Sur une base nouvelle retiree du seigle ergote, l'ergothioneine. Rend 
Acad Sci. 1909;149:222-4. 
358. Kerley RN, McCarthy C, Kell DB, Kenny LC. The potential therapeutic effects of 
ergothioneine in pre-eclampsia. Free Radical Biology and Medicine. 2018;117:145-57. 
359. LaMarca BB, Bennett WA, Alexander BT, Cockrell K, Granger JP. Hypertension 
produced by reductions in uterine perfusion in the pregnant rat: role of tumor necrosis 
factor-alpha. Hypertension. 2005;46(4):1022-5. 
214 
 
360. Sakrak O, Kerem M, Bedirli A, Pasaoglu H, Akyurek N, Ofluoglu E, et al. 
Ergothioneine modulates proinflammatory cytokines and heat shock protein 70 in 
mesenteric ischemia and reperfusion injury. The Journal of surgical research. 
2008;144(1):36-42. 
361. Deiana M, Rosa A, Casu V, Piga R, Assunta Dessi M, Aruoma OI. L-ergothioneine 
modulates oxidative damage in the kidney and liver of rats in vivo: studies upon the profile 
of polyunsaturated fatty acids. Clin Nutr. 2004;23(2):183-93. 
362. Kurzmann HHTaG. A Microcolorimetric determination of creatine in urine by the 
Jaffe reaction  Jounal of Biological Chemistry 1954;208:853-62. 
363. Bridges LE, Williams CL, Pointer MA, Awumey EM. Mesenteric artery contraction 
and relaxation studies using automated wire myography. Journal of visualized experiments 
: JoVE. 2011(55):3119. 
364. Cocheme HM, Logan A, Prime TA, Abakumova I, Quin C, McQuaker SJ, et al. Using 
the mitochondria-targeted ratiometric mass spectrometry probe MitoB to measure H2O2 
in living Drosophila. Nature protocols. 2012;7(5):946-58. 
365. Chappell L. Vitamin C and E supplementation in women at risk of preeclampsia is 
associated with changes in indices of oxidative stress and placental function. Am J Obstet 
Gynecol. 2002;187:777-84. 
366. Guijarro MV, Indart A, Aruoma OI, Viana M, Bonet B. Effects of ergothioneine on 
diabetic embryopathy in pregnant rats. Food and chemical toxicology : an international 
journal published for the British Industrial Biological Research Association. 
2002;40(12):1751-5. 
367. Logan A, Cocheme HM, Li Pun PB, Apostolova N, Smith RA, Larsen L, et al. Using 
exomarkers to assess mitochondrial reactive species in vivo. Biochimica et biophysica acta. 
2014;1840(2):923-30. 
368. Romero R, Chaiworapongsa T. Preeclampsia: a link between trophoblast 
dysregulation and an antiangiogenic state. J Clin Invest. 2013;123(7):2775-7. 
369. Doridot L, Chatre L, Ducat A, Vilotte JL, Lombes A, Mehats C, et al. Nitroso-redox 
balance and mitochondrial homeostasis are regulated by STOX1, a pre-eclampsia-
associated gene. Antioxidants & redox signaling. 2014;21(6):819-34. 
370. Widschwendter M, Schröcksnadel H, Mörtl MG. Pre-eclampsia: a disorder of 
placental mitochondria? Molecular medicine today. 1998;4(7):286-91. 
371. Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the activation 
and regulation of innate and adaptive immunity. Nat Rev Immunol. 2011;11(8):519-31. 
372. Tsukimori K, Tsushima A, Fukushima K, Nakano H, Wake N. Neutrophil-derived 
reactive oxygen species can modulate neutrophil adhesion to endothelial cells in 
preeclampsia. Am J Hypertens. 2008;21(5):587-91. 
373. Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal 
inflammatory response to pregnancy. Am J Obstet Gynecol. 1999;180(2 Pt 1):499-506. 
374. Sacks G, Studena K, Sargent K, Redman C. Normal pregnancy and preeclampsia 
both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. 
Am J Obstet Gynecol. 1998;179:80 - 6. 
375. Lau SY, Guild SJ, Barrett CJ, Chen Q, McCowan L, Jordan V, et al. Tumor Necrosis 
Factor-Alpha, Interleukin-6, and Interleukin-10 Levels are Altered in Preeclampsia: A 
Systematic Review and Meta-Analysis. Am J Reprod Immunol. 2013;70(5):412-27. 
376. Chen H, Li J, Li N, Liu H, Tang J. Increased circulating trimethylamine N-oxide plays a 
contributory role in the development of endothelial dysfunction and hypertension in the 
RUPP rat model of preeclampsia. Hypertension in pregnancy : official journal of the 
International Society for the Study of Hypertension in Pregnancy. 2019:1-9. 
377. Yu W, Gao W, Rong D, Wu Z, Khalil RA. Molecular determinants of microvascular 
dysfunction in hypertensive pregnancy and preeclampsia. Microcirculation. 2018:e12508. 
215 
 







Oxidative stress in pre-eclampsia; have we been looking in the wrong
place?
Rachel D. Williamson a,⇑, Cathal McCarthy a, Fergus P. McCarthy a,b, Louise C. Kenny a
a Irish Centre for Fetal and Neonatal Translational Research (INFANT), Cork University Maternity Hospital, Cork, Ireland
bDivision of Women’s Health KCL, Women’s Health Academic Centre KHP, St Thomas’s Hospital, London, United Kingdom
1. Introduction
Pre-eclampsia is a disorder of late pregnancy. It is a major cause
of maternal and perinatal morbidity and mortality, accounting for
nearly 18% of all maternal deaths worldwide; an estimated 77,000
maternal deaths per year [1]. Poor placentation is considered to be
an initial cause of the placental ischemia [2]. Placental ischemia in
turn gives rise to oxidative stress in the placenta and leads to shed-
ding of syncytiotrophoblast debris into the maternal circulation
provoking a systemic maternal inflammatory response and release
of sFLT and sENG causing maternal vascular endothelial dysfunc-
tion. The ubiquitous nature of the maternal vascular endothelium
accounts for the diverse multi-system nature of pre-eclampsia.
Currently there is no treatment for pre-eclampsia except deliv-
ery of the placenta and the baby, with the attendant risk of iatro-
genic prematurity and significant neonatal morbidity and
mortality. As a result, intensive research endeavours have focused
on defining the molecular mechanisms of pre-eclampsia and the
identification of new pre-symptomatic biomarkers of the condi-
tion. This review focuses on the role of elevated oxidative stress
in the pathology of pre-eclampsia and potential therapeutic agents
targeting oxidative stress that may prevent or ameliorate this
disorder.
2. Reactive oxygen species (ROS)
Reactive oxygen species are typically recognised as two groups;
free radicals and non-radical products. Free radicals include super-
oxide (O2), the hydroxyl radical (HO), lipid peroxy-radicals (LOO)
and alkoxy-radicals (LO). Non-radical derivatives are more stable
with a longer half-life, however, they can have strong oxidant
properties. Non-radicals include hydrogen peroxide (H2O2), perox-
ynitrite (ONOO) and hypochlorous acid (HOCl) [3]. O2 acts as
an oxidant as well as a reductant in biological systems [4]. O2
serves as an origin for many other biologically relevant ROS includ-
ing H2O2, HO radical and ONOO [3]. H2O2 is created by dis-
mutation of O2, this molecule can occur spontaneously or it can
be promoted by superoxide dismutase (SOD). Hydroxyl radical
(HO) is created when O2 donates one electron to H2O2 in a reaction
known as the Haber Weiss Reaction. The HO molecule is a highly
reactive oxidant that attacks a variety of biomolecules such as
lipids, proteins and DNA. Peroxynitrite (OONO) results from the
spontaneous reaction between O2 and NO. OONO is known to
be a very strong oxidant and it can react with lipids, DNA and pro-
teins [3]. This molecule reacts and modifies proteins and other cel-
lular structures inflicting oxidative damage on these molecules.
3. Sources of ROS
Sources of ROS include NADPH Oxidase, xanthine oxidase and
the mitochondria. NADPH oxidases are activated by a variety of
physiological and pathophysiological stimuli including inflamma-
tory cytokines, mechanical forces and growth factors. Xanthine
oxidoreductase exists in two forms; xanthine oxidase and xanthine
dehydrogenase. Xanthine oxidase transfers electrons to oxygen
from NADH and uric acid and generates O2 and H2O2, whereas
xanthine dehydrogenase transfers the electrons from hypoxan-
thine and xanthine to NAD+ generating NADH and uric acid [3].
When a critical cysteine residue is oxidised by peroxynitrite, xan-
thine dehydrogenase (XDH) is converted to xanthine oxidase. Xan-
thine oxidase has been shown to contribute to experimental
hypertension in animal models, however currently there is limited
evidence supporting the role of xanthine oxidase in human hyper-
tension [5]. Mitochondria are responsible for ATP production in the
cell through oxidative phosphorylation. The electron transport
chain involves NADH and flavinadenine dinucleotide (FADH) which
act as electron transporters. Electrons go through four stages and
finally electrons are transferred to an oxygen molecule. During
normal mitochondrial function, electrons transfer from one com-
plex to the next efficiently and there is minimal loss or leakage
from the electron transport chain. However, oxidative stress is
inherently linked to mitochondrial dysfunction due to disruption
in the electron transfer between acceptors during oxidative phos-
phorylation in the inner mitochondrial membrane resulting in
electron leakage.
The natural defence against ROS comprises both enzymatic and
non-enzymatic systems. Superoxide dismutase (SOD) is a well-
known antioxidant enzyme that prevents free radical mediated
injury in vivo and in vitro by metabolising superoxide anions that
are known to damage human tissues [6]. SOD is categorised into
three isoforms, cytosolic CU, Zn-SOD, and mitochondrial Mn-SOD,
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which catalyse the dismutation of O2 into H2O2 and O2. A decrease
in the endogenous SOD antioxidant defence systems weakens the
normal metabolic removal of O2. Additionally, endogenous protein
alpha-1-microglobulin acts as a radical scavenger and an antioxi-
dant. It provides protection to tissue and protects the mitochondria
from oxidative damage. Non-enzymatic antioxidants act as ROS
scavengers and include vitamins A, C and E; glutathione, bilirubin
and uric acid. Vitamin E is a fat-soluble vitamin and its main role is
to protect against lipid peroxidation. Vitamin C scavenges free
radicals in aqueous solution.
4. Oxidative stress and pre-eclampsia
Oxidative stress is an imbalance between the production of ROS
and antioxidant defences [3], resulting in increased levels of ROS
with resultant damage of cellular components including DNA, pro-
teins and lipids. Normal pregnancy is characterised by a low grade
oxidative stress; there are increased circulating levels of oxidised
low-density lipoproteins and a reduction in total antioxidant
capacity in pregnant women when compared with non-pregnant
women [7]. Excessive oxidative stress is generally thought to be
involved in the pathology of many pregnancy-related disorders
such as fetal growth restriction (FGR), pre-eclampsia and miscar-
riage. Dysfunctional placentation is proposed to provoke a hypoxic
reperfusion injury causing elevated oxidative stress in pre-
eclampsia. By 10–12 weeks’ gestation in normal pregnancy mater-
nal blood flow in the placenta causes a local increase in oxygen and
elevation in the activity of the antioxidant enzymes [8]. However,
in pregnancies subsequently complicated by pre-eclampsia there is
a decrease in antioxidant enzyme activity at the same gestation [9].
ROS are generally unstable and have a very short half-life,
therefore accurately assessing O2 and H2O2 in the clinical setting
is difficult. To address this, methods have been developed to mea-
sure stable markers of ROS that reflect an oxidative stress status.
Biomarkers of oxidative stress in human samples include serum
lipid hydroperoxides, plasma malondialdehyde (MDA) or urine
F2-isoprostanes and uric acid [10]. Lipid peroxidation involves
polyunsaturated fatty acids, including phospholipids, glycolipids
and cholesterol that are vulnerable targets of oxidation. Increased
lipid peroxidation plays a vital role in the pathology of pre-
eclampsia by provoking endothelial dysfunction. MDA levels have
been found to be significantly higher in pre-eclampsia in compar-
ison with uncomplicated pregnancy [7]. Additionally, antioxidant
SOD levels were significantly lower in pre-eclampsia in this study
[7]. F2-isoprostanes are prostaglandin-like compounds produced
in vivo by free radical induced peroxidation and are measured in
human tissues and biological fluids [11]. In women with pre-
eclampsia, isoprostanes have been shown to be elevated in the
placenta [12]. Uric acid is the end product of purine degradation
catalysed by the enzyme xanthine dehydrogenase and xanthine
oxidase and its production is increased in oxidative stress [13].
Hyperuricemia in pre-eclampsia was thought to result exclusively
from reduced renal clearance, however levels of uric acid are now
also believed to increase by trophoblast breakdown, cytokine
release and ischemia.
In recent years, overproduction of cell-free fetal haemoglobin
(HbF) has been implicated as a new pathological factor of pre-
eclampsia [14]. Haemoglobin reacts spontaneously with oxygen
generating free oxygen radicals. Haemoglobin and its degradation
products are toxic and can lead to oxidative stress in the maternal
circulation [15]. A recent study of 433 women in early pregnancy,
86 of whom developed pre-eclampsia measured serum HbF levels
from the first trimester and reported that the mean concentration
of HbF in the women who went on to develop pre-eclampsia was
significantly higher than in the control group [16]. Research from
our group demonstrated elevated levels of several haemoglobin
related metabolites including heme, bilirubin and biliverdin which
were shown to be all increased in pre-eclampsia patients [17]. The
metabolite heme binds to nitric oxide causing vasoconstriction,
which may be central in pre-eclampsia.
5. Targeting oxidative stress in pre-eclampsia
5.1. Vitamins
Vitamin C and E are exogenous antioxidants known to down-
regulate NADPH oxidase, a major source of ROS in the vascular
wall, and also up regulate eNOS, which leads to vasorelaxation
and a reduction in blood pressure [18]. The therapeutic potential
of these particular antioxidants in the prevention of conditions
associated with oxidative stress is supported by an extensive evi-
dence base comprising of experimental studies [19], observational
studies [20] and small clinical studies [21]. However, in stark con-
trast, large scale appropriately powered randomised clinical trials
(RCTs) have been overwhelmingly disappointing. The VIP trial
was a RCT of vitamin C and vitamin E in 2410 women identified
as being at an increased risk of pre-eclampsia [22]. This study
assigned the women with 1000 mg vitamin C and 400 IU vitamin
E or the matched placebo daily from the period of the second tri-
mester of pregnancy until delivery. This trial concluded that sup-
plementation with vitamin C and vitamin E did not prevent pre-
eclampsia. However, a secondary outcome from this clinical trial
showed that vitamin supplementation increased the rate of babies
born with low birthweight [22]. Another multicentre, randomised,
double-blinded trial was carried out on 10,154 nulliparous women
looking at vitamin C and vitamin E to prevent complications in
pregnancy [23]. The primary outcome for this clinical trial was sev-
ere pregnancy-associated hypertension or severe or mild hyperten-
sion with many clinical outcomes such as eclamptic seizures. From
their data in this clinical trial, supplementation with vitamin C and
E did not reduce the incidence of pregnancy-associated hyperten-
sion or pre-eclampsia in low risk nulliparous women [23]. In com-
parison with the VIP trial, this study did not find significance
between group differences in the rates of low birth rate and still-
birth. DAPIT was a randomised placebo-controlled clinical trial in
the UK and Northern Ireland from 2003–2008 assessing vitamin
C and vitamin E supplementation for the prevention of pre-
eclampsia in women with type 1 diabetes [24]. Women in this
study were randomly allocated to receive 1000 mg of vitamin C
and 400 IU vitamin E or matched placebo every-day from between
8 weeks’ gestation and 22 weeks gestation until delivery. This
study showed no significant differences between vitamins and
the placebo groups for any of the maternal outcomes. However,
plasma ascorbate concentrations for both vitamins were signifi-
cantly higher in the women that took the vitamins in comparison
to the placebo group at 26 weeks’ gestation and 34 weeks’ gesta-
tion with a low antioxidant status at baseline [24]. In summary,
in contrast to a significant supportive pre-clinical research base,
these large clinical trials suggest that antioxidant therapy is inef-
fective in the treatment of disorders such as pre-eclampsia.
5.2. Nitric oxide
Nitric oxide (NO) is a major endothelium-derived vasoactive
mediator [25] which acts as a potent vasodilator regulating vascu-
lar tone and tissue blood flow, as well as inhibiting platelet aggre-
gation and leucocyte adhesions on the endothelial surface [26]. NO
is synthesised by NO synthase (NOS) and activates soluble guanylyl
cyclase to convert guanosine triphosphate (GTP) to cyclic
guanosine monophosphate (cGMP), which is then degraded by
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phosphodiesterase 5 (PDE5) to guanosine monophosphate (GMP).
Interruption of both NO and its secondary messenger cGMP has
been implicated in the pathophysiology of pre-eclampsia [27].
NO signalling cascade is important for the placental function and
development of vascular network. The altered balance of NO and
ROS are thought to play a critical role in the pathogenesis of pre-
eclampsia [28]. NO causes dilation of the utero-placental arteries,
which is essential for trophoblast invasion and remodelling of
the endothelium [29]. From these findings, it was hypothesised
that low levels of NO may contribute to impaired cytotrophoblast
invasion that is seen in pre-eclampsia.
In recent years, NO has become a promising therapeutic target
for cardiovascular diseases such as atherosclerosis that are associ-
ated with oxidative stress [30]. Many studies have shown that
endothelium-derived NO acquires an atheroprotective effect.
Research has shown that responses to nitroglycerine cause vasodi-
lation in coronary arteries which indicates the smooth muscle is
responsive to NO. Furthermore, studies have examined the possi-
bility of reversing endothelial dysfunction by enhancing the
release of NO from the endothelium by stimulation of NOS or by
protecting NO from oxidative inactivation [31].
Sildenafil citrate is a cGMP specific phosphodiesterase inhibitor,
which potentiates the action of NO by inhibiting the degradation of
cGMP. Herraiz et al. examined perinatal outcome after administra-
tion of sildenafil in a pre-eclampsia model in rats [32]. Sildenafil
was shown to restore normal values of blood pressure and reduce
proteinuria in a rat model of pre-eclampsia. Similarly, sildenafil has
been shown to reduce plasma levels of sFlt-1 and sEng, in pre-
eclamptic (l-NAME induced) Sprague–Dawley rats [33]. These
two studies show the potential of sildenafil as a protective therapy
for pre-eclampsia. However, in a small placebo controlled RCT of
sildenafil in women with established pre-eclampsia showed no
significant difference in time from randomisation to delivery in
the two groups. [34]. However, there was a small increase in birth
weight in the babies born to women in the sildenafil arm. Sildenafil
may work by increasing uteroplacental circulation and perfusion
which improves gaseous and nutrient exchange, improving fetal
growth.
In vitro, sildenafil modifies the function of myometrial arteries
but not the omental and chorionic arteries in placental bed biop-
sies from women with pre-eclampsia [34]. Sildenafil may not work
in the treatment of pre-eclampsia due to the omental and chorionic
arteries not being NO responsive. However, the effect that was
seen was greater in IUGR than PE, suggesting chorionic plate ves-
sels might be more relevant to the pathophysiology of PE. There
is evidence from ex vivo and animal models of growth restriction
that sildenafil citrate increases average pup birth weight and
improves uteroplacental blood flow [35]. As a result this drug is
now being investigated in a randomised double blind, placebo-
controlled clinical trial (the STRIDER study) to quantify the effects
of administration of sildenafil on pregnancy outcome in severe
early-onset FGR [36].
5.3. Selenium
Glutathione peroxidase (GPx) and thioredoxinreductase
(ThxRed) are selenoproteins with a selenium atom (Se) integrated
in their active site in the form of selenocysteine [37]. This integra-
tion is essential for complete catalytic activity and as a result the
activity and expression of these proteins are extremely sensitive
to the amount of selenium present [38]. In vivo studies have shown
that rats develop a pre-eclampsia-like syndrome following with-
drawal of selenium in their diet [39]. Serum concentrations of sele-
nium, expression and activity levels of glutathione peroxidase in
maternal and umbilical venous blood samples were significantly
reduced [40]. However, selenium concentrations were further
reduced in umbilical venous samples in pre-eclampsia patients,
[40]. The functional role of selenoproteins was examined in rela-
tion to protecting trophoblast cells from oxidative stress by up-
regulating the selenoproteins GPx and ThxRed [37]. Cells were
treated with either H2O2, t-butyl H2O2and cumene-H2O2 respec-
tively to induce oxidative stress. The study showed all 3 forms of
peroxide induced cellular stress and this increase could be reversed
by supplementation with both inorganic and organic forms of sele-
nium. Watson et al., concluded that Se mediates its protective
effects through up regulation of the antioxidant enzyme activity
of GPx and ThxRed which in turn increases the trophoblast capac-
ity to tolerate oxidative stress [37]. More recently, the effects of
selenium on markers of risk of pre-eclampsia in pregnant women
was examined in a pilot randomised, control trial [41]. 230 women
were randomised and given either 60 lg/d (re-enriched yeast) or
placebo from 12–14 weeks’ gestation until delivery. Whole blood
selenium concentrations were measured at both baseline and
35 weeks gestation and furthermore, plasma selenoproteins P
(SEPP1) concentrations were examined at 35 weeks’ gestation. This
study showed that between 12 and 35 weeks gestation, whole
blood selenium concentrations were increased significantly in the
selenium treated women opposed to the placebo group. Further-
more, SEEP1 concentrations measured at 35 weeks were also sig-
nificantly higher in the treatment group than the placebo group.
5.4. Lifestyle
Lifestyle modifications including exercise, weight loss, diet
change and reduced salt intake improve endothelial function, pro-
tect against vascular disease, lower blood pressure and might also
lead to reduced vascular complications in patients with hyperten-
sion [42]. Prolonged exercise activates the Nrf2 pathway leading to
the up-regulation of endogenous antioxidants including SOD, glu-
tathione and peroxiredoxin [43]. However, the evidence to support
advice on exercise for pregnant women with hypertensive disor-
ders in pregnancy is limited. According to the American College
of Obstetrics and Gynaecology (ACOG), pre-eclampsia is an abso-
lute contraindication to aerobic exercise in pregnancy [44] as
opposed to RCOG which advises caution while exercising with
medical disorders in pregnancy [45]. Studies which have investi-
gated whether exercise in pregnancy reduces the risk of pre-
eclampsia, analysis suggests a reduced risk of preeclampsia with
increasing levels of physical activity before pregnancy and during
early pregnancy [46]. A recent study has shown a trend towards
a protective effect of exercise and the occurrence of pre-
eclampsia [47].
5.5. Mitochondria-targeted antioxidants
Mitochondria are the central cellular source of ROS. The pla-
centa is a highly metabolic organ with vast numbers of functional
mitochondria to manage the increasing demands of pregnancy.
Mitochondrial dysfunction is a pathogenic mediator of oxidative
stress and there is circumstantial evidence linking mitochondrial
dysfunction with pre-eclampsia [48]. Research has shown elevated
mitochondrial lipid peroxidation and increased evidence of suscep-
tibility to oxidation in mitochondria of pre-eclamptic placentas
[49]. Furthermore, increased activity of the placental mitochon-
drial electron transport chain in preterm pre-eclamptic patients
compared to normotensive controls has been reported [50].
Alpha-1-mjcroglobulin (A1M) is a scavenger of free heme and rad-
icals and protects cells against haemoglobin and heme induced
oxidative damage. Increased levels of A1M have been reported in
plasma and urine of women with pre-eclampsia [51]. Furthermore,
A1M binds to the mitochondrial complex 1 subunit NDUFAB1 and
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protects against mitochondrial swelling upon exposure to heme
and ROS [52].
Recent work from our group demonstrated increased produc-
tion of mitochondrial-specific superoxide in human umbilical vein
endothelial cells (HUVEC) treated with pre-eclampsia plasma sam-
ples compared with normotensive controls [53]. The field of mito-
chondrial pharmacology has greatly progressed recently with a
number of different pharmacology approaches in development,
to tackle mitochondrial dysfunction. Interestingly, there is sub-
stantial evidence demonstrating that mitochondrial-targeted
antioxidants may alleviate the clinical characteristics of pre-
eclampsia. Recent work identified that mitochondria-targeted
antioxidants (Mito-Tempo) alleviated endothelial dysfunction,
increased vascular nitric oxide production, reduced mitochondrial
superoxide and subsequent hypertension in two in vivo models of
hypertension [54]. Mito-Tempo reduced mROS and increased
vasodilation of visceral adipose arteries from morbidly obese sub-
jects highlighting its potential to successfully treat pre-eclampsia
in this obese cohort [55].
Based on the evidence discussed above (and summarised in
Fig. 1), oxidative damage is a significant pathological mediator of
pre-eclampsia and therefore it is critical to identify therapeutics
targeting this process.
6. Conclusions
Oxidative stress occurs when the generation of ROS overpowers
the fundamental antioxidant defences. In normal pregnancy the
production of ROS increases towards the end of gestation, however
antioxidant volume increases in order to maintain oxidative bal-
ance. In this review, we provided evidence of elevated oxidative
stress and its role in the pathogenesis of pre-eclampsia. We also
discuss novel antioxidant targets that warrant further investiga-
tion before entering the clinical arena as therapies. Future direc-
tions for potential treatments of pre-eclampsia should possibly
target oxidative stress through mitochondrial-targeted antioxi-
dants and selenium supplementation.
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1. Introduction
Pre-eclampsia is a pregnancy disease that complicates 2–5% of
pregnancies worldwide [1]. It is characterised by the development of
hypertension and proteinuria after 20 weeks’ gestation [2]. Pre-
eclampsia is thought to occur secondary to abnormal placentation in
early pregnancy [3] resulting from impaired placental trophoblast in-
vasion and subsequent generation of an ischemic environment [4].
Placental ischemia is proposed to increase placental oxidative stress
leading to the shedding of syncytiotrophoblast debris into the maternal
circulation where it initiates a systemic maternal inflammatory re-
sponse and subsequent endothelial dysfunction [5].
Oxidative stress is a cellular or physiological condition of elevated
levels of reactive oxygen species (ROS) which damage cell structure and
function. Antioxidant enzymes including superoxide dismutase (SOD)
and glutathione peroxidase are components of the body’s mechanism
for combating oxidative stress. SOD is a powerful antioxidant that
catalyses the reaction between two identical molecules of superoxide
radical into oxygen or hydrogen peroxide. There is significant evidence
that oxidative stress plays a role in the pathophysiology of pre-
eclampsia [6,7]. Normal pregnancy is associated with an increase in
oxidative stress due to a rise in maternal metabolism and maternal
blood flow in the placenta by 10–12weeks’ gestation [8]. However, in
pregnancies complicated by pre-eclampsia there is an exaggerated
oxidative stress phenotype with a correspondent deficient antioxidant
response.
Mitochondria are the dominant cellular source of ROS and there is
strong evidence that mitochondrial ROS (mROS) play an important role
in a variety of physiological processes including the regulation of cell
differentiation, apoptosis, redox cell signalling and inflammation
[9–11]. Furthermore, our research has implicated mitochondrial dys-
function as a potential mediator of oxidative stress in pre-eclampsia
[10]. Cell-free DNA (cf-DNA) has been investigated as a universal di-
agnostic biomarker for a number of clinical applications, such as
prenatal diagnosis and cancer monitoring [12,13]. Circulating cell free
DNA is composed of both nuclear and mitochondrial DNA. Mitochon-
drial DNA (mtDNA) encodes for 37 genes programmed by the mi-
tochondrial genome [14] and is often used as a biomarker of mi-
tochondrial dysfunction. mtDNA are particularly vulnerable to
oxidative damage due to its intimate location in the electron transport
chain (ETC) in the mitochondrial matrix and its lack of protective his-
tones [15]. More recently, there is emerging evidence suggesting that
cell-free mtDNA (cf-mtDNA) is linked to disease progression such as,
cardiovascular disease [16]. Circulating DNA in maternal plasma is
mostly of maternal origin (hematopoietic and stromal derived) de-
pending on gestational week and maternal bodyweight. Approximately
5–20% of the circulating DNA is derived from fetal/placental cells [17].
Our research has previously shown an increase in mtDNA in plasma
samples at time of disease (TOD) in women with pre-eclampsia [18].
Hence the aim of this study was to characterise the role of mitochon-
drial dysfunction in women with pre-eclampsia compared to un-
complicated pregnancies by assessing levels of antioxidant enzyme su-
peroxide dismutase and mtDNA at earlier time-points in pregnancy. We
also examined if lifestyle and dietary factors affected mtDNA levels in
pregnancy. We hypothesised that mitochondrial dysfunction plays a
role in the pathogenesis of pre-eclampsia.
2. Methods
2.1. Study subjects
Subjects were recruited from the Screening for Pregnancy Endpoints
(SCOPE) study Ireland which is an international multicentre pro-
spective cohort study of nulliparous singleton pregnancies aimed to
develop a screening test to predict adverse pregnancy outcomes in-
cluding pre-eclampsia, SGA infants and spontaneous pre-term birth
[19,20]. The clinical research ethics committee, University College
Cork, approved the collection and use of samples for research purposes.
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A nested case-control study within SCOPE Ireland was conducted which
included all pre-eclampsia cases in SCOPE Ireland and matched controls
with a case-to-control ratio of 1:2. Pre-eclampsia cases were defined as
women with systolic blood pressure≥ 140mm Hg and/or diastolic
blood pressure≥ 90mm Hg on at least two occasions 4 hrs apart after
20 weeks’ gestation and with proteinuria (24 h urinary pro-
tein≥ 300mg or urine dipstick protein≥+2). Randomly selected
controls were taken from healthy pregnant women who had un-
complicated pregnancies which were defined as pregnancies not af-
fected by pre-eclampsia, preterm birth or growth restriction and de-
livered at> 37weeks. All blood pressure readings were<140 and/
or< 90mmHg prior to the onset of labour. These were matched with
the cases for maternal age, body mass index (BMI) and gestational age.
Both 15 and 20week samples were taken from the SCOPE study from
women who subsequently went onto develop pre-eclampsia (n= 60)
and controls (n= 120). Samples were also taken from a subset of
women (n= 25) at the time of disease (TOD) with pre-eclampsia.
2.2. Superoxide dismutase enzyme activity
Superoxide dismutase activity was quantified in citrate plasma
samples using a superoxide dismutase assay kit (Cayman chemical)
which was used as per manufacturer’s instructions. This assay utilizes
tetrazolium salt for detection of superoxide radicals generated by xan-
thine oxidase and hypoxanthine. This assay measures a combination of
activity from all three isoforms.
2.3. Sample collection and DNA extractions
Plasma samples were collected in BD Heparin Vacutainer tubes,
placed on ice, and centrifuged at 2400g for 10min at 4°C according to
the standardised protocol. Plasma samples were stored at −80°C until
analysis. Samples were analysed in a blinded manner. Total DNA was
extracted from 200 µl of plasma from both controls and cases respec-
tively with a QIAamp DNA mini kit (Qiagen). DNA was sonicated at
38 kHz ± 10% for 10min to optimise DNA yield.
2.4. mtDNA quantification
Mitochondrial DNA was measured by real-time PCR using StepOne
Plus Detection system using Taqman assays for mitochondrial DNA
(hMitoF5, hMitoR5) [21]. Absolute quantification of the concentration
of mitochondrial DNA (mtDNA) was determined by standard curve
analysis and presented as copies/ml [21,22].
2.5. Maternal lifestyle factors
Women were asked at recruitment (15 ± 1weeks of gestation) and
at their second visit (20 ± 1weeks of gestation) how many times each
week did they carry out exercise that did not result in heavy breathing,
which was the SCOPE definition of moderate-intensity exercise. The
response was categorised as never, 1–3 times a week and daily.
Similarly, the questionnaire administered at both time points asked
women to report the frequency in which the consumed fruit and leafy
vegetables. Scoring was similar to exercise, where the response was
categorised as never, less than five pieces a week, and daily.
Multivitamins were categorised into never, less than daily and daily.
2.6. Statistical analysis
Analysis was performed using GraphPad Prism and SPSS version 22
(SPSS Inc. Chicago, Illinois). Data were presented using median
(± Interquartile range [IQR]) and comparisons of data between cases
and controls were performed using a non-parametric Mann Whitney U
test or Wilcoxon signed rank test as appropriate when data was not
normally distributed. Data that was normally distributed were re-
presented as mean (± SEM) and comparisons of data between cases
and controls were performed using an unpaired t-test. P values < 0.05
were considered as statistically significant. Chi-squared test and the
odds ratio (OR) was used to compare categorical variables.
3. Results:
3.1. Patient characteristics
There were 1774 participants in the SCOPE Ireland study. 68 (3.8%)
women were diagnosed with pre-eclampsia and 60 were included in the
nested case-control study with 120 participants selected as controls.
The 60 women with pre-eclampsia were composed of 39 women who
developed term pre-eclampsia and 21 preterm pre-eclampsia cases. As
all cases and controls were matched nulliparous women, there was no
significant differences observed between case-controls studies for ma-
ternal age, BMI, and gestational age at delivery. There was a significant
difference in mean arterial blood pressure (MAP) in controls versus
cases at both 15 and 20weeks’ gestation respectively (median [IQR];
78.0 mmHg [73.33–83.33], n= 120, vs median [IQR]; 82.0mmHg
[75.0–87.66], n= 60, p=0.0015 and media [IQR] 80.41mmHg
[75.3333–85.0], n= 120, vs median [IQR]; 83.5 mmHg [77.5–89.83]
n=60, p=0.02). There was a significant difference in birthweight in
controls compared to cases (3608.93 g ± 411.90 vs
2990.86 g ± 759.24; n=120, n= 60; p < 0.0001). (Table 1).
3.2. Evidence of altered plasma SOD activity before pre-eclampsia
There was a statistically significant reduction in antioxidant SOD
activity at 15 weeks’ gestation between controls and cases (1.94 ng/
ml ± 0.06 vs 1.69 ng/ml ± 0.06; n=60, n= 119; p < 0.01; 95%
CI; 0.04–0.45; Fig. 1A). There was no significant difference in SOD
activity at 20 weeks’ gestation between controls and cases, (0.82 ng/
ml ± 0.02 vs 0.77 ng/ml ± 0.03; n=119p=0.21; 95% CI;
Table 1
Patient Characteristics in the study cohort.
Preterm pre-eclampsia (n= 21) Term pre-eclampsia (n= 39) No pre-eclampsia (n= 120)
Mean Maternal age, years 31 29 29
Mean BMI 25 26 25
Maternal
Mean Arterial Blood Pressure at 15 weeks 82.33 [74.16–86.33] 81.5 [74.58–88.0] 78 [73.33–83.33]
Mean Arterial Blood Pressure at 20 weeks 81.33 [77.66–89.66] 83 [76.08–87.0] 80.41 [75.33–85.0]
Fetal
Mean Birth weight, g 2104 3300 3608
Mean gestational age at delivery 34 38 40
Perinatal death 1 1 0
Data are presented as mean or Median [IQR]. Mean Arterial blood pressure was calculated as MAP= (2×diastolic)+ systolic/3.
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−0.02–0.12; Fig. 1B).
3.3. Increased ΔmtDNA levels was evident between 15 and 20 weeks’ before
pre-eclampsia
There was no significant difference in the amount of total DNA
between controls and cases at both 15 and 20weeks’ gestation
(15 weeks: 7.06 ng/ml ± 4.08 vs 7.70 ng/ml ± 5.43 , n= 60n=120,
p=0.38; 20 weeks 6.71 ± 3.26 vs 7.15 ± 3.44 , n= 60n=120,
p=0.40; Fig. 2A). There was no significant difference in mtDNA at
15 weeks’ gestation between controls and cases (median [IQR]: 2832.96
copies/ml [1711.17–5002.82] vs 2337.32 copies/ml
[1357.11–5328.35], n= 58–117; p < 0.3381, Fig. 2B). Similarly,
there was no significant difference in mtDNA at 20 weeks’ gestation
between controls and cases and (median [IQR]: 2885.57 copies/ml
[1914.54–4834.12] vs 3307.7 copies/ml [1544.49–7396.92],
n= 58–117; p < 0.7873, Fig. 2C). As pregnancy progressed the
amount of mtDNA significantly increased in pre-eclampsia and healthy
pregnancies (median [IQR]: 2337.32 copies/ml [1357.11–5328.35],
3307.7 copies/ml [1544.49–7396.92] and 6449.8 copies/ml
[477.54–11145.9] n=58 and n=22.p < 0.0001, and median [IQR]:
2855.41 copies/ml [1740.19–5322.08], 2900.95 copies/ml
[1958.36–5055.16], 5983.88 copies/ml [3209.67–16901.5] n-117 and
n=23. P=0.009, Fig. 2D) at 15 weeks’, 20 weeks’ and TOD
respectively.
However the mean difference in mtDNA between 15weeks’ and
20weeks’ gestation was significantly higher in cases compared with
controls (2236 ± 796.0 copies/ml vs −555.3 ± 599.3 copies/ml
mtDNA concentration in plasma, p= 0.0065; Fig. 2E).
3.4. Lifestyle and nutritional factors; effect of these factors on mtDNA
Moderate exercise had no significant impact on the amount of
mtDNA in controls vs cases at 15 or 20 weeks’ gestation OR 1.00; [CI
1.00–1.00 vs 1.00 CI [1.00–1.00] respectively (Table 2A). When as-
sessing dietary factors such as leafy vegetable intake, fruit intake and
multivitamin consumption, similarly there was no effect on the amount
of mtDNA at 15 or 20 weeks’ gestation in controls vs cases (Tables 3A,
3B, 3C).
4. Discussion
Mitochondrial dysfunction is a pathogenic mediator of oxidative
stress in pre-eclampsia with elevated mitochondrial lipid peroxidation
and increased vulnerability to oxidation evident in placental mi-
tochondria in pregnancies complicated by pre-eclampsia [23]. In this
present study we showed a significant reduction in antioxidant SOD
activity at 15 weeks’ gestation and an increase in the mean difference in
Fig. 1. A) SOD activity (U/ml) was significantly reduced at 15 weeks in cases compared to healthy controls (P < 0.01). B) SOD activity (U/ml) at 20 weeks was
reduced in cases compared to healthy controls. Data are expressed as mean ± SEM.
Fig. 2. A) Total DNA in maternal plasma in controls and cases showed no significant difference. B) mtDNA at 15 weeks showed no significant difference in controls
when compared to cases C) mtDNA at 20weeks was higher in controls compared to cases but not statistically significant D) Mitochondrial dysfunction is significantly
increased as gestation progresses in pre-eclampsia and uncomplicated pregnancies (p < 0.001 and p= 0.0009) respectively.●=cases,■=control. Data represented
as the median; [IQR]. E) Significant increase in the mean difference in mtDNA concentration between 15 and 20 weeks gestation in cases compared to controls
(P < 0.01). Data represented as the mean; [SEM].
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mtDNA (between 15 and 20weeks’ gestation) in cases compared to
controls.
Oxidative stress results from an imbalance in the production of ROS
and the responsive antioxidant levels. There is a vast amount of evi-
dence for antioxidant decline and elevation of ROS in pre-eclampsia
[7,24]. SOD is the first barrier and antioxidant defence against ROS and
its activity is increased in the placenta of a normal pregnancy [25],
while SOD activity in placental tissue from women with pre-eclampsia
is decreased [26]. In our study, we showed lower levels of SOD activity
at 15 weeks’ gestation in cases compared to controls. This correlates
with previous work which showed lower levels of SOD at both 10–14
and 20–24weeks’ gestation respectively in pre-eclampsia [27]. Simi-
larly, the levels of maternal erythrocyte SOD were also lower in the
second half of pregnancy in pre-eclampsia when compared with nor-
motensive pregnancies [7].
Mitochondrial DNA is correlated with the number and size of the
mitochondria [28], furthermore mtDNA are particularly susceptible to
oxidative damage. While the origin of cf-mtDNA is difficult to pheno-
type, the quantitative assessment of cf-mtDNA may permit the evalua-
tion of mitochondrial dysfunction in pre-eclampsia. There have been a
number of studies that suggest mitochondrial abundance may be as-
sociated with placental insufficiency and pre-eclampsia [29–32]. Our
research previously showed evidence of increased mtDNA at time of
disease in women with pre-eclampsia, furthermore, we provided addi-
tional evidence of mitochondrial dysfunction by demonstrating in-
creased mitochondrial-specific ROS and reduced oxygen consumption
[18]. In this current study, while there was no significant difference in
mtDNA copy number at both 15 and 20weeks’ gestation respectively in
cases compared with controls, we reported a significant increase in the
mean difference in mtDNA copy number between 15 and 20weeks’
gestation in cases compared with controls.
Given the critical role of SOD antioxidants in mediating oxidative
damage provoked by exaggerated superoxide generation, the compro-
mised antioxidant defence evident at 15 weeks’ gestation in cases in our
study group may be partly responsible for increased vulnerability of
mtDNA damage as evident by the increase in mean difference in mtDNA
between 15 and 20weeks’ gestation. Previous work in retinal en-
dothelial cells overexpressing SOD2 [33] and in SOD2-depleted chon-
drocytes [34] has established an essential protective role for this en-
zyme in preventing mtDNA damage. Furthermore, we showed that
mtDNA copy number increases as pregnancy progresses in women with
pre-eclampsia and we hypothesise that the initial insult to mitochon-
drial antioxidant function seen early in pregnancy (15 weeks) could be
exacerbated later in pregnancy resulting in a more significant increase
Table 2
The effect of lifestyle factors (Exercise) on mtDNA in cases compared to controls at 15 and 20 weeks’ gestation.
Moderate exercise activity N=58 Case (mtDNA copy number/ml) N=117 Control (mtDNA (copy number/ml OR (95% CI)
Never exercised 19 1631.02 (815.92–3445.15) 23 2817.51 (1856.43–5602.91) 1.00 1.00–1.00
More than Once a week 31 2742.43 (1510.48–5328.35) 60 2676.89 (1669.87–3734.28)
Daily 8 3928.08 (934.06–11509.39) 34 3070.21 (1912.75–5322.08)
Never exercised 12 3242 (1367.75–9276.86) 20 2649.15 (1849.56–4454.55) 1.00 1.00–1.00
More than once a week 37 3249.79 (1493.10–7562.22) 67 2847.66 (1758.46–4248.59)
Daily 9 4198.29 (1632.68–5398.94) 30 2790.07 (1998.00–5385.22)
Table 3(A)
The effect of dietary factors (Fruit intake) on mtDNA in cases compared to controls at 15 and 20weeks’ gestation.
High fruit intake N=58 Case (mtDNA copy number/ml) N=117 Control (mtDNA copy number/ml) OR (95% CI)
Never 7 2158.15 (1357.11–3119.63) 9 1856.43 (617.47–9759.18) 1.00 1.00–1.00
< 6 times a week 11 3445.15 (1140.94–6661.19) 25 2617.49 (1683.27–4005.63)
> 5 a day 40 2466.71 (1339.17–4526.35) 83 2829.32 (1868.68–4786.10)
Never 0 1 6802.61 1.00 1.00–1.00
< 6 times a week 6 2650.57 (1063.15–6136.60) 16 2384.71 (1471.25–5954.11)
> 5 a day 52 3344.25 (1548.32–7395.89) 108 2856.83 (1980.26–4711.28)
Table 3(B)
The effect of dietary factors (leafy vegetable intake) on mtDNA in cases compared to controls at 15 and 20 weeks’ gestation.
Leafy vegetable intake N=58 Case (mtDNA copy number/ml) N=117 Control (mtDNA (copy number/ml OR (95% CI)
Never 22 2064.62 (1443.17–5873.68) 49 2862.43 (1964.75–5110.42) 1.00 1.00–1.00
< 6 times a week 27 2133.39 (1140.94–4068.91) 42 2547.10 (1644.76–4838.29)
> 5 a day 9 3119.63 (1677.58–5812.97) 26 2676.89 (1184.76–3950.15)
Never 1 4198.29 (4198.29–4198.29) 3 1846.20 (1108.22) 1.00 1.00–1.00
< 6 times a week 23 3104.99 (1366.01–7396.91) 46 2596.07 (1636.75–4126.70)
> 5 a day 34 3315.32 (1518.79–6499.72) 68 3067.12 (2151.85–5347.62)
Table 3(C)
The effect of dietary factors (Multivitamin intake) on mtDNA in cases compared to controls at 15 and 20 weeks’ gestation.
Multivitamin intake N=58 Case (mtDNA copy number/ml) N=117 Control (mtDNA (copy number/ml OR (95% CI)
No 44 2206.55 (1186.20–4709.44) 71 2617.49 (1856.43–4778.04) 1.00 1–1.00
Daily 14 2745.61 (1504.21–6598.51) 39 2850.34 (1626.85–5111.71)
Less than daily 0 7 3518.35 (1856.43–4315.26)
No 38 4032.60 (1744.82–7789.96) 57 2777.50 (1769.47–5184.31) 1.00 1.00–1.00
Less than daily 4 1374.57 (332.18–5948.15) 15 3647.68 (2278.63–4711.28)
Daily 16 2384.71 (1471.25–5954.11) 45 2754.95 (1822.09–4421.01)
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in mtDNA copy number in pre-eclampsia as we previously described.
The strength of our data compared to previous work in this area is
attributable to the longitudinal examination of mtDNA through gesta-
tion, whereas previous studies have focused on mtDNA quantitation in
the third trimester of pregnancy. This work correlates with previous
studies, where mtDNA copy number was assessed in a case-control
study and reported that the odds of pre-eclampsia were positively as-
sociated with increased maternal blood mtDNA copy number [31].
These findings strongly suggest that altered mitochondrial function is
evident very early in the development of pre-eclampsia. This study was
performed in the Irish SCOPE cohort and while we provide evidence of
mitochondrial dysfunction in pre-eclampsia, further larger studies in
different populations are warranted.
Lifestyle interventions such as healthy diet (fruit and vegetable
consumption) and exercise have been examined in mitochondrial dis-
eases [35,36]. In recent years, exercise has been intensively researched
in relation to reducing risk of pre-eclampsia [37,38]. The next step in
this study was to assess whether lifestyle and nutritional factors had an
effect on the amount of mtDNA in controls and cases. However, we
showed that exercise had no significant difference on mtDNA copy
number during pregnancy in controls or cases. Similarly, a previous
study assessed exercise and mtDNA copy number in controls and pre-
eclampsia cases and showed no association between exercise and
mtDNA copy number [31].
Diet has been suggested to play a potential role in the management
of pre-eclampsia [39]. In our study we found no association between
fruit and vegetable intake on mtDNA copy number in control and cases.
Similarly, Clausen et al, showed no association between pregnancies
affected by pre-eclampsia and healthy pregnancies when investigating
meat, fish, vegetables and fruit intake [40]. Finally we investigated
multivitamin intake and its association with mtDNA copy number in
control and cases and found no association. Both Vitamin C and E have
been extensively studied as antioxidant therapeutic options in pre-
eclampsia [41,42], however the results were largely disappointing. This
may have occurred as these exogenous antioxidant vitamins do not
penetrate the intracellular source of ROS, the mitochondria, and are
sequestered in the cytosol. Therefore, we propose a mitochondrial-tar-
geted antioxidant may represent a more promising clinically effective
treatment strategy for pre-eclampsia.
5. Conclusion
In this study, we provide evidence that in early gestation there is a
significant reduction in mitochondrial antioxidant SOD activity in
women who developed pre-eclampsia. Furthermore, there is a sig-
nificant increase in ΔmtDNA levels between 15 and 20weeks’ in women
who subsequently went on to develop pre-eclampsia. Our findings
support a pathogenic role for mitochondrial dysfunction in the patho-
physiology of pre-eclampsia. Finally, we found no effect of either life-
style or dietary factors in mediating mitochondrial dysfunction in this
study cohort, highlighting the potential need for the development for
mitochondrial targeted antioxidants as potential therapeutic targets to
treat pre-eclampsia.
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Activation of a TLR9 mediated 
innate immune response in 
preeclampsia
Rachel D. Williamson1, Fergus P. McCarthy1, Louise C. Kenny1,3 & Cathal M. McCarthy1,2
Preeclampsia is a multisystemic disorder leading to the development of a placental ischemic 
microenvironment with a resultant increase in oxidative stress. There is evidence that mitochondrial 
dysfunction and the innate immune system both play a role in the pathophysiology of this disease. 
Mitochondrial DAMPs such as mtDNA bind specific pattern recognition receptors such as Toll-like 
receptor 9 (TLR9) on the endosomal surface of immune cells, in particular neutrophils, subsequently 
activating them and triggering an innate response. We hypothesised that the exaggerated innate 
immune response seen in preeclampsia is provoked by dysfunctional mitochondria. Here we provide 
evidence that TLR9 activity is significantly increased at time of disease in women with preeclampsia. 
Furthermore, we show activation of neutrophil markers, Calprotectin, Myeloperoxidase (MPO), and IL-8 
are significantly increased at time of disease compared to uncomplicated pregnancies. This research 
supports a potential role of TLR9 activation of an innate immune response evident in preeclampsia 
which may possibly be initially triggered by dysfunctional mitochondria.
Preeclampsia is multifactorial disorder of pregnancy that is defined by the onset of hypertension and protein-
uria after 20 weeks’ gestation. One of the most established characteristics of this disorder is the inability of the 
trophoblasts to invade the maternal uterine decidual arteries, resulting in poor placentation. Production of pla-
cental anti-angiogenic factors such as soluble fms-related tyrosine kinase 1 (sFlt-1) and soluble endoglin (sEng) 
have been extensively researched in pre-eclampsia1,2. More recently, the cardiovascular system and its role in 
the development of preeclampsia is being explored3. Other pathological characteristics of preeclampsia include 
placental and systemic oxidative stress and dysfunction of the maternal vasculature4,5. In normal pregnancies 
there is evidence of a controlled systemic inflammatory response where cytokines promote the infiltration of the 
spiral arteries by invading trophoblast cells6. This controlled inflammatory response becomes dysregulated in 
preeclampsia resulting in abnormal activation of monocytes, neutrophils and the endothelium causing maternal 
inflammation7. There is overwhelming evidence that oxidative stress plays a key role in the pathophysiology of 
preeclampsia8,9. In turn oxidative stress, as a result of a placental ischemic microenvironment, releases reactive 
oxygen species into the maternal circulation, which can provoke a systemic inflammatory response10. The innate 
immune system acts as both a protector and effector during pregnancy. The innate system encompasses neutro-
phils, dendritic cells, natural killer cells and macrophages and these immune responders are activated to protect 
the mother from pathogens. Toll-like receptors (TLRs) are a family of type I transmembrane pattern recognition 
receptors (PRRs) that identify invading pathogens or endogenous damage signals and instigate an innate immune 
response. TLR9 can detect conserved sequences known as pathogen-associated molecular patterns (PAMPs) and 
also specifically respond to endogenous molecular structures known as damage-associated molecular patterns 
(DAMPs) via unmethylated CpG dinucleotide motifs as evident on mitochondrial DNA11. Activation of endo-
somal TLR9 involves an intracytoplasmic signalling cascade that leads to the up-regulation of pro-inflammatory 
transcription factors and subsequent liberation of pro-inflammatory cytokines12. There is evidence of increased 
TLR9 expression in both placental tissue and peripheral blood mononuclear cells (PBMC) from patients with 
preeclampsia compared with controls13,14.
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Neutrophils are short-lived effector cells of the innate immune system. These immune cells are activated in 
women during pregnancy and are further stimulated in preeclampsia15. Histopathological evidence has shown 
extensive infiltration of neutrophils in the systemic vasculature of women with preeclampsia compared to 
controls16,17. Neutrophils express a number of TLR’s on their surface including TLR918. Mitochondrial DNA 
(mtDNA) has been shown to activate neutrophils via a TLR9 signalling cascade, which elicits a neutrophil 
pro-inflammatory phenotype19–21. Neutrophil activation results in the secretion of a number of markers including 
reactive oxygen species (ROS), matrix metalloproteinase-8 (MMP-8), calprotectin, myeloperoxidase (MPO) and 
the pro-inflammatory cytokine IL-822.
Our research has previously provided evidence of a role for mitochondrial dysfunction in the pathophysiology 
of preeclampsia with an increase in ΔmtDNA evident between 15 and 20 weeks in women with preeclampsia23. 
Interestingly we also showed a significant increase in mtDNA at time of disease (TOD) in women with preec-
lampsia compared to controls24. The aim of this study was to investigate if the increase in mtDNA we previously 
reported in preeclampsia triggers activation of TLR9 signalling cascade. We also wanted to determine if a subse-
quent neutrophil pro-inflammatory phenotype was elicited in preeclampsia compared to controls by measuring a 
number of neutrophil activation markers longitudinally in pregnancy. We hypothesised that dysfunctional mito-
chondria provokes an exaggerated innate immune response in preeclampsia.
Results
Determination of TLR9 activity and downstream markers of neutrophil activation at 15 weeks’ 
gestation. To determine if TLR9 was activated by circulating mediators present in preeclampsia, HEK-TLR9 
cells were treated with 3% plasma. The level of neutrophil activation markers, calprotectin, MPO, MMP8 and 
IL-8 were also examined. Firstly, there was no significant increase in TLR9 activity at 15 weeks’ gestation in cases 
compared to controls (0.28 ± 0.02 v 0.2 ± 0.02; P = 0.99) (Fig. 1a). We subsequently measured a number of well 
described markers of neutrophil activation in both study groups at 15 weeks’ gestation. There was no signifi-
cant increase in calprotectin (1319 ng/ml ± 87.96, v 1198 ng/ml ± 56.76; P = 0.23) (Fig. 1b) or myeloperoxidase 
(Median [IQR]: 6.72 ng/ml [2.20–13.13] v 4.83 ng/ml [2.11–8.41]; P = 0.14) between cases and controls (Fig. 1c). 
There was also no significant difference in MMP8 (1041.27 pg/ml ± 42.96 v 1075.62 pg/ml ± 88.24; P = 0.69) 
(Fig. 1d) or the pro-inflammatory cytokine IL-8 (median [IQR]: 8.99 [3.32–30.70] v 9.32 [2.18–29.85]; P = 0.95) 
between cases and controls at 15 weeks’ gestation (Fig. 1e).
Determination of TLR9 activity and downstream markers of neutrophil activation at 20 weeks’ 
gestation. There was no significant increase in TLR9 activity at 20 weeks’ gestation in cases compared to 
controls (0.29 ± 0.01, v 0.30 ± 0.02; P = 0.88) (Fig. 2a). While there was no change in the levels of calprotectin 
between cases and controls at 20 weeks’ gestation (1155 ng/ml ± 68.45 v 1234 ng/ml ± 61.10; P = 0.42) (Fig. 2b), 
there was a significant increase in myeloperoxidase in cases compared to controls (Median [IQR]: 5.02 ng/ml 
[2.36–9.08] v 7.07 ng/ml [2.74–17.24]; P = 0.02) (Fig. 2c). There was no significant change in the levels of MMP8 
between cases and controls (1116.73 pg/ml ± 48.24 v 1053.74 pg/ml ± 54.05; P = 0.41) (Fig. 2d). There was no 
significant increase in IL-8 in cases compared to controls at 20 weeks’ gestation (Median [IQR]: 7.95 pg/ml [2.52–
30.31] v 13.49 pg/ml [3.66–46.66]; P = 0.14) (Fig. 2e).
Activation of TLR9 activity provokes a neutrophil-derived pro-inflammatory phenotype at time 
of disease in preeclampsia. There was a significant increase in TLR9 activity at TOD in preeclampsia 
cases compared to controls (0.29 ± 0.01 v 0.35 ± 0.01; P = 0.01) (Fig. 3a). Subsequently, there was also a signif-
icant increase in both calprotectin (1946.55 ng/ml ± 155.08 v 1516.45 ng/ml ± 145.84; P = 0.04) (Fig. 3b) and 
Figure 1. TLR9 activity and downstream markers of neutrophil activation did not alter at 15 weeks’ gestation. 
There was no significant increase in TLR9 activity (a) or neutrophil activation markers Calprotectin (b), MPO, 
(c) MMP-8 (d) and IL-8 (e) at 15 weeks’ gestation between cases and controls.
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myeloperoxidase (Median [IQR]: 8.33 ng/ml [5.70–14.20] v 4.52 ng/ml [3.53–8.73]; P = 0.01) (Fig. 3c) respec-
tively at TOD in cases compared to controls. There was no significant increase in MMP-8 in cases when com-
pared with controls at time of TOD, (842.92 pg/ml ± 87.07 v 1140.64 pg/ml ± 144.77; P = 0.08) (Fig. 3d). Finally, 
there was a significant increase in the pro-inflammatory cytokine IL-8 (Median [IQR]: 6.13 pg/ml [1.18–28.68] v 
24.63 pg/ml [5.37–71.20]; P = 0.01) at TOD in cases compared to controls (Fig. 3e).
Evidence of elevated innate immune response across gestation in preeclampsia. We investi-
gated if the neutrophil-mediated innate immune response were altered longitudinally in pregnancy. Initially, 
there was no difference in TLR9 activity across gestation in controls. (Fig. 4a). Similarly, there was no significant 
change in calprotectin, MPO and IL-8 expression in controls (Fig. 4b,c,e). MMP-8 was significantly decreased in 
uncomplicated pregnancies (Fig. 4d).
In cases complicated with preeclampsia, both TLR9 and calprotectin were significantly increased across 
gestation (0.28 ± 0.02, 0.30 ± 0.02, 0.37 ± 0.02; P = 0.01) and (1318.69 ng/ml ± 87.95, 1233.77 ng/ml ± 68.45, 
Figure 2. TLR9 activity and downstream markers of neutrophil activation did not alter at 20 weeks’ gestation. 
There was no significant increase in TLR9 activity (a) or neutrophil activation markers Calprotectin (b), MMP-8 
(d) and IL-8 (e) at 20 weeks’ gestation between cases and controls. MPO expression (c) is significantly increased 
in cases compared with controls (P = 0.02).
Figure 3. Circulating plasma mediators activate a TRL9-mediated innate immune response in preeclampsia at 
TOD. TLR-9 activity (a), Calprotectin (b), MPO (c), and IL-8 (e) are significantly increased at time of disease 
in cases compared to controls (P = 0.01). There was no significant increase in MMP-8 at TOD in cases in 
comparison to controls.
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1946.55 ng/ml ± 145.84; P = 0.0001) respectively. (Fig. 5a,b). There was no significant increase in MPO, (6.72 ng/
ml [2.20–13.13], 7.09 ng/ml [2.74–17.24], 8.33 ng/ml [5.70–14.20]; P = 0.14), MMP-8 (1075.62 pg/ml ± 88.24, 
1053.74 pg/ml ± 54.05, 1140.64 pg/ml ± 87.08; P = 0.82) or IL-8 (9.32 pg/ml [2.18–29.85], 13.49 pg/ml [3.66–
46.66], and 24.63 pg/ml [5.37–71.20]; P = 0.13) across gestation in preeclampsia cases (Fig. 5c–e).
Determination of TLR9 activity and downstream markers of neutrophil activation in preterm 
cases versus term cases. We next explored if there was a difference in the neutrophil pro-inflammatory 
phenotype across all time-points in women who developed preeclampsia and delivered either before 37 weeks or 
after 37 weeks’ gestation (Table 1). There was no significant difference in TLR9 activity in preterm preeclampsia 
compared to term preeclampsia across gestation. Similarly, there was no statistical significance at each time-point 
when comparing expression of calprotectin, MPO and MMP8 in preterm preeclampsia versus term preeclampsia. 
Interestingly IL-8 expression is initially increased at 15 weeks’ gestation in women who developed preterm preec-
lampsia, but the cytokine levels reduce as pregnancy progresses.
Figure 4. Normal pregnancy did not activate a TLR9 mediated innate immune response. There was no 
significant increase in TLR9 activity (a), Calprotectin (b), MPO (c) in healthy control pregnancies across 
gestation. MMP8 (d) is significantly reduced at term pregnancies (P = 0.01), while IL-8 (e) showed no 
significant difference across gestation in healthy control pregnancies.
Figure 5. Neutrophil activation markers are increased across pregnancyin preeclampsia. TLR9 activity (a), 
Calprotectin (b), are both significantly increased across gestation in cases with preeclampsia (P = 0.01). There 
was no significant increase in neutrophil activation markers MPO (c), MMP8 (d) and IL-8 (e) across gestation 
in cases with preeclampsia.
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Discussion
Pregnancy is associated with a maternal systemic inflammatory response; however, this response is exaggerated in 
preeclampsia. There has been a number of studies which have provided evidence of increased neutrophil activa-
tion in women with preeclampsia16,25,26. In this present study, we investigated if circulating mediators (including 
mtDNA)23, trigger TLR9 activity with the subsequent downstream activation of a neutrophil-mediated innate 
immune response in women with preeclampsia and healthy controls. We showed TLR9 activity is significantly 
increased in women with preeclampsia compared to healthy controls at time of disease. There was a correspond-
ing increase in production of downstream neutrophil activation markers, calprotectin, myeloperoxidase, MMP8 
and the pro-inflammatory cytokine IL-8 in women with preeclampsia compared to healthy controls at time of 
disease, indicating that complete activation of neutrophil pro-inflammatory phenotype only became evident late 
in pregnancy in preeclampsia.
The innate immune response plays a well described role in the pathophysiology of preeclampsia. 
Mitochondrial DAMPs such as mtDNA bind specific pattern recognition receptors such as TLR9 on the endo-
somal surface of the immune cells, in particular, neutrophils and activate an innate response. TLR9 receptors are 
also localised to trophoblasts and the villous stromal vascular endothelium and their expression is increased in 
preeclampsia13. We have shown a significant increase in TLR9 activity using a reporter cell assay incubated with 
plasma taken at time of disease in preeclampsia cases compared to healthy controls. Furthermore, previous work 
in our lab using the same study group samples examined mtDNA (as a marker of mitochondrial dysfunction) 
and reported that mtDNA was also significantly increased at time of disease in preeclampsia cases in the same 
study cohort23. This indicates that the increase in mitochondrial DAMP (mtDNA) at time of disease may activate 
a TLR9 mediated innate immune response in preeclampsia cases only. Exciting new work by He et al. has iden-
tified an additional role for TLR9 in preeclampsia where they established that TLR9 supressed angiogenesis in 
part by increasing sFlt-1 expression in a murine model of preeclampsia27. Furthermore, research carried out in 
spontaneous hypertensive rats, illustrated circulating mtDNA may lead to the activation of the innate immune 
system through TLR921. Research by Goulopoulou et al., has also shown preliminary data indicating that TLR9 
activation provokes preeclampsia–like symptoms in pregnant rats20 emphasising the pathogenic role of TLR9 in 
preeclampsia.
Calprotectin is a calcium binding protein and is located in the cytosol of neutrophils and is released upon neu-
trophil activation. In our study, calprotectin was significantly increased at time of disease compared to controls. 
This is in agreement with recent studies which have reported increase in calprotectin at term in preeclampsia26. 
Akçum et al., reported increased circulating calprotectin levels at term in women with preeclampsia, and inter-
estingly found an additional increase in women with severe preeclampsia.
MPO is a lysosomal enzyme mainly produced and released by activated neutrophils. In this study, we showed 
a significant increase in MPO in cases as early as 20 weeks’ gestation when compared with controls and this 
significant increase was equally evident at time of disease in preeclampsia. Previous studies measuring MPO in 
preeclampsia have reported conflicting results; some studies have reported no difference in MPO in preeclampsia 
in samples taken at 24 weeks or later in the third trimester28,29, whereas Gandley et al., reported a 3-fold increase 
in circulating MPO levels in women with preeclampsia compared to matched healthy controls at 32–38 weeks’ 
gestation30. The variation in MPO levels in previous preeclampsia studies may be due to small sample size. In 
our study we compared 60 cases and 120 matched controls, which to our knowledge is one of the biggest studies 
carried out in relation to MPO and preeclampsia.
MMP8 is part of the MMP family which consists of 23 zinc and calcium dependent proteases that effect differ-
ent mechanisms of the extracellular matrix. In recent years, MMPs have become a target of interest in preeclamp-
sia due to its role in vascular function and remodelling31,32. Recent research shows strong evidence that MMP8 
play an important role in mediating endothelial cell angiogenesis32. Furthermore, endothelial dysfunction is a 
pathogenic characteristic of preeclampsia, dysregulated MMP8 expression may play a crucial role in the disrup-
tion of angiogenesis in preeclampsia leading to endothelial dysfunction. In our study, there was an increase in 
circulating levels of MMP8 expression at TOD in women with preeclampsia cases compared to healthy controls.
Cytokines and chemokines have been extensively studied as markers of inflammation involved in the patho-
physiology of preeclampsia. In this study, we showed a significant increase in circulating IL-8 levels at time of 
disease in cases compared to controls. IL-8 has previously shown to be increased in women with preeclampsia 
Neutrophil markers
15 weeks 
(Preterm N = 19)
15 weeks 
(Term N = 38) P Value
20 weeks 
(Preterm N = 19)
20 weeks 
(Term N = 37) P Value
TOD  
(Preterm N = 6)
TOD (Term 
N = 16) P Value
TLR9 Signal 0.31 ± 0.05 0.27 ± 0.03 0.66 0.30 ± 0.06 0.29 ± 0.03 0.41 0.37 ± 0.03 0.39 ± 0.04 0.713
Calprotectin (ng/ml) 1043.15 ng/ml ± 126.19
1645.66 ng/
ml ± 187.30 0.16
886.99 ± ng/ml 
245.48
1167.96 ng/




ml ± 170.62 0.77











MMP8 (pg/ml) 1138.41 pg/ml ± 149.24
989.38 pg/








ml ± 182.92 0.12











Table 1. Plasma levels of TLR9 activity, neutrophil activation markers and pro-inflammatory cytokine IL-8 in 
patients with preterm and term preeclampsia. Data is presented as mean ± SEM and median (25–75 percentiles) 
where applicable.
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in the third trimester33. A recent study reported a significant increase in IL-8 in early gestation (5–15 weeks’) in 
women who subsequently went on to develop preeclampsia. However, a limitation of their study was the small 
sample size (n = 9)34. Other studies investigating IL-8 throughout pregnancy reported similar results to ours with 
no significant increase evident in the second trimester35,36 but a significant increase in IL-8 is evident in the third 
trimester in women with preeclampsia compared to healthy controls37.
Preterm preeclampsia occurs before 37 weeks’ gestation and is frequently regarded as a slightly different phe-
notype to preeclampsia occurring at term. Therefore, we investigated whether neutrophil activation triggers an 
altered innate immune response in preterm preeclampsia compared to term preeclampsia. In this study, there 
was no statistically significant difference in the concentration of neutrophil activation makers in preterm versus 
term in our cohort.
When investigating the activation of a TLR9 mediated innate immune response across pregnancy, there was 
no significant difference in expression of any of the neutrophil markers measured in healthy controls. However, in 
preeclampsia, significant increases were seen in neutrophil activation markers, TLR9 and calprotectin, illustrating 
that the innate immune response may be initially triggered earlier in preeclampsia but complete activation is not 
significantly evident until later in pregnancy. This is in agreement with recent studies of maternal inflammation 
(cytokines such as IL-6, TNF-α) in preeclampsia, whereby low level inflammation is evident early in pregnancies 
but is amplified in the third trimester of pregnancy38–40. This current study shows that the TLR9 activation of the 
innate immune system may play a role in the pathophysiology of preeclampsia in late gestation.
Conclusion
Here we provide evidence that circulating plasma mediators may activate a TRL9-mediated innate immune 
response in preeclampsia. We show that the activity of TLR9, a receptor for mtDNA, is significantly increased 
at time of disease in preeclampsia. Subsequently we have shown increased production of neutrophil activation 
markers particularly late in pregnancy in preeclampsia. Finally, we have shown that possible activation of TLR-9 
by dysfunctional mitochondria may provoke an exaggerated neutrophil-mediated innate immune response in 
preeclampsia.
Material and Methods
Study subjects. Subjects were recruited from the Screening for Pregnancy Endpoints (SCOPE) study Ireland 
which is an international multicentre prospective cohort study of nulliparous singleton pregnancies aimed to 
develop a screening test to predict adverse pregnancy outcomes including preeclampsia, SGA infants and spon-
taneous pre-term birth41,42. A nested case-control study within SCOPE Ireland was conducted which included all 
preeclampsia cases in SCOPE Ireland and matched controls with a case-to-control ratio of 1:2. Preeclampsia cases 
was defined as a systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg on at least two 
occasions 4 hrs apart after 20 weeks’ gestation and with proteinuria (24 hour urinary protein ≥300 mg or urine 
dipstick protein ≥+2). Randomly selected controls were taken from healthy pregnant women who had uncom-
plicated pregnancies which were defined as pregnancies not affected by preeclampsia, preterm birth or growth 
restriction and delivered at >37 weeks. All blood pressure readings were <140 and/or <90 mmHg prior to the 
onset of labour. These were matched with the cases for maternal age, body mass index (BMI) and gestational 
age. Both 15 and 20 week samples were taken from the SCOPE study from women who subsequently went onto 
develop preeclampsia (n = 60) and controls (n = 120). Samples were also taken from a subset of women (n = 25) 
at the time of disease (TOD) with preeclampsia and matched controls. The 60 women with preeclampsia were 
composed of 39 women who developed term preeclampsia and 21 preterm preeclampsia cases. The SCOPE study 
was conducted according to the guidelines laid down in the Declaration of Helsinki, and all the procedures were 
approved by the Clinical Research Ethics Committee of the Cork Teaching (EMC5(10)05/02/08), and all women 
provided written informed consent.
Sample collection. Plasma samples were collected in BD Heparin Vacutainer tubes, placed on ice, and cen-
trifuged at 2,400 g for 10 minutes at 4 °C according to a standardised protocol. Plasma samples were stored at 
−80 °C until analysis.
TLR-9 activity. TLR9 ligand activity was monitored with HEK-blue TLR9 Reporter Cell assay (InvivoGen). 
All experiments were performed using a cell density of 50,000 cells in a 96 well plate. Cells were initially seeded 
and left overnight prior to treatment for 24 hrs with 3% plasma taken at 15 and 20 weeks’ gestation (cases, n = 60, 
controls, n = 120) and TOD (cases, n = 25, controls, n = 25). The supernatant was incubated with Quanti-Blue 
detection medium (InvivoGen) and the activity was read on a Varioskan Flash plate reader (Thermo Scientific) 
at 630 nm.
Calprotectin analysis. Plasma calprotectin (S100A8/S100A9) concentrations were measured by 
enzyme-linked immunosorbent assay (ELISA) using human S100A8/S100A9 Quantikine kit. Heparin plasma 
samples from all time-points were initially diluted a 100-fold in assay buffer and then directly added to a 
pre-coated plate. The ELISA was performed as per manufacturers’ instructions.
Myeloperoxidase, MMP8, IL-8 analysis. Myeloperoxidase (MPO), Matrix metalloproteinases-8 
(MMP8) and interleukin-8 (IL-8) concentrations were measured respectively at all time-points by individual 
ELISA DuoSet kits (R&D SYSTEMS. USA & Canada). ELISA was carried out as per manufacturer’s instructions.
Statistical analysis. Analysis was performed using GraphPad Prism. Data were presented using median 
(±Interquartile range [IQR]) and comparisons of data between cases and controls were performed using a 
non-parametric Mann Whitney U test or Wilcoxon signed rank test as appropriate when data was not normally 
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distributed. Data that was normally distributed were represented as mean (±SEM) and comparisons of data 
between cases and controls were performed using an unpaired t-test. P values < 0.05 were considered as statisti-
cally significant.
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Introduction: Placental oxidative stress due to abnormal placentation is proposed to play a 
vital role in the pathophysiology of preeclampsia. There is preliminary evidence implicating 
mitochondrial dysfunction as a mediator of exaggerated oxidative stress, which is evident in 
preeclampsia. The aim of this study was to investigate the potential therapeutic properties of 
L-(+)-ergothioneine, a promising antioxidant, in an in vitro model of oxidative stress. 
Methods: JEG-3 placental choriocarcinoma cells were pre-treated with 1mM L-(+)-
ergothioneine, 20µM Mito-Tempo and 1mM N-acetylcysteine for 2hrs and subsequently 
treated with 200µM H2O2 for 4hrs. Cell viability, mitochondrial-specific superoxide levels, 
mitochondrial mass and oxygen consumption rate were measured. 
Results:  Pre-treatment with L-(+)-ergothioneine significantly increased cytoprotection in 
JEG-3 cells while also significantly reducing mitochondrial-specific superoxide (100% v 
48.4% ± 13.8%, n=3; P≤0.01). Compared with MitoTempo and N-acetylcysteine, L-(+)-
ergothioneine  had a more pronounced effect across all measured parameters. The 
orchestrator of mitochondrial function, PGC-1α, as well as UCP-1 were significantly altered 
in cells pre-treated with L-(+)-ergothioneine and subsequently exposed to oxidative stress. 
Furthermore, pre-treatment with L-(+)-ergothioneine increased the maximal (uncoupled) 
oxygen consumption rate of the cells. 
Discussion: Here we provide evidence of L-(+)-ergothioneine’s potential protective activity 
and mechanisms in an in vitro model of oxidative stress. L-(+)-ergothioneine alleviated the 
effects of the H2O2 oxidative insult by reducing mitochondrial-specific superoxide generation. 
We provide evidence that ERG mediates its protective effects, at least in part, by regulating 
markers involved in mild mitochondrial uncoupling while increasing the maximal respiratory 
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Preeclampsia is characterised as novo hypertension in pregnancy (BP ≥140 mm Hg systolic 
or ≥90 mm Hg diastolic) at or after 20 weeks’ gestation, accompanied by proteinuria and/or 
evidence of maternal acute kidney injury (AKI), neurological features, haemolysis, liver 
dysfunction, or fetal growth restriction [1]. Annually, preeclampsia results in over 500,000 
fetal and neonatal deaths and more than 70,000 maternal deaths globally [1]. There is 
substantial evidence that defective placentation in early pregnancy is a vital event in the 
development of this condition [2]. Furthermore, the ischemic placental microenvironment is 
initially triggered by a reduction in placental perfusion due to oscillations in oxygen delivery 
to the placenta and fetus, in turn resulting in exaggerated oxidative stress [3]. Inflammation is 
also a significant accompaniment [4]. To date, research has shown that abnormally elevated 
oxidative stress is present in preeclampsia as early as 8-10 weeks’ gestation [5]. 
There are many sources of reactive oxygen species (ROS) within the cell; however, 
mitochondria are the dominant cellular producer of ROS [6]. There is growing evidence that 
mitochondrial dysfunction may play a role in the pathophysiology of preeclampsia [7,8] as 
there are elevated levels of mtDNA in plasma from women with preeclampsia when 
compared with matched healthy controls [6].  Mitochondrial DNA is generally sequestered 
inside mitochondria; however after physiological stressors such as trauma, infection, or 
oxidative stress, mtDNA molecules are detectable in the circulation [9]. Furthermore, there is 
evidence of diminished mitochondrial antioxidant defence in preeclampsia as early as 15 
weeks’ gestation [8,10].  
The placenta requires an extensive quotient of functional mitochondria to meet the elevated 
metabolic demands of pregnancy. To maintain the appropriate number, function and 





proliferation-activated receptor ƴ co-activator 1α (PGC-1α) is a transcriptional coactivator 
that regulates numerous auxiliary biological functions associated with mitochondria, 
including antioxidant defense system, angiogenesis, cellular respiration and oxidative 
metabolism [13,14]. Furthermore, PGC-1α directs a wide programme of mitochondrial gene 
expression of mitochondrial-ROS detoxifying enzymes including superoxide dismutases 
(SOD1, SOD2) and uncoupling protein-1 (UCP-1), which are directly induced by this 
transcriptional orchestrator [15]. UCP-1 is a mitochondrial transporter present in the inner 
mitochondrial membrane with a well-known role in mediating adaptive thermogenesis [14]; 
more recently it has been shown to regulate exaggerated mROS production, in part via mild 
uncoupling [16]. 
L-(+)-ergothioneine  (ERG) is a dietary, water-soluble amino acid derived from histidine, 
cysteine and methionine. It is synthesised by various bacteria and fungi and taken up by 
higher organisms. Many physiological roles have been proposed for ERG including immune 
regulation, scavenging of free radicals and cation chelation [17]. Furthermore, ERG has been 
shown to possess cytoprotective and antioxidant properties in both in vitro and in vivo models 
[17-25], in addition to being involved in anti-inflammatory responses [26]. ERG crosses the 
intestinal epithelium using the type 1 organic cation transporter SLC22A4 (previously known 
as OCTN1) [27]. SLC22A4 was initially considered to be a carnitine transporter; however it 
transports ERG at a rate almost two orders of magnitude higher [28,29], indicating that the 
ability to accumulate ERG was selected by evolution. ERG accumulates in conditions of high 
oxidative stress, indicating that it may be an encouraging agent for diseases involving 
oxidative stress, such as preeclampsia [30,31]. ERG is a commercially available amino acid, 
has proven pharmacovigilance for consumption in humans [32], and no adverse effects were 
seen in pregnant Sprague Dawley rats [33], indicating its potential as a safe treatment for 





The aim of this study is to investigate the mechanistic role of ERG in modulating 
mitochondrial function in an in vitro model of placental oxidative stress, and to assess its 
potential role as a novel therapeutic agent for preeclampsia.  
 
2.0 Materials and Methods: 
2.1 Cell culture and treatments. 
The human JEG-3 choriocarcinoma placental cell line (ATTC), which are representative of 
extravillous trophoblasts were grown in Ham’s F-12 (Invitrogen) media supplemented with 
10% Fetal bovine serum (FBS), 1% L-glutamine and 1% Penicillin Streptomycin 
(Biosciences). Cells were maintained at 37 ͦC and 5% CO2 and were routinely passaged at 80% 
confluency. All experiments were performed on cells seeded 24-48 hrs in advance and serum 
starved for 1 hour prior to treatments. Cells were pre-treated initially with increasing 
concentrations of L-(+)-ergothioneine (1µM–1mM) and Mito-Tempo (1µM-100µM), and N-
acetylcysteine (NAC) (1µM-1mM) for 24hrs. For co-treatments, cells were pre-treated with 
optimal concentrations of 1mM L-(+)-ergothioneine, 20 µM Mito-Tempo and 1µM N-
acetylcysteine (NAC) for 2 hrs and 200µM H2O2 was then added for either 24hrs, except for 
mitochondrial superoxide and mass measurements where cells with treated with 200µM H2O2  
for 4hrs. The oxidative stressor insult (200µM H2O2) was chosen based on our previous in vitro 
investigations [36]. 
 
2.2 Assessment of Cell Viability using MTT assay 
The thiazolyl blue tetrazolium bromide MTT assay assesses cell viability, cells were treated 
as described in section 2.1 and were incubated at 37 ͦC with MTT solution for 4 hrs. 





absorbance read at 570 nm, with 630 nm as a reference. Cell viability % = absorbance of each 
treated cells/absorbance of control- (DMSO-) treated cells x100. 
 
2.3 Isolation of RNA and Real-time PCR analysis 
RNA was extracted using the RNeasy mini-kit (Qiagen). Transcripts encoding Peroxisome 
proliferator-activated receptor-gamma coactivator (PGC-1α), superoxide dismutase (SOD1), 
SOD2, uncoupling protein-1 (UCP-1) and SLC22A4 were quantified by real-time PCR using 
the StepONE Plus Detection system. Taqman assay (Applied Biosciences) and Sybr Green 
primers were used for quantification. The amounts of the target gene was normalised to the 
geometric mean of internal control gene 18S, and were determined using the comparative 2-
ΔΔCT method [37].    
 
2.4 Detection of mitochondrial superoxide by fluorescence microscopy 
MitoSOX Red fluorescence reagent (Invitrogen) was used to measure intramitochondrial 
superoxide. This fluorogenic dye is specifically oxidised by superoxide anions in the 
mitochondria. This oxidation reaction produces a red fluorescent dye once bound to the 
mitochondrial DNA. Cells were treated as described in section 2.1. Media were then removed 
and 0.5µM MitoSOX red was added to the cells for 30 mins at 37˚C. Cells were then fixed 
and permeabilized prior to nuclear staining with DAPI. Mean fluorescence intensity was 
analysed using Image J software in at least 10 random fields of view and compared to DMSO 
controls.  
 
2.5 Determination of mitochondrial mass  
Mitochondrial mass was measured using the MitoID green fluorescent marker (Enzo Life 





organic probe that is considered to localise to the mitochondria irrespective of any membrane 
potential they might possess. All experiments were performed at a cell density of 50,000 cells 
per well in a 12 well plate. Cells were serum starved for 1 hour and subsequently pre-treated 
with either 1mM L-(+)-ergothioneine, 1mM NAC or 20 µM Mito-Tempo for 2 hrs. Thereafter, 
cells were treated with 200 µM H2O2 for 4 hrs.  
 
2.6 Mitochondrial Oxygen Consumption (OCR) 
Mitochondrial bioenergetics were assessed using the Seahorse XF 96 Extracellular Flux 
Analyser and XF Wave Analysis software version 1.4 and Seahorse XF 96 extracellular flux 
assay kits (Agilent Technologies, Santa Clara, CA, USA). JEG-3 cells were seeded at 45,000 
cells/well on Seahorse XF96 cell culture microplates in DMEM media containing 10% FBS, 
1% L-glutamine and 1% Penicillin-Streptomycin. All experiments were performed on cells 
seeded 24 hrs in advance and serum-starved for 1 hour prior to treatments. Cells were pre-
treated with 1mM ERG or vehicle for 6 hrs. All chemicals used to evaluate mitochondrial 
bioenergetics were from Agilent Technologies (Santa Clara, CA, USA). Following ERG 
treatment, cell culture media were replaced with non-buffered DMEM-based XF modified 
media containing 10 mM glucose and 1 mM pyruvate and baseline respiration rates were 
recorded. 
 To evaluate mitochondrial function, oligomycin A (1μM), inhibitor of mitochondrial 
membrane adenosine triphosphate (ATP) synthase, Carbonyl cyanide-4-
(trifluoromethoxy)phenylhydrazone (FCCP)(0.3μM), an uncoupler of oxidative 
phosphorylation, and a mixture of antimycin A (1μM) and rotenone (1μM), which are complex 
I and complex III inhibitors, were used. The instrument was programmed for 3 cycles of drug 
injection followed by 3 mixing steps and 3 measuring periods (3 min each). The overall 





at least three times with a minimum of 15–20 technical replicates for each treatment and 
normalized to total cellular protein content using Pierce™ BCA Protein Assay Kit (Thermo 
Fisher Scientific, Dublin, Ireland).  
 
2.7 Statistical analyses 
Analyses were performed using GraphPad Prism. Data were presented as mean (±SEM), or 
fold change relative to control. Comparisons of data between in vitro groups were performed 
using one-way ANOVA and Mann Whitney U-Test. For analysing the differences over the 
course of the Seahorse assay, two-way Repeated Measures ANOVA, followed by Bonferroni 

















3.0 Results:  
3.1 Determine the preferred concentration of antioxidants on cell viability  
To examine the preferred concentration of ERG, JEG-3 cells were treated with a range of 
increasing concentrations (1μM to 1mM) for 24 hrs. In summary, 1mM ERG was used for 
subsequent experiments (Figure 1A). Similar cell viability assays were performed with a 
mitochondrial-targeted antioxidant Mito-Tempo (1μM- 100μM) (Figure 1B) and NAC a non-
mitochondrial antioxidant (1μM-1mM) (Figure 1C).  In summary, 20μM Mito-Tempo and 
1mM of ERG and 1mM NAC were used in subsequent experiments. 
3.2 Cytoprotective effects of ERG on H2O2 -induced cell death. 
The next set of experiments was designed to determine whether ERG had cytoprotective 
properties on H2O2-treated cells. H2O2 is commonly used as a cellular stressor representative 
of oxidative stress in in vitro models. 200 µM H2O2 was used for subsequent experiments 
(Figure 1D). Pre-treatment with 1mM ERG significantly rescued H2O2 –induced cell death 
(91% ± 5% v 47 % ± 10.0%, n=3, P= 0.01), when compared with the mitochondrial-targeted 
antioxidant Mito-Tempo (72% ± 8% v 47% ± 10%, n=3, P=0.11). Furthermore, the ERG-
mediated protective effect was similar to that of the non-mitochondrial antioxidant NAC 







Figure 1: Cytoprotective effects of ERG, MitoTempo and NAC on H2O2 –induced-cell 
death. A-C) The dose-dependent effect of ERG, MitoTempo and NAC on JEG-3 cell 
viability was assessed using a MTT assay. JEG-3 cells were treated with varying 
concentrations of  ERG, MitoTempo and NAC for 24 hrs. Data are expressed as mean ± 
SEM. D) Dose dependent effect of H2O2 on JEG-3 cell viability was assessed using a MTT 
assay. JEG-3 cells were treated with varying concentrations of H2O2 for 24 hrs. Data are 
expressed as mean ± SEM. E) ERG is protective of H2O2-induced cell death in JEG-3 cells. 
Cells were pre-treated with 1mM ERG, 20μM MitoTempo and 1mM NAC for 2 hrs and 
subsequently exposed to 200µM H2O2 for 4 hrs, cell viability was assessed by MTT assay. 
Data are expressed as mean ±SEM. (*P<0.05, **P<0.01; v Control). Data are representatives 








3.3 ERG reduces mitochondrial specific ROS production in H2O2 treated cells  
Increased production of mitochondrial-specific ROS (mROS) is inherently linked to 
mitochondrial dysfunction. To examine mitochondrial-specific superoxide production, cells 
were labelled with MitoSOX Red fluorescent dye and quantified by fluorescent microscopy. 
Mitochondrial-specific superoxide was significantly reduced in cells pre-treated with ERG 
(100% v 48% ± 14%, n=3; P<0.01) compared with control cells (Figure 2). Similarly, 
MitoTempo significantly reduced mitochondrial-specific superoxide production, (100% v 
51% ± 12%, n=3; P= 0.01), while NAC didn’t significantly reduce mROS production 
respectively (100% v 68% ± 7%, n=3 P= 0.08). 
 
Figure 2: ERG reduced mitochondrial superoxide levels in JEG-3 cells. JEG-3 cells were 
pre-treated with ERG, MitoTempo and NAC for 2hrs and subsequently treated with H2O2 for 
4hrs and mitochondrial-specific superoxide was detected using fluorogenic MitoSox Red dye. 





independent experiments and are expressed as difference in percentage pixel intensity 
between study groups ± SEM. *P<0.01.   
3.4 ERG did not affect mitochondrial mass in JEG-3 treated cells.  
The effect of ERG on mitochondrial mass in JEG-3 cells was measured using fluorescent 
MitoID Green. MitoID Green accumulates in the mitochondria and becomes fluorescent in a 
lipid environment, fluorescence was quantified by microscopy. There was no significant 
change in mitochondrial mass in cells pre-treated with ERG compared to control cells (85% ± 
7% v 100%, n=3, P=0.06). Equally, MitoTempo (84% ± 27% v 100%, n=3, P= 0.35) or NAC 
treated cells didn’t significantly alter mitochondrial mass when compared to control cells 
(81% ± 7% v 100%, n=3; P=0.06) (Figure 3). 
 
Figure 3: Effect of antioxidants on mitochondrial mass in H2O2 treated cells.  JEG-3 
cells were pre-treated with ERG, MitoTempo and NAC for 2 hrs and subsequently treated 
with H2O2 for 4hrs. Mitochondrial mass was determined using fluorogenic MitoID green 
reagent. Mitochondrial mass was quantified using Image J software. Data is the mean of 3 
independent experiments and are expressed as difference in percentage pixel intensity 







3.5 ERG regulates endogenous UCP-1 expression in placental cells 
We assessed the effect of ERG treatment on expression of PGC-1α and its directly regulated 
mitochondrial target genes SOD1, SOD2 and UCP-1.  We also measured SLC22A4 
expression in ERG-treated cells. This study showed that ERG treatment did not have a 
significant effect on the expression of PGC-1α, SOD1, SOD2, SLC22A4 in JEG-3 cells 
compared with untreated cells. (Figure 4). However, UCP-1 expression was significantly 
increased in cells treated with ERG (2 fold ± 0.5, n=3, P=0.04) compared to untreated cells.   
 
Figure 4: Effects of ERG on endogenous expression of mitochondrial-detoxifying 
enzymes in untreated JEG-3 cells. JEG-3 cells were treated with 1mM ERG for 24hrs and 
placental expression of transcripts for mitochondrial-detoxifying enzymes were quantified by 





determined in JEG-3 cells. Data from 3 independent experiments are mean fold change 
compared to untreated JEG-3 cells ± SEM. *P<0.05.  
 
3.6. ERG alters mitochondrial bioenergetics via increasing the maximal (uncoupled) 
OCR  
We characterised the effect of ERG treatment on mitochondrial bioenergetics (Figure 5A) 
based on the changes in OCR rate in response to modulators of respiration that target 
components of oxidative phosphorylation. First, ERG treatment did not significantly increase 
the basal OCR (Figure 5B, 0.72 ± 0.18 pmol/min O2/µg protein vs. 0.96 ± 0.13 pmol/min O2/µg 
protein, p= 0.099) or (as judged by oligomycin-sensitivity) the proportion of basal OCR 
coupled to ATP synthesis (Figure 5B, 0.56  ±  0.13 pmol/min O2/µg protein vs. 0.70 ± 0.09, 
p=0.12) of JEG-3 cells. FCCP administration uncouples respiration from ATP synthesis and 
removes respiratory control, thereby indicating the maximum OCR the cells could sustain. 
ERG treatment led to a significantly higher uncoupled OCR rate (Figure 5B, 1.06 ± 0.16 
pmol/min O2/µg protein vs. 0.59 ± 0.15 pmol/min O2/µg protein, p= 0.02). Finally, there were 
no endpoint differences detected after the simultaneous administration of rotenone and 
antimycin A (Figure 5B, 0.46 ± 0.13 pmol/min O2/µg protein vs. 0.47 ± 0.08 pmol/min O2/µg 







Figure 5. ERG modifies the maximal uncoupling OCR of JEG-3 cells. (A) Bioenergetic 
profiles of JEG-3 cells treated with 1mM ERG and control for 6hrs. (B) Oxygen consumption 
rates (OCR), and maximal respiration (OCR after FCCP administration). Data are 

































representative of 3 independent experiments and expressed as mean ±SEM, (A) Two-way 
ANOVA, *p<0.05, ***p<0.001 vs Control (B) Mann-Whitney U-test, *p<0.05 vs Control. 
 
3.7 ERG alters the profile of mitochondrial superoxide detoxifying enzymes in response 
to oxidative stress   
ERG significantly increased the expression of PGC-1α (1.8-fold ± 0.3, n=3, P= 0.03) 
compared to control cells (Figure 6). Additionally, Mito-Tempo (1.5 fold ± 0.2, n=3, P=0.04) 
and NAC (1.4 fold ± 0.1, n=3, P=0.002) significantly increased PCG-1α expression, albeit 
with a reduced effect. UCP-1 is known to mediate mROS production in part by mild 
uncoupling therefore, we wanted to investigate the effect of ERG treatment on UCP-1 
expression. ERG significantly increased the expression of UCP-1 (1.6 fold ± 0.3, n=3, 
P=0.03) compared with controls (Figure 6). Mito-Tempo and NAC did not alter UCP-1 
expression. The expression of SOD1, SOD2 or SLC22A4 did not change in response to any 








Figure 6: Effect of ERG, MitoTempo and NAC on placental expression of 
mitochondrial-detoxifying enzymes in H2O2 treated cells: JEG-3 cells were pre-treated 
with ERG, MitoTempo and NAC for 2 hrs prior to exposure to H2O2 for 4 hrs and gene 
expression of markers of mitochondrial-detoxifying enzymes were quantified by real-time 
PCR. The amounts of amplified products were expressed relative to geometric mean of 18S 
internal controls. Data are mean fold change compared to controls ± SEM. *P<0.01. Data are 













It is well known that oxidative stress is a prime mediator in the pathophysiology of 
preeclampsia, and more recently there has been a specific focus on the role of mitochondrial 
dysfunction in regulating oxidative stress in preeclampsia [36,38]. However, a number of 
antioxidants have been notably unsuccessful as treatment strategies for preeclampsia [39,40]. 
This may be due to the fact that they remain sequestered in the cytoplasm and fail to reach the 
mitochondria, therefore restricting their capacity to alter the oxidative damage seen in 
preeclampsia, or because in the presence of free iron they are actually pro-oxidant [6]. The 
overall aim of this study was to explore the mechanism of action of a novel nutraceutical 
antioxidant, L-(+)-ergothioneine,  in regulating mitochondrial function in an in vitro model of 
placental oxidative stress, and subsequently elucidate its role as a potential novel therapeutic 
target for preeclampsia.   
Initially, we wished to investigate the cytoprotective effects of ERG on H2O2-induced 
oxidative damage in JEG-3 cells. We observed that 1mM ERG significantly preserved cell 
viability in response to the oxidative stress. Similarly, Paul et al, showed ERG exerted 
cytoprotective effects on HeLa cells following H2O2 treatment. Furthermore, these authors 
indicated that depletion of SLC22A4 markedly augmented sensitivity to pyrogallol-induced 
cell damage and death, reinforcing the physiologic antioxidant role of ERG [41]. ERG has 
previously been used for the treatment of oxidative stress in human brain microvascular 
endothelial cells (HBMECs) where Li et al., showed ERG reduced cell death as well as 
oxidative stress [42]. MitoTempo is an extensively studied mitochondrial-targeted antioxidant 
[36]; therefore, we wanted to compare the efficacy of ERG in protecting mitochondrial 
function in comparison to the established MitoTempo. We demonstrated that ERG had 





In the present study, we showed that ERG significantly reduced mitochondrial-specific ROS 
production in JEG-3 cells. Similarly, MitoTempo significantly reduced mROS production but 
with less potency than ERG. We have previously shown that MitoTempo also reduced mROS 
production in HUVEC cells incubated with plasma from women with preeclampsia [36]. In 
comparison, ERG was significantly more effective than was the non-mitochondrial 
antioxidant, NAC in reducing mROS generation, highlighting that ERG may combat 
placental oxidative stress evident in preeclampsia by regulating mitochondrial reactive 
oxygen species production.  
Mitochondrial biogenesis is involved in the control of cell metabolism, signal transduction 
and regulation of mROS production. Mitochondrial mass reflects the equilibrium between 
rates of biogenesis and degradation [43]. We measured mitochondrial mass and found no 
significant difference in JEG-3 cells pre-treated with ERG which would suggest that the 
dampening of mROS upon ERG treatment is not directly related to a disruption in 
mitochondrial mass. We previously reported that mitochondrial-targeted antioxidant 
MitoTempo reduced mROS generation without altering mitochondrial mass in preeclampsia 
plasma treated HUVEC [36], a similar effect was also evident in placental cells upon 
MitoTempo treatment.  
PGC-1α is coinduced with numerous ROS-detoxifying enzymes upon exposure of cells to an 
oxidative stressor and is often required for the activation of many these ROS-detoxifying 
enzymes, including SOD1, SOD2 and UCP-1 [15]. Under non-pathological circumstances, 
the production of mROS is strictly regulated by many antioxidant systems in order to sustain 
redox-signaling homeostasis. We subsequently investigated the effect of ERG on both 
endogenous and H2O2-induced expression of PGC-1α and its target genes UCP-1 and SOD1 
and SOD2 antioxidants in JEG-3 cells. We found no significant effect of ERG on SOD 





effect on the expression of either antioxidant. We have previously shown that MitoTempo-
mediated reduction of mROS in HUVEC cells also didn’t directly alter the expression of 
SOD antioxidants.  
However, we identified a significant increase in both endogenous and H2O2-induced 
expression of both PGC-1α and its downstream target UCP-1, in cells treated with ERG. 
PGC-1α has previously been shown to be significantly reduced in placental tissue in women 
with preeclampsia [44], additionally, there was significant evidence of dysregulation of 
mitochondrial biogenesis in these placental tissues. UCP-1 is directly regulated by PGC-1α 
[15] and has recently been shown to regulate mROS production, in addition to its recognised 
role in adaptive thermogenesis (45, 46). Mild uncoupling due to increased UCP-1 expression 
may participate in an antioxidant defense mechanism to dampen exaggerated mROS 
production.  
Proton leakage back to the mitochondrial matrix from the intermembrane space induced by 
UCP-1, alters the apparent degree of membrane energisation and also decreases mROS 
production [46]. In support of this, FCCP-induced OCR was significantly increased following 
ERG treatment with a resultant increase in maximal respiratory capacity. The reduction in 
mROS as a result of ERG treatment may be related to this alteration in mitochondrial 
bioenergetics, by priming the placental mitochondria to be better equipped to combat 
oxidative insult. While both MitoTempo and NAC had a marginal effect on PGC-1α 
expression, there was no additional effect on UCP-1 expression suggesting that ERG 
treatment may recruit alternative transcriptional machinery which amplify the UCP-1 
response. 
Here we provide evidence that the nutraceutical antioxidant ERG has significant 





generation of mROS without altering mitochondrial mass or antioxidant expression. This 
study presents novel data that ERG may be mediating its effects via increasing UCP-1 
expression which induces mild coupling and while also increasing respiratory capacity, 
thereby positively modifying the cells capacity to respond to oxidative insult. Finally, our 
study provides evidence that directly targeting mitochondrial superoxide scavenging with 
ERG could be a therapeutic candidate for the treatment of preeclampsia.   
 
Acknowledgments. CMcC and LK thanks Health Research Board Ireland, Health Research 
Award (HRA-POR-2015-1240) for financial support. and DBK thanks the Novo Nordisk 

























1. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. The 
hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management 
recommendations for international practice. Pregnancy Hypertension. 2018;13:291-310. 
2. Young BC, Levine RJ, Karumanchi SA. Pathogenesis of preeclampsia. Annual review of 
pathology. 2010;5:173-92. 
3. Redman CW. Preeclampsia: a multi-stress disorder. La Revue de medecine interne. 2011;32 
Suppl 1:S41-4. 
4. Kell DB, Kenny LC. A Dormant Microbial Component in the Development of Preeclampsia. 
Frontiers in medicine. 2016;3:60-. 
5. Burton GJ, Jauniaux E. Placental oxidative stress: from miscarriage to preeclampsia. J Soc 
Gynecol Investig. 2004;11(6):342-52. 
6. Kell DB. Iron behaving badly: inappropriate iron chelation as a major contributor to the 
aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC medical 
genomics. 2009;2:2. 
7. McCarthy CM, Kenny LC. Mitochondrial [dys]function; culprit in pre-eclampsia? Clinical 
science (London, England : 1979). 2016;130(14):1179-84. 
8. Williamson RD, McCarthy FP, Khashan AS, Totorika A, Kenny LC, McCarthy C. Exploring the 
role of mitochondrial dysfunction in the pathophysiology of pre-eclampsia. Pregnancy Hypertension. 
2018;13:248-53. 
9. Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, et al. Circulating mitochondrial 
DAMPs cause inflammatory responses to injury. Nature. 2010;464(7285):104-7. 
10. Wang Y, Walsh SW. Antioxidant activities and mRNA expression of superoxide dismutase, 
catalase, and glutathione peroxidase in normal and preeclamptic placentas. Journal of the Society 
for Gynecologic Investigation. 1996;3(4):179-84. 
11. Caja S, Enriquez JA. Mitochondria in endothelial cells: Sensors and integrators of 
environmental cues. Redox Biol. 2017;12:821-7. 
12. Puigserver P. Tissue-specific regulation of metabolic pathways through the transcriptional 
coactivator PGC1-alpha. Int J Obes (Lond). 2005;29 Suppl 1:S5-9. 
13. Kelly DP, Scarpulla RC. Transcriptional regulatory circuits controlling mitochondrial 
biogenesis and function. Genes Dev. 2004;18(4):357-68. 
14. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM. A cold-inducible 
coactivator of nuclear receptors linked to adaptive thermogenesis. Cell. 1998;92(6):829-39. 
15. St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jager S, et al. Suppression of reactive oxygen 
species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell. 2006;127(2):397-408. 
16. Oelkrug R, Kutschke M, Meyer CW, Heldmaier G, Jastroch M. Uncoupling protein 1 decreases 
superoxide production in brown adipose tissue mitochondria. J Biol Chem. 2010;285(29):21961-8. 
17. Zhu BZ, Mao L, Fan RM, Zhu JG, Zhang YN, Wang J, et al. Ergothioneine prevents copper-
induced oxidative damage to DNA and protein by forming a redox-inactive ergothioneine-copper 
complex. Chemical research in toxicology. 2011;24(1):30-4. 
18. Hartman PE. [32] Ergothioneine as antioxidant.  Methods in Enzymology. 186: Academic 
Press; 1990. p. 310-8. 
19. Asmus K-D, Bensasson RV, Bernier J-L, Houssin R, Land EJ. One-electron oxidation of 
ergothioneine and analogues investigated by pulse radiolysis: redox reaction involving ergothioneine 
and vitamin C. Biochemical Journal. 1996;315(2):625. 
20. Akanmu D, Cecchini R, Aruoma OI, Halliwell B. The antioxidant action of ergothioneine. 
Archives of Biochemistry and Biophysics. 1991;288(1):10-6. 
21. Franzoni F, Colognato R, Galetta F, Laurenza I, Barsotti M, Di Stefano R, et al. An in vitro 





glutathione, uric acid and trolox. Biomedicine & pharmacotherapy = Biomedecine & 
pharmacotherapie. 2006;60(8):453-7. 
22. Martin KR. The bioactive agent ergothioneine, a key component of dietary mushrooms, 
inhibits monocyte binding to endothelial cells characteristic of early cardiovascular disease. Journal 
of medicinal food. 2010;13(6):1340-6. 
23. Halliwell B, Cheah IK, Drum CL. Ergothioneine, an adaptive antioxidant for the protection of 
injured tissues? A hypothesis. Biochemical and biophysical research communications. 
2016;470(2):245-50. 
24. Cheah IK, Halliwell B. Ergothioneine; antioxidant potential, physiological function and role in 
disease. Biochimica et biophysica acta. 2012;1822(5):784-93. 
25. Song TY, Chen CL, Liao JW, Ou HC, Tsai MS. Ergothioneine protects against neuronal injury 
induced by cisplatin both in vitro and in vivo. Food and chemical toxicology : an international journal 
published for the British Industrial Biological Research Association. 2010;48(12):3492-9. 
26. Laurenza I, Colognato R, Migliore L, Del Prato S, Benzi L. Modulation of palmitic acid-induced 
cell death by ergothioneine: evidence of an anti-inflammatory action. BioFactors (Oxford, England). 
2008;33(4):237-47. 
27. Wagner DJ, Hu T, Wang J. Polyspecific organic cation transporters and their impact on drug 
intracellular levels and pharmacodynamics. Pharmacological research. 2016;111:237-46. 
28. Grundemann D, Harlfinger S, Golz S, Geerts A, Lazar A, Berkels R, et al. Discovery of the 
ergothioneine transporter. Proc Natl Acad Sci U S A. 2005;102(14):5256-61. 
29. Tschirka J, Kreisor M, Betz J, Grundemann D. Substrate Selectivity Check of the 
Ergothioneine Transporter. Drug metabolism and disposition: the biological fate of chemicals. 
2018;46(6):779-85. 
30. Motohashi N, Mori I, Sugiura Y. Complexing of copper ion by ergothioneine. Chemical & 
pharmaceutical bulletin. 1976;24(10):2364-8. 
31. Taubert D, Jung N, Goeser T, Schomig E. Increased ergothioneine tissue concentrations in 
carriers of the Crohn's disease risk-associated 503F variant of the organic cation transporter OCTN1. 
Gut. 2009;58(2):312-4. 
32. Cheah IK, Tang RM, Yew TS, Lim KH, Halliwell B. Administration of Pure Ergothioneine to 
Healthy Human Subjects: Uptake, Metabolism, and Effects on Biomarkers of Oxidative Damage and 
Inflammation. Antioxidants & redox signaling. 2017;26(5):193-206. 
33. Forster R, Spezia F, Papineau D, Sabadie C, Erdelmeier I, Moutet M, et al. Reproductive 
safety evaluation of L-(+)-ergothioneine . Food and chemical toxicology : an international journal 
published for the British Industrial Biological Research Association. 2015;80:85-91. 
34. urck DB, Jean-Louis ; Burlingame, Barbara ; Dean, Tara ; Fairweather-Tait, Susan ; Heinonen, 
Marina ; Hirsch-Ernst, Karen Ildico ; Mangelsdorf, Inge ; McArdle, Harry J ; Naska, Androniki ; 
Neuhäuser-Berthold, Monika ; Nowicka, Grażyna ; Pentieva, Kristina ; Sanz, Yolanda ; Siani, Alfonso ; 
Sjödin, Anders ; Stern, Martin ; Tomé, Daniel ; Vinceti, Marco ; Willatts, Peter ; Engel, Karl–Heinz ; 
Marchelli, Rosangela ; Pöting, Annette ; Poulsen, Morten ; Schlatter, Josef ; Ackerl, Reinhard ; van 
Loveren, Henk. Safety of synthetic l-ergothioneine (Ergoneine®) as a novel food pursuant to 
Regulation (EC) No 258/97. EFSA Journal. 2016;Vol. 14,No. 11. 
35. Efsa Panel on Dietetic Products N, Allergies, Turck D, Bresson J-L, Burlingame B, Dean T, et al. 
Statement on the safety of synthetic L-(+)-ergothioneine  as a novel food – supplementary dietary 
exposure and safety assessment for infants and young children, pregnant and breastfeeding women. 
EFSA Journal. 2017;15(11):e05060. 
36. McCarthy C, Kenny LC. Therapeutically targeting mitochondrial redox signalling alleviates 
endothelial dysfunction in preeclampsia. Scientific reports. 2016;6:32683. 
37. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. 





38. Vaka VR, McMaster KM, Cunningham MW, Jr., Ibrahim T, Hazlewood R, Usry N, et al. Role of 
Mitochondrial Dysfunction and Reactive Oxygen Species in Mediating Hypertension in the Reduced 
Uterine Perfusion Pressure Rat Model of Preeclampsia. Hypertension. 2018. 
39. Chappell L. Effect of antioxidants on the occurrence of pre-eclampsia in women at increased 
risk: a randomized trial. Lancet. 1999;354:810-6. 
40. Poston L, Briley AL, Seed PT, Kelly FJ, Shennan AH. Vitamin C and vitamin E in pregnant 
women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. Lancet. 
2006;367(9517):1145-54. 
41. Paul BD, Snyder SH. The unusual amino acid L-(+)-ergothioneine  is a physiologic 
cytoprotectant. Cell Death Differ. 2010;17(7):1134-40. 
42. Li RW, Yang C, Sit AS, Kwan YW, Lee SM, Hoi MP, et al. Uptake and protective effects of 
ergothioneine in human endothelial cells. The Journal of pharmacology and experimental 
therapeutics. 2014;350(3):691-700. 
43. Dominy JE, Puigserver P. Mitochondrial biogenesis through activation of nuclear signaling 
proteins. Cold Spring Harb Perspect Biol. 2013;5(7). 
44. Zhou X, Han T-L, Chen H, Baker PN, Qi H, Zhang H. Impaired mitochondrial fusion, 
autophagy, biogenesis and dysregulated lipid metabolism is associated with preeclampsia. 
Experimental Cell Research. 2017;359(1):195-204. 
45. Dlasková A, Clarke KJ, Porter RK. The role of UCP 1 in production of reactive oxygen species 
by mitochondria isolated from brown adipose tissue. Biochimica et Biophysica Acta (BBA) - 
Bioenergetics. 2010;1797(8):1470-6. 
46. Kazak L, Chouchani ET, Stavrovskaya IG, Lu GZ, Jedrychowski MP, Egan DF, et al. UCP1 
deficiency causes brown fat respiratory chain depletion and sensitizes mitochondria to calcium 







































    
    
    
    
    









Disclaimer: The manuscript and its contents are confidential, 
 intended for journal review purposes only, and not to be further 
 disclosed. 
URL: http://hype-submit.aha-j urnals.org 
Title: L-(+)-ergothioneine significantly improves the clinical 
 characteristics of preeclampsia in the r duced uterine perfusion 
 pressure rat model 
Manuscript number: HYPE201913929 
Author(s): Cathal McCarthy, University College Cork 
Rachel Williamson, University College Cork 
Fergus McCarthy, The Irish Centre for Fetal and Neonatal 
 Translational Research, University College Cork, 
Samprikta Manna, University College Cork 
Emer Groarke, Cork University Hospital 
Douglas Kell, University of Liverpool 






















    
    
    
    
    









Title:  L-(+)-ergothioneine significantly improves the clinical characteristics of 
preeclampsia in the reduced uterine perfusion pressure rat model 
Rachel D. Williamson
1







, Douglas B. Kell
4,5





Irish Centre for Fetal and Neonatal Translational Research (INFANT), Cork 
University Maternity Hospital, Cork, Ireland. 
2 
Department of Pharmacology and Therapeutics, Western Gateway Building, 
University College Cork, Cork, Ireland. 
3 
Clinical Biochemistry, Cork University Hospital, Cork, Ireland. 
4
 Dept of Biochemistry, Institute of Integrative Biology, Faculty of Health and Life 
Sciences, University of Liverpool, Crown St, Liverpool L69 7ZB, UK 
5
Novo Nordisk Foundation Centre for Biosustainability, Technical University of 
Denmark, Building 220, Kemitorvet, 2800 Kgs. Lyngby, Denmark 
6
Department of Women’s and Children’s Health, Institute of Translational Medicine, 
University of Liverpool 
Short Title: L-ergothioneine as a treatment for Preeclampsia 
Corresponding Author: Dr. Cathal McCarthy, Room 2.48, Department of 
Pharmacology and Therapeutics, Western Gateway Building, University College 
Cork, Cork, Ireland. Email: cmccarthy@ucc.ie 























    
    
    
    
    











Preeclampsia is a multifactorial hypertensive disorder of pregnancy founded on 
abnormal placentation, and the resultant placental ischemic microenvironment is 
thought to play a crucial role in its pathophysiology. Placental ischemia due to 
fluctuations in the delivery of oxygen results in oxidative stress, and recent evidence 
suggests that mitochondrial dysfunction may be a prime mediator. However, large 
clinical trials of therapeutic antioxidants such as vitamins C and E for the treatment 
of preeclampsia have been disappointing. L-(+)-ergothioneine (ERG), an unusual 
amino acid betaine derived from histidine, has important cytoprotective and 
antioxidant properties under conditions of high oxidative stress. In this study, we 
investigated the potential therapeutic effects of administration of ERG in the reduced 
uterine perfusion pressure (RUPP) rat model of preeclampsia.  
L-ergothioneine (25mg/kg/day) was administered to rats on gestational day 11. On 
gestational day 14 RUPP surgery was performed and on gestational day 19, blood 
pressure (mean arterial pressure) and fetal growth were measured. Production of 
mitochondrial-specific H2O2 was analysed in vivo in kidney samples. ERG 
ameliorated the hypertension and significantly increased pup weight in RUPP rats. 
ERG also significantly decreased circulating levels of anti-angiogenic sFlt-1 in 
RUPP rats. Mitochondrial-specific H2O2 was also significantly decreased in kidney 
tissue in RUPP rats treated with ERG. These data support the potential use of ERG 
























    
    
    
    
    











Preeclampsia is a multisystemic disorder of pregnancy which results in high blood 
pressure accompanied by and/or proteinuria, acute kidney injury (AKI) and/or liver 
dysfunction fetal growth restriction (FGR) after 20 weeks’ gestation (1) It affects 
more than eight million pregnancies worldwide annually, and is the leading cause of 
maternal death (2). Despite extensive research, the exact pathophysiological 
mechanisms underlying this syndrome remain poorly elucidated.  Nonetheless, 
defective placentation is strongly considered to be a critical event in the pathology of 
the disorder (2). Failure to remodel spiral arteries results in high-pressure blood-
flow-mediated placental damage and intermittent fluctuations in oxygen delivery, 
which exposes the placenta to oxidative stress (3). The resultant placental ischaemic 
microenvironment is inherently linked to increased production and secretion of 
deleterious soluble mediators that provoke extensive maternal inflammation and 
endothelial dysfunction (4).  Several reports have observed higher levels of markers 
of oxidative stress (including F2-isoprostanes, nitrotyrosine and 4-hydroxynonenal 
staining) in placental tissue from preeclamptic pregnancies compared with those 
from uncomplicated pregnancies (5-8).  
While there are a number of different cellular sources of reactive oxygen species 
(ROS), mitochondria are the major cellular producers (9).  Furthermore, in terms of 
preeclampsia, there is growing evidence incriminating mitochondrial dysfunction in 
its underlying pathophysiology (10). Initial studies showed increased mitochondrial 
lipid peroxidation and enhanced susceptibility to oxidative damage in placental 
tissue of pregnancies complicated by preeclampsia (11).  More recently,  work has 






















    
    
    
    
    










function in the metabolite profile of plasma samples taken at 15 week’s gestation 
from patients who subsequently developed preeclampsia (12). 
While there is significant evidence for the pathogenic role of oxidative stress in the 
development of preeclampsia, clinical trials of antioxidant interventions were 
disappointing and not clinically effective in treating the disorder. One very plausible 
explanation is that these antioxidants missed the intracellular location of ROS 
production, namely the mitochondria; hence they have failed to alleviate the 
pathological oxidative damage. Another is that molecules such as L-ascorbate can 
actually be pro-oxidant in the presence of free iron (9). L-ergothioneine (ERG) is an 
unusual thio-histidine betaine amino acid and is a naturally occurring anti-oxidant 
discovered over a century ago in the rye ergot (13-16).  The predominant role of 
ERG, via a variety of mechanisms, is to serve as an antioxidant and cellular 
protectant against various kinds of reactive oxygen species (17). Additionally, there 
has been some circumstantial evidence that ERG could target mitochondria (18) and 
hence could dampen exaggerated mitochondrial-specific ROS in response to 
oxidative stress.  
Therefore, we aimed to investigate the role of ERG as a potential therapeutic target 
for preeclampsia using the reduced uterine perfusion pressure (RUPP) model in 
pregnant rats. The placental ischaemic RUPP model has numerous features of 
preeclampsia that are clinically evident in women and has been used as a preclinical 
model for the investigation of novel therapeutic targets for the treatment of 
preeclampsia (19, 20). Moreover, we additionally wanted to examine if ERG 
ameliorated the clinical characteristics of preeclampsia in part via regulation of 
mitochondrial-specific ROS production. To this end, we used a novel ratiometric 






















    
    
    
    
    










generates a MitoP phenol product upon reaction with H2O2 which can be 
subsequently be analysed ex vivo by mass spectrometry. 
 
Materials and Methods  
Animals:  
Sprague Dawley-timed pregnant rats were supplied and maintained by the University 
College Cork Biological Services Unit. Animals were maintained at a temperature of 
21˚C, with a 12-hour light/dark cycle and free access to food and tap water. All the 
procedures were performed in accordance with National Guidelines and the 
European Directive 2010/63/EU, under an authorization issued by the Health 
Products Regulatory Authority Ireland and approved by the Animal Ethics 
Committee of University College Cork (AE19130/P037).  
RUPP procedure  
The RUPP procedure is a well-established surgical model for studying the link 
between placental ischemia and hypertension in the pregnant rat and has been 
previously described in detail (19, 21). In brief, on gestational day (GD) 14, under 
isoflurane anaesthesia, RUPP reduction in blood flow to the uteroplacental unit was 
achieved by placing a silver clip (0.2 mm ID) on the abdominal aorta (one clip) 
above the iliac bifurcation. Two further clips (0.1 mm ID) were carefully placed 
around the left and right ovarian arteries. Sham surgery was performed as controls, 
which involved abdominal incision but didn’t involve insertion of any clips on either 






















    
    
    
    
    










inserted into the carotid artery and on GD19 mean arterial blood pressure (MABP) 
was recorded in conscious animals.  
L-ergothioneine in vivo experimental protocol  
Four experimental groups were used to investigate the effect of administration of 
ERG in the RUPP rat model of pre-eclampsia. Pregnant rats were divided into Sham 
(n=8), Sham+ERG (n=8) or RUPP (n=8), and RUPP+ERG (n=8). ERG was 
administered at (25mg/kg/day) in their drinking water on GD11 until the end of the 
experiment on GD19. The dose for ERG (25mg/kg/day) were selected based on 
previously published rodent studies using this antioxidant (22, 23).  L-ergothioneine 
was provided by Tetrahedron (Paris, France; www.tetrahedron.fr).  
Plasma Collection  
Blood collected from EDTA vacutainers were centrifuged at 2000 x g and 2400 x g 
for 10 minutes at 4˚C, plasma was removed and stored at -80˚C for further analysis.  
Urine analysis  
On GD18, each rat was singularly housed in a metabolic cage and urine collected 
overnight. All samples were stored immediately following collection at -80
o
C. 
Microalbumin:creatinine ratios were calculated following measurement of albumin 
using an immuno-turbidimetric test for the quantitative determination of albumin in 
an OLYMPUS AU5832 analyser® and urine creatinine using a kinetic colour test 
(Jaffé method) (24). Similarly, protein: creatinine ratios were calculated following 
measurement of protein by adding benzethonium chloride which resulted in the 
formation of a fine suspension, which was then quantified turbidimetrically at 525 






















    
    
    
    
    










Measurement of anti-angiogenic protein sFlt-1 by ELISA 
Circulating sFlt-1 concentration in plasma samples from all experimental groups 
were quantified by enzyme-linked immunosorbent assay (ELISA) using a 
Quantikine sFlt-1 immunoassay (R&D Systems) as per manufacturers’ instructions.  
Isolation of RNA and Real-time PCR analysis 
RNA was extracted from placental tissue using the Trizol method. SLC22A4 (ERG 
transporter), superoxide dismutase 1 (SOD1), SOD2, and uncoupling protein-1 
(UCP-1), PCG-1α and Nrf2 gene expression was quantified by Real-time PCR using 
StepONE Plus Detection system. Taqman assays (Applied Biosciences) and Sybr 
Green primers were used for quantification. The amounts of the target genes were 
normalised to the geometric mean of internal control gene 18S, and were determined 




In all groups, third order mesenteric arteries were dissected and mounted on a 4-
channel wire myograph (Model 610 mol/L Danish Myo Technology) containing 
oxygenated (95% O2 and 5% CO2) physiological salt solution (PSS) at 37˚C. Vessels 
were normalized to achieve a transmural pressure of 100mmHg using the DMT 
Normalization software. Isometric tension was recorded and displayed using 
Powerlab Chart Software (AD Instruments). The viability of the smooth muscle was 
examined by the addition of a 123 mM KCl solution. After PSS washes, 



























    
    
    
    
    























 M) respectively (25, 26). 
Estimation of mitochondrial H2O2 in the RUPP model in vivo  
Mitochondrial hydrogen peroxide was measured in vivo using the Cayman Chemical 
Hydrogen Peroxide Ratiometric MaxSpec kit based on the MitoB mass 
spectrometric probe method described previously (27). Briefly, 75 nmol MitoB in 
50μl saline was administered by tail-vein injection to rats in the 4 experimental 
groups on GD19, 4 hours prior to end of the experiment. At the end of the procedure, 
kidney tissues were dissected out, snap frozen and stored at −80 °C. For 
mitochondrial H2O2 analysis, kidney tissues were homogenised, spiked with 
deuterated internal standards and MitoB and its product MitoP were extracted using 
acetonitrile/formic acid. MitoB and MitoP present in kidney tissue were measured 
using UPLC Xevo TQD mass spectrometer (Waters) and the amounts of MitoP and 
MitoB in each sample were determined relative to a standard curve. The 
MitoP/MitoB ratios for each sample were then calculated. 
Statistical analysis  
All data are expressed as mean ± SEM, or fold change relative to control. Analysis 
was performed using GraphPad Prism and student t test was applied when 






















    
    
    
    
    











L-ergothioneine ameliorated RUPP-induced hypertension  
Mean arterial blood pressure (MABP) was significantly increased in the RUPP group 
compared with sham group (129 ± 3 mmHg vs 117 ± 7 mmHg, P = 0.05; N=8, 
Figure 1A). Furthermore, administration of ERG significantly reduced MABP in the 
RUPP rats (129 ± 3 mmHg v 115 ± 4 mmHg), P = 0.01; N=8, Figure 1A). MABP in 
sham rats treated with ERG was not significantly different from RUPP rats treated 
with ERG, indicating the beneficial effect of ERG antioxidant in reducing blood 
pressure occurs in response to placental ischemia. There was no significant 
difference in microalbumin:creatinine (MCR) ratio in the RUPP group compared to 
Sham group, nor was there a significant difference in the MCR ratio in the RUPP 
rats treated with ERG (Figure 1B).  
L-ergothioneine improves fetal weight 
Fetal birth weight was significantly decreased in the RUPP group compared to the 
Sham group (1.8 ± 0.04g v 2 ± 0.03g; P= 0.0004; Figure 2A). Administration of 
ERG significantly rescued fetal growth restriction in the RUPP rats (2 ± 0.03 g v 1.8 
± 0.04g, P= 0.0006; Figure 2A). Placental weights were significantly reduced in 
RUPP group compared to Sham group (0.4 ± 0.01g v 0.5 ± 0.01g; P= 0.002, Figure 
2B). The administration of ERG had no effect on placental weight in the RUPP rats 
(0.4 ± 0.01g v 0.4 ± 0.01g) (Figure 2B). A significant decrease in pup number was 
observed in the RUPP group compared to Sham group (11 ± 1 v 14 ± 1 P= 0.02, 
Figure 3C). There was no significant difference in pup number in RUPP rats treated 
with ERG relative to RUPP rats (13 ± 2 v 11 ± 1). Pup weight was not significantly 






















    
    
    
    
    










effect of ERG in rescuing fetal weight during placental ischemia. There was no 
significant difference in the crown to rump length (CRL) of pups in any of the 
studied groups (Figure S1. Supplemental Material). Finally, maternal weight did not 
differ between any of the studied groups. (Figure S2. Supplemental Material). 
L-ergothioneine reduces circulating sFlt-1 levels 
There was a significant increase in the circulating soluble anti-angiogenic mediator 
sFlt-1 in the RUPP group compared to the sham group (1995 ± 97 pg/ml v 1185± 
349 pg/ml, P= 0.04) (Figure 3). Administration of ERG significantly decreased 
circulating sFlt-1 levels in RUPP rats (1367 ± 245 pg/ml, P= 0.04; Figure 3). 
Effect of L-ergothioneine on vasorelaxation in the RUPP model  
Mesenteric arteries from the RUPP group displayed impaired vasorelaxation in 
response to bradykinin (BK) when compared to the sham group (Rmax: 28 ± 7% 
versus 52 ± 9%; P= 0.01, log EC50: -6.6 ± 0.2 versus -6.8 ± 0.3 mol/L; P=0.7, 
Figure 4A). However, no significant differences were seen in the vascular response 
to the endothelial independent vasodilator sodium nitroprusside (SNP) (Rmax: 78 ± 
5% versus 80 ± 5%; P= 0.36, log EC50: -7.1 ± 0.2 versus -7.2 ± 0.4 mol/L, P=0.9, 
Figure S3.A) or Acetylcholine (ACh) (Rmax: 83 ± 8% versus 81 ± 6%; P= 0.1, log 
EC50: -7.1 ± 0.2 versus -7 ± 0.1mol/L, P= 0.6 Figure S.3B). Treatment with ERG 
had no significant effect on the vasorelaxant responses of mesenteric vessels in 
response to BK (Rmax: 23 ± 5% versus 28 ± 7%; P= 0.9, log EC50:-6.7 ± 0.2 versus -
6.8 ± 0.2 mol/L, P=0.7, Figure 4B), or SNP (Rmax: 78 ± 6% versus 74 ± 4%; P= 0.8, 






















    
    
    
    
    










L-ergothioneine alters placental expression of markers of mitochondrial ROS- 
detoxifying enzymes 
Placental expression of mitochondrial orchestrator proliferator activated receptor γ 
co-activator 1-α (PGC-1α) (1 ± 0.4 fold vs 0.4± 0.5 fold, n=8, P= 0.01, Figure 5A) 
and mitochondrial-ROS detoxifying enzymes including uncoupling protein 1 (UCP-
1) (1 ± 0.5 fold vs 0.2 ± 0.5 fold, P= 0.04) were significantly decreased in the RUPP 
rats. Nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a transcriptional regulator of 
the mitochondrial antioxidant defence system and coactivated by PGC-1α was also 
significantly reduced in the RUPP rats (1 ± 0.2 fold vs 0.4 ± 0.4 fold, n=8,  P= 0.01, 
Figure 5A). Placental expression of SOD1 antioxidant was significantly increased (1 
± 0.3 fold vs 1.4 ± 0.3 fold, n=8, P= 0.02; Figure 5B), while mitochondrial SOD2 
antioxidant was significantly reduced (1 ± 0.3 fold vs 0.6 ± 0.3 fold, n=8, P= 0.01, 
Figure 5B) in RUPP rats compared with sham group. 
ERG treatment significantly increased placental expression of PGC-1α (1.7 ± 0.3 
fold vs 1 ± 0.5 fold, n=8, P= 0.02), UCP-1 (4.9 ± 0.6 fold vs 1 ± 0.5 fold, n=8, P= 
0.001) and Nrf2 (1.6 ± 0.3 fold vs 1 ± 0.4 fold, n=8, P= 0.02, Figure 5A) in RUPP 
rats. ERG treatment significantly increased placental expression of SOD2 in RUPP 
rats (1.5 ± 0.3 fold vs 1 ± 0.3 fold, n=8, P= 0.02, Figure 5B). There was no 
significant difference in placental expression of the ERG transporter OCTN1 in any 






















    
    
    
    
    










L-ergothioneine reduces mitochondria-specific H2O2 production in the kidney  
MitoP/MitoB ratio was increased in kidney tissue of RUPP rats compared with the 
sham group (0.029 ± 0.001 v 0.024 ± 0.006; n=3, P=0.3, Figure 6), indicating for the 
first time that mitochondrial-specific H2O2 is increased in vivo as a result of placental 
ischaemia. Furthermore, pre-treatment with ERG significantly reduced the 
MitoP/MitoB ratio in kidney tissue in RUPP rats (0.022 ± 0.003 v 0.029 ± 0.001; 
n=3, P=0.05, Figure 6), establishing that L-ergothioneine reduces mitochondrial-


































    
    
    
    
    











Despite a significant amount of evidence for the pathological role of oxidative stress 
in the development of preeclampsia, clinical data from two major antioxidant 
vitamin trials have been negative (28, 29). One possible reason for these negative 
findings  may be due to the fact these interventions missed the primary intracellular 
producer of ROS, namely the mitochondria; or because in the presence of free or 
poorly liganded iron substances such as ascorbate are actually pro-oxidant (9).  In the 
present study, L-ergothioneine, an amino acid with potent antioxidant properties, 
attenuated hypertension and rescued fetal growth restriction in the preclinical RUPP 
rat model of preeclampsia, which closely mimics many aspects of preeclampsia 
during human pregnancy. Additionally, this study also reported the novel finding of 
reduced mitochondrial H2O2 levels in vivo following L-ergothioneine administration. 
This work has highlighted that L-ergothioneine acts as a potent antioxidant, that 
ameliorates a number of phenotypic features of preeclampsia in a preclinical model 
of disease and mediated in part by the reduction of mitochondrial-specific ROS. This 
work consequently proposes the potential of ERG as a viable therapeutic for the 
prevention of preeclampsia. 
L-ergothioneine is a water-soluble amino acid that is derived entirely from dietary 
sources. It has garnered much attention recently as a potential therapeutic 
intervention (13, 30-33), partly due to its preferential accumulation within tissues 
undergoing significant oxidative stress. A recent study investigating the reproductive 
safety profile of ERG in pregnant Sprague Dawley rats, established that ERG was 
well tolerated and with no adverse effects on a number of parameters (number of 
mating days, gestation length, pup viability index or litter parameters) (34). 






















    
    
    
    
    










formation and quality (31).  Collectively these data suggest ERG treatment may be 
safe to use in pregnancy and may prevent embryo malformations mediated by 
oxidative stress early in pregnancy. Consequently, we decided to administer ERG at 
an early point in pregnancy (GD11) in the preclinical RUPP model of preeclampsia. 
The therapeutic effects of ERG in response to induced tissue damage in models of 
ischemia-reperfusion injury in the liver (35) and intestine (22)  have previously been 
reported by the dampening of markers of oxidative stress and inflammation. Our 
novel data using ERG reported a reduction in hypertension and an improvement in 
fetal weight in response to placental ischemia in the preclinical RUPP model of 
preeclampsia, in part due to regulation of mitochondrial-specific ROS.  Recent 
evidence identified a prominent role for mitochondrial-specific ROS (mROS) in 
modulating hypertension (36). Using two in vivo murine models of hypertension 
(Ang II-induced and DOCA salt), this group established that using a mitochondria-
targeted antioxidant (Mito-Tempo) alleviated endothelial dysfunction, reduced 
vascular mitochondrial superoxide and subsequent hypertension (36).  Furthermore, 
similar to our work, Vaka et al showed in the preclinical RUPP model that placental 
ischemia dysregulated mitochondrial function with elevated mROS and identified 
that treatment with mitochondrial targeted antioxidants attenuated hypertension with 
improvement in fetal outcomes in treated RUPP rats (37). 
Deleterious circulating mediators including sFlt-1 are secreted in response to 
placental ischemia and have devastating consequences on the maternal vasculature. 
Furthermore, we previously detected increased levels of mitochondrial-specific 
superoxide production in HUVEC’s incubated with plasma from women with 
preeclampsia compared with matched controls and non-pregnant controls (38). 






















    
    
    
    
    










sFlt-1 and mitochondrial complex IV, suggesting that sFlt-1 may be harmful to 
mitochondria in preeclampsia (30).  In our study, ERG treatment reduced the 
circulating levels of sFlt-1 in RUPP rats, indicating that ERG may preserve 
mitochondrial function in part by reducing the availability of sFlt-1 to induce 
mitochondrial damage. The reduction in sFlt-1 as a result of ERG treatment did not 
result in a subsequent reduction in maternal vascular dysfunction in the RUPP rats.  
The capacity to accurately measure the concentration of reactive oxygen species, in 
particular mitochondrial-specific ROS in vivo, has proved to be extremely 
challenging yet is essential in understanding their physiological roles in certain 
diseases. The detection of mitochondrial-specific ROS such as superoxide using 
fluorescent probes can be inferred, with certain caveats, by determining the changes 
in fluorescence, or ex-vivo tissue measurements of ETC complexes but these 
methods can be less selective and sensitive. One potential alternative is to use 
exogenous ratiometric probes (MitoB) injected into the animal models, that readily 
accumulate in mitochondria of tissues due to its possession of a 
triphenylphosphonium cation and which reacts with H2O2  in vivo to produce a 
diagnostic exomarker (MitoP) that can be accurately quantified by mass 
spectrometry (39).  
In this study, we have shown for the first time that this method of measuring 
mitochondrial H2O2 production in vivo is applicable in a rat model, without any 
adverse effects on reproductive safety. Furthermore, we reported that mitochondrial 
H2O2 was  increased in kidney tissue in the RUPP group compared with the sham 
group. This is in agreement with recent work by Vaka et al, who showed an increase 
in mROS in kidney tissue in the RUPP group by examining ETC activity and 






















    
    
    
    
    










More importantly, treatment with ERG resulted in a significant reduction in 
mitochondrial-specific H2O2 production in kidney tissue in RUPP rats, indicating 
that ERG may be mediating its therapeutic effects in part by directly reducing mROS 
production in the preclinical model of preeclampsia. Further evidence to support our 
theory is provided by the fact that placental expression of markers of mitochondrial-
ROS detoxifying enzymes and their transcriptional regulators were significantly 
improved in ERG-treated RUPP rats, in contrast to their reduced expression in RUPP 
rats.  
At present, only one study has investigated the pharmacokinetics of ERG 
administration in human subjects (30).  ERG was rapidly absorbed and retained 
within the tissue/plasma with relatively low urinary excretion (<4% of administered 
dose). This work was further extended by Tang et al. who established that ERG and 
its metabolites are widely distributed in various tissues in male mice administered 
ERG over a range of days. This group also established that ERG was highly retained 
in the body and suggested this could be as a result of possible reabsorption by the 
kidneys (40). 
This study provides evidence of the therapeutic potential of ERG in a preclinical 
model of preeclampsia.  ERG improved both hypertension and fetal weight in the 
RUPP rat model of preeclampsia. Furthermore, ERG treatment significantly altered 
mitochondrial function in both the kidney and placental tissue which may in part be 
responsible for the beneficial effects on phenotypic features of preeclampsia in the 
RUPP model. Given its favourable safety profile, its long half-life and resistance to 
auto-oxidation and multiple mechanisms of action, not least its ability to regulate 
mitochondrial function, further studies are needed to explicitly define the protective 
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Figure 1A: L-ergothioneine attenuates blood pressure in reduced uterine 
perfusion pressure (RUPP) rats: a) RUPP rats (n=8) showed significantly elevated 
mean arterial blood pressure (MABP) compared with sham group (n=8). L-
ergothioneine (25mg/kg/day) reduced MABP in RUPP rats (n=8). Data is presented 
as mean ± SEM, *P<0.05, **P<0.01. 













Figure 1B: L-ergothioneine did not alter microalbumin:creatinine ratio in 
RUPP rats: Administration of L-ergothioneine (25mg/kg/day) did not significantly 






















    
    
    
    
    






















Figure 2: L-ergothioneine improves fetal outcomes in RUPP rats: RUPP rats 
(n=8) show reduced A) pup weight and B) placental weight and C) litter size 
compared with sham group (n=8).  Administration of L-ergothioneine 
(25mg/kg/day) improved fetal outcome in RUPP rats. Data are presented as mean ± 
SEM, *P<0.05, **P<0.01, ***P<0.001.
A) B) 
C) 









































































    
    
    
    
    











Figure 3: L-ergothioneine reduces circulating anti-angiogenic factor sFlt-1 in RUPP 
rats: Circulating levels of sFlt-1 were significantly increased in RUPP rats (n=8) compared 
with sham controls (n=8). Administration of L-ergothioneine significantly reduced 

















































    
    
    
    
    































Figure 4: Impaired vasorelaxtion in mesenteric arteries in RUPP rats: RUPP rats (n=8) 
showed significantly impaired vasorelaxation in response to bradykinin compared to the 
sham group (n=8). Administration of L-ergothioneine did not attenuate the impaired 
vasorelaxation to bradykinin. Relaxation is calculated as a percentage of the maximum 





























    
    
    
    
    





















Figure 5: L-ergothioneine regulates placental expression of mitochondrial-ROS 
detoxifying enzymes in RUPP rats: A) Placental expression of PGC-1α, UCP-1 and Nrf2 
expression were significantly reduced in RUPP rats (n=8) compared with sham group (n=8). 
Administration of L-ergothioneine significantly increased placental expression of all these 
mitochondrial markers in RUPP rats. B) Placental expression of antioxidant SOD1 was 
significantly increased while mitochondrial SOD2 expression was significantly decreased in 
the RUPP group compared to sham group. Administration of L-ergothioneine significantly 
increased mitochondrial antioxidant SOD2 expression in RUPP rats.  OCTN1 expression was 
not significantly different between any of the studied groups. Data are presented as mean ± 










































































    
    
    
    
    





































Figure 6:  L-ergothioneine reduces mitochondrial-specific H2O2 levels. 
Rats were injected with MitoB for 4 hrs and the ratios of MitoP/MitoB were determined by 
LC/MS/MS. Data is represented as Mean ± SEM of 3 samples per group and corrected for 
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Preeclampsia is a multifactorial hypertensive disorder of pregnancy founded on 
abnormal placentation, and the resultant placental ischemic microenvironment is 
thought to play a crucial role in its pathophysiology. Placental ischemia due to 
fluctuations in the delivery of oxygen results in oxidative stress, and recent evidence 
suggests that mitochondrial dysfunction may be a prime mediator. However, large 
clinical trials of therapeutic antioxidants such as vitamins C and E for the treatment 
of preeclampsia have been disappointing. L-(+)-ergothioneine (ERG), an unusual 
amino acid betaine derived from histidine, has important cytoprotective and 
antioxidant properties under conditions of high oxidative stress. In this study, we 
investigated the potential therapeutic effects of administration of ERG in the reduced 
uterine perfusion pressure (RUPP) rat model of preeclampsia.  
L-ergothioneine (25mg/kg/day) was administered to rats on gestational day 11. On 
gestational day 14 RUPP surgery was performed and on gestational day 19, blood 
pressure (mean arterial pressure) and fetal growth were measured. Production of 
mitochondrial-specific H2O2 was analysed in vivo in kidney samples. ERG 
ameliorated the hypertension and significantly increased pup weight in RUPP rats. 
ERG also significantly decreased circulating levels of anti-angiogenic sFlt-1 in 
RUPP rats. Mitochondrial-specific H2O2 was also significantly decreased in kidney 
tissue in RUPP rats treated with ERG. These data support the potential use of ERG 
























    
    
    
    
    











Preeclampsia is a multisystemic disorder of pregnancy which results in high blood 
pressure accompanied by and/or proteinuria, acute kidney injury (AKI) and/or liver 
dysfunction fetal growth restriction (FGR) after 20 weeks’ gestation (1) It affects 
more than eight million pregnancies worldwide annually, and is the leading cause of 
maternal death (2). Despite extensive research, the exact pathophysiological 
mechanisms underlying this syndrome remain poorly elucidated.  Nonetheless, 
defective placentation is strongly considered to be a critical event in the pathology of 
the disorder (2). Failure to remodel spiral arteries results in high-pressure blood-
flow-mediated placental damage and intermittent fluctuations in oxygen delivery, 
which exposes the placenta to oxidative stress (3). The resultant placental ischaemic 
microenvironment is inherently linked to increased production and secretion of 
deleterious soluble mediators that provoke extensive maternal inflammation and 
endothelial dysfunction (4).  Several reports have observed higher levels of markers 
of oxidative stress (including F2-isoprostanes, nitrotyrosine and 4-hydroxynonenal 
staining) in placental tissue from preeclamptic pregnancies compared with those 
from uncomplicated pregnancies (5-8).  
While there are a number of different cellular sources of reactive oxygen species 
(ROS), mitochondria are the major cellular producers (9).  Furthermore, in terms of 
preeclampsia, there is growing evidence incriminating mitochondrial dysfunction in 
its underlying pathophysiology (10). Initial studies showed increased mitochondrial 
lipid peroxidation and enhanced susceptibility to oxidative damage in placental 
tissue of pregnancies complicated by preeclampsia (11).  More recently,  work has 






















    
    
    
    
    










function in the metabolite profile of plasma samples taken at 15 week’s gestation 
from patients who subsequently developed preeclampsia (12). 
While there is significant evidence for the pathogenic role of oxidative stress in the 
development of preeclampsia, clinical trials of antioxidant interventions were 
disappointing and not clinically effective in treating the disorder. One very plausible 
explanation is that these antioxidants missed the intracellular location of ROS 
production, namely the mitochondria; hence they have failed to alleviate the 
pathological oxidative damage. Another is that molecules such as L-ascorbate can 
actually be pro-oxidant in the presence of free iron (9). L-ergothioneine (ERG) is an 
unusual thio-histidine betaine amino acid and is a naturally occurring anti-oxidant 
discovered over a century ago in the rye ergot (13-16).  The predominant role of 
ERG, via a variety of mechanisms, is to serve as an antioxidant and cellular 
protectant against various kinds of reactive oxygen species (17). Additionally, there 
has been some circumstantial evidence that ERG could target mitochondria (18) and 
hence could dampen exaggerated mitochondrial-specific ROS in response to 
oxidative stress.  
Therefore, we aimed to investigate the role of ERG as a potential therapeutic target 
for preeclampsia using the reduced uterine perfusion pressure (RUPP) model in 
pregnant rats. The placental ischaemic RUPP model has numerous features of 
preeclampsia that are clinically evident in women and has been used as a preclinical 
model for the investigation of novel therapeutic targets for the treatment of 
preeclampsia (19, 20). Moreover, we additionally wanted to examine if ERG 
ameliorated the clinical characteristics of preeclampsia in part via regulation of 
mitochondrial-specific ROS production. To this end, we used a novel ratiometric 






















    
    
    
    
    










generates a MitoP phenol product upon reaction with H2O2 which can be 
subsequently be analysed ex vivo by mass spectrometry. 
 
Materials and Methods  
Animals:  
Sprague Dawley-timed pregnant rats were supplied and maintained by the University 
College Cork Biological Services Unit. Animals were maintained at a temperature of 
21˚C, with a 12-hour light/dark cycle and free access to food and tap water. All the 
procedures were performed in accordance with National Guidelines and the 
European Directive 2010/63/EU, under an authorization issued by the Health 
Products Regulatory Authority Ireland and approved by the Animal Ethics 
Committee of University College Cork (AE19130/P037).  
RUPP procedure  
The RUPP procedure is a well-established surgical model for studying the link 
between placental ischemia and hypertension in the pregnant rat and has been 
previously described in detail (19, 21). In brief, on gestational day (GD) 14, under 
isoflurane anaesthesia, RUPP reduction in blood flow to the uteroplacental unit was 
achieved by placing a silver clip (0.2 mm ID) on the abdominal aorta (one clip) 
above the iliac bifurcation. Two further clips (0.1 mm ID) were carefully placed 
around the left and right ovarian arteries. Sham surgery was performed as controls, 
which involved abdominal incision but didn’t involve insertion of any clips on either 






















    
    
    
    
    










inserted into the carotid artery and on GD19 mean arterial blood pressure (MABP) 
was recorded in conscious animals.  
L-ergothioneine in vivo experimental protocol  
Four experimental groups were used to investigate the effect of administration of 
ERG in the RUPP rat model of pre-eclampsia. Pregnant rats were divided into Sham 
(n=8), Sham+ERG (n=8) or RUPP (n=8), and RUPP+ERG (n=8). ERG was 
administered at (25mg/kg/day) in their drinking water on GD11 until the end of the 
experiment on GD19. The dose for ERG (25mg/kg/day) were selected based on 
previously published rodent studies using this antioxidant (22, 23).  L-ergothioneine 
was provided by Tetrahedron (Paris, France; www.tetrahedron.fr).  
Plasma Collection  
Blood collected from EDTA vacutainers were centrifuged at 2000 x g and 2400 x g 
for 10 minutes at 4˚C, plasma was removed and stored at -80˚C for further analysis.  
Urine analysis  
On GD18, each rat was singularly housed in a metabolic cage and urine collected 
overnight. All samples were stored immediately following collection at -80oC. 
Microalbumin:creatinine ratios were calculated following measurement of albumin 
using an immuno-turbidimetric test for the quantitative determination of albumin in 
an OLYMPUS AU5832 analyser® and urine creatinine using a kinetic colour test 
(Jaffé method) (24). Similarly, protein: creatinine ratios were calculated following 
measurement of protein by adding benzethonium chloride which resulted in the 
formation of a fine suspension, which was then quantified turbidimetrically at 525 






















    
    
    
    
    










Measurement of anti-angiogenic protein sFlt-1 by ELISA 
Circulating sFlt-1 concentration in plasma samples from all experimental groups 
were quantified by enzyme-linked immunosorbent assay (ELISA) using a 
Quantikine sFlt-1 immunoassay (R&D Systems) as per manufacturers’ instructions.  
Isolation of RNA and Real-time PCR analysis 
RNA was extracted from placental tissue using the Trizol method. SLC22A4 (ERG 
transporter), superoxide dismutase 1 (SOD1), SOD2, and uncoupling protein-1 
(UCP-1), PCG-1α and Nrf2 gene expression was quantified by Real-time PCR using 
StepONE Plus Detection system. Taqman assays (Applied Biosciences) and Sybr 
Green primers were used for quantification. The amounts of the target genes were 
normalised to the geometric mean of internal control gene 18S, and were determined 
using the comparative 2-ΔΔCT method. 
Isometric Myography 
In all groups, third order mesenteric arteries were dissected and mounted on a 4-
channel wire myograph (Model 610 mol/L Danish Myo Technology) containing 
oxygenated (95% O2 and 5% CO2) physiological salt solution (PSS) at 37˚C. Vessels 
were normalized to achieve a transmural pressure of 100mmHg using the DMT 
Normalization software. Isometric tension was recorded and displayed using 
Powerlab Chart Software (AD Instruments). The viability of the smooth muscle was 
examined by the addition of a 123 mM KCl solution. After PSS washes, 
concentration responses were carried out with thromboxane mimetic U46619 (9,11-






















    
    
    
    
    










Bradykinin (BK; 10-8 to 10-5 M), Acetylcholine (ACh; 10-8 to 10-5 M), or Sodium 
Nitroprusside (SNP; 10-8 to 10-5 M) respectively (25, 26). 
Estimation of mitochondrial H2O2 in the RUPP model in vivo  
Mitochondrial hydrogen peroxide was measured in vivo using the Cayman Chemical 
Hydrogen Peroxide Ratiometric MaxSpec kit based on the MitoB mass 
spectrometric probe method described previously (27). Briefly, 75 nmol MitoB in 
50μl saline was administered by tail-vein injection to rats in the 4 experimental 
groups on GD19, 4 hours prior to end of the experiment. At the end of the procedure, 
kidney tissues were dissected out, snap frozen and stored at −80 °C. For 
mitochondrial H2O2 analysis, kidney tissues were homogenised, spiked with 
deuterated internal standards and MitoB and its product MitoP were extracted using 
acetonitrile/formic acid. MitoB and MitoP present in kidney tissue were measured 
using UPLC Xevo TQD mass spectrometer (Waters) and the amounts of MitoP and 
MitoB in each sample were d termined relative to a standard curve. The 
MitoP/MitoB ratios for each sample were then calculated. 
Statistical analysis  
All data are expressed as mean ± SEM, or fold change relative to control. Analysis 
was performed using GraphPad Prism and student t test was applied when 






















    
    
    
    
    











L-ergothioneine ameliorated RUPP-induced hypertension  
Mean arterial blood pressure (MABP) was significantly increased in the RUPP group 
compared with sham group (129 ± 3 mmHg vs 117 ± 7 mmHg, P = 0.05; N=8, 
Figure 1A). Furthermore, administration of ERG significantly reduced MABP in the 
RUPP rats (129 ± 3 mmHg v 115 ± 4 mmHg), P = 0.01; N=8, Figure 1A). MABP in 
sham rats treated with ERG was not significantly different from RUPP rats treated 
with ERG, indicating the beneficial effect of ERG antioxidant in reducing blood 
pressure occurs in response to placental ischemia. There was no significant 
difference in microalbumin:creatinine (MCR) ratio in the RUPP group compared to 
Sham group, nor was there a significant difference in the MCR ratio in the RUPP 
rats treated with ERG (Figure 1B).  
L-ergothioneine improves fetal weight 
Fetal birth weight was significantly decreased in the RUPP group compared to the 
Sham group (1.8 ± 0.04g v 2 ± 0.03g; P= 0.0004; Figure 2A). Administration of 
ERG significantly rescued fetal growth restriction in the RUPP rats (2 ± 0.03 g v 1.8 
± 0.04g, P= 0.0006; Figure 2A). Placental weights were significantly reduced in 
RUPP group compared to Sham group (0.4 ± 0.01g v 0.5 ± 0.01g; P= 0.002, Figure 
2B). The administration of ERG had no effect on placental weight in the RUPP rats 
(0.4 ± 0.01g v 0.4 ± 0.01g) (Figure 2B). A significant decrease in pup number was 
observed in the RUPP group compared to Sham group (11 ± 1 v 14 ± 1 P= 0.02, 
Figure 3C). There was no significant difference in pup number in RUPP rats treated 
with ERG relative to RUPP rats (13 ± 2 v 11 ± 1). Pup weight was not significantly 






















    
    
    
    
    










effect of ERG in rescuing fetal weight during placental ischemia. There was no 
significant difference in the crown to rump length (CRL) of pups in any of the 
studied groups (Figure S1. Supplemental Material). Finally, maternal weight did not 
differ between any of the studied groups. (Figure S2. Supplemental Material). 
L-ergothioneine reduces circulating sFlt-1 levels 
There was a significant increase in the circulating soluble anti-angiogenic mediator 
sFlt-1 in the RUPP group compared to the sham group (1995 ± 97 pg/ml v 1185± 
349 pg/ml, P= 0.04) (Figure 3). Administration of ERG significantly decreased 
circulating sFlt-1 levels in RUPP rats (1367 ± 245 pg/ml, P= 0.04; Figure 3). 
Effect of L-ergothioneine on vasorelaxation in the RUPP model  
Mesenteric arteries from the RUPP group displayed impaired vasorelaxation in 
response to bradykinin (BK) when compared to the sham group (Rmax: 28 ± 7% 
versus 52 ± 9%; P= 0.01, log EC50: -6.6 ± 0.2 versus -6.8 ± 0.3 mol/L; P=0.7, 
Figure 4A). However, no significant differences were seen in the vascular response 
to the endothelial independent vasodilator sodium nitroprusside (SNP) (Rmax: 78 ± 
5% versus 80 ± 5%; P= 0.36, log EC50: -7.1 ± 0.2 versus -7.2 ± 0.4 mol/L, P=0.9, 
Figure S3.A) or Acetylcholine (ACh) (Rmax: 83 ± 8% versus 81 ± 6%; P= 0.1, log 
EC50: -7.1 ± 0.2 versus -7 ± 0.1mol/L, P= 0.6 Figure S.3B). Treatment with ERG 
had no significant effect on the vasorelaxant responses of mesenteric vessels in 
response to BK (Rmax: 23 ± 5% versus 28 ± 7%; P= 0.9, log EC50:-6.7 ± 0.2 versus -
6.8 ± 0.2 mol/L, P=0.7, Figure 4B), or SNP (Rmax: 78 ± 6% versus 74 ± 4%; P= 0.8, 






















    
    
    
    
    










L-ergothioneine alters placental expression of markers of mitochondrial ROS- 
detoxifying enzymes 
Placental expression of mitochondrial orchestrator proliferator activated receptor γ 
co-activator 1-α (PGC-1α) (1 ± 0.4 fold vs 0.4± 0.5 fold, n=8, P= 0.01, Figure 5A) 
and mitochondrial-ROS detoxifying enzymes including uncoupling protein 1 (UCP-
1) (1 ± 0.5 fold vs 0.2 ± 0.5 fold, P= 0.04) were significantly decreased in the RUPP 
rats. Nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a transcriptional regulator of 
the mitochondrial antioxidant defence system and coactivated by PGC-1α was also 
significantly reduced in the RUPP rats (1 ± 0.2 fold vs 0.4 ± 0.4 fold, n=8,  P= 0.01, 
Figure 5A). Placental expression of SOD1 antioxidant was significantly increased (1 
± 0.3 fold vs 1.4 ± 0.3 fold, n=8, P= 0.02; Figure 5B), while mitochondrial SOD2 
antioxidant was significantly reduced (1 ± 0.3 fold vs 0.6 ± 0.3 fold, n=8, P= 0.01, 
Figure 5B) in RUPP rats compared with sham group. 
ERG treatment significantly increased placental expression of PGC-1α (1.7 ± 0.3 
fold vs 1 ± 0.5 fold, n=8, P= 0.02), UCP-1 (4.9 ± 0.6 fold vs 1 ± 0.5 fold, n=8, P= 
0.001) and Nrf2 (1.6 ± 0.3 fold vs 1 ± 0.4 fold, n=8, P= 0.02, Figure 5A) in RUPP 
rats. ERG treatment significantly increased placental expression of SOD2 in RUPP 
rats (1.5 ± 0.3 fold vs 1 ± 0.3 fold, n=8, P= 0.02, Figure 5B). There was no 
significant difference in placental expression of the ERG transporter OCTN1 in any 






















    
    
    
    
    










L-ergothioneine reduces mitochondria-specific H2O2 production in the kidney  
MitoP/MitoB ratio was increased in kidney tissue of RUPP rats compared with the 
sham group (0.029 ± 0.001 v 0.024 ± 0.006; n=3, P=0.3, Figure 6), indicating for the 
first time that mitochondrial-specific H2O2 is increased in vivo as a result of placental 
ischaemia. Furthermore, pre-treatment with ERG significantly reduced the 
MitoP/MitoB ratio in kidney tissue in RUPP rats (0.022 ± 0.003 v 0.029 ± 0.001; 
n=3, P=0.05, Figure 6), establishing that L-ergothioneine reduces mitochondrial-


































    
    
    
    
    











Despite a significant amount of evidence for the pathological role of oxidative stress 
in the development of preeclampsia, clinical data from two major antioxidant 
vitamin trials have been negative (28, 29). One possible reason for these negative 
findings  may be due to the fact these interventions missed the primary intracellular 
producer of ROS, namely the mitochondria; or because in the presence of free or 
poorly liganded iron substances such as ascorbate are actually pro-oxidant (9).  In the 
present study, L-ergothioneine, an amino acid with potent antioxidant properties, 
attenuated hypertension and rescued fetal growth restriction in the preclinical RUPP 
rat model of preeclampsia, which closely mimics many aspects of preeclampsia 
during human pregnancy. Additionally, this study also reported the novel finding of 
reduced mitochondrial H2O2 levels in vivo following L-ergothioneine administration. 
This work has highlighted that L-ergothioneine acts as a potent antioxidant, that 
ameliorates a number of phenotypic features of preeclampsia in a preclinical model 
of disease and mediated in part by the reduction of mitochondrial-specific ROS. This 
work consequently proposes the potential of ERG as a viable therapeutic for the 
prevention of preeclampsia. 
L-ergothioneine is a water-soluble amino acid that is derived entirely from dietary 
sources. It has garnered much attention recently as a potential therapeutic 
intervention (13, 30-33), partly due to its preferential accumulation within tissues 
undergoing significant oxidative stress. A recent study investigating the reproductive 
safety profile of ERG in pregnant Sprague Dawley rats, established that ERG was 
well tolerated and with no adverse effects on a number of parameters (number of 
mating days, gestation length, pup viability index or litter parameters) (34). 






















    
    
    
    
    










formation and quality (31).  Collectively these data suggest ERG treatment may be 
safe to use in pregnancy and may prevent embryo malformations mediated by 
oxidative stress early in pregnancy. Consequently, we decided to administer ERG at 
an early point in pregnancy (GD11) in the preclinical RUPP model of preeclampsia. 
The therapeutic effects of ERG in response to induced tissue damage in models of 
ischemia-reperfusion injury in the liver (35) and intestine (22)  have previously been 
reported by the dampening of markers of oxidative stress and inflammation. Our 
novel data using ERG reported a reduction in hypertension and an improvement in 
fetal weight in response to placental ischemia in the preclinical RUPP model of 
preeclampsia, in part due to regulation of mitochondrial-specific ROS.  Recent 
evidence identified a prominent role for mitochondrial-specific ROS (mROS) in 
modulating hypertension (36). Using two in vivo murine models of hypertension 
(Ang II-induced and DOCA salt), this group established that using a mitochondria-
targeted antioxidant (Mito-Tempo) alleviated endothelial dysfunction, reduced 
vascular mitochondrial superoxide and subsequent hypertension (36).  Furthermore, 
similar to our work, Vaka et al showed in the preclinical RUPP model that placental 
ischemia dysregulated mitochondrial function with elevated mROS and identified 
that treatment with mitochondrial targeted antioxidants attenuated hypertension with 
improvement in fetal outcomes in treated RUPP rats (37). 
Deleterious circulating mediators including sFlt-1 are secreted in response to 
placental ischemia and have devastating consequences on the maternal vasculature. 
Furthermore, we previously detected increased levels of mitochondrial-specific 
superoxide production in HUVEC’s incubated with plasma from women with 
preeclampsia compared with matched controls and non-pregnant controls (38). 






















    
    
    
    
    










sFlt-1 and mitochondrial complex IV, suggesting that sFlt-1 may be harmful to 
mitochondria in preeclampsia (30).  In our study, ERG treatment reduced the 
circulating levels of sFlt-1 in RUPP rats, indicating that ERG may preserve 
mitochondrial function in part by reducing the availability of sFlt-1 to induce 
mitochondrial damage. The reduction in sFlt-1 as a result of ERG treatment did not 
result in a subsequent reduction in maternal vascular dysfunction in the RUPP rats.  
The capacity to accurately measure the concentration of reactive oxygen species, in 
particular mitochondrial-specific ROS in vivo, has proved to be extremely 
challenging yet is essential in understanding their physiological roles in certain 
diseases. The detection of mitochondrial-specific ROS such as superoxide using 
fluorescent probes can be inferred, with certain caveats, by determining the changes 
in fluorescence, or ex-vivo tissue measurements of ETC complexes but these 
methods can be less selective and sensitive. One potential alternative is to use 
exogenous ratiometric probes (MitoB) injected into the animal models, that readily 
accumulate in mitochondria of tissues due to its possession of a 
triphenylphosphonium cation and which reacts with H2O2  in vivo to produce a 
diagnostic exomarker (MitoP) that can be accurately quantified by mass 
spectrometry (39).  
In this study, we have shown for the first time that this method of measuring 
mitochondrial H2O2 production in vivo is applicable in a rat model, without any 
adverse effects on reproductive safety. Furthermore, we reported that mitochondrial 
H2O2 was  increased in kidney tissue in the RUPP group compared with the sham 
group. This is in agreement with recent work by Vaka et al, who showed an increase 
in mROS in kidney tissue in the RUPP group by examining ETC activity and 






















    
    
    
    
    










More importantly, treatment with ERG resulted in a significant reduction in 
mitochondrial-specific H2O2 production in kidney tissue in RUPP rats, indicating 
that ERG may be mediating its therapeutic effects in part by directly reducing mROS 
production in the preclinical model of preeclampsia. Further evidence to support our 
theory is provided by the fact that placental expression of markers of mitochondrial-
ROS detoxifying enzymes and their transcriptional regulators were significantly 
improved in ERG-treated RUPP rats, in contrast to their reduced expression in RUPP 
rats.  
At present, only one study has investigated the pharmacokinetics of ERG 
administration in human subjects (30).  ERG was rapidly absorbed and retained 
within the tissue/plasma with relatively low urinary excretion (<4% of administered 
dose). This work was further extended by Tang et al. who established that ERG and 
its metabolites are widely distributed in various tissues in male mice administered 
ERG over a range of days. This group also established that ERG was highly retained 
in the body and suggested this could be as a result of possible reabsorption by the 
kidneys (40). 
This study provides evidence of the therapeutic potential of ERG in a preclinical 
model of preeclampsia.  ERG improved both hypertension and fetal weight in the 
RUPP rat model of preeclampsia. Furthermore, ERG treatment significantly altered 
mitochondrial function in both the kidney and placental tissue which may in part be 
responsible for the beneficial effects on phenotypic features of preeclampsia in the 
RUPP model. Given its favourable safety profile, its long half-life and resistance to 
auto-oxidation and multiple mechanisms of action, not least its ability to regulate 
mitochondrial function, further studies are needed to explicitly define the protective 






















    
    
    
    
    










Acknowledgements:  We thank Dr. Jean-Claude Yadan, PhD, Tetrahedron, Paris 
France for providing us with L-ergothioneine. We thank Emer Groarke, Clinical 
Biochemist, Cork University Hospital, Cork for helping with the measurement of 
microalbumin creatinine ratios of urine samples. 
Sources of Funding: CMcC, RW thank Health Research Board Ireland, Health 
Research Award (HRA-POR-2015-1240) for financial support. LK thanks Science 
Foundation Ireland (SFI) Program Grant for INFANT(12/RC/2272) and DBK thanks 
the Novo Nordisk Foundation (grant NNF10CC1016517) for financial support. 
 
Disclosures: DBK is a named inventor on a patent application involving the 
































    
    
    
    
    











1. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, 
et al. The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & 
management recommendations for international practice. Pregnancy Hypertension. 
2018;13:291-310. 
2. Tranquilli AL, Dekker G, Magee L, Roberts J, Sibai BM, Steyn W, et al. The 
classification, diagnosis and management of the hypertensive disorders of 
pregnancy: A revised statement from the ISSHP. Pregnancy Hypertension: An 
International Journal of Women's Cardiovascular Health. 2014;4(2):97-104. 
3. Redman CW. Preeclampsia: a multi-stress disorder. La Revue de medecine 
interne. 2011;32 Suppl 1:S41-4. 
4. Hubel CA. Oxidative stress in the pathogenesis of preeclampsia. Proc Soc 
Exp Biol Med. 1999;222(3):222-35. 
5. Giilmezoglu AM, Oosthuizen MMJ, Hofmeyr GJ. Placental 
Malondialdehyde and Glutathione Levels in a Controlled Trial of Antioxidant 
Treatment in Severe Preeclampsia. Hypertension in Pregnancy. 1996;15(3):287-95. 
6. Gratacos E, Casals E, Deulofeu R, Cararach V, Alonso PL, Fortuny A. Lipid 
peroxide and vitamin E patterns in pregnant women with different types of 
hypertension in pregnancy. Am J Obstet Gynecol. 1998;178(5):1072-6. 
7. Walsh SW, Vaughan JE, Wang Y, Roberts LJ, 2nd. Placental isoprostane is 
significantly increased in preeclampsia. FASEB journal : official publication of the 
Federation of American Societies for Experimental Biology. 2000;14(10):1289-96. 
8. Noris M, Todeschini M, Cassis P, Pasta F, Cappellini A, Bonazzola S, et al. 
L-arginine depletion in preeclampsia orients nitric oxide synthase toward oxidant 






















    
    
    
    
    










9. Kell DB. Iron behaving badly: inappropriate iron chelation as a major 
contributor to the aetiology of vascular and other progressive inflammatory and 
degenerative diseases. BMC medical genomics. 2009;2:2. 
10. McCarthy CM, Kenny LC. Mitochondrial [dys]function; culprit in pre-
eclampsia? Clinical science (London, England : 1979). 2016;130(14):1179-84. 
11. Wang Y, Walsh SW. Placental mitochondria as a source of oxidative stress in 
pre-eclampsia. Placenta. 1998;19(8):581-6. 
12. Kenny LC, Broadhurst DI, Dunn W, Brown M, North RA, McCowan L, et 
al. Robust early pregnancy prediction of later preeclampsia using metabolomic 
biomarkers. Hypertension. 2010;56(4):741-9. 
13. Tanret C. Sur une base nouvelle retiree du seigle ergote, l'ergothioneine. 
Rend Acad Sci. 1909;149:222-4. 
14. Halliwell B, Cheah IK, Drum CL. Ergothioneine, an adaptive antioxidant for 
the protection of injured tissues? A hypothesis. Biochemical and biophysical 
research communications. 2016;470(2):245-50. 
15. Paul BD, Snyder SH. The unusual amino acid L-ergothioneine is a 
physiologic cytoprotectant. Cell Death Differ. 2010;17(7):1134-40. 
16. Zhu BZ, Mao L, Fan RM, Zhu JG, Zhang YN, Wang J, et al. Ergothioneine 
prevents copper-induced oxidative damage to DNA and protein by forming a redox-
inactive ergothioneine-copper complex. Chemical research in toxicology. 
2011;24(1):30-4. 
17. Kerley RN, McCarthy C, Kell DB, Kenny LC. The potential therapeutic 























    
    
    
    
    










18. Lamhonwah AM, Tein I. Novel localization of OCTN1, an organic 
cation/carnitine transporter, to mammalian mitochondria. Biochemical and 
biophysical research communications. 2006;345(4):1315-25. 
19. Granger JP, LaMarca BB, Cockrell K, Sedeek M, Balzi C, Chandler D, et al. 
Reduced uterine perfusion pressure (RUPP) model for studying cardiovascular-renal 
dysfunction in response to placental ischemia. Methods in molecular medicine. 
2006;122:383-92. 
20. LaMarca BB, Bennett WA, Alexander BT, Cockrell K, Granger JP. 
Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of 
tumor necrosis factor-alpha. Hypertension. 2005;46(4):1022-5. 
21. McCarthy FP, Drewlo S, Kingdom J, Johns EJ, Walsh SK, Kenny LC. 
Peroxisome proliferator-activated receptor-gamma as a potential therapeutic target in 
the treatment of preeclampsia. Hypertension. 2011;58(2):280-6. 
22. Sakrak O, Kerem M, Bedirli A, Pasaoglu H, Akyurek N, Ofluoglu E, et al. 
Ergothioneine modulates proinflammatory cytokines and heat shock protein 70 in 
mesenteric ischemia and rep rfusion injury. The Journal of surgical research. 
2008;144(1):36-42. 
23. Deiana M, Rosa A, Casu V, Piga R, Assunta Dessi M, Aruoma OI. L-
ergothioneine modulates oxidative damage in the kidney and liver of rats in vivo: 
studies upon the profile of polyunsaturated fatty acids. Clin Nutr. 2004;23(2):183-93. 
24. Kurzmann HHTaG. A Microcolorimetric determination of creatine in urine 
by the Jaffe reaction  Jounal of Biological Chemistry 1954;208:853-62. 
25. Walsh SK, English FA, Johns EJ, Kenny LC. Plasma-mediated vascular 
dysfunction in the reduced uterine perfusion pressure model of preeclampsia: a 






















    
    
    
    
    










26. Bridges LE, Williams CL, Pointer MA, Awumey EM. Mesenteric artery 
contraction and relaxation studies using automated wire myography. Journal of 
visualized experiments : JoVE. 2011(55):3119. 
27. Cocheme HM, Logan A, Prime TA, Abakumova I, Quin C, McQuaker SJ, et 
al. Using the mitochondria-targeted ratiometric mass spectrometry probe MitoB to 
measure H2O2 in living Drosophila. Nature protocols. 2012;7(5):946-58. 
28. Poston L, Briley AL, Seed PT, Kelly FJ, Shennan AH. Vitamin C and 
vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised 
placebo-controlled trial. Lancet. 2006;367(9517):1145-54. 
29. Chappell L. Vitamin C and E supplementation in women at risk of 
preeclampsia is associated with changes in indices of oxidative stress and placental 
function. Am J Obstet Gynecol. 2002;187:777-84. 
30. Cheah IK, Tang RM, Yew TS, Lim KH, Halliwell B. Administration of Pure 
Ergothioneine to Healthy Human Subjects: Uptake, Metabolism, and Effects on 
Biomarkers of Oxidative Damage and Inflammation. Antioxidants & redox 
signaling. 2017;26(5):193-206. 
31. Guijarro MV, Indart A, Aruoma OI, Viana M, Bonet B. Effects of 
ergothioneine on diabetic embryopathy in pregnant rats. Food and chemical 
toxicology : an international journal published for the British Industrial Biological 
Research Association. 2002;40(12):1751-5. 
32. Cheah IK, Ng LT, Ng LF, Lam VY, Gruber J, Huang CYW, et al. Inhibition 
of amyloid-induced toxicity by ergothioneine in a transgenic Caenorhabditis elegans 
model. FEBS Lett. 2019. 
33. Ames BN. Prolonging healthy aging: Longevity vitamins and proteins. Proc 






















    
    
    
    
    










34. Forster R, Spezia F, Papineau D, Sabadie C, Erdelmeier I, Moutet M, et al. 
Reproductive safety evaluation of L-Ergothioneine. Food and chemical toxicology : 
an international journal published for the British Industrial Biological Research 
Association. 2015;80:85-91. 
35. Bedirli A, Sakrak O, Muhtaroglu S, Soyuer I, Guler I, Riza Erdogan A, et al. 
Ergothioneine pretreatment protects the liver from ischemia-reperfusion injury 
caused by increasing hepatic heat shock protein 70. The Journal of surgical research. 
2004;122(1):96-102. 
36. Dikalova AE, Bikineyeva AT, Budzyn K, Nazarewicz RR, McCann L, Lewis 
W, et al. Therapeutic targeting of mitochondrial superoxide in hypertension. 
Circulation research. 2010;107(1):106-16. 
37. Vaka VR, McMaster KM, Cunningham MW, Jr., Ibrahim T, Hazlewood R, 
Usry N, et al. Role of Mitochondrial Dysfunction and Reactive Oxygen Species in 
Mediating Hypertension in the Reduced Uterine Perfusion Pressure Rat Model of 
Preeclampsia. Hypertension. 2018. 
38. McCarthy C, Kenny LC. Therapeutically targeting mitochondrial redox 
signalling alleviates endothelial dysfunction in preeclampsia. Scientific reports. 
2016;6:32683. 
39. Logan A, Cocheme HM, Li Pun PB, Apostolova N, Smith RA, Larsen L, et 
al. Using exomarkers to assess mitochondrial reactive species in vivo. Biochimica et 
biophysica acta. 2014;1840(2):923-30. 
40. Tang RMY, Cheah IK, Yew TSK, Halliwell B. Distribution and 
























    
    
    
    
    












Figure 1A: L-ergothioneine attenuates blood pressure in reduced uterine 
perfusion pressure (RUPP) rats: a) RUPP rats (n=8) showed significantly elevated 
mean arterial blood pressure (MABP) compared with sham group (n=8). L-
ergothioneine (25mg/kg/day) reduced MABP in RUPP rats (n=8). Data is presented 
as mean ± SEM, *P<0.05, **P<0.01. 
 
Figure 1B: L-ergothioneine did not alter microalbumin:creatinine ratio in RUPP 
rats: Administration of L-ergothioneine (25mg/kg/day) did not significantly affect 
microalbumin:creatinine ratio in RUPP rats.  














































    
    
    
    
    






















Figure 2: L-ergothioneine improves fetal outcomes in RUPP rats: RUPP rats (n=8) 
show reduced A) pup weight and B) placental weight and C) litter size compared with 
sham group (n=8).  Administration of L-ergothioneine (25mg/kg/day) improved fetal 




































































    
    
    
    
    











Figure 3: L-ergothioneine reduces circulating anti-angiogenic factor sFlt-1 in RUPP rats: 
Circulating levels of sFlt-1 were significantly increased in RUPP rats (n=8) compared with 
sham controls (n=8). Administration of L-ergothioneine significantly reduced circulating sFlt-















































    
    
    
    
    











Figure 4: Impaired vasorelaxtion in mesenteric arteries in RUPP rats: RUPP rats (n=8) 
showed significantly impaired vasorelaxation in response to bradykinin compared to the sham 
group (n=8). Administration of L-ergothioneine did not attenuate the impaired vasorelaxation 
to bradykinin. Relaxation is calculated as a percentage of the maximum contraction and 















































    
    
    
    
    





















Figure 5: L-ergothioneine regulates placental expression of mitochondrial-ROS 
detoxifying enzymes in RUPP rats: A) Placental expression of PGC-1α, UCP-1 and Nrf2 
expression were significantly reduced in RUPP rats (n=8) compared with sham group (n=8). 
Administration of L-ergothioneine significantly increased placental expression of all these 
mitochondrial markers in RUPP rats. B) Placental expression of antioxidant SOD1 was 
significantly increased while mitochondrial SOD2 expression was significantly decreased in 
the RUPP group compared to sham group. Administration of L-ergothioneine significantly 
increased mitochondrial antioxidant SOD2 expression in RUPP rats.  OCTN1 expression was 
not significantly different between any of the studied groups. Data are presented as mean ± 


































































    
    
    
    
    











Figure 6:  L-ergothioneine reduces mitochondrial-specific H2O2 levels. 
Rats were injected with MitoB for 4 hrs and the ratios of MitoP/MitoB were determined by 
LC/MS/MS. Data is represented as Mean ± SEM of 3 samples per group and corrected for 
ratio. Statistical analysis was determined by a two-tailed student t-test: * P < 0.05.  
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